{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import json\n",
    "from datetime import date\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\"total\": 150, \"data\": [{\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"NCI9673\"}, {\"name\": \"Study Protocol Other Identifier\", \"value\": \"P9673_R03PAPPHOLD01\"}], \"amendment_date\": \"2021-03-11T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"Yale University Cancer Center LAO\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Patients must have histologically or cytologically confirmed previously treated metastatic squamous cell carcinoma of the anal canal\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Patients must have measurable disease according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess the measurable disease must have been completed within 28 days prior to study drug initiation\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Patients must have been treated with at least one prior systemic treatment for incurable advanced or metastatic SCCA of the anal canal; prior treatment for metastatic disease is not required for patients who develop new metastatic lesions during or within 6 months of completion of chemoradiation for limited-stage disease; patients who receive chemotherapy for incurable advanced or metastatic SCCA of the anal canal must wait a minimum >= 28 days (6 weeks for nitrosoureas or mitomycin C) after the date of completion of chemotherapy prior to initiating treatment with nivolumab on this study; patients who undergo palliative radiotherapy to a site of tumor must wait a minimum >= 28 days from the date of completion of radiotherapy prior to initiating treatment with nivolumab (Part A and B) or nivolumab +/- Ipilimumab (Part B) on this study\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 80%)\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Leukocytes >= 2,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Absolute neutrophil count >= 1,500/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Hemoglobin >= 9.0 gm/dL\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Platelets >= 100,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Before study enrollment, women of child bearing potential must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; the subject must sign an informed consent form documenting this discussion; the effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women of childbearing potential MUST have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab with or without ipilimumab; the minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG; if the pregnancy test is positive, the subject must not receive nivolumab with or without ipilimumab and must not be enrolled in the study\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"WOCBP receiving nivolumab (Parts A+B) or nivolumab and ipilimumab (Part B) will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product; men receiving nivolumab (Parts A+B) or nivolumab and ipilimumab (Part B only) and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product; these durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately; if, following initiation of the investigational product, it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of investigational product exposure, including during at least 6 half-lives after product administration, the investigational product will be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for subject safety); the investigator must immediately notify BMS of this event and record the pregnancy on the Pregnancy Surveillance Form (not an severe adverse event [SAE] form); initial information on a pregnancy must be reported immediately to BMS, and the outcome information provided once the outcome is known; completed Pregnancy Surveillance Forms must be forwarded to BMS according to SAE reporting procedures; any pregnancy that occurs in a female partner of a male study participant should be reported to the sponsor. Information on this pregnancy will be collected on the Pregnancy Surveillance Form; protocol-required procedures for study discontinuation and follow-up must be performed on the subject unless contraindicated by pregnancy (e.g., X-ray studies); other appropriate pregnancy follow-up procedures should be considered if indicated. In addition, the investigator must report and follow-up on information regarding the course of the pregnancy, including perinatal and neonatal outcome. Infants should be followed for a minimum of 8 weeks\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Ability to understand and the willingness to sign a written informed consent document\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Brain metastases are allowed if they have been adequately treated with radiotherapy or surgery and have been stable for at least three months prior to registration; eligible subjects should be neurologically asymptomatic; there is no magnetic resonance imaging (MRI) evidence of progression for a minimum of 4 weeks after treatment is complete and within 28 days prior to the first dose of nivolumab administration; there must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Willingness for evaluation of cardiac function including electrocardiography (EKG) and echocardiogram (ECHO) cardiogram for any patients with a history of congestive heart failure (CHF) or at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs as clinically indicated\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"All patients must be willing to undergo testing for human immunodeficiency virus (HIV) testing if not tested within the past 6 months\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"If HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be eligible for study provided that their CD4+ count >= 300/uL; their viral load is undetectable; they are currently receiving highly active antiretroviral therapy (HAART)\"}, {\"inclusion_indicator\": true, \"display_order\": 21, \"description\": \"All HIV+ patients will be under the care of an infectious diseases specialist; if a relationship with an infectious diseases specialist is not established, infectious disease specialist will be consulted; records of all viral counts and peripheral T-cell counts must be sent to the study coordinator in order to follow these values over the course of treatment\"}, {\"inclusion_indicator\": true, \"display_order\": 22, \"description\": \"All patients must be willing to be tested for hepatitis screening; patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above; patients must be followed by a hepatologist during the course of this study\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier (i.e., grade >= 2 AE present); palliative (limited-field) radiation therapy is permitted, as long as the lesion being considered for palliative radiation is not a target lesion\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Patients who are receiving any other investigational agents\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed cell death ligand 2 (PD-L2), anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab (Parts A+ B) and/or ipilimumab (Part B)\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"History of severe hypersensitivity reaction to any monoclonal antibody\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids (defined as corticosteroid use of duration one month or greater), should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn\\u2019s, ulcerative colitis, and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or anti-phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"Ontario\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"416-946-4501\", \"recruitment_status_date\": \"2018-10-26\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"610 University Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"M5G 2M9\", \"contact_email\": \"clinical.trials@uhn.on.ca\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Toronto\", \"org_email\": \"clinical.trials@uhn.on.ca\", \"org_country\": \"Canada\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University Health Network-Princess Margaret Hospital\"}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"217-876-4762\", \"recruitment_status_date\": \"2015-12-29\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2300 North Edwards Street\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"62526\", \"contact_email\": \"morganthaler.jodi@mhsil.com\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Decatur\", \"org_email\": \"morganthaler.jodi@mhsil.com\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"217-876-6601\", \"org_name\": \"Decatur Memorial Hospital\", \"org_coordinates\": {\"lon\": -88.9645, \"lat\": 39.9062}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"217-545-7929\", \"recruitment_status_date\": \"2018-10-26\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"801 North Rutledge\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"62702\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Springfield\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"217-545-7929\", \"org_name\": \"Southern Illinois University School of Medicine\", \"org_coordinates\": {\"lon\": -89.6438, \"lat\": 39.8235}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"773-702-8222\", \"recruitment_status_date\": \"2021-08-16\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1900 Silver Cross Boulevard\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"60451\", \"contact_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Lenox\", \"org_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"815-300-1100\", \"org_name\": \"UC Comprehensive Cancer Center at Silver Cross\", \"org_coordinates\": {\"lon\": -87.9609, \"lat\": 41.5052}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"717-531-3779\", \"recruitment_status_date\": \"2016-03-25\", \"org_address_line_2\": \"MCH103\", \"org_va\": false, \"org_address_line_1\": \"500 University Drive\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"17033-0850\", \"contact_email\": \"CTO@hmc.psu.edu\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Hershey\", \"org_email\": \"CTO@hmc.psu.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"717-531-5471\", \"org_name\": \"Penn State Milton S Hershey Medical Center\"}, {\"org_state_or_province\": \"TN\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-811-8480\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"719 Thompson Lane\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"37204\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Nashville\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"615-322-2064\", \"org_name\": \"Vanderbilt Breast Center at One Hundred Oaks\", \"org_coordinates\": {\"lon\": -86.7746, \"lat\": 36.1067}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"111 Beach Road\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"06824\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Fairfield\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-255-2766\", \"org_name\": \"Smilow Cancer Hospital Care Center-Fairfield\", \"org_coordinates\": {\"lon\": -73.268, \"lat\": 41.1692}}, {\"org_state_or_province\": \"NE\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"402-559-5600\", \"recruitment_status_date\": \"2020-10-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"111 North 175th Street\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"68118\", \"contact_email\": null, \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Omaha\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"(402)-559-6941\", \"org_name\": \"Nebraska Medicine-Village Pointe\", \"org_coordinates\": {\"lon\": -96.1767, \"lat\": 41.2632}}, {\"org_state_or_province\": \"NE\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"402-559-6941\", \"recruitment_status_date\": \"2020-10-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2500 Bellevue Medical Center Drive\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"68123\", \"contact_email\": \"unmcrsa@unmc.edu\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Bellevue\", \"org_email\": \"unmcrsa@unmc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"(402)-559-6941\", \"org_name\": \"Nebraska Medicine-Bellevue\", \"org_coordinates\": {\"lon\": -95.9545, \"lat\": 41.1019}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"773-702-8222\", \"recruitment_status_date\": \"2021-08-16\", \"org_address_line_2\": \"Center for Advanced Care\", \"org_va\": false, \"org_address_line_1\": \"14290 South LaGrange Road\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"60462\", \"contact_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Orland Park\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"(773)-834-7424\", \"org_name\": \"University of Chicago Medicine-Orland Park\", \"org_coordinates\": {\"lon\": -87.8577, \"lat\": 41.6163}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2021-05-12\", \"org_address_line_2\": \"Suite 215 and Suite 010\", \"org_va\": false, \"org_address_line_1\": \"2750 Clay Edwards Drive\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"64116\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"North Kansas City\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"(913)-945-7552\", \"org_name\": \"University of Kansas Cancer Center at North Kansas City Hospital\", \"org_coordinates\": {\"lon\": -94.5733, \"lat\": 39.1494}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"323-865-0451\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": \"University of Southern California\", \"org_va\": false, \"org_address_line_1\": \"1441 Eastlake Avenue\", \"org_tty\": null, \"org_family\": \"USC Norris Comprehensive Cancer Center\", \"org_postal_code\": \"90033\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Los Angeles\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"323-865-3000\", \"org_name\": \"USC / Norris Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -118.211, \"lat\": 34.0504}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"323-865-0451\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1200 North State Street\", \"org_tty\": null, \"org_family\": \"USC Norris Comprehensive Cancer Center\", \"org_postal_code\": \"90033\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Los Angeles\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"323-865-0451\", \"org_name\": \"Los Angeles County-USC Medical Center\", \"org_coordinates\": {\"lon\": -118.211, \"lat\": 34.0504}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"916-734-3089\", \"recruitment_status_date\": \"2016-09-21\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4501 X Street\", \"org_tty\": null, \"org_family\": \"UC Davis Comprehensive Cancer Center\", \"org_postal_code\": \"95817\", \"contact_email\": null, \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Sacramento\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"916-734-3089\", \"org_name\": \"University of California Davis Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -121.4572, \"lat\": 38.5503}}, {\"org_state_or_province\": \"CO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"720-848-0650\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1665 Aurora Court\", \"org_tty\": null, \"org_family\": \"University of Colorado Cancer Center\", \"org_postal_code\": \"80045\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Aurora\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"720-848-0650\", \"org_name\": \"University of Colorado Hospital\", \"org_coordinates\": {\"lon\": -104.837, \"lat\": 39.7462}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"94 Woodland Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06105\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Hartford\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"860-714-4680\", \"org_name\": \"Smilow Cancer Hospital Care Center at Saint Francis\", \"org_coordinates\": {\"lon\": -72.7035, \"lat\": 41.7741}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"333 Cedar Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06520\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-785-5702\", \"org_name\": \"Yale University\", \"org_coordinates\": {\"lon\": -72.9291, \"lat\": 41.31}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"20 York Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06510\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-688-4242\", \"org_name\": \"Smilow Cancer Center/Yale-New Haven Hospital\", \"org_coordinates\": {\"lon\": -72.9252, \"lat\": 41.3068}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"200 Kenendy Drive\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06790\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Torrington\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"860-489-6718\", \"org_name\": \"Smilow Cancer Hospital-Torrington Care Center\", \"org_coordinates\": {\"lon\": -73.1283, \"lat\": 41.8368}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": \"Suite 203\", \"org_va\": false, \"org_address_line_1\": \"5520 Park Avenue\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06611\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Trumbull\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": \"203-502-8409\", \"org_phone\": \"203-502-8400\", \"org_name\": \"Smilow Cancer Hospital Care Center-Trumbull\", \"org_coordinates\": {\"lon\": -73.2099, \"lat\": 41.2599}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"111 Goose Lane\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06437\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Guilford\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-453-9192\", \"org_name\": \"Smilow Cancer Hospital Care Center - Guiford\", \"org_coordinates\": {\"lon\": -72.7006, \"lat\": 41.335}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": \"Suite B\", \"org_va\": false, \"org_address_line_1\": \"1075 Chase Parkway\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06708\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Waterbury\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-755-6311\", \"org_name\": \"Smilow Cancer Hospital-Waterbury Care Center\", \"org_coordinates\": {\"lon\": -73.0677, \"lat\": 41.5493}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": \"Suite 6\", \"org_va\": false, \"org_address_line_1\": \"350 Seymour Avenue\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06418\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Derby\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": \"203-734-1665\", \"org_phone\": \"203-734-1664\", \"org_name\": \"Smilow Cancer Hospital-Derby Care Center\", \"org_coordinates\": {\"lon\": -73.101, \"lat\": 41.3352}}, {\"org_state_or_province\": \"DC\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"202-444-2223\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": \"Lombardi Comprehensive Cancer Center\", \"org_va\": false, \"org_address_line_1\": \"3800 Reservoir Road Northwest\", \"org_tty\": null, \"org_family\": \"Georgetown Lombardi Comprehensive Cancer Center\", \"org_postal_code\": \"20007\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Washington\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"202-784-4344\", \"org_phone\": \"202-444-0381\\r202-444-4000\", \"org_name\": \"MedStar Georgetown University Hospital\", \"org_coordinates\": {\"lon\": -77.0771, \"lat\": 38.9147}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"312-695-1301\", \"recruitment_status_date\": \"2021-08-02\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"303 East Chicago Avenue\", \"org_tty\": null, \"org_family\": \"Robert H. Lurie Comprehensive Cancer Center\", \"org_postal_code\": \"60611\", \"contact_email\": \"cancer@northwestern.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Chicago\", \"org_email\": \"cancer@northwestern.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"312-695-1301\", \"org_name\": \"Northwestern University\", \"org_coordinates\": {\"lon\": -87.6187, \"lat\": 41.8946}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"773-702-8222\", \"recruitment_status_date\": \"2021-08-16\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5841 South Maryland Avenue\", \"org_tty\": null, \"org_family\": \"University of Chicago Comprehensive Cancer Center\", \"org_postal_code\": \"60637\", \"contact_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Chicago\", \"org_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"org_country\": \"United States\", \"org_fax\": \"773-702-9311\", \"org_phone\": \"773-834-7424\\r773-702-6180\", \"org_name\": \"University of Chicago Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -87.6021, \"lat\": 41.781}}, {\"org_state_or_province\": \"KS\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2020-09-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"3901 Rainbow Boulevard\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"66160\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Kansas City\", \"org_email\": \"ctnursenav@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"913-945-7552\", \"org_name\": \"University of Kansas Cancer Center\", \"org_coordinates\": {\"lon\": -94.6108, \"lat\": 39.0552}}, {\"org_state_or_province\": \"KS\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2021-05-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"12200 West 110th Street\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"66210\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Overland Park\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"913-234-0400\", \"org_name\": \"University of Kansas Cancer Center-Overland Park\", \"org_coordinates\": {\"lon\": -94.7059, \"lat\": 38.9245}}, {\"org_state_or_province\": \"KS\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2020-09-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2330 Shawnee Mission Parkway\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"66205\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Westwood\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University of Kansas Hospital-Westwood Cancer Center\", \"org_coordinates\": {\"lon\": -94.6315, \"lat\": 39.0312}}, {\"org_state_or_province\": \"MI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-865-1125\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1500 East Medical Center Drive\", \"org_tty\": null, \"org_family\": \"University of Michigan Rogel Cancer Center\", \"org_postal_code\": \"48109\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Ann Arbor\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-865-1125\", \"org_name\": \"University of Michigan Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -83.7144, \"lat\": 42.2909}}, {\"org_state_or_province\": \"MI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"313-576-9790\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4100 John R Street\", \"org_tty\": null, \"org_family\": \"The Barbara Ann Karmanos Cancer Institute\", \"org_postal_code\": \"48201\", \"contact_email\": \"ctoadmin@karmanos.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Detroit\", \"org_email\": \"ctoadmin@karmanos.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-527-6266\", \"org_name\": \"Wayne State University/Karmanos Cancer Institute\", \"org_coordinates\": {\"lon\": -83.0598, \"lat\": 42.3465}}, {\"org_state_or_province\": \"MI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"313-576-9790\", \"recruitment_status_date\": \"2020-11-05\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"31995 Northwestern Highway\", \"org_tty\": null, \"org_family\": \"The Barbara Ann Karmanos Cancer Institute\", \"org_postal_code\": \"48334\", \"contact_email\": \"ctoadmin@karmanos.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Farmington Hills\", \"org_email\": \"ctoadmin@karmanos.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"313-576-9363\", \"org_name\": \"Weisberg Cancer Treatment Center\", \"org_coordinates\": {\"lon\": -83.3489, \"lat\": 42.5067}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-600-3606\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"660 South Euclid Avenue\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63110\", \"contact_email\": \"info@siteman.wustl.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Louis\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Washington University School of Medicine\", \"org_coordinates\": {\"lon\": -90.267, \"lat\": 38.6267}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-600-3606\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"11125 Dunn Road\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63136\", \"contact_email\": \"info@siteman.wustl.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Louis\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-747-9355\", \"org_name\": \"Siteman Cancer Center at Christian Hospital\", \"org_coordinates\": {\"lon\": -90.2608, \"lat\": 38.7423}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-600-3606\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"Ten Barnes West Drive\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63141\", \"contact_email\": \"info@siteman.wustl.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Creve Coeur\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Siteman Cancer Center at West County Hospital\", \"org_coordinates\": {\"lon\": -90.4582, \"lat\": 38.6572}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2021-05-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4881 North East Goodview Circle\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"64064\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Lee's Summit\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University of Kansas Cancer Center - Lee's Summit\", \"org_coordinates\": {\"lon\": -94.3634, \"lat\": 38.9847}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2021-05-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"8700 Green Hills Road\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"64154\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Kansas City\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"816-746-4570\", \"org_name\": \"University of Kansas Cancer Center - North\", \"org_coordinates\": {\"lon\": -94.631, \"lat\": 39.2774}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-600-3606\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"150 Entrance Way\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63376\", \"contact_email\": \"info@siteman.wustl.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Peters\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"636-916-9920\", \"org_name\": \"Siteman Cancer Center at Saint Peters Hospital\", \"org_coordinates\": {\"lon\": -90.6176, \"lat\": 38.8003}}, {\"org_state_or_province\": \"NC\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"888-275-3853\", \"recruitment_status_date\": \"2020-06-17\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}, {\"org_state_or_province\": \"NE\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"402-559-6941\", \"recruitment_status_date\": \"2020-10-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"987680 Nebraska Medical Center\", \"org_tty\": null, \"org_family\": \"Fred & Pamela Buffett Cancer Center\", \"org_postal_code\": \"68198\", \"contact_email\": \"unmcrsa@unmc.edu\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Omaha\", \"org_email\": \"unmcrsa@unmc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"402-559-3853\", \"org_name\": \"University of Nebraska Medical Center\", \"org_coordinates\": {\"lon\": -95.9773, \"lat\": 41.2551}}, {\"org_state_or_province\": \"NJ\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"732-235-7356\", \"recruitment_status_date\": \"2020-06-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"195 Little Albany Street\", \"org_tty\": null, \"org_family\": \"Rutgers Cancer Institute of New Jersey\", \"org_postal_code\": \"08903\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Brunswick\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"732-235-8675\", \"org_name\": \"Rutgers Cancer Institute of New Jersey\", \"org_coordinates\": {\"lon\": -74.447, \"lat\": 40.5102}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-767-9355\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"Elm and Carlton Streets\", \"org_tty\": null, \"org_family\": \"Roswell Park Cancer Institute\", \"org_postal_code\": \"14263\", \"contact_email\": \"askroswell@roswellpark.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Buffalo\", \"org_email\": \"askroswell@roswellpark.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-275-7724\", \"org_name\": \"Roswell Park Cancer Institute\", \"org_coordinates\": {\"lon\": -78.8765, \"lat\": 42.8868}}, {\"org_state_or_province\": \"OH\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-293-5066\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"410 West Tenth Avenue\", \"org_tty\": null, \"org_family\": \"Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute\", \"org_postal_code\": \"43210\", \"contact_email\": \"Jamesline@osumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Columbus\", \"org_email\": \"Jamesline@osumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"866-627-7616\", \"org_name\": \"Ohio State University Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -83.0218, \"lat\": 40.0051}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"412-647-8073\", \"recruitment_status_date\": \"2020-12-10\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5150 Centre Avenue\", \"org_tty\": null, \"org_family\": \"University of Pittsburgh Cancer Institute\", \"org_postal_code\": \"15232\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Pittsburgh\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"412-647-8073\", \"org_name\": \"University of Pittsburgh Cancer Institute (UPCI)\", \"org_coordinates\": {\"lon\": -79.9323, \"lat\": 40.4529}}, {\"org_state_or_province\": \"TN\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-811-8480\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2200 Pierce Avenue\", \"org_tty\": null, \"org_family\": \"Vanderbilt-Ingram Cancer Center\", \"org_postal_code\": \"37232\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Nashville\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-936-8422\", \"org_name\": \"Vanderbilt University/Ingram Cancer Center\", \"org_coordinates\": {\"lon\": -86.8096, \"lat\": 36.1437}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"214-590-5582\", \"recruitment_status_date\": \"2020-06-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5201 Harry Hines Boulevard\", \"org_tty\": null, \"org_family\": \"Harold C. Simmons Comprehensive Cancer Center\", \"org_postal_code\": \"75235\", \"contact_email\": \"canceranswerline@UTSouthwestern.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Dallas\", \"org_email\": \"canceranswerline@UTSouthwestern.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"214-590-5582\", \"org_name\": \"Parkland Memorial Hospital\", \"org_coordinates\": {\"lon\": -96.8477, \"lat\": 32.8302}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"214-648-7097\", \"recruitment_status_date\": \"2020-06-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5323 Harry Hines Boulevard\", \"org_tty\": null, \"org_family\": \"Harold C. Simmons Comprehensive Cancer Center\", \"org_postal_code\": \"75390\", \"contact_email\": \"canceranswerline@UTSouthwestern.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Dallas\", \"org_email\": \"canceranswerline@UTSouthwestern.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"214-648-7097\", \"org_name\": \"UT Southwestern/Simmons Cancer Center-Dallas\", \"org_coordinates\": {\"lon\": -96.7016, \"lat\": 32.8432}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"877-632-6789\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1515 Holcombe Boulevard\", \"org_tty\": null, \"org_family\": \"MD Anderson Cancer Center\", \"org_postal_code\": \"77030\", \"contact_email\": \"askmdanderson@mdanderson.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Houston\", \"org_email\": \"askmdanderson@mdanderson.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-632-6789\", \"org_name\": \"M D Anderson Cancer Center\", \"org_coordinates\": {\"lon\": -95.4026, \"lat\": 29.7059}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"214-648-7097\", \"recruitment_status_date\": \"2020-06-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"400 West Magnolia Avenue\", \"org_tty\": null, \"org_family\": \"Harold C. Simmons Comprehensive Cancer Center\", \"org_postal_code\": \"76104\", \"contact_email\": \"canceranswerline@UTSouthwestern.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Fort Worth\", \"org_email\": \"canceranswerline@UTSouthwestern.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"214-645-4673\", \"org_name\": \"UT Southwestern/Simmons Cancer Center-Fort Worth\", \"org_coordinates\": {\"lon\": -97.3172, \"lat\": 32.7282}}, {\"org_state_or_province\": \"VA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": null, \"recruitment_status_date\": \"2021-02-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"401 College Street\", \"org_tty\": null, \"org_family\": \"Massey Cancer Center\", \"org_postal_code\": \"23298\", \"contact_email\": \"CTOclinops@vcu.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Richmond\", \"org_email\": \"klcampbell@vcu.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"804-628-1939\", \"org_name\": \"Virginia Commonwealth University/Massey Cancer Center\", \"org_coordinates\": {\"lon\": -77.4296, \"lat\": 37.5427}}, {\"org_state_or_province\": \"WI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-622-8922\", \"recruitment_status_date\": \"2020-06-11\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"600 Highland Avenue\", \"org_tty\": null, \"org_family\": \"University of Wisconsin Carbone Cancer Center\", \"org_postal_code\": \"53792\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Madison\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"608-262-5223\", \"org_name\": \"University of Wisconsin Hospital and Clinics\", \"org_coordinates\": {\"lon\": -89.4329, \"lat\": 43.0769}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"Six Devine Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06473\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"North Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Yale-New Haven Hospital North Haven Medical Center\", \"org_coordinates\": {\"lon\": -72.8559, \"lat\": 41.3808}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-600-3606\", \"recruitment_status_date\": \"2020-06-11\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5225 Midamerica Plaza\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63129\", \"contact_email\": \"info@siteman.wustl.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Louis\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-600-3606\", \"org_name\": \"Siteman Cancer Center-South County\", \"org_coordinates\": {\"lon\": -90.3236, \"lat\": 38.4581}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2020-04-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"230 Waterford Parkway South\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06385\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Waterford\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"860-444-3744\", \"org_name\": \"Smilow Cancer Hospital Care Center - Waterford\", \"org_coordinates\": {\"lon\": -72.1558, \"lat\": 41.3583}}, {\"org_state_or_province\": \"KS\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2021-05-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"10720 Nall Avenue\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"66211\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Overland Park\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University of Kansas Hospital-Indian Creek Campus\", \"org_coordinates\": {\"lon\": -94.6366, \"lat\": 38.9266}}, {\"org_state_or_province\": \"KS\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"913-588-3671\", \"recruitment_status_date\": \"2020-09-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4350 Shawnee Mission Parkway\", \"org_tty\": null, \"org_family\": \"University of Kansas Cancer Center\", \"org_postal_code\": \"66205\", \"contact_email\": \"KUCC_Navigation@kumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Fairway\", \"org_email\": \"KUCC_Navigation@kumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"913-945-7552\", \"org_name\": \"University of Kansas Clinical Research Center\", \"org_coordinates\": {\"lon\": -94.6315, \"lat\": 39.0312}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To evaluate overall response rate (ORR) with nivolumab in patients with previously treated metastatic squamous cell carcinoma (SCCA) of the anal canal. (Part A)\\r\\nII. To determine an improvement in progression-free survival (PFS) when nivolumab is combined with ipilimumab versus (vs.) nivolumab alone in patients with previously treated metastatic SCCA (Part B).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To evaluate progression-free survival (PFS) of nivolumab in patients with previously treated metastatic SCCA of the anal canal. (Part A)\\r\\nII. To evaluate overall survival (OS) in patients with previously treated metastatic SCCA of the anal canal treated with nivolumab. (Part A)\\r\\nIII. To evaluate the grade 3 and 4 toxicity rate in patients with previously treated metastatic SCCA of the anal canal when treated with nivolumab. (Part A)\\r\\nIV. To evaluate the overall response rate (ORR) of nivolumab plus or minus ipilimumab in patients with previously treated metastatic SCCA of the anal canal. (Part B)\\r\\nV. To evaluate overall survival (OS) in patients with previously treated metastatic SCCA of the anal canal treated with nivolumab plus or minus ipilimumab. (Part B)\\r\\nVI. To evaluate the grade 3 and 4 toxicity rate in patients with previously treated metastatic SCCA of the anal canal when treated with nivolumab plus or minus ipilimumab. (Part B)\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To evaluate ORR, PFS, and OS based on expression of programmed cell death 1 ligand 1 (PD-L1), programmed cell death 1 (PD-1), peritumoral cluster of differentiation (CD)8+ tumor infiltrating lymphocytes (TILs), peritumoral CD4+ TILs, and regulatory T cells as analyzed from tumor biopsies in previously treated patients with metastatic SCCA of the anal canal when treated with nivolumab. (Part A)\\r\\nII. To evaluate radiographic responses according to relative changes in proportions of anti-human papillomavirus (HPV) specific CD8+ and CD4+ TILs and regulatory T cells in patients with previously treated metastatic SCCA of the anal canal following treatment with nivolumab, analyzed from serial peripheral blood samples. (Part A)\\r\\nIII. To evaluate ORR, PFS, and OS based on expression of PD-L1, PD-1, peritumoral CD8+ tumor infiltrating lymphocytes (TILs), peritumoral CD4+ TILs, and regulatory T cells as analyzed from tumor biopsies in previously treated patients with metastatic SCCA of the anal canal when treated with nivolumab plus or minus ipilimumab. (Part B)\\r\\nIV. To evaluate radiographic responses according to relative changes in proportions of anti-HPV specific CD8+ and CD4+ TILs and regulatory T cells in patients with previously treated metastatic SCCA of the anal canal following treatment with nivolumab plus or minus ipilimumab. (Part B)\\r\\n\\r\\nOUTLINE:\\r\\nPART A: Patients receive nivolumab intravenously (IV) over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nPART B: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM I: Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nARM II: Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 100 days and then every 3 months for 2 years.\", \"official_title\": \"A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to time of treatment discontinuation\", \"name\": \"Expression of biomarkers using immunohistochemistry and blood samples (Part A)\", \"description\": \"Descriptive statistics including plots, mean, median and standard deviations will be used to summarize data. For continuous outcomes, t-test and analysis of variance will be used to compare outcome measures across patient characteristics. Pair-wise comparisons will be performed using pre- and post-therapy samples from each patient. The chi-square test or Fisher\\u2019s exact test will be used to test the association between two categorical variables. Both univariate and multivariate logistic regressions will be performed to model prognostic factors.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Incidence of grade 3/4/5 adverse events (Part B)\", \"description\": \"Will be assessed by CTCAE version 5.0.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 100 days post-treatment\", \"name\": \"Number of participants with toxicities (Part A)\", \"description\": \"Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The most frequent of adverse events measured relative to the total number of patients treated, and the toxicities tabulated by grade according to CTCAE.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Overall response rate: number of participants with response (Part A)\", \"description\": \"Responses assessed using computed tomography (CT) scans or magnetic resonance imaging according to standard Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria in order to assess disease progression. Complete Response (CR): Disappearance all target lesions; any pathological lymph nodes reduction in short axis to < 10 mm (< 1 cm). Partial Response (PR): > 30% decrease in sum diameters of target lesions. Progressive Disease (PD): > 20% increase in sum diameters lesions. (Note: appearance of one or > new lesions considered progressions). Stable Disease (SD): Neither shrinkage qualify for PR nor increase for PD.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Overall response rates (Part B)\", \"description\": \"Responses assessed using CT scans or magnetic resonance imaging according to standard RECIST 1.1 criteria in order to assess disease progression. CR: Disappearance all target lesions; any pathological lymph nodes reduction in short axis to < 10 mm (< 1 cm). PR: > 30% decrease in sum diameters of target lesions. PD: > 20% increase in sum diameters lesions. (Note: appearance of one or > new lesions considered progressions). SD: Neither shrinkage qualify for PR nor increase for PD.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From initiation of treatment with nivolumab until death, assessed up to 2 years\", \"name\": \"Overall survival (Part A and B)\", \"description\": \"Time measured from initiation of treatment with nivolumab till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 95% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From initiation of treatment with nivolumab until the time of disease progression, assessed up to 2 years\", \"name\": \"Progression-free Survival (Part A)\", \"description\": \"From initiation of treatment with nivolumab until the time of disease progression, time measured in months. Kaplan-Meier analysis performed to estimate the median progression-free survival with a 90% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time period from the date of randomization to the date of PD or death whichever occurred first, assessed up to 2 years\", \"name\": \"Progression-free survival (PFS) (Part B)\", \"description\": null, \"type_code\": \"PRIMARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 3, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT02314169\", \"biomarkers\": null, \"classification_code\": \"Efficacy\", \"current_trial_status_date\": \"2020-04-28\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Anal Cancer\", \"Metastatic Anal Carcinoma\", \"Metastatic Cancer from the Anus\", \"Metastatic Carcinoma from the Anus\", \"Secondary Cancer from the Anus\", \"Secondary Carcinoma from the Anus\"], \"nci_thesaurus_concept_id\": \"C5612\", \"name\": \"Metastatic Anal Canal Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C7489\", \"C170514\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Anal Canal Cancer AJCC v6\", \"Stage IV Anal Canal Cancer AJCC v6 and v7\", \"Stage IV Anal Canal Cancer AJCC v7\", \"Stage IV Anal Canal Carcinoma AJCC v6 and v7\", \"Stage IV Anal Carcinoma AJCC v6 and v7\", \"stage IV anal cancer\"], \"nci_thesaurus_concept_id\": \"C6873\", \"name\": \"Stage IV Anal Canal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C133787\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7469\", \"name\": \"Anal Canal Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C7489\", \"C9161\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26695\", \"name\": \"Anal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26695\", \"name\": \"Anal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170514\", \"name\": \"Metastatic Anal Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C9291\", \"C133839\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Anal Cancer (all types)\", \"Anal Carcinoma\", \"Anal cancer\", \"Anal cancer, NOS\", \"Cancer of Anus\", \"Cancer of the Anus\", \"Carcinoma of Anus\", \"Carcinoma of the Anus\", \"anal cancer\"], \"nci_thesaurus_concept_id\": \"C9291\", \"name\": \"Anal Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C7379\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Cancer (all types)\", \"Anal Carcinoma\", \"Anal cancer\", \"Anal cancer, NOS\", \"Cancer of Anus\", \"Cancer of the Anus\", \"Carcinoma of Anus\", \"Carcinoma of the Anus\", \"anal cancer\"], \"nci_thesaurus_concept_id\": \"C9291\", \"name\": \"Anal Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C7379\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Anal Squamous Cell Carcinoma\", \"Epidermoid Anal Carcinoma\", \"Epidermoid Carcinoma of Anus\", \"Epidermoid Carcinoma of the Anus\", \"Squamous Cell Anal Carcinoma\", \"Squamous Cell Carcinoma of Anus\", \"Squamous Cell Carcinoma of the Anus\", \"Squamous cell carcinoma - anus\", \"Squamous cell carcinoma of the anus\"], \"nci_thesaurus_concept_id\": \"C9161\", \"name\": \"Anal Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C9291\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Canal Carcinoma\", \"Anal Canal and Perianal Gland Cancer\", \"Anal Canal and Perianal Gland Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7489\", \"name\": \"Anal Canal Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C9291\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Anal Canal Carcinoma\", \"Anal Canal and Perianal Gland Cancer\", \"Anal Canal and Perianal Gland Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7489\", \"name\": \"Anal Canal Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C9291\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Canal Carcinoma by AJCC v6 and v7 Stage\", \"Anal Carcinoma by AJCC v6 and v7 Stage\"], \"nci_thesaurus_concept_id\": \"C133787\", \"name\": \"Anal Canal Cancer by AJCC v6 and v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C7489\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Anal Tumor\", \"Malignant Neoplasm of Anus\", \"Malignant Neoplasm of the Anus\", \"Malignant Tumor of Anus\", \"Malignant Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C7379\", \"name\": \"Malignant Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2877\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Anal Tumor\", \"Malignant Neoplasm of Anus\", \"Malignant Neoplasm of the Anus\", \"Malignant Tumor of Anus\", \"Malignant Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C7379\", \"name\": \"Malignant Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2877\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162255\", \"name\": \"Metastatic Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Anal Neoplasms, Benign and Malignant\", \"Anal Tumor\", \"Anal Tumors\", \"Anus Neoplasm\", \"Neoplasm of Anus\", \"Neoplasm of the Anus\", \"Tumor of Anus\", \"Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C2877\", \"name\": \"Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26695\", \"C3052\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Neoplasms, Benign and Malignant\", \"Anal Tumor\", \"Anal Tumors\", \"Anus Neoplasm\", \"Neoplasm of Anus\", \"Neoplasm of the Anus\", \"Tumor of Anus\", \"Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C2877\", \"name\": \"Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26695\", \"C3052\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Digestive System Carcinoma\", \"Metastatic Gastrointestinal Carcinoma\", \"Metastatic Gastrointestinal System Cancer\", \"Metastatic Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C133839\", \"name\": \"Metastatic Digestive System Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C96963\", \"C3482\", \"C162255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"9673\", \"active_sites_count\": 46, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"nci_thesaurus_concept_id\": \"C68814\", \"name\": \"Nivolumab\", \"description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}], \"name\": \"Part A (nivolumab)\", \"description\": \"Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Yervoy\", \"Ipilimumab\"], \"nci_thesaurus_concept_id\": \"C2654\", \"name\": \"Ipilimumab\", \"description\": \"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128036\", \"C129822\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"intervention_name\": \"Nivolumab\", \"category\": \"agent\", \"intervention_code\": \"C68814\", \"intervention_description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-CTLA4 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128036\", \"name\": \"Anti-CTLA-4 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\", \"C20401\", \"C163758\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immune Checkpoint Modulator\", \"category\": \"agent category\", \"intervention_code\": \"C141144\", \"intervention_description\": \"\", \"parents\": [\"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"intervention_name\": \"Monoclonal Antibody Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C20401\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"intervention_name\": \"Targeted Therapy Agent\", \"category\": \"agent category\", \"intervention_code\": \"C163758\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"intervention_name\": \"Antineoplastic Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C129822\", \"intervention_description\": \"\", \"parents\": [\"C129821\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"intervention_name\": \"Antineoplastic Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C129821\", \"intervention_description\": \"\", \"parents\": [\"C274\", \"C307\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"intervention_name\": \"Anti-PD1 Monoclonal Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C128037\", \"intervention_description\": \"\", \"parents\": [\"C20401\", \"C124946\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"intervention_name\": \"PD1 Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C124946\", \"intervention_description\": \"\", \"parents\": [\"C143250\", \"C163758\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"intervention_name\": \"Immune Checkpoint Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C143250\", \"intervention_description\": \"\", \"parents\": [\"C141144\"]}], \"name\": \"Part B Arm II (nivolumab, ipilimumab)\", \"description\": \"Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"intervention_name\": \"Nivolumab\", \"category\": \"agent\", \"intervention_code\": \"C68814\", \"intervention_description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C128037\", \"C129822\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"intervention_name\": \"Anti-PD1 Monoclonal Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C128037\", \"intervention_description\": \"\", \"parents\": [\"C20401\", \"C124946\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"intervention_name\": \"Monoclonal Antibody Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C20401\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"intervention_name\": \"PD1 Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C124946\", \"intervention_description\": \"\", \"parents\": [\"C143250\", \"C163758\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"intervention_name\": \"Immune Checkpoint Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C143250\", \"intervention_description\": \"\", \"parents\": [\"C141144\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immune Checkpoint Modulator\", \"category\": \"agent category\", \"intervention_code\": \"C141144\", \"intervention_description\": \"\", \"parents\": [\"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"intervention_name\": \"Targeted Therapy Agent\", \"category\": \"agent category\", \"intervention_code\": \"C163758\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"intervention_name\": \"Antineoplastic Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C129822\", \"intervention_description\": \"\", \"parents\": [\"C129821\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"intervention_name\": \"Antineoplastic Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C129821\", \"intervention_description\": \"\", \"parents\": [\"C274\", \"C307\"]}], \"name\": \"Part B Arm I (nivolumab)\", \"description\": \"Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2014-02420\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body\\u2019s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.\", \"brief_title\": \"Nivolumab with or without Ipilimumab in Treating Patients with Refractory Metastatic Anal Canal Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 137, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2015-05-01\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": \"9673\", \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": \"OPEN\", \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Anus\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Cathy Eng\", \"study_source\": \"National\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"AMC-095\"}, {\"name\": \"Study Protocol Other Identifier\", \"value\": \"PAMC-095_R03PAPP01\"}], \"amendment_date\": \"2021-03-11T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"AIDS Malignancy Consortium\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Participants must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; participants with uncontrolled Kaposi sarcoma are permitted (KS must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable KS despite HAART for greater than or equal to 3 months)\\r\\n* For participants in the 24 participant solid tumor cohort, only those histologies not known to respond to single agent nivolumab (such as pancreas, prostate, and microsatellite stable [MSS] colorectal cancer) will be excluded\\r\\n* For participants in the relapsed refractory HIV-cHL expansion cohort, participants must have histologically confirmed, relapsed/refractory (defined as relapsed/refractory to one or greater lines of therapy) HIV-associated classical Hodgkin lymphoma\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant\\u2019s relevant medical history and/or current management of HIV infection\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; scans must have been performed within 4 weeks prior to registration; Note: for participants with Kaposi sarcoma, the following apply: at least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Prior therapy for metastatic disease permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; radiotherapy must be completed at least 4 weeks prior to registration\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Leukocytes >= 2,000/mm^3 (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Absolute neutrophil count >= 1,000/mm^3 (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Platelets >= 75,000/mm^3 (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert\\u2019s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: AST (serum glutamic oxaloacetic transaminase [SGOT])/ALT (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Creatinine < 1.5 UNL or creatinine clearance (CrCl) > 50 ml/min (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Hemoglobin >= 9 g/dL (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum albumin >= 2.8 g/dL (within 2 weeks prior to enrollment)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Leukocyte count: no lower limit (within 2 weeks prior to enrollment) (participants may receive granulocyte colony stimulating factor [GCSF] and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Absolute neutrophil count: >= 1,000/mm^3, unless decreased due to bone marrow involvement with lymphoma (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Platelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphoma (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Hemoglobin: >= 9 g/dL unless bone marrow involvement secondary to Hodgkin lymphoma is present (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin: =< 1.5 x institutional upper limit of normal (ULN), or =< 3 x ULN for participants with Gilbert\\u2019s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without AST or ALT elevation, and must have a total bilirubin less than 3.0 mg/dL) (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 21, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: AST (SGOT)/ALT (SGPT): =< 3 x ULN (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 22, \"description\": \"PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Creatinine: < 1.5 x upper normal limit (UNL) or CrCl > 50ml/min (within 2 weeks prior to enrollment) (participants may receive GCSF and transfusions to meet these parameters)\"}, {\"inclusion_indicator\": true, \"display_order\": 23, \"description\": \"HIV viral load should be well suppressed, defined as below the limit of detection of the local assay or below 75 copies/mL by Food and Drug Administration (FDA)-approved assays, within 4 weeks prior to registration\"}, {\"inclusion_indicator\": true, \"display_order\": 24, \"description\": \"CD4 counts: \\r\\n* For Stratum 1: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any United States (U.S.) laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent\\r\\n* For Stratum 2: CD4 cell count between 100-200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent\\r\\n* Expansion Cohort: CD4 cell count for this cohort will be specified once Stratum 1 and Stratum 2 have completed enrollment\\r\\n* Solid Tumor Expansion Cohort: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent\\r\\n* cHL Cohort: CD4 cell count of at least 100 cells/mm^3\"}, {\"inclusion_indicator\": true, \"display_order\": 25, \"description\": \"Participants must be purified protein derivative (PPD) negative; alternatively, the QuantiFERON-tuberculosis (TB) Gold In-Tube (QFT-GIT) assay can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 12 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 26, \"description\": \"The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 72 hours prior enrollment and the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception; WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\"}, {\"inclusion_indicator\": true, \"display_order\": 27, \"description\": \"Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 28, \"description\": \"Participants who have hepatitis C (both reactive anti-hepatitis C virus [HCV] antibody and detectable HCV ribonucleic acid [RNA]) and hepatitis B (hepatitis B surface antigen [HBsAg] positive and anti-hepatitis B core [HBc]-total positive), may be enrolled, provided total bilirubin is =< 1.5 x institutional ULN, and AST (SGOT) and ALT (SGPT) must be =< 3 X institutional upper limit of normal, and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) < 100 IU/mL (if hepatitis B positive) within 2 weeks prior to enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 29, \"description\": \"Ability to understand and to sign a written informed consent document\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Participants who have received any other investigational agents within the 4 weeks prior to enrollment; concurrent radiation therapy is not permitted, except palliative (limited-field) radiation therapy, if all of the following criteria are met:\\r\\n* Repeat imaging demonstrates no new sites of bone metastases\\r\\n* The lesion being considered for palliative radiation is not a target lesion\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Participants with known brain metastases or leptomeningeal metastases must be excluded unless they qualify for enrollment as described below because of poor prognosis and concerns regarding progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; participants with brain metastases are permitted if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks or more after treatment is complete and within 4 weeks prior to the first dose of nivolumab administration\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Participants should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 2 weeks of study drug administration; these drugs may interfere with the activity of ipilimumab and nivolumab if administered at the time of the first ipilimumab dose; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >= 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted; use of anabolic steroids is permitted\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Participants with clinical or radiographic evidence of pancreatitis are excluded\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Participants should be excluded if they have had prior treatment with an anti-PD-1, anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death ligand 2 (PD-L2), anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways; prior immune modulating therapy including vaccines may be eligible; prior immune events must be evaluated and the risk for new events which may represent continued sub clinical disease or a new process at previously damaged site or immune potentiation (e.g. ipilimumab followed by IL2 causing bowel perforation, ipilimumab followed by indoleamine 2,3-dioxygenase [IDO] inhibitor resulting in clinical hypophysitis); please keep in mind that inflammatory events may occur weeks to months following the last dose of ipilimumab and possibly nivolumab; assessment of potential effects of prior therapy should include:\\r\\n* Immune status\\r\\n* Organ damage\\r\\n* Risk of autoimmunity\\r\\n* Immunopotentiation\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except =< grade 2 alopecia, neuropathy, and other non-clinically significant adverse events (AEs)\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"The participant has a primary brain tumor\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"Participant has >= grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative)\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"Opportunistic infection within the last 3 months\"}, {\"inclusion_indicator\": false, \"display_order\": 41, \"description\": \"Participants with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn\\u2019s, ulcerative colitis, hepatitis; and participants with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; participants with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; participants with rheumatoid arthritis and other arthropathies, Sjogren\\u2019s syndrome and psoriasis controlled with topical medication and participants with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible; participants are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)\"}, {\"inclusion_indicator\": false, \"display_order\": 42, \"description\": \"Participants who have had evidence of Clostridium (C.) difficile infection, active or acute diverticulitis, intra-abdominal abscess, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis, which are known risk factors for bowel perforation, should be evaluated for the potential need for additional treatment before coming on study\"}, {\"inclusion_indicator\": false, \"display_order\": 43, \"description\": \"cHL COHORT ONLY: history of allogeneic transplant\"}, {\"inclusion_indicator\": true, \"display_order\": 44, \"description\": \"Criteria for Solid Tumor Expansion and Lymphoma Cohorts:\\r\\n* Inclusion and exclusion criteria for this cohort are the same as above, with the following rule for CD4 count based on tolerability in Phase I; if, participants with lymphocyte T CD4 count between 100-200/mm^3 (Stratum 2) are shown to tolerate treatment in the Phase I dose de-escalation portion at the same dose level as those with CD4 counts > 200/mm^3 (Stratum 1), participants in the expansion cohort with CD4 counts >= 100/mm^3 are permitted; otherwise, the expansion is open to all solid tumor patients except those whose tumors are known not to respond to nivolumab (pancreas, prostate and MSS colon cancer); for the relapsed refractory HIV-cHL cohort, participants with CD4 count >= 100/mm^3 are permitted\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"New South Wales\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"(718) 904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"University\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"2052\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Sydney\", \"org_email\": null, \"org_country\": \"Australia\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University of New South Wales\"}, {\"org_state_or_province\": \"New South Wales\", \"contact_name\": \"Mark N. Polizzotto\", \"contact_phone\": \" 61-2-9385-0900\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"390 Victoria Street\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"2010\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Darlinghurst\", \"org_email\": null, \"org_country\": \"Australia\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Saint Vincent's Hospital\"}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": \"Pharmacy Department Lower Level 172\", \"org_va\": false, \"org_address_line_1\": \"1901 West Harrison Street\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"60612\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Chicago\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"312-864-6000\", \"org_name\": \"John H Stroger Jr Hospital of Cook County\", \"org_coordinates\": {\"lon\": -87.6877, \"lat\": 41.8804}}, {\"org_state_or_province\": \"WA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1100 Ninth Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"98101\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Seattle\", \"org_email\": \"vmmc.cancer_clinical_research@VirginiaMason.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Virginia Mason Medical Center\", \"org_coordinates\": {\"lon\": -122.3343, \"lat\": 47.6115}}, {\"org_state_or_province\": \"WA\", \"contact_name\": \"David M. Aboulafia\", \"contact_phone\": \"206-223-6193\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1201 Ninth Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"98101-2795\", \"contact_email\": \"hemdma@vmmc.org\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Seattle\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Benaroya Research Institute at Virginia Mason\"}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Mark Andrew Dickson\", \"contact_phone\": \"646-888-4164\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"500 Westchester Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"10604\", \"contact_email\": \"dicksonm@mskcc.org\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"West Harrison\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"914-367-7000\", \"org_name\": \"Memorial Sloan Kettering Westchester\", \"org_coordinates\": {\"lon\": -73.7433, \"lat\": 41.0555}}, {\"org_state_or_province\": \"NJ\", \"contact_name\": \"Mark Andrew Dickson\", \"contact_phone\": \"646-888-4164\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"480 Red Hill Road\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"07748\", \"contact_email\": \"dicksonm@mskcc.org\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Middletown\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"(212)-639-7202\", \"org_name\": \"Memorial Sloan Kettering Monmouth\", \"org_coordinates\": {\"lon\": -74.1116, \"lat\": 40.3908}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"William Wachsman\", \"contact_phone\": \"858-552-8585ext2628\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"200 West Arbor Drive\", \"org_tty\": null, \"org_family\": \"Moores Comprehensive Cancer Center\", \"org_postal_code\": \"92103\", \"contact_email\": \"wwachsman@ucsd.edu\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"San Diego\", \"org_email\": \"cancercto@ucsd.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"858-822-5354\", \"org_name\": \"University of California San Diego\", \"org_coordinates\": {\"lon\": -117.1677, \"lat\": 32.7476}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1001 Potrero Avenue\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94110\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"Zuckerberg San Francisco General Hospital\", \"org_coordinates\": {\"lon\": -122.4153, \"lat\": 37.7496}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Scott D. Christensen\", \"contact_phone\": \"916-734-5967\", \"recruitment_status_date\": \"2020-07-29\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4501 X Street\", \"org_tty\": null, \"org_family\": \"UC Davis Comprehensive Cancer Center\", \"org_postal_code\": \"95817\", \"contact_email\": \"schristensen@ucdavis.edu\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Sacramento\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"916-734-3089\", \"org_name\": \"University of California Davis Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -121.4572, \"lat\": 38.5503}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"3855 Health Sciences Drive\", \"org_tty\": null, \"org_family\": \"Moores Comprehensive Cancer Center\", \"org_postal_code\": \"92093\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"La Jolla\", \"org_email\": \"cancercto@ucsd.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"858-822-5354\\r858-657-7000\", \"org_name\": \"UC San Diego Moores Cancer Center\", \"org_coordinates\": {\"lon\": -117.2575, \"lat\": 32.8339}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Chia-Ching (Jackie) Wang\", \"contact_phone\": \"415-443-5080\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"505 Parnassus Avenue\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"Chia-Ching.Wang@ucsf.edu\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Parnassus\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": \"Suite 100\", \"org_va\": false, \"org_address_line_1\": \"1399 South Roxbury Drive\", \"org_tty\": null, \"org_family\": \"Jonsson Comprehensive Cancer Center\", \"org_postal_code\": \"90035\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Los Angeles\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"UCLA Center for Clinical AIDS Research and Education\", \"org_coordinates\": {\"lon\": -118.3865, \"lat\": 34.0513}}, {\"org_state_or_province\": \"FL\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1475 Northwest 12th Avenue\", \"org_tty\": null, \"org_family\": \"Sylvester Comprehensive Cancer Center\", \"org_postal_code\": \"33136\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Miami\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"305-243-2647\", \"org_name\": \"University of Miami Miller School of Medicine-Sylvester Cancer Center\", \"org_coordinates\": {\"lon\": -80.2039, \"lat\": 25.7869}}, {\"org_state_or_province\": \"FL\", \"contact_name\": \"Michael Shafique\", \"contact_phone\": \"813-745-3959\", \"recruitment_status_date\": \"2020-12-23\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"12902 Magnolia Drive\", \"org_tty\": null, \"org_family\": \"Moffitt Cancer Center\", \"org_postal_code\": \"33612\", \"contact_email\": \"michael.shafique@moffitt.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Tampa\", \"org_email\": \"ClinicalTrials@moffitt.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-679-0775\", \"org_name\": \"Moffitt Cancer Center\", \"org_coordinates\": {\"lon\": -82.45, \"lat\": 28.0508}}, {\"org_state_or_province\": \"MD\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"600 North Wolfe Street\", \"org_tty\": null, \"org_family\": \"Sidney Kimmel Comprehensive Cancer Center\", \"org_postal_code\": \"21287\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Baltimore\", \"org_email\": \"jhcccro@jhmi.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"410-955-8804\", \"org_name\": \"Johns Hopkins University/Sidney Kimmel Cancer Center\", \"org_coordinates\": {\"lon\": -76.5621, \"lat\": 39.3021}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"660 South Euclid Avenue\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63110\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Louis\", \"org_email\": \"info@siteman.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Washington University School of Medicine\", \"org_coordinates\": {\"lon\": -90.267, \"lat\": 38.6267}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Lee Ratner\", \"contact_phone\": \"314-362-8836\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"One Barnes Jewish Hospital Plaza\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63110\", \"contact_email\": \"lratner@dom.wustl.edu\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Saint Louis\", \"org_email\": \"info@ccadmin.wustl.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Barnes-Jewish Hospital\", \"org_coordinates\": {\"lon\": -90.267, \"lat\": 38.6267}}, {\"org_state_or_province\": \"MO\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4921 Parkview Place\", \"org_tty\": null, \"org_family\": \"Alvin J. Siteman Cancer Center\", \"org_postal_code\": \"63110\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Saint Louis\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"314-747-7236\", \"org_name\": \"Siteman Cancer Center at Washington University\", \"org_coordinates\": {\"lon\": -90.267, \"lat\": 38.6267}}, {\"org_state_or_province\": \"NC\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": \"Lineberger Comprehensive Cancer Center Third Floor Administrative Tower CB 7295\", \"org_va\": false, \"org_address_line_1\": \"450 West Drive\", \"org_tty\": null, \"org_family\": \"UNC Lineberger Comprehensive Cancer Center\", \"org_postal_code\": \"27599\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Chapel Hill\", \"org_email\": \"cancerclinicaltrials@med.unc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"UNC Lineberger Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -79.0561, \"lat\": 35.9134}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1275 York Avenue\", \"org_tty\": null, \"org_family\": \"Memorial Sloan Kettering Cancer Center\", \"org_postal_code\": \"10065\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New York\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"212-639-2000\", \"org_name\": \"Memorial Sloan Kettering Cancer Center\", \"org_coordinates\": {\"lon\": -73.9624, \"lat\": 40.7656}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1825 Eastchester Road\", \"org_tty\": null, \"org_family\": \"Albert Einstein Cancer Center\", \"org_postal_code\": \"10461\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Bronx\", \"org_email\": \"eskwak@montefiore.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"718-904-2730\", \"org_name\": \"Montefiore Medical Center-Weiler Hospital\", \"org_coordinates\": {\"lon\": -73.8398, \"lat\": 40.8469}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"111 East 210th Street\", \"org_tty\": null, \"org_family\": \"Albert Einstein Cancer Center\", \"org_postal_code\": \"10467\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Bronx\", \"org_email\": \"eskwak@montefiore.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"718-904-2730\", \"org_name\": \"Montefiore Medical Center - Moses Campus\", \"org_coordinates\": {\"lon\": -73.8721, \"lat\": 40.8778}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1695 Eastchester Road\", \"org_tty\": null, \"org_family\": \"Albert Einstein Cancer Center\", \"org_postal_code\": \"10461\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Bronx\", \"org_email\": \"eskwak@montefiore.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"718-904-2730\", \"org_name\": \"Montefiore Medical Center-Einstein Campus\", \"org_coordinates\": {\"lon\": -73.8398, \"lat\": 40.8469}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Mark Andrew Dickson\", \"contact_phone\": \"646-888-4164\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"650 Commack Road\", \"org_tty\": null, \"org_family\": \"Memorial Sloan Kettering Cancer Center\", \"org_postal_code\": \"11725\", \"contact_email\": \"dicksonm@mskcc.org\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Commack\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"631-623-4000\", \"org_name\": \"Memorial Sloan Kettering Commack\", \"org_coordinates\": {\"lon\": -73.2805, \"lat\": 40.8411}}, {\"org_state_or_province\": \"NY\", \"contact_name\": \"Mark Andrew Dickson\", \"contact_phone\": \"646-888-4164\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1101 Hempstead Turnpike\", \"org_tty\": null, \"org_family\": \"Memorial Sloan Kettering Cancer Center\", \"org_postal_code\": \"11553\", \"contact_email\": \"dicksonm@mskcc.org\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Uniondale\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"212-639-7202\", \"org_name\": \"Memorial Sloan Kettering Nassau\", \"org_coordinates\": {\"lon\": -73.591, \"lat\": 40.7016}}, {\"org_state_or_province\": \"OH\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"410 West Tenth Avenue\", \"org_tty\": null, \"org_family\": \"Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute\", \"org_postal_code\": \"43210\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Columbus\", \"org_email\": \"Jamesline@osumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"866-627-7616\", \"org_name\": \"Ohio State University Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -83.0218, \"lat\": 40.0051}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"3400 Civic Center Boulevard\", \"org_tty\": null, \"org_family\": \"Abramson Cancer Center\", \"org_postal_code\": \"19104\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Philadelphia\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-474-9892\", \"org_name\": \"University of Pennsylvania/Abramson Cancer Center\", \"org_coordinates\": {\"lon\": -75.1995, \"lat\": 39.9616}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"3401 North Broad Street\", \"org_tty\": null, \"org_family\": \"Fox Chase Cancer Center\", \"org_postal_code\": \"19140\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"APPROVED\", \"org_city\": \"Philadelphia\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"215-728-2983\", \"org_name\": \"Temple University Hospital\", \"org_coordinates\": {\"lon\": -75.145, \"lat\": 40.0122}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Douglas Francis Beach\", \"contact_phone\": \"215-829-6307\", \"recruitment_status_date\": \"2020-03-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"800 Spruce Street\", \"org_tty\": null, \"org_family\": \"Abramson Cancer Center\", \"org_postal_code\": \"19107\", \"contact_email\": \"Douglas.Beach@uphs.upenn.edu\", \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Philadelphia\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-789-7366\", \"org_name\": \"Pennsylvania Hospital\", \"org_coordinates\": {\"lon\": -75.1581, \"lat\": 39.9516}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Sravanti P Teegavarapu\", \"contact_phone\": \"713-798-3750\", \"recruitment_status_date\": \"2020-07-21\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"One Baylor Plaza\", \"org_tty\": null, \"org_family\": \"Dan L Duncan Comprehensive Cancer Center\", \"org_postal_code\": \"77030\", \"contact_email\": \"teegavar@bcm.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Houston\", \"org_email\": \"burton@bcm.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -95.4026, \"lat\": 29.7059}}, {\"org_state_or_province\": \"WA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"325 Ninth Avenue\", \"org_tty\": null, \"org_family\": \"Fred Hutchinson/University of Washington Cancer Consortium\", \"org_postal_code\": \"98104\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Seattle\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-852-8546\", \"org_name\": \"Harborview Medical Center\", \"org_coordinates\": {\"lon\": -122.326, \"lat\": 47.6024}}, {\"org_state_or_province\": \"WA\", \"contact_name\": \"Lakshmi Rajdev\", \"contact_phone\": \"718-904-2754\", \"recruitment_status_date\": \"2020-07-09\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"825 Eastlake Avenue\", \"org_tty\": null, \"org_family\": \"Fred Hutchinson/University of Washington Cancer Consortium\", \"org_postal_code\": \"98109\", \"contact_email\": \"lrajdev@montefiore.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Seattle\", \"org_email\": \"contactus@seattlecca.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"855-557-0555\\r800-804-8824\", \"org_name\": \"Seattle Cancer Care Alliance\", \"org_coordinates\": {\"lon\": -122.3461, \"lat\": 47.6307}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To demonstrate safety and feasibility of ipilimumab and nivolumab at the standard doses of drug in solid tumor and relapsed refractory HIV-classical Hodgkin lymphoma (cHL) participants with human immunodeficiency virus (HIV) infection given the possibility of increased toxicity based on immune activation, co-morbidity, or interference with highly active antiretroviral therapy (HAART) therapy. (Dose De-escalation and Dose Expansion Cohorts)\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab, on immune function (HIV viral load in plasma using conventional assay, CD4+ and CD8+ cells). (Dose De-escalation Cohort)\\r\\nII. To preliminarily assess objective response rates associated with treatment for commonly represented solid tumors (Kaposi sarcoma, anal cancer, and lung cancer) and relapsed refractory HIV-cHL. (Solid Tumor Dose Expansion and cHL Cohorts)\\r\\nIII. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab, on immune function (HIV viral load in plasma using conventional HIV assay, CD4+, and CD8+ cells). (Solid Tumor Dose Expansion and cHL Cohorts)\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. Understand the immune response to agent in the context of antiretroviral therapy (ART), of altered immune function, and repertoire due to prior HIV infection.\\r\\nIa. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab, on intratumor immune cells by immunohistochemistry (IHC) such as PD1, programmed cell death 1 ligand 1 (PDL-1), and others.\\r\\nIb. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on circulating cytokine markers by multiplex assay, such as: interleukin (IL)-2, IL-4, IL-6, IL-10, IL-8, interferon gamma-induced protein 10 (IP10), chemokine (C-X-C motif) ligand 13 (CXCL13), interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, soluble IL-2 receptor (sIL2R)-alpha, sCD27, soluble TNF receptor (sTNFR)1, and sTNFR2.\\r\\nII. To understand the response of human tumor viruses (human papillomavirus [HPV], Epstein-Barr virus [EBV], Kaposi's sarcoma-associated herpesvirus [KSHV]) to agent.\\r\\nIIa. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on herpesvirus loads (EBV, KSHV, cytomegalovirus [CMV]) in plasma.\\r\\nIIb. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on latent herpesvirus (EBV, KSHV, CMV) in peripheral blood mononuclear cells (PBMC).\\r\\nIIc. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on herpesvirus specific CD8 and CD4 T cells in PBMC.\\r\\nIId. In cases of Kaposi sarcoma, to evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on viral transcription in tumor biopsies.\\r\\nIIe. In cases of anal cancer, to evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on HPV types in anal swabs, when feasible.\\r\\nIII. Understand the response of HIV to agent.\\r\\nIIIa. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on latent HIV loads in PBMC using outgrowth assay.\\r\\nIIIb. To evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab on HIV reactive T cells.\\r\\n\\r\\nOUTLINE: This is a dose-escalation study of nivolumab.\\r\\n\\r\\nPatients receive nivolumab intravenously (IV) over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 16 weeks or 112 days (based on 5 half lives).\", \"official_title\": \"A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma\", \"_phase_sort_order\": 4, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Baseline up to 3 years\", \"name\": \"Change in HIV viral load\", \"description\": \"Change in HIV viral load from pre-study to the end of study will be examined using a nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 3 years\", \"name\": \"Change in immune status\", \"description\": \"Change in immune status from pre-study to the end of study will be examined using a nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Circulating cytokine markers\", \"description\": \"Will be assessed by multiplex assay. Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Herpesvirus loads (Epstein-Barr virus [EBV], Kaposi sarcoma herpes virus [KSHV], cytomegalovirus [CMV]) in plasma\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Herpesvirus specific CD8 and CD4 T cells in PBMC\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"HIV reactive T cells\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Human papillomavirus types in anal swabs (anal cancer cases)\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Immune function\", \"description\": \"Descriptive statistics will be generated to evaluate the effects of single agent nivolumab, and the combination of ipilimumab and nivolumab, on immune function (human immunodeficiency virus [HIV] viral load, CD4 and CD8 cells).\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Intratumor immune cells\", \"description\": \"Will be assessed by immunohistochemistry. Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Latent herpesvirus (EBV, KSHV, CMV) in peripheral blood mononuclear cell (PBMC)\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Latent HIV loads in PBMC\", \"description\": \"Will be assessed using outgrowth assay. Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"56 days\", \"name\": \"Maximum tolerated dose of nivolumab\", \"description\": \"Will be defined as the starting dose level at which 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least >= 2 participants encountering DLT. Toxicity data will be presented by type and severity for each dose group and overall; the incidence of toxicity related dose reductions and treatment discontinuations will be summarized.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Objective response rate\", \"description\": \"The proportion of patients achieving objective responses (by Response Evaluation Criteria In Solid Tumors 1.1 or Kaposi's sarcoma response criteria, which includes RECIST for visceral disease, or by Response Evaluation Criteria in Lymphoma for classical Hodgkin lymphoma [cHL]) and their corresponding 95% confidence intervals (calculated using exact binomial) will be reported separately for solid tumor and cHL according to treatment (combination therapy and single agent) using designated response criteria. Descriptive statistics will also be compiled for duration of response.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 3 years\", \"name\": \"Viral transcription in tumor biopsies (Kaposi sarcoma cases)\", \"description\": \"Descriptive statistics will be generated. Changes from pre-study to end of study will be explored using nonparametric Wilcoxon signed-rank test.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}], \"phase\": \"I\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT02408861\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"HIV-1 Positive\", \"HIV-1+\", \"HIV1 Positive\", \"HIV1+\"], \"nci_thesaurus_concept_id\": \"C129253\", \"name\": \"Human Immunodeficiency Virus 1 Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C15175\", \"C26683\", \"C3367\", \"C35553\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C15175\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"HIV Positive\", \"HIV Positivity\", \"HIV positive\", \"HIV test positive\", \"Positive\"], \"nci_thesaurus_concept_id\": \"C15175\", \"name\": \"Human Immunodeficiency Virus Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C26683\", \"C3367\", \"C35553\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35553\", \"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Abnormal Lab Test Result\", \"Abnormal Laboratory Test\", \"Abnormal, NOS\"], \"nci_thesaurus_concept_id\": \"C26683\", \"name\": \"Abnormal Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C35553\", \"name\": \"Abnormal Blood Chemistry and Hematology Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C26683\", \"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C26683\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": \"SAFETY\", \"current_trial_status_date\": \"2020-07-09\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Malignant Solid Neoplasm\", \"Metastatic Solid Neoplasm\", \"Metastatic Solid Tumor\", \"Metastatic Tumor\"], \"nci_thesaurus_concept_id\": \"C127155\", \"name\": \"Metastatic Malignant Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C132146\", \"C36263\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Unresectable Solid Neoplasm\"], \"nci_thesaurus_concept_id\": \"C127156\", \"name\": \"Unresectable Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C9292\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Malignant Solid Neoplasm\", \"Advanced Non-Hematologic Malignancy\", \"Advanced Solid Neoplasm\", \"Advanced Solid Tumor\"], \"nci_thesaurus_concept_id\": \"C129707\", \"name\": \"Advanced Malignant Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C127155\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Classic Hodgkin Lymphoma\", \"Relapsed Classical Hodgkin Lymphoma\"], \"nci_thesaurus_concept_id\": \"C133592\", \"name\": \"Recurrent Classical Hodgkin Lymphoma\", \"type\": [\"stage\"], \"parents\": [\"C7164\", \"C4937\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Classic Hodgkin Lymphoma\"], \"nci_thesaurus_concept_id\": \"C133736\", \"name\": \"Refractory Classical Hodgkin Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C7164\", \"C8836\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"HIV\", \"Human Immunodeficiency Virus Infection\"], \"nci_thesaurus_concept_id\": \"C3108\", \"name\": \"HIV Infection\", \"type\": [\"subtype\"], \"parents\": [\"C3439\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"KS\", \"Kaposi sarcoma\", \"Kaposi's Sarcoma\", \"Kaposi's sarcoma\", \"Multiple Hemorrhagic Sarcoma\", \"Multiple hemorrhagic sarcoma\"], \"nci_thesaurus_concept_id\": \"C9087\", \"name\": \"Kaposi Sarcoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C27697\", \"C8538\", \"C27707\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Cancer (all types)\", \"Anal Carcinoma\", \"Anal cancer\", \"Anal cancer, NOS\", \"Cancer of Anus\", \"Cancer of the Anus\", \"Carcinoma of Anus\", \"Carcinoma of the Anus\", \"anal cancer\"], \"nci_thesaurus_concept_id\": \"C9291\", \"name\": \"Anal Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C7379\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Soft Tissue Disease\", \"Soft Tissue Diseases\", \"Soft Tissue Disorders\"], \"nci_thesaurus_concept_id\": \"C27042\", \"name\": \"Soft Tissue Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27574\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CHL\", \"Classic Hodgkin Lymphoma\", \"Classical Hodgkin's Lymphoma\", \"cHL\", \"classical Hodgkin lymphoma\"], \"nci_thesaurus_concept_id\": \"C7164\", \"name\": \"Classical Hodgkin Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C9357\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Blood Vessel Tumor\"], \"nci_thesaurus_concept_id\": \"C7387\", \"name\": \"Blood Vessel Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7388\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HL\", \"Hodgkin disease\", \"Hodgkin disease, NOS\", \"Hodgkin lymphoma\", \"Hodgkin lymphoma, NOS\", \"Hodgkin's Disease\", \"Hodgkin's Lymphoma\", \"Malignant lymphoma, Hodgkin\"], \"nci_thesaurus_concept_id\": \"C9357\", \"name\": \"Hodgkin Lymphoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C3208\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Clinical Infection\", \"ID\", \"INFECTION\", \"Infection\", \"Infectious\", \"Infectious Disease\", \"Infectious Diseases and Manifestations\", \"Unspecified Infection\", \"infection\"], \"nci_thesaurus_concept_id\": \"C26726\", \"name\": \"Infectious Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C93210\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Soft Tissue\", \"Neoplasm of the Soft Tissue\", \"Soft Tissue Neoplasm\", \"Soft Tissue Tumors\", \"Soft tissue neoplasm, NOS\", \"Tumor of Soft Tissue\", \"Tumor of the Soft Tissue\"], \"nci_thesaurus_concept_id\": \"C3377\", \"name\": \"Soft Tissue Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C3810\", \"C27042\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172133\", \"name\": \"Recurrent Malignant Lymphoid Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7065\", \"C27358\", \"C147861\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Cancer\", \"advanced cancer\"], \"nci_thesaurus_concept_id\": \"C9270\", \"name\": \"Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27707\", \"name\": \"Virus-Related Sarcoma\", \"type\": [\"subtype\"], \"parents\": [\"C9306\", \"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Anal Tumor\", \"Malignant Neoplasm of Anus\", \"Malignant Neoplasm of the Anus\", \"Malignant Tumor of Anus\", \"Malignant Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C7379\", \"name\": \"Malignant Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2877\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm by Etiology\"], \"nci_thesaurus_concept_id\": \"C27933\", \"name\": \"Neoplasm by Cause\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"LYMPHOMA, MALIGNANT\", \"Lymphoma (Hodgkin and Non-Hodgkin)\", \"Lymphoma (Hodgkin's and Non-Hodgkin's)\", \"Lymphoma, NOS\", \"Lymphomatous\", \"Malignant Lymphoma\", \"lymphoma\"], \"nci_thesaurus_concept_id\": \"C3208\", \"name\": \"Lymphoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C7065\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Solid Neoplasm\"], \"nci_thesaurus_concept_id\": \"C132146\", \"name\": \"Malignant Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C9292\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CHL\", \"Classic Hodgkin Lymphoma\", \"Classical Hodgkin's Lymphoma\", \"cHL\", \"classical Hodgkin lymphoma\"], \"nci_thesaurus_concept_id\": \"C7164\", \"name\": \"Classical Hodgkin Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C9357\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157686\", \"name\": \"Refractory Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cardiovascular Tumor\"], \"nci_thesaurus_concept_id\": \"C4784\", \"name\": \"Cardiovascular Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2931\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Blood Vessel Tumor\"], \"nci_thesaurus_concept_id\": \"C8538\", \"name\": \"Malignant Blood Vessel Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7387\", \"C7390\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Solid Neoplasm\", \"Solid Tumour\", \"Solid tumor, NOS\", \"solid tumor\"], \"nci_thesaurus_concept_id\": \"C9292\", \"name\": \"Solid Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Hematologic Cancer\"], \"nci_thesaurus_concept_id\": \"C27357\", \"name\": \"Refractory Hematologic Malignancy\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C120186\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Unspecified Vascular Problem\", \"Vascular Disease\", \"Vascular disease\"], \"nci_thesaurus_concept_id\": \"C35117\", \"name\": \"Vascular Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2931\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"NON-NEOPLASTIC\", \"Non-Neoplastic Disease\", \"Non-neoplastic Disorder\", \"Non-neoplastic condition, NOS\", \"Non-neoplastic disorder, NOS\"], \"nci_thesaurus_concept_id\": \"C53529\", \"name\": \"Non-Neoplastic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Viral Disease\", \"Viral Disorder\"], \"nci_thesaurus_concept_id\": \"C3439\", \"name\": \"Viral Infection\", \"type\": [\"subtype\"], \"parents\": [\"C26726\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Solid Neoplasm\"], \"nci_thesaurus_concept_id\": \"C132146\", \"name\": \"Malignant Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C9292\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Infection Related Cancer\", \"Infection Related Malignancy\", \"Infection-Related Cancer\", \"Infection-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27223\", \"name\": \"Infection-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27224\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Mesenchymal Tumor, Malignant\", \"Mesenchymal tumor, malignant\", \"SAR\", \"SARCOMA, MALIGNANT\", \"Sarcoma of Soft Tissue and Bone\", \"Sarcoma of the Soft Tissue and Bone\", \"Sarcoma, NOS\", \"Sarcoma, Not Otherwise Specified\", \"sarcoma\"], \"nci_thesaurus_concept_id\": \"C9118\", \"name\": \"Sarcoma\", \"type\": [\"maintype\"], \"parents\": [\"C3810\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C114940\", \"name\": \"Malignant Cardiovascular Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4784\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-Neoplastic Disease by Special Category\"], \"nci_thesaurus_concept_id\": \"C53547\", \"name\": \"Non-Neoplastic Disorder by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C53529\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Vascular Tissue\", \"Neoplasms, Vascular\", \"Tumor of Vascular Tissue\", \"Tumors, Vascular\", \"Vascular Neoplasms\", \"Vascular Tissue Neoplasm\", \"Vascular Tissue Tumor\", \"Vascular Tumor\", \"Vascular Tumors\", \"Vascular tumor, NOS\"], \"nci_thesaurus_concept_id\": \"C7388\", \"name\": \"Vascular Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4784\", \"C35117\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Solid Neoplasm\", \"Solid Tumour\", \"Solid tumor, NOS\", \"solid tumor\"], \"nci_thesaurus_concept_id\": \"C9292\", \"name\": \"Solid Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Hematologic Cancer\", \"Recurrent Hematologic Malignancy\", \"Relapsed Hematologic Cancer\", \"Relapsed Hematologic Malignancy\"], \"nci_thesaurus_concept_id\": \"C27358\", \"name\": \"Recurrent Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C27134\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C134157\", \"name\": \"Recurrent Lymphoma\", \"type\": [\"stage\"], \"parents\": [\"C3208\", \"C172133\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27224\", \"name\": \"Infection-Related Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27933\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HHV-8 Related Malignancy\", \"HHV-8-Related Malignancy\", \"Human Herpes Virus 8 Related Malignancy\", \"Human Herpes Virus 8-Related Malignancy\", \"Human Herpes Virus 8-Related Malignant Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27697\", \"name\": \"HHV8-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C134154\", \"name\": \"Refractory Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C3208\", \"C172280\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Virus Related Cancer\", \"Virus Related Malignancy\", \"Virus-Related Cancer\", \"Virus-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27673\", \"name\": \"Virus-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27223\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26695\", \"name\": \"Anal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancerous Tumor of Blood Vessel\", \"Malignant Tumor of Blood Vessel\", \"Malignant Vascular Tissue Neoplasm\", \"Malignant Vascular Tissue Tumor\", \"Malignant Vascular Tumor\", \"Vascular Neoplasms, Malignant\"], \"nci_thesaurus_concept_id\": \"C7390\", \"name\": \"Malignant Vascular Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C114940\", \"C7388\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Connective Tissue Sarcoma\", \"Non-Rhabdo. soft tissue sarcoma\", \"Non-Rhabdomyosarcoma soft tissue sarcoma, NOS\", \"Sarcoma of Soft Tissue\", \"Sarcoma of the Soft Tissue\", \"Soft tissue sarcoma\", \"soft tissue sarcoma\"], \"nci_thesaurus_concept_id\": \"C9306\", \"name\": \"Soft Tissue Sarcoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4867\", \"C9118\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C147861\", \"name\": \"Recurrent Lymphoproliferative Disorder\", \"type\": [\"stage\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HL\", \"Hodgkin disease\", \"Hodgkin disease, NOS\", \"Hodgkin lymphoma\", \"Hodgkin lymphoma, NOS\", \"Hodgkin's Disease\", \"Hodgkin's Lymphoma\", \"Malignant lymphoma, Hodgkin\"], \"nci_thesaurus_concept_id\": \"C9357\", \"name\": \"Hodgkin Lymphoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C3208\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Connective and Soft Tissue Tumor\", \"Musculoskeletal and Soft Tissue Neoplasm\", \"Musculoskeletal and Soft Tissue Tumor\", \"Neoplasm of Skeletal and Soft Tissue\", \"Neoplasm of Soft Tissue and Bone\", \"Neoplasm of Soft Tissue and Skeleton\", \"Skeletal and Soft Tissue Neoplasm\", \"Skeletal and Soft Tissue Tumor\", \"Soft Tissue and Bone Neoplasm\", \"Soft Tissue and Bone Tumor\", \"Tumor of Skeletal and Soft Tissue\", \"Tumor of Soft Tissue and Bone\", \"Tumor of Soft Tissue and Skeleton\"], \"nci_thesaurus_concept_id\": \"C3810\", \"name\": \"Connective and Soft Tissue Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27574\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Cancer\", \"clinical resistance\", \"refractory cancer\", \"resistant cancer\"], \"nci_thesaurus_concept_id\": \"C120186\", \"name\": \"Refractory Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C7628\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Tumor\"], \"nci_thesaurus_concept_id\": \"C7628\", \"name\": \"Refractory Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Hodgkin's Disease\", \"Refractory Hodgkin's Lymphoma\"], \"nci_thesaurus_concept_id\": \"C8836\", \"name\": \"Refractory Hodgkin Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C9357\", \"C134154\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Connective and Soft Tissue Disease\", \"Connective and Soft Tissue Diseases\"], \"nci_thesaurus_concept_id\": \"C27574\", \"name\": \"Connective and Soft Tissue Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Hodgkin's Disease\", \"Recurrent Hodgkin's Lymphoma\"], \"nci_thesaurus_concept_id\": \"C4937\", \"name\": \"Recurrent Hodgkin Lymphoma\", \"type\": [\"stage\"], \"parents\": [\"C9357\", \"C134157\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"LYMPHOMA, MALIGNANT\", \"Lymphoma (Hodgkin and Non-Hodgkin)\", \"Lymphoma (Hodgkin's and Non-Hodgkin's)\", \"Lymphoma, NOS\", \"Lymphomatous\", \"Malignant Lymphoma\", \"lymphoma\"], \"nci_thesaurus_concept_id\": \"C3208\", \"name\": \"Lymphoma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C7065\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Soft Tissue\", \"Malignant Neoplasm of the Soft Tissue\", \"Malignant Soft Tissue Tumor\", \"Malignant Tumor of Soft Tissue\", \"Malignant Tumor of the Soft Tissue\", \"Soft tissue tumor, malignant\"], \"nci_thesaurus_concept_id\": \"C4867\", \"name\": \"Malignant Soft Tissue Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cardiovascular Disease\", \"Cardiovascular Disease (CVD)\", \"Cardiovascular Disorder, NOS\", \"Cardiovascular_Disease\", \"Disorder of Cardiovascular System\"], \"nci_thesaurus_concept_id\": \"C2931\", \"name\": \"Cardiovascular Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Malignant Solid Neoplasm\", \"Metastatic Solid Neoplasm\", \"Metastatic Solid Tumor\", \"Metastatic Tumor\"], \"nci_thesaurus_concept_id\": \"C127155\", \"name\": \"Metastatic Malignant Solid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C132146\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anal Neoplasms, Benign and Malignant\", \"Anal Tumor\", \"Anal Tumors\", \"Anus Neoplasm\", \"Neoplasm of Anus\", \"Neoplasm of the Anus\", \"Tumor of Anus\", \"Tumor of the Anus\"], \"nci_thesaurus_concept_id\": \"C2877\", \"name\": \"Anal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26695\", \"C3052\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Inflammatory Disease\", \"Inflammatory_Disease\"], \"nci_thesaurus_concept_id\": \"C93210\", \"name\": \"Inflammatory Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C53547\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172280\", \"name\": \"Refractory Malignant Lymphoid Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7065\", \"C27357\", \"C157686\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"AMC-095\", \"active_sites_count\": 22, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Yervoy\", \"Ipilimumab\"], \"nci_thesaurus_concept_id\": \"C2654\", \"name\": \"Ipilimumab\", \"description\": \"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128036\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"nci_thesaurus_concept_id\": \"C68814\", \"name\": \"Nivolumab\", \"description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-CTLA4 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128036\", \"name\": \"Anti-CTLA-4 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\", \"C20401\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}], \"name\": \"Treatment (nivolumab, ipilimumab)\", \"description\": \"Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2015-00461\", \"why_study_stopped\": null, \"brief_summary\": \"This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment, or solid tumors that have spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors compared to ipilimumab with nivolumab alone.\", \"brief_title\": \"Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 96, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2015-08-27\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": \"AMC-095\", \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": \"OPEN\", \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Lakshmi Rajdev\", \"study_source\": \"National\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"1604017576\"}], \"amendment_date\": \"2021-09-29T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Yale University Cancer Center LAO\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined by estrogen receptor [ER] < 1%, progesterone receptor [PR] < 1% and HER2 1+ or less by immunohistochemistry [IHC]; if HER-2 expression is 2+, a negative fluorescence in situ hybridization [FISH] testing is required) (c) pancreatic adenocarcinoma (PDAC), or (d) small cell lung cancer (SCLC)\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type; for NSCLC, it is either PD-1/PD-L1 inhibitor, or platinum-containing chemotherapy, or an EGFR tyrosine kinase inhibitor or an ALK inhibitor if sensitizing mutation present; TNBC: platinum-containing chemotherapy; PDAC: fluorouracil (5-FU-), gemcitabine-, or taxane-containing chemotherapy either with or without radiation therapy; SCLC: platinum-containing chemotherapy for limited or extensive stage disease\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Toxicities of prior therapy (except alopecia) should be resolved to =< grade 1 as per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0; patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free T4 within normal range, may be considered eligible after discussion with the study principal investigator (PI)\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (Karnofsky >= 50%)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Life expectancy of >= 4 months\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Leukocytes >= 3,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Absolute neutrophil count >= 1,500/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Platelets >= 100,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Hemoglobin > 9 g/dL\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Creatinine =< 1.5 x ULN OR\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal; the creatinine clearance is calculated using Cockcroft-Gault formula\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"A urine protein: creatinine ratio of < 1 or < 1 g protein on 24-hour urine collection\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"International normalized ration (INR) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Activated partial thromboplastin time (aPTT) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmed\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Adequately controlled thyroid function defined by free T4 within normal range, with no symptoms of thyroid dysfunction\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"Adequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of BP while on protocol\"}, {\"inclusion_indicator\": true, \"display_order\": 21, \"description\": \"Patients who have the following risk factors are considered to be at increased risk for cardiac toxicities, and must have documented left ventricular ejection fraction (LVEF) by echocardiogram greater than institution\\u2019s lower limit of normal (or 55% if threshold for normal not otherwise specified by institutional guidelines) obtained within 3 months\\r\\n* Prior treatment with anthracyclines\\r\\n* Prior treatment with trastuzumab\\r\\n* A New York Heart Association (NYHA) classification of II controlled with treatment\\r\\n* Prior central thoracic radiation therapy (RT), including RT to the heart\\r\\n* History of myocardial infarction within 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)\"}, {\"inclusion_indicator\": true, \"display_order\": 22, \"description\": \"The effects of cediranib and olaparib on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of cediranib and olaparib administration\"}, {\"inclusion_indicator\": true, \"display_order\": 23, \"description\": \"Ability to understand and the willingness to sign a written informed consent document\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Patients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Patients should not have received any other investigational agents within the past 4 weeks\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should be excluded from this clinical trial, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events (AEs); screening brain MRI (or CT if MRI contraindicated) will be required for patients with recurrent NSCLC, TNBC, or SCLC; brain MRI (or CT if MRI contraindicated) is required for PDAC if clinically suspected by patient\\u2019s symptoms or neurological exam; should patient found to have brain metastasis, treatment of brain metastasis must precede the participation in this study; for patients with known and treated brain metastases is allowed in this study if they fulfill the following criteria:\\r\\n* The lesions have improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery and off steroids for at least 6 weeks\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Patients who have received prior inhibitor of VEGF signaling and a poly (ADP-ribose) polymerases (PARP) inhibitor administered in combination; unless administered in combination, patients who received a prior PARP inhibitor or a prior VEGF-signaling inhibitor agent are allowed after discussing with the PI\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Current use of natural herbal products or other complementary alternative medications (CAM) or \\u201cfolk remedies\\u201d\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Patients with concomitant or prior invasive malignancies within the past 3 years; subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"History of myocardial infarction within 6 months prior to registration\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"History of stroke or transient ischemic attack within 6 months prior to registration\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"NYHA classification of III or IV\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Current cardiac arrhythmia requiring concurrent use of anti-arrhythmic drugs\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"History of hypertensive crisis or hypertensive encephalopathy within 3 years prior to registration\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Clinically significant peripheral vascular disease or abdominal aortic aneurysm (> 5 cm) or aortic dissection; if known history of abdominal aortic aneurysm with >= 4 cm in diameter, all of the following must be met: \\r\\n* An ultrasound (US) within the last 6 months prior to registration will be required to document that it is =< 5 cm\\r\\n* Patient must be asymptomatic from the aneurysm\\r\\n* Blood pressure must be well controlled as defined in this protocol\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"History of bowel obstruction within 1 month prior to starting study drugs\"}, {\"inclusion_indicator\": false, \"display_order\": 41, \"description\": \"History of hemoptysis or any significant bleeding within the last 1 month prior to enrollment\"}, {\"inclusion_indicator\": false, \"display_order\": 42, \"description\": \"Presence of cavitation of central pulmonary lesion\"}, {\"inclusion_indicator\": false, \"display_order\": 43, \"description\": \"History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation within the 3 months prior to enrollment\"}, {\"inclusion_indicator\": false, \"display_order\": 44, \"description\": \"Patients may not have current dependency on intravenous (IV) hydration or total parenteral nutrition (TPN)\"}, {\"inclusion_indicator\": false, \"display_order\": 45, \"description\": \"Patients may not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the P.I.; given the increases risk of serious bleeding from cediranib, patients who are on greater than or equal to 2 anti-thrombotic agents, including but not limited to anti-platelet agents (non-steroidal anti-inflammatory drugs [NSAIDs]/aspirin, clopidogrel), heparin, low molecular weight heparin (LMWH), warfarin, and a direct thrombin inhibitor, will be excluded\"}, {\"inclusion_indicator\": false, \"display_order\": 46, \"description\": \"Patients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated\"}, {\"inclusion_indicator\": false, \"display_order\": 47, \"description\": \"Pregnant women are excluded from this study because olaparib and cediranib have the potential for teratogenic or abortifacient effects; due to the fact that there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib and cediranib, breastfeeding should be discontinued if the mother is treated with cediranib and olaparib\"}, {\"inclusion_indicator\": false, \"display_order\": 48, \"description\": \"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV-positive patients with undetectable viral loads and CD4 counts > 300, and not on any antiretroviral therapy may be allowed after discussing with the principle investigator\"}, {\"inclusion_indicator\": false, \"display_order\": 49, \"description\": \"Any condition that, in the opinion of the treating investigator would interfere with evaluation of the investigational product or interpretation of subject safety or study results\"}, {\"inclusion_indicator\": true, \"display_order\": 50, \"description\": \"Age >= 18 years. There is no dosing or adverse event data currently available on the use of cediranib or olaparib in patients < 18 years of age, thus excluding them from enrollment\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"Ontario\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"416-946-4501\", \"recruitment_status_date\": \"2021-06-03\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"610 University Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"M5G 2M9\", \"contact_email\": \"clinical.trials@uhn.on.ca\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Toronto\", \"org_email\": \"clinical.trials@uhn.on.ca\", \"org_country\": \"Canada\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"University Health Network-Princess Margaret Hospital\"}, {\"org_state_or_province\": \"British Columbia\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"888-939-3333\", \"recruitment_status_date\": \"2020-06-17\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"600 West 10th Avenue\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"V5Z 4E6\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"Vancouver\", \"org_email\": null, \"org_country\": \"Canada\", \"org_fax\": null, \"org_phone\": \"604-877-6000\", \"org_name\": \"BCCA-Vancouver Cancer Centre\"}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"858-822-5354\", \"recruitment_status_date\": \"2020-10-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"200 West Arbor Drive\", \"org_tty\": null, \"org_family\": \"Moores Comprehensive Cancer Center\", \"org_postal_code\": \"92103\", \"contact_email\": \"cancercto@ucsd.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Diego\", \"org_email\": \"cancercto@ucsd.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"858-822-5354\", \"org_name\": \"University of California San Diego\", \"org_coordinates\": {\"lon\": -117.1677, \"lat\": 32.7476}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"877-827-3222\", \"recruitment_status_date\": \"2020-06-17\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": null, \"recruitment_status\": \"TEMPORARILY_CLOSED_TO_ACCRUAL\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"916-734-3089\", \"recruitment_status_date\": \"2020-03-23\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4501 X Street\", \"org_tty\": null, \"org_family\": \"UC Davis Comprehensive Cancer Center\", \"org_postal_code\": \"95817\", \"contact_email\": null, \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Sacramento\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"916-734-3089\", \"org_name\": \"University of California Davis Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -121.4572, \"lat\": 38.5503}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"858-822-5354\", \"recruitment_status_date\": \"2020-10-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"3855 Health Sciences Drive\", \"org_tty\": null, \"org_family\": \"Moores Comprehensive Cancer Center\", \"org_postal_code\": \"92093\", \"contact_email\": \"cancercto@ucsd.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"La Jolla\", \"org_email\": \"cancercto@ucsd.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"858-822-5354\\r858-657-7000\", \"org_name\": \"UC San Diego Moores Cancer Center\", \"org_coordinates\": {\"lon\": -117.2575, \"lat\": 32.8339}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2016-12-02\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"333 Cedar Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06520\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-785-5702\", \"org_name\": \"Yale University\", \"org_coordinates\": {\"lon\": -72.9291, \"lat\": 41.31}}, {\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2016-12-02\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"20 York Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06510\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-688-4242\", \"org_name\": \"Smilow Cancer Center/Yale-New Haven Hospital\", \"org_coordinates\": {\"lon\": -72.9252, \"lat\": 41.3068}}, {\"org_state_or_province\": \"FL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-679-0775\", \"recruitment_status_date\": \"2016-12-02\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"12902 Magnolia Drive\", \"org_tty\": null, \"org_family\": \"Moffitt Cancer Center\", \"org_postal_code\": \"33612\", \"contact_email\": \"ClinicalTrials@moffitt.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Tampa\", \"org_email\": \"ClinicalTrials@moffitt.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-679-0775\", \"org_name\": \"Moffitt Cancer Center\", \"org_coordinates\": {\"lon\": -82.45, \"lat\": 28.0508}}, {\"org_state_or_province\": \"MA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"877-442-3324\", \"recruitment_status_date\": \"2019-01-04\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"450 Brookline Avenue\", \"org_tty\": null, \"org_family\": \"Dana-Farber/Harvard Cancer Center\", \"org_postal_code\": \"02215\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Boston\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"617-632-3000\", \"org_name\": \"Dana-Farber Cancer Institute\", \"org_coordinates\": {\"lon\": -71.1025, \"lat\": 42.3469}}, {\"org_state_or_province\": \"MI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"313-576-9790\", \"recruitment_status_date\": \"2021-06-16\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4100 John R Street\", \"org_tty\": null, \"org_family\": \"The Barbara Ann Karmanos Cancer Institute\", \"org_postal_code\": \"48201\", \"contact_email\": \"ctoadmin@karmanos.org\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Detroit\", \"org_email\": \"ctoadmin@karmanos.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-527-6266\", \"org_name\": \"Wayne State University/Karmanos Cancer Institute\", \"org_coordinates\": {\"lon\": -83.0598, \"lat\": 42.3465}}, {\"org_state_or_province\": \"MI\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"313-576-9790\", \"recruitment_status_date\": \"2021-06-16\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"31995 Northwestern Highway\", \"org_tty\": null, \"org_family\": \"The Barbara Ann Karmanos Cancer Institute\", \"org_postal_code\": \"48334\", \"contact_email\": \"ctoadmin@karmanos.org\", \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Farmington Hills\", \"org_email\": \"ctoadmin@karmanos.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"313-576-9363\", \"org_name\": \"Weisberg Cancer Treatment Center\", \"org_coordinates\": {\"lon\": -83.3489, \"lat\": 42.5067}}, {\"org_state_or_province\": \"TN\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-811-8480\", \"recruitment_status_date\": \"2016-12-02\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2200 Pierce Avenue\", \"org_tty\": null, \"org_family\": \"Vanderbilt-Ingram Cancer Center\", \"org_postal_code\": \"37232\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Nashville\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-936-8422\", \"org_name\": \"Vanderbilt University/Ingram Cancer Center\", \"org_coordinates\": {\"lon\": -86.8096, \"lat\": 36.1437}}, {\"org_state_or_province\": \"TX\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"877-632-6789\", \"recruitment_status_date\": \"2017-02-14\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1515 Holcombe Boulevard\", \"org_tty\": null, \"org_family\": \"MD Anderson Cancer Center\", \"org_postal_code\": \"77030\", \"contact_email\": \"askmdanderson@mdanderson.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Houston\", \"org_email\": \"askmdanderson@mdanderson.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-632-6789\", \"org_name\": \"M D Anderson Cancer Center\", \"org_coordinates\": {\"lon\": -95.4026, \"lat\": 29.7059}}, {\"org_state_or_province\": \"VA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": null, \"recruitment_status_date\": \"2020-11-19\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"401 College Street\", \"org_tty\": null, \"org_family\": \"Massey Cancer Center\", \"org_postal_code\": \"23298\", \"contact_email\": \"CTOclinops@vcu.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Richmond\", \"org_email\": \"klcampbell@vcu.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"804-628-1939\", \"org_name\": \"Virginia Commonwealth University/Massey Cancer Center\", \"org_coordinates\": {\"lon\": -77.4296, \"lat\": 37.5427}}, {\"org_state_or_province\": \"FL\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-679-0775\", \"recruitment_status_date\": \"2019-02-15\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4101 Jim Walter Boulevard\", \"org_tty\": null, \"org_family\": \"Moffitt Cancer Center\", \"org_postal_code\": \"33607\", \"contact_email\": \"ClinicalTrials@moffitt.org\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Tampa\", \"org_email\": \"ClinicalTrials@moffitt.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"800-679-0775\", \"org_name\": \"Moffitt Cancer Center-International Plaza\", \"org_coordinates\": {\"lon\": -82.5019, \"lat\": 27.963}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To determine the objective response rate (ORR) of cediranib (cediranib maleate) plus olaparib in combination in patients with advanced or metastatic solid tumors of the following tumor types: non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer (SCLC).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To assess the safety and tolerability of oral administration of cediranib in combination with olaparib in patients with select advanced solid tumors.\\r\\nII. To estimate progression free survival (PFS) in each tumor cohort.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To estimate the prevalence of the mutations of deoxyribonucleic acid (DNA) repair genes in tumors using the BROCA panel and to correlate tumor regression with mutations status. (Integrated)\\r\\nII. To evaluate changes in tumor hypoxia on cediranib treatment compared to baseline by [F-18] fluoromisonidazole (FMISO) positron emission tomography/computed tomography (PET/CT) in patients with NSCLC. \\r\\nIII. To evaluate levels of angiogenesis/inflammatory markers including VEGF at baseline and on treatment.\\r\\nIV. To evaluate levels of circulating tumor deoxyribonucleic acid (ctDNA) at baseline and on treatment. \\r\\n\\r\\nOUTLINE:\\r\\nPatients receive cediranib maleate orally (PO) once daily (QD) on day 1. Patients undergoing FMISO scan also receive olaparib PO twice daily (BID) beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 4 weeks and then every 4 weeks thereafter.\", \"official_title\": \"A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"AstraZeneca Pharmaceuticals LP\", \"functional_role\": \"AGENT_SOURCE\"}, {\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Baseline to post therapy\", \"name\": \"Changes in level of circulating tumor deoxyribonucleic acid (ctDNA) (all cohorts)\", \"description\": \"Will be assessed using paired t- test or Wilcoxon signed-rank.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline to post-therapy\", \"name\": \"Changes in levels of angiogenesis/ inflammatory markers (angiome panel) (all cohorts)\", \"description\": \"Will be assessed using paired t- test or Wilcoxon signed-rank.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline to post-cediranib monotherapy\", \"name\": \"Changes in tumor hypoxia by imaging\", \"description\": \"Measured by 18F-fluoromisonidazole positron emission tomography/computed tomography scans (non-small cell lung cancer). For the pre- and post-cediranib therapy outcome analysis, paired t- test or Wilcoxon signed-rank test will be applied for the continuous variables.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 4 weeks after completion of study treatment\", \"name\": \"Incidence of adverse events\", \"description\": \"Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percentages and frequencies for categorical parameters, will be presented. Adverse medical events will be tabulated. National Cancer Institute toxicity grade 3 and grade 4 laboratory abnormalities will be listed.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 4 weeks after completion of study treatment\", \"name\": \"Objective response rate\", \"description\": \"Measured by Response Evaluation Criteria in Solid Tumors version 1.1. The exact two-sided 95% confidence interval for the objective response rate will be reported.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Prevalence of the mutations of deoxyribonucleic acid (DNA) repair genes in each tumor cohort\", \"description\": \"In the first 20 endpoint-evaluable patients with non-small cell lung cancer and 20 endpoint-evaluable patients with triple negative breast cancer, the exploratory analyses will be done using Fisher\\u2019s exact tests, Mann-Whitney U tests or McNemar\\u2019s test depending on the type of data observed.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"The duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up to 4 weeks after completion of study treatment\", \"name\": \"Progression-free survival\", \"description\": \"Estimated using the Kaplan-Meier method with the 95% confidence intervals. Thomas and Grunkemeier confidence interval will be reported. The possible risk factors will be compared for survival with log-rank test. For multivariate analysis, the proportional hazards Cox model will be applied to investigate potential prognostic factors, such as age and stage of disease on the survival data. The adjusted p-values of the hazard ratios and the adjusted 95% confidence interval will be reported.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT02498613\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER Alpha Negative\", \"ER Negative\", \"ER-\", \"ER-Alpha Negative\", \"ERA Negative\", \"ESR Negative\", \"ESR1 Negative\", \"ESRA Negative\", \"ESTRR Negative\", \"Estrogen Receptor 1 Negative\", \"Estrogen Receptor Alpha Negative\", \"NR3A1 Negative\", \"Negative\", \"Negative Estrogen Receptor\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Negative\", \"estrogen receptor negative\"], \"nci_thesaurus_concept_id\": \"C15493\", \"name\": \"Estrogen Receptor Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16150\", \"C165233\", \"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C35681\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C16150\", \"C165233\", \"C38349\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Negative\", \"PGR Negative\", \"PR Negative\", \"PR-\", \"progesterone receptor negative\"], \"nci_thesaurus_concept_id\": \"C15497\", \"name\": \"Progesterone Receptor Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16149\", \"C165233\", \"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35681\", \"C36292\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C16149\", \"C28656\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ERBB2 Negative\", \"HER-2 Negative\", \"HER2 Negative\"], \"nci_thesaurus_concept_id\": \"C68749\", \"name\": \"HER2/Neu Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16152\", \"C165233\", \"C16612\", \"C17756\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C35681\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C16152\", \"C17756\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER-Negative PR-Negative ERBB2-Negative\", \"ER-PR-HER2/neu-\", \"ER-negative PR-negative HER2/neu-negative\", \"ER/PR/HER2 Negative\", \"ESR1/PGR/ERBB2 Negative Finding\", \"Triple Negative Breast Cancer Finding\", \"Triple Negative Breast Cancer Result\", \"Triple-Negative Breast Cancer Result\", \"triple-negative breast cancer\"], \"nci_thesaurus_concept_id\": \"C71428\", \"name\": \"Triple-Negative Breast Cancer Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C165233\", \"C16612\", \"C17756\", \"C20103\", \"C20420\", \"C20709\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C28656\", \"C3367\", \"C35681\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C94299\", \"C17756\", \"C38349\", \"C28656\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C54362\", \"name\": \"Transcription Regulation Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER Alpha Status\", \"ER Status\", \"ER-Alpha Status\", \"ERA Status\", \"ESR Status\", \"ESR1 Status\", \"ESRA Status\", \"ESTRR Status\", \"Estrogen Receptor\", \"Estrogen Receptor 1 Status\", \"Estrogen Receptor Alpha Status\", \"NR3A1 Status\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Status\"], \"nci_thesaurus_concept_id\": \"C16150\", \"name\": \"Estrogen Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C38349\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2 Status\", \"Her2/Neu Value\"], \"nci_thesaurus_concept_id\": \"C16152\", \"name\": \"HER2/Neu Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17756\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C17756\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2\", \"Erb-b2 Receptor Tyrosine Kinase 2 Gene\", \"HER2\", \"HER2/Neu\", \"NEU\"], \"nci_thesaurus_concept_id\": \"C17756\", \"name\": \"ERBB2 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PgR Status\", \"Progesterone Receptor\"], \"nci_thesaurus_concept_id\": \"C16149\", \"name\": \"Progesterone Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C36292\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C28656\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Transcription Factor\"], \"nci_thesaurus_concept_id\": \"C20420\", \"name\": \"Transcription Factor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C54362\"], \"parents\": [\"C54362\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Negative\", \"negative test result\"], \"nci_thesaurus_concept_id\": \"C35681\", \"name\": \"Negative Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C94299\", \"name\": \"Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20709\", \"name\": \"Nuclear Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C21295\", \"C54362\"], \"parents\": [\"C20103\", \"C20420\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER\", \"ESR1\", \"Estrogen Receptor 1 Gene\"], \"nci_thesaurus_concept_id\": \"C38349\", \"name\": \"ESR1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Absent\", \"LOST\", \"Loss of Expression\", \"Negative\", \"Not Expressed\"], \"nci_thesaurus_concept_id\": \"C165233\", \"name\": \"Expression Negative\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35681\", \"C7057\", \"C77140\"], \"parents\": [\"C35681\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PGR\", \"PR\", \"Progesterone Receptor Gene\"], \"nci_thesaurus_concept_id\": \"C28656\", \"name\": \"PGR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": \"Efficacy\", \"current_trial_status_date\": \"2016-04-26\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153348\", \"name\": \"Metastatic Triple-Negative Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C165698\", \"C71732\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156094\", \"name\": \"Metastatic Lung Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2926\", \"C153202\", \"C165537\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156095\", \"name\": \"Metastatic Lung Small Cell Carcinoma\", \"type\": [\"grade\", \"subtype\"], \"parents\": [\"C4917\", \"C153202\", \"C157602\", \"C158911\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C160295\", \"name\": \"Unresectable Lung Small Cell Carcinoma\", \"type\": [\"grade\", \"subtype\"], \"parents\": [\"C4917\", \"C155902\", \"C165454\", \"C172806\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162016\", \"name\": \"Unresectable Pancreatic Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C8294\", \"C129654\", \"C5018\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165491\", \"name\": \"Unresectable Triple-Negative Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C71732\", \"C158752\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IV\", \"Breast Carcinoma Stage IV\", \"Stage IV Breast Cancer AJCC v6\", \"Stage IV Breast Cancer AJCC v6 and v7\", \"Stage IV Breast Cancer AJCC v7\", \"Stage IV Breast Carcinoma\", \"stage IV breast cancer\"], \"nci_thesaurus_concept_id\": \"C3995\", \"name\": \"Stage IV Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C90513\", \"C91230\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Lung Non-Small Cell Cancer AJCC v7\", \"Stage IV NSCLC\", \"Stage IV Non-Oat Cell Carcinoma of Lung\", \"Stage IV Non-Oat Cell Carcinoma of the Lung\", \"Stage IV Non-Oat Cell Lung Carcinoma\", \"Stage IV Non-Small Cell Carcinoma of Lung\", \"Stage IV Non-Small Cell Carcinoma of the Lung\", \"Stage IV Non-Small Cell Lung Cancer AJCC v7\", \"Stage IV Non-Small Cell Lung Carcinoma\", \"stage IV non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C4012\", \"name\": \"Stage IV Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88891\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Non-Resectable Carcinoma of Pancreas\", \"Non-Resectable Carcinoma of the Pancreas\", \"Non-Resectable Pancreas Carcinoma\", \"Non-Resectable Pancreatic Carcinoma\", \"Pancreatic Carcinoma, Non-Resectable\", \"Unresectable Pancreatic Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5018\", \"name\": \"Unresectable Pancreatic Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C3850\", \"C155903\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Pancreatic Cancer Stage IV\", \"Stage IV Carcinoma of Pancreas\", \"Stage IV Carcinoma of the Pancreas\", \"Stage IV Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7\", \"Stage IV Pancreatic Cancer AJCC v6\", \"Stage IV Pancreatic Cancer AJCC v6 and v7\", \"Stage IV Pancreatic Cancer AJCC v7\", \"Stage IV Pancreatic Carcinoma\", \"stage IV pancreatic cancer\"], \"nci_thesaurus_concept_id\": \"C5711\", \"name\": \"Stage IV Pancreatic Cancer\", \"type\": [\"stage\"], \"parents\": [\"C134902\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Small Cell Carcinoma AJCC v7\", \"Stage III Small Cell Carcinoma of Lung\", \"Stage III Small Cell Carcinoma of the Lung\", \"Stage III Small Cell Lung Carcinoma\", \"Stage III Small Cell Lung Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C6679\", \"name\": \"Stage III Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C136496\", \"C88890\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIA Lung Small Cell Carcinoma AJCC v7\", \"Stage IIIA Small Cell Carcinoma of Lung\", \"Stage IIIA Small Cell Carcinoma of the Lung\", \"Stage IIIA Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6680\", \"name\": \"Stage IIIA Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C7853\", \"C6679\", \"C5646\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIB Lung Small Cell Carcinoma AJCC v7\", \"Stage IIIB Small Cell Carcinoma of Lung\", \"Stage IIIB Small Cell Carcinoma of the Lung\", \"Stage IIIB Small Cell Lung Carcinoma\", \"Stage IIIB Small Cell Lung Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C6681\", \"name\": \"Stage IIIB Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C6679\", \"C5647\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Lung Small Cell Carcinoma AJCC v7\", \"Stage IV Small Cell Carcinoma of Lung\", \"Stage IV Small Cell Carcinoma of the Lung\", \"Stage IV Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6682\", \"name\": \"Stage IV Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C9049\", \"C136496\", \"C88891\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Triple-Negative Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C71732\", \"name\": \"Triple-Negative Breast Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C53553\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IIIA\", \"Breast Carcinoma Stage IIIA\", \"Stage IIIA Breast Cancer AJCC v7\", \"Stage IIIA Breast Carcinoma\", \"stage IIIA breast cancer\"], \"nci_thesaurus_concept_id\": \"C7770\", \"name\": \"Stage IIIA Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Non-Small Cell Cancer AJCC v7\", \"Stage III NSCLC\", \"Stage III Non-Oat Cell Carcinoma of Lung\", \"Stage III Non-Oat Cell Carcinoma of the Lung\", \"Stage III Non-Oat Cell Lung Carcinoma\", \"Stage III Non-Small Cell Carcinoma of Lung\", \"Stage III Non-Small Cell Carcinoma of the Lung\", \"Stage III Non-Small Cell Lung Cancer AJCC v7\", \"Stage III Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7778\", \"name\": \"Stage III Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88890\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IIIB\", \"Breast Carcinoma Stage IIIB\", \"Stage IIIB Breast Cancer AJCC v7\", \"Stage IIIB Breast Carcinoma\", \"stage IIIB breast cancer\"], \"nci_thesaurus_concept_id\": \"C7782\", \"name\": \"Stage IIIB Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Pancreatic Cancer Stage III\", \"Stage III Carcinoma of Pancreas\", \"Stage III Carcinoma of the Pancreas\", \"Stage III Exocrine and Endocrine Pancreatic Cancer AJCC v6 and v7\", \"Stage III Pancreatic Cancer AJCC v6\", \"Stage III Pancreatic Cancer AJCC v6 and v7\", \"Stage III Pancreatic Cancer AJCC v7\", \"Stage III Pancreatic Carcinoma\", \"stage III pancreatic cancer\"], \"nci_thesaurus_concept_id\": \"C7787\", \"name\": \"Stage III Pancreatic Cancer\", \"type\": [\"stage\"], \"parents\": [\"C134902\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Breast Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88376\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91230\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Breast Cancer AJCC v7\", \"stage IIIC breast cancer\"], \"nci_thesaurus_concept_id\": \"C88377\", \"name\": \"Stage IIIC Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C8933\", \"name\": \"Metastatic Pancreatic Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4124\", \"C156069\", \"C8294\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Non Small Cell Lung Cancer Stage IIIA\", \"Non Small Cell Lung Cancer, Stage IIIA\", \"Stage IIIA Lung Non-Small Cell Cancer AJCC v7\", \"Stage IIIA NSCLC\", \"Stage IIIA Non-Oat Cell Carcinoma of Lung\", \"Stage IIIA Non-Oat Cell Carcinoma of the Lung\", \"Stage IIIA Non-Oat Cell Lung Carcinoma\", \"Stage IIIA Non-Small Cell Carcinoma of Lung\", \"Stage IIIA Non-Small Cell Carcinoma of the Lung\", \"Stage IIIA Non-Small Cell Lung Cancer AJCC v7\", \"Stage IIIA Non-Small Cell Lung Carcinoma\", \"stage IIIA non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C9102\", \"name\": \"Stage IIIA Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C7778\", \"C5646\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Non Small Cell Lung Cancer Stage IIIB\", \"Non Small Cell Lung Cancer, Stage IIIB\", \"Stage IIIB Lung Non-Small Cell Cancer AJCC v7\", \"Stage IIIB NSCLC\", \"Stage IIIB Non-Oat Cell Carcinoma of Lung\", \"Stage IIIB Non-Oat Cell Carcinoma of the Lung\", \"Stage IIIB Non-Oat Cell Lung Carcinoma\", \"Stage IIIB Non-Small Cell Carcinoma of Lung\", \"Stage IIIB Non-Small Cell Carcinoma of the Lung\", \"Stage IIIB Non-Small Cell Lung Cancer AJCC v7\", \"Stage IIIB Non-Small Cell Lung Carcinoma\", \"stage IIIB non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C9103\", \"name\": \"Stage IIIB Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C7778\", \"C5647\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Ductal Adenocarcinoma of Pancreas\", \"Ductal Adenocarcinoma of the Pancreas\", \"PDA\", \"PDAC\", \"Pancreas Ductal Adenocarcinoma\", \"Pancreatic Infiltrating Duct Carcinoma, NOS\", \"Pancreatic Infiltrating Duct Carcinoma, Not Otherwise Specified\", \"Pancreatic Tubular Adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C9120\", \"name\": \"Pancreatic Ductal Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C8294\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Small Cell Carcinoma\"], \"nci_thesaurus_concept_id\": \"C158911\", \"name\": \"Metastatic Small Cell Neuroendocrine Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C155869\", \"C3915\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C155903\", \"name\": \"Unresectable Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C96963\", \"C148124\", \"C162845\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165454\", \"name\": \"Unresectable Lung Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C5670\", \"C7377\", \"C179420\", \"C168973\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C4124\", \"name\": \"Metastatic Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91232\", \"name\": \"Lung Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136491\", \"name\": \"Lung Non-Small Cell Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C91232\", \"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Pancreas\", \"Cancer of the Pancreas\", \"Carcinoma of Pancreas\", \"Carcinoma of the Pancreas\", \"Exocrine Pancreas Carcinoma\", \"Pancreas Cancer\", \"Pancreas Carcinoma\", \"Pancreatic Carcinoma\", \"Pancreatic cancer (excluding Islets), NOS\", \"Pancreatic cancer (not Islets)\", \"exocrine cancer\", \"pancreatic cancer\"], \"nci_thesaurus_concept_id\": \"C3850\", \"name\": \"Pancreatic Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C7430\", \"C166418\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165698\", \"name\": \"Metastatic Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C5214\", \"C4124\", \"C153238\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Pancreas\", \"Malignant Neoplasm of the Pancreas\"], \"nci_thesaurus_concept_id\": \"C9005\", \"name\": \"Malignant Pancreatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C3305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C155869\", \"name\": \"Metastatic Neuroendocrine Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3482\", \"C156485\", \"C3773\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIB Carcinoma of Lung\", \"Stage IIIB Carcinoma of the Lung\", \"Stage IIIB Lung Cancer AJCC v7\", \"Stage IIIB Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5647\", \"name\": \"Stage IIIB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Stage IIIA Carcinoma of Lung\", \"Stage IIIA Carcinoma of the Lung\", \"Stage IIIA Lung Cancer AJCC v7\", \"Stage IIIA Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5646\", \"name\": \"Stage IIIA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"High Grade Lung Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C45569\", \"name\": \"Lung Neuroendocrine Carcinoma\", \"type\": [\"grade\", \"subtype\"], \"parents\": [\"C4878\", \"C5670\", \"C173385\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C155902\", \"name\": \"Unresectable Lung Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4878\", \"C148124\", \"C179420\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26842\", \"name\": \"Pancreatic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Triple-Negative Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C71732\", \"name\": \"Triple-Negative Breast Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C53553\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Oat Cell Carcinoma\", \"Lung Small Cell Carcinoma\", \"Lung Small Cell Neuroendocrine Carcinoma\", \"Oat Cell Carcinoma of Lung\", \"Oat Cell Carcinoma of the Lung\", \"Oat Cell Lung Carcinoma\", \"SCLC\", \"Small Cell Carcinoma of Lung\", \"Small Cell Carcinoma of the Lung\", \"Small Cell Lung Carcinoma\", \"Small Cell Neuroendocrine Carcinoma of Lung\", \"Small Cell Neuroendocrine Carcinoma of the Lung\", \"Small cell lung cancer\", \"small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C4917\", \"name\": \"Small Cell Lung Cancer\", \"type\": [\"grade\", \"maintype\", \"subtype\"], \"parents\": [\"C45569\", \"C3915\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153238\", \"name\": \"Metastatic Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C3482\", \"C170728\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C176862\", \"name\": \"Metastatic Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3576\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Small Cell Carcinoma AJCC v7\", \"Stage III Small Cell Carcinoma of Lung\", \"Stage III Small Cell Carcinoma of the Lung\", \"Stage III Small Cell Lung Carcinoma\", \"Stage III Small Cell Lung Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C6679\", \"name\": \"Stage III Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C136496\", \"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Exocrine Pancreas Neoplasm\", \"Exocrine Pancreas Tumor\", \"Neoplasm of Exocrine Pancreas\", \"Neoplasm of the Exocrine Pancreas\", \"Pancreatic Exocrine Tumor\", \"Tumor of Exocrine Pancreas\", \"Tumor of the Exocrine Pancreas\"], \"nci_thesaurus_concept_id\": \"C4445\", \"name\": \"Pancreatic Exocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153202\", \"name\": \"Metastatic Lung Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4878\", \"C3482\", \"C176862\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Breast Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88376\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91230\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Endocrine System Neoplasm\", \"Endocrine System Tumor\", \"Endocrine Tumor\"], \"nci_thesaurus_concept_id\": \"C3010\", \"name\": \"Endocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3009\", \"C3709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma - pancreas\", \"Adenocarcinoma of Pancreas\", \"Adenocarcinoma of the Pancreas\", \"Adenocarcinoma of the pancreas\", \"Pancreas Adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C8294\", \"name\": \"Pancreatic Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C3850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179420\", \"name\": \"Unresectable Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3576\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C158752\", \"name\": \"Unresectable Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C148124\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C168973\", \"name\": \"Unresectable Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3809\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIA Carcinoma of Lung\", \"Stage IIIA Carcinoma of the Lung\", \"Stage IIIA Lung Cancer AJCC v7\", \"Stage IIIA Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5646\", \"name\": \"Stage IIIA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170728\", \"name\": \"Metastatic Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9335\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Exocrine and Endocrine Pancreatic Cancer by AJCC v6 and v7 Stage\", \"Exocrine and Endocrine Pancreatic Carcinoma by AJCC v6 and v7 Stage\", \"Pancreatic Carcinoma by AJCC v6 and v7 Stage\"], \"nci_thesaurus_concept_id\": \"C134902\", \"name\": \"Pancreatic Cancer by AJCC v6 and v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C3850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165537\", \"name\": \"Metastatic Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3482\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pancreaticobiliary Cancer\", \"Pancreaticobiliary Carcinoma\", \"Pancreatobiliary Cancer\"], \"nci_thesaurus_concept_id\": \"C166418\", \"name\": \"Pancreatobiliary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C96963\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162845\", \"name\": \"Unresectable Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Small Cell Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136496\", \"name\": \"Lung Small Cell Carcinoma by AJCC v7 Stage\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C91232\", \"C4917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non-Resectable Carcinoma of Pancreas\", \"Non-Resectable Carcinoma of the Pancreas\", \"Non-Resectable Pancreas Carcinoma\", \"Non-Resectable Pancreatic Carcinoma\", \"Pancreatic Carcinoma, Non-Resectable\", \"Unresectable Pancreatic Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5018\", \"name\": \"Unresectable Pancreatic Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C3850\", \"C155903\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148124\", \"name\": \"Unresectable Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Unresectable Malignant Tumor\"], \"nci_thesaurus_concept_id\": \"C27359\", \"name\": \"Unresectable Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C173385\", \"name\": \"Neuroendocrine Carcinoma, Excluding Head and Neck\", \"type\": [\"grade\", \"subtype\"], \"parents\": [\"C3773\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Limited Stage Lung Small Cell Carcinoma\", \"Limited Stage Small Cell Carcinoma of Lung\", \"Limited Stage Small Cell Carcinoma of the Lung\", \"Limited Stage Small Cell Lung Carcinoma\", \"limited-stage small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C7853\", \"name\": \"Limited Stage Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C4917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C155852\", \"name\": \"Metastatic Malignant Pancreatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9005\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Non-Small Cell Cancer AJCC v7\", \"Stage III NSCLC\", \"Stage III Non-Oat Cell Carcinoma of Lung\", \"Stage III Non-Oat Cell Carcinoma of the Lung\", \"Stage III Non-Oat Cell Lung Carcinoma\", \"Stage III Non-Small Cell Carcinoma of Lung\", \"Stage III Non-Small Cell Carcinoma of the Lung\", \"Stage III Non-Small Cell Lung Cancer AJCC v7\", \"Stage III Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7778\", \"name\": \"Stage III Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88890\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156485\", \"name\": \"Metastatic Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Oat Cell Cancer\", \"Oat Cell Carcinoma\", \"Oat cell carcinoma\", \"Small Cell Cancer\", \"Small Cell NEC\", \"Small Cell Neuroendocrine Carcinoma\", \"Small cell carcinoma, NOS\", \"Small cell neuroendocrine carcinoma\", \"oat cell cancer\"], \"nci_thesaurus_concept_id\": \"C3915\", \"name\": \"Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3773\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C53553\", \"name\": \"Breast Carcinoma by Gene Expression Profile\", \"type\": [\"subtype\"], \"parents\": [\"C5214\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"NEC\", \"Neuroendocrine Carcinoma\", \"Neuroendocrine cancer, NOS\", \"Neuroendocrine carcinoma, NOS\"], \"nci_thesaurus_concept_id\": \"C3773\", \"name\": \"Neuroendocrine Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3575\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma of Breast\", \"Adenocarcinoma of the Breast\", \"Mammary adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C5214\", \"name\": \"Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88891\", \"name\": \"Stage IV Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Pancreas\", \"Neoplasm of the Pancreas\", \"Pancreas Neoplasm\", \"Pancreas Tumor\", \"Pancreatic Tumor\", \"Tumor of Pancreas\", \"Tumor of the Pancreas\"], \"nci_thesaurus_concept_id\": \"C3305\", \"name\": \"Pancreatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C26842\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170458\", \"name\": \"Metastatic Pancreatobiliary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C133839\", \"C166418\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Unresectable Gastrointestinal System Adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C129654\", \"name\": \"Unresectable Digestive System Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C155903\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162255\", \"name\": \"Metastatic Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neuroendocrine Neoplasm of Lung\", \"Neuroendocrine Neoplasm of the Lung\", \"Pulmonary Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C5670\", \"name\": \"Lung Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Extensive Disease Small Cell Lung Cancer\", \"Extensive Disease Small Cell Lung Carcinoma\", \"Extensive Stage Lung Small Cell Carcinoma\", \"Extensive Stage Oat Cell Carcinoma of Lung\", \"Extensive Stage Oat Cell Carcinoma of the Lung\", \"Extensive Stage Oat Cell Lung Carcinoma\", \"Extensive Stage SCLC\", \"Extensive Stage Small Cell Carcinoma of Lung\", \"Extensive Stage Small Cell Carcinoma of the Lung\", \"Extensive Stage Small Cell Lung Carcinoma\", \"Small Cell Lung Cancer, Extensive Stage\", \"extensive-stage small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C9049\", \"name\": \"Extensive Stage Small Cell Lung Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C4917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Endocrine System\", \"Endocrine Disease\", \"Endocrine Disorder\", \"Endocrinopathy\", \"Thyroid or other glandular disorders\"], \"nci_thesaurus_concept_id\": \"C3009\", \"name\": \"Endocrine System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Stage III Lung Non-Small Cell Cancer AJCC v7\", \"Stage III NSCLC\", \"Stage III Non-Oat Cell Carcinoma of Lung\", \"Stage III Non-Oat Cell Carcinoma of the Lung\", \"Stage III Non-Oat Cell Lung Carcinoma\", \"Stage III Non-Small Cell Carcinoma of Lung\", \"Stage III Non-Small Cell Carcinoma of the Lung\", \"Stage III Non-Small Cell Lung Cancer AJCC v7\", \"Stage III Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7778\", \"name\": \"Stage III Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Stage III Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88890\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"NEN\", \"Neuroendocrine Neoplasm\", \"neuroendocrine tumor\"], \"nci_thesaurus_concept_id\": \"C3809\", \"name\": \"Neuroendocrine Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C3010\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157602\", \"name\": \"Metastatic Lung Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C5670\", \"C7377\", \"C156485\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91232\", \"name\": \"Lung Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136491\", \"name\": \"Lung Non-Small Cell Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C91232\", \"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156069\", \"name\": \"Metastatic Pancreatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C155852\", \"C170458\", \"C3850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v6 Stage\"], \"nci_thesaurus_concept_id\": \"C90513\", \"name\": \"Breast Cancer by AJCC v6 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Digestive System Carcinoma\", \"Metastatic Gastrointestinal Carcinoma\", \"Metastatic Gastrointestinal System Cancer\", \"Metastatic Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C133839\", \"name\": \"Metastatic Digestive System Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C96963\", \"C3482\", \"C162255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172806\", \"name\": \"Unresectable Neuroendocrine Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3773\", \"C148124\", \"C168973\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Exocrine Pancreas Tumor\", \"Malignant Neoplasm of Exocrine Pancreas\", \"Malignant Neoplasm of the Exocrine Pancreas\", \"Malignant Tumor of Exocrine Pancreas\", \"Malignant Tumor of the Exocrine Pancreas\"], \"nci_thesaurus_concept_id\": \"C7430\", \"name\": \"Malignant Exocrine Pancreas Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9005\", \"C4445\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91230\", \"name\": \"Breast Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Endocrine Neoplasm, Malignant\", \"Endocrine cancer, NOS\", \"Malignant Endocrine Gland Neoplasm\", \"Malignant Endocrine Gland Tumor\", \"Malignant Endocrine Tumor\", \"Malignant Neoplasm of Endocrine Gland\", \"Malignant Neoplasm of the Endocrine Gland\", \"Malignant Tumor of Endocrine Gland\", \"Malignant Tumor of the Endocrine Gland\", \"endocrine cancer\"], \"nci_thesaurus_concept_id\": \"C3575\", \"name\": \"Malignant Endocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3010\", \"C9305\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"9881\", \"active_sites_count\": 11, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Laboratory Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C64263\", \"name\": \"Laboratory Biomarker Analysis\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C63333\", \"C74957\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Lynparza\", \"Olaparib\"], \"nci_thesaurus_concept_id\": \"C71721\", \"name\": \"Olaparib\", \"description\": \"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C62554\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Medical Imaging, Positron Emission Tomography\", \"PET\", \"PET Scan\", \"Positron Emission Tomography Scan\", \"Positron-Emission Tomography\", \"Positron Emission Tomography\"], \"nci_thesaurus_concept_id\": \"C17007\", \"name\": \"Positron Emission Tomography\", \"description\": null, \"category\": \"other\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C17369\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Recentin\", \"Cediranib Maleate\"], \"nci_thesaurus_concept_id\": \"C48379\", \"name\": \"Cediranib Maleate\", \"description\": \"The maleate salt of an indole ether quinazoline derivative with antineoplastic activities.  Competing with adenosine triphosphate, cediranib  binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1742\", \"C1967\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"18F-MISO\", \"18F-Misonidazole\", \"FMISO\", \"18F-Fluoromisonidazole\"], \"nci_thesaurus_concept_id\": \"C52180\", \"name\": \"18F-Fluoromisonidazole\", \"description\": \"A radiofluorinated 2-nitroimidazole derivate with hypoxia-specific tracer activity.  Misonidazole is reduced under hypoxic conditions and in reduced form covalently binds to macromolecules in hypoxic cells. 18F (fluorine-18) radiofluorination of misonidazole to form 18F-fluoromisonidazole allows radioisotopic imaging of reduced misonidazole bound to macromolecules in hypoxic cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C2124\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C63333\", \"name\": \"Biomarker Analysis\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C74957\", \"name\": \"Mixed Category Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25294\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lab Test\", \"Lab Tests\", \"Laboratory Test\", \"Test\", \"Tests\", \"Laboratory Procedure\"], \"nci_thesaurus_concept_id\": \"C25294\", \"name\": \"Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Poly(ADP-Ribose) Polymerase Inhibitor\", \"PARP Inhibitor\"], \"nci_thesaurus_concept_id\": \"C62554\", \"name\": \"PARP Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Imaging Technique\", \"Imaging\", \"Imaging Procedures\", \"Imaging Technique\", \"Medical Imaging\", \"Imaging Technique\"], \"nci_thesaurus_concept_id\": \"C17369\", \"name\": \"Imaging Technique\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Angiogenesis Antagonists\", \"Angiogenesis Blockers\", \"Anti-Angiogenic Agents\", \"Antiangiogenesis Agents\", \"Antiangiogenic Agent\", \"Angiogenesis Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1742\", \"name\": \"Angiogenesis Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PTK Inhibitors\", \"Protein Tyrosine Kinase Inhibitors\", \"TK Inhibitors\", \"Tyrosine Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1967\", \"name\": \"Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protein Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1404\", \"name\": \"Protein Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radio Conjugates\"], \"nci_thesaurus_concept_id\": \"C2124\", \"name\": \"Radioconjugate\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C1446\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radioactive Pharmaceutical\", \"Radiochemical\", \"Radiopharmaceuticals\", \"Radiopharmaceutical Compound\"], \"nci_thesaurus_concept_id\": \"C1446\", \"name\": \"Radiopharmaceutical Compound\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C1909\"]}], \"name\": \"Treatment (cediranib maleate, olaparib)\", \"description\": \"Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2015-01097\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.\", \"brief_title\": \"A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 126, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2016-04-26\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": \"9881\", \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": \"OPEN\", \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Joseph Woong Kim\", \"study_source\": \"National\", \"completion_date\": \"2021-12-31\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"16-20911\"}, {\"name\": \"Study Protocol Other Identifier\", \"value\": \"167513\"}, {\"name\": \"Study Protocol Other Identifier\", \"value\": \"TBCRC 44\"}], \"amendment_date\": \"2021-05-03T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Cross-over\", \"lead_org\": \"University of California San Francisco\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Advanced breast cancer with locally recurrent chest wall disease not amenable to surgical excision with curative intent\\r\\n* Distant sites of disease are allowed\\r\\n* Prior radiation to the chest wall is not required\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"The following disease subtypes are eligible:\\r\\n* Triple negative disease (defined as estrogen receptor [ER] < 10%, progesterone receptor [PR] < 10%, HER2 negative)\\r\\n* Hormone receptor positive, HER2 negative disease with evidence of progression on at least two prior lines of hormone therapy, unless, per treating investigator\\u2019s judgement, is not considered a candidate for further endocrine therapy\\r\\n* HER2 positive disease with evidence of disease progression on trastuzumab, pertuzumab, T-DM1 and oral tyrosine kinase inhibitor unless contraindicated with no other HER2 targeted therapy options available. Patients in this category will be classified by ER status\\r\\n** Histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) methodology using standard criteria.\\r\\n** Cardiac function must be determined within 4 weeks of study entry to be >= 50% using electrocardiography (ECHO) or multigated acquisition scan (MUGA)\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Any number of prior lines of therapy are allowed\\r\\n* Prior platinum based therapy is allowed in the following settings:\\r\\n** Treatment in the neoadjuvant and/or adjuvant setting without clear progression of disease\\r\\n** Treatment in the metastatic setting without clear progression of disease\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"At least two weeks from last systemic chemotherapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less; subjects with =< grade 2 neuropathy are an exception to this criterion; no specific window is required for hormone therapy\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"At least two weeks from last radiation therapy, with recovery of all treatment related toxicity to grade 1 or less (excluding alopecia)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Prior central nervous system (CNS) disease is allowed if stable for at least one month since whole brain radiation therapy, and 2 weeks since stereotactic radiotherapy, and not requiring steroids; patients whose CNS disease was surgically treated may be enrolled if stable for at least one month, and not requiring steroids\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Able to provide tissue from a newly obtained core or excisional biopsy of a chest wall tumor lesion; newly-obtained is defined as a specimen any time after the last systemic or local therapy utilized to treat the disease; subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the study chair\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Willing and able to provide written informed consent\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Absolute neutrophil count (ANC) >= 1,000 /mcL (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Platelets >= 100,000/mcL (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (within 10 business days of treatment initiation)\\r\\n* Creatinine clearance should be calculated per institutional standard\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Albumin >= 2.5 g/dL (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 business days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"Female subjects of childbearing potential should be willing to use an acceptable form of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\"}, {\"inclusion_indicator\": true, \"display_order\": 21, \"description\": \"Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Treatment with an investigational agent within 4 weeks of the first dose of treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"A diagnosis of immunodeficiency or is currently receiving systemic steroid therapy at any dose or is receiving any other form of immunosuppressive therapy; steroid therapy is not allowed within 7 days prior to the first dose of trial treatment; however, topical and intranasal corticosteroids are allowed, and not an exclusion for participation\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Known active TB (Bacillus tuberculosis); patients with a distant history of tuberculosis that was appropriately treated and have no evidence of active infection are eligible to participate; patients with a history of latent tuberculosis that was appropriately treated are also eligible to participate\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Hypersensitivity to pembrolizumab or any of its excipients\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Hypersensitivity to carboplatin or cisplatin\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\\r\\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion\\r\\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Has an active infection requiring systemic therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject\\u2019s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, screening visit through 120 days after the last dose of trial treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; has been on any prior Merck MK-3475 (pembrolizumab) studies\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug; administration of killed vaccines is allowed\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"CA\", \"contact_name\": \"Hope S. Rugo\", \"contact_phone\": \"415-353-7618\", \"recruitment_status_date\": \"2017-09-07\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": \"Hope.Rugo@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"DC\", \"contact_name\": \"Paula R Pohlmann\", \"contact_phone\": \"202-444-4655\", \"recruitment_status_date\": \"2018-07-10\", \"org_address_line_2\": \"Lombardi Comprehensive Cancer Center\", \"org_va\": false, \"org_address_line_1\": \"3800 Reservoir Road Northwest\", \"org_tty\": null, \"org_family\": \"Georgetown Lombardi Comprehensive Cancer Center\", \"org_postal_code\": \"20007\", \"contact_email\": \"Paula.R.Pohlmann@gunet.georgetown.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Washington\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"202-784-4344\", \"org_phone\": \"202-444-0381\\r202-444-4000\", \"org_name\": \"MedStar Georgetown University Hospital\", \"org_coordinates\": {\"lon\": -77.0771, \"lat\": 38.9147}}, {\"org_state_or_province\": \"IL\", \"contact_name\": \"Rita Nanda\", \"contact_phone\": \"773-834-2756\", \"recruitment_status_date\": \"2018-08-21\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5841 South Maryland Avenue\", \"org_tty\": null, \"org_family\": \"University of Chicago Comprehensive Cancer Center\", \"org_postal_code\": \"60637\", \"contact_email\": \"rnanda@medicine.bsd.uchicago.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Chicago\", \"org_email\": \"cancerclinicaltrials@bsd.uchicago.edu\", \"org_country\": \"United States\", \"org_fax\": \"773-702-9311\", \"org_phone\": \"773-834-7424\\r773-702-6180\", \"org_name\": \"University of Chicago Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -87.6021, \"lat\": 41.781}}, {\"org_state_or_province\": \"IN\", \"contact_name\": \"Anna Maria Vita Storniolo\", \"contact_phone\": null, \"recruitment_status_date\": \"2018-06-25\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"535 Barnhill Drive\", \"org_tty\": null, \"org_family\": \"Indiana University Melvin and Bren Simon Cancer Center\", \"org_postal_code\": \"46202\", \"contact_email\": \"astornio@iu.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Indianapolis\", \"org_email\": \"iutrials@iu.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"317-274-2552\", \"org_name\": \"Indiana University/Melvin and Bren Simon Cancer Center\", \"org_coordinates\": {\"lon\": -86.163, \"lat\": 39.7837}}, {\"org_state_or_province\": \"MA\", \"contact_name\": \"Neelima Vidula\", \"contact_phone\": \"617-726-6500\", \"recruitment_status_date\": \"2018-08-03\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"55 Fruit Street\", \"org_tty\": null, \"org_family\": \"Dana-Farber/Harvard Cancer Center\", \"org_postal_code\": \"02114\", \"contact_email\": \"nvidula@mgh.harvard.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Boston\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"617-726-2000\", \"org_name\": \"Massachusetts General Hospital Cancer Center\", \"org_coordinates\": {\"lon\": -71.068, \"lat\": 42.3621}}, {\"org_state_or_province\": \"MN\", \"contact_name\": \"Minetta C. Liu\", \"contact_phone\": null, \"recruitment_status_date\": \"2017-03-03\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"200 First Street Southwest\", \"org_tty\": null, \"org_family\": \"Mayo Clinic Cancer Center\", \"org_postal_code\": \"55905\", \"contact_email\": \"Liu.Minetta@mayo.edu\", \"recruitment_status\": \"APPROVED\", \"org_city\": \"Rochester\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"507-284-0161\", \"org_phone\": \"507-538-7623\", \"org_name\": \"Mayo Clinic in Rochester\", \"org_coordinates\": {\"lon\": -92.4912, \"lat\": 44.0368}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Rachel C. Jankowitz\", \"contact_phone\": \"412-641-6500\", \"recruitment_status_date\": \"2018-06-19\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5150 Centre Avenue\", \"org_tty\": null, \"org_family\": \"University of Pittsburgh Cancer Institute\", \"org_postal_code\": \"15232\", \"contact_email\": \"jankowitzr@upmc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Pittsburgh\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"412-647-8073\", \"org_name\": \"University of Pittsburgh Cancer Institute (UPCI)\", \"org_coordinates\": {\"lon\": -79.9323, \"lat\": 40.4529}}, {\"org_state_or_province\": \"TN\", \"contact_name\": \"Vandana Gupta Abramson\", \"contact_phone\": \"615-875-9636\", \"recruitment_status_date\": \"2018-05-17\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2200 Pierce Avenue\", \"org_tty\": null, \"org_family\": \"Vanderbilt-Ingram Cancer Center\", \"org_postal_code\": \"37232\", \"contact_email\": \"Vandana.Abramson@vanderbilt.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Nashville\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-936-8422\", \"org_name\": \"Vanderbilt University/Ingram Cancer Center\", \"org_coordinates\": {\"lon\": -86.8096, \"lat\": 36.1437}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Hope S. Rugo\", \"contact_phone\": \"415-353-7618\", \"recruitment_status_date\": \"2017-09-07\", \"org_address_line_2\": \"Floor 6\", \"org_va\": false, \"org_address_line_1\": \"490 Illinois Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"Hope.Rugo@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"University of California San Francisco\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To determine the disease control rate (including complete response [CR], partial response [PR] and stable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To determine the disease control rate (including CR, PR and stable disease as defined by immune-related (ir)RECIST at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.\\r\\nII. To determine progression free survival in patients treated with pembrolizumab and carboplatin versus (vs.) carboplatin alone.\\r\\nIII. To determine the toxicity of pembrolizumab and carboplatin vs. carboplatin alone.\\r\\nIV. To determine 18 week disease control rate based on tumor PD-L1 expression via immunohistochemistry.\\r\\nV. To determine the overall response rate of patients treated with pembrolizumab and carboplatin vs. carboplatin alone.\\r\\nVI. Support standardized gut microbiome sample collection, storage, preparation and analysis to optimize scientific discovery potential by minimizing variation due to methodologic differences in sample collection, storage, preparation and analysis, as well as permitting cross-study comparisons and testing of multiple analytics platforms to explore gut microbiome associations with the clinical response to immunotherapy.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM A: Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients may discontinue carboplatin and receive pembrolizumab alone. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. \\r\\n\\r\\nARM B: Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Patients may also receive carboplatin IV on day 1 at the discretion of the investigator. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 30 days.\", \"official_title\": \"A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"From the baseline until the chest wall disease progression or death from any cause, assessed at 18 months\", \"name\": \"Disease control rate (complete response [CR]/partial response [PR]/stable disease [SD])\", \"description\": \"Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Disease control will also be based on PD-L1 expression via immunohistochemistry. Will be summarized by treatment arms using the Kaplan-Meier method, including graphical displays.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 18 months\", \"name\": \"Objective response rate (ORR) defined as CR/PR\", \"description\": \"Assessed by RECIST. Will be summarized by treatment arms using the Kaplan-Meier method, including graphical displays.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 18 months\", \"name\": \"ORR defined as CR/PR\", \"description\": \"Assessed by immune-related (ir)RECIST. Will be summarized by treatment arms using the Kaplan-Meier method, including graphical displays.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 18 months\", \"name\": \"Progression free survival\", \"description\": \"Supportive analyses will be done using estimates of progression free survival between treatment arms by the Kaplan-Meier method in order to account for any censoring patients. Will be summarized by treatment arms using the Kaplan-Meier method, including graphical displays.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 2, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03095352\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER Alpha Negative\", \"ER Negative\", \"ER-\", \"ER-Alpha Negative\", \"ERA Negative\", \"ESR Negative\", \"ESR1 Negative\", \"ESRA Negative\", \"ESTRR Negative\", \"Estrogen Receptor 1 Negative\", \"Estrogen Receptor Alpha Negative\", \"NR3A1 Negative\", \"Negative\", \"Negative Estrogen Receptor\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Negative\", \"estrogen receptor negative\"], \"nci_thesaurus_concept_id\": \"C15493\", \"name\": \"Estrogen Receptor Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16150\", \"C165233\", \"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C35681\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C16150\", \"C165233\", \"C38349\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Negative\", \"PGR Negative\", \"PR Negative\", \"PR-\", \"progesterone receptor negative\"], \"nci_thesaurus_concept_id\": \"C15497\", \"name\": \"Progesterone Receptor Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16149\", \"C165233\", \"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35681\", \"C36292\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C16149\", \"C28656\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER-Negative PR-Negative ERBB2-Negative\", \"ER-PR-HER2/neu-\", \"ER-negative PR-negative HER2/neu-negative\", \"ER/PR/HER2 Negative\", \"ESR1/PGR/ERBB2 Negative Finding\", \"Triple Negative Breast Cancer Finding\", \"Triple Negative Breast Cancer Result\", \"Triple-Negative Breast Cancer Result\", \"triple-negative breast cancer\"], \"nci_thesaurus_concept_id\": \"C71428\", \"name\": \"Triple-Negative Breast Cancer Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C165233\", \"C16612\", \"C17756\", \"C20103\", \"C20420\", \"C20709\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C28656\", \"C3367\", \"C35681\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C94299\", \"C17756\", \"C38349\", \"C28656\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C54362\", \"name\": \"Transcription Regulation Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PGR\", \"PR\", \"Progesterone Receptor Gene\"], \"nci_thesaurus_concept_id\": \"C28656\", \"name\": \"PGR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER Alpha Status\", \"ER Status\", \"ER-Alpha Status\", \"ERA Status\", \"ESR Status\", \"ESR1 Status\", \"ESRA Status\", \"ESTRR Status\", \"Estrogen Receptor\", \"Estrogen Receptor 1 Status\", \"Estrogen Receptor Alpha Status\", \"NR3A1 Status\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Status\"], \"nci_thesaurus_concept_id\": \"C16150\", \"name\": \"Estrogen Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C38349\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2\", \"Erb-b2 Receptor Tyrosine Kinase 2 Gene\", \"HER2\", \"HER2/Neu\", \"NEU\"], \"nci_thesaurus_concept_id\": \"C17756\", \"name\": \"ERBB2 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C94299\", \"name\": \"Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20709\", \"name\": \"Nuclear Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C21295\", \"C54362\"], \"parents\": [\"C20103\", \"C20420\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PgR Status\", \"Progesterone Receptor\"], \"nci_thesaurus_concept_id\": \"C16149\", \"name\": \"Progesterone Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C36292\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C28656\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Negative\", \"negative test result\"], \"nci_thesaurus_concept_id\": \"C35681\", \"name\": \"Negative Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER\", \"ESR1\", \"Estrogen Receptor 1 Gene\"], \"nci_thesaurus_concept_id\": \"C38349\", \"name\": \"ESR1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Absent\", \"LOST\", \"Loss of Expression\", \"Negative\", \"Not Expressed\"], \"nci_thesaurus_concept_id\": \"C165233\", \"name\": \"Expression Negative\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35681\", \"C7057\", \"C77140\"], \"parents\": [\"C35681\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Transcription Factor\"], \"nci_thesaurus_concept_id\": \"C20420\", \"name\": \"Transcription Factor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C54362\"], \"parents\": [\"C54362\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2017-09-07\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage III Breast Cancer AJCC v8\", \"Anatomic Stage III Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139541\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139533\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage IIIA Breast Cancer AJCC v8\", \"Anatomic Stage IIIA Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139542\", \"name\": \"Stage IIIA Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139541\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage IIIB Breast Cancer AJCC v8\", \"Anatomic Stage IIIB Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139543\", \"name\": \"Stage IIIB Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139541\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage IIIC Breast Cancer AJCC v8\", \"Anatomic Stage IIIC Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139544\", \"name\": \"Stage IIIC Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139541\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage IV Breast Cancer AJCC v8\", \"Anatomic Stage IV Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139545\", \"name\": \"Stage IV Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139533\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage III Breast Cancer AJCC v8\", \"Prognostic Stage III Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139582\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139554\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage IIIA Breast Cancer AJCC v8\", \"Prognostic Stage IIIA Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139583\", \"name\": \"Stage IIIA Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139582\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage IIIB Breast Cancer AJCC v8\", \"Prognostic Stage IIIB Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139584\", \"name\": \"Stage IIIB Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139582\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage IIIC Breast Cancer AJCC v8\", \"Prognostic Stage IIIC Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139585\", \"name\": \"Stage IIIC Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139582\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage IV Breast Cancer AJCC v8\", \"Prognostic Stage IV Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139587\", \"name\": \"Stage IV Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139554\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Hormone Receptor Positive Breast Adenocarcinoma\", \"Refractory Hormone Receptor-Positive Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C157057\", \"name\": \"Refractory Hormone Receptor Positive Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C157056\", \"C165703\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C158752\", \"name\": \"Unresectable Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C148124\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162648\", \"name\": \"Advanced Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153171\", \"C153238\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C175236\", \"name\": \"Advanced Triple-Negative Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C165700\", \"C153348\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Chest Wall Tumor\", \"Malignant Neoplasm of Chest Wall\", \"Malignant Neoplasm of the Chest Wall\", \"Malignant Tumor of Chest Wall\", \"Malignant Tumor of the Chest Wall\"], \"nci_thesaurus_concept_id\": \"C4580\", \"name\": \"Malignant Chest Wall Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4929\", \"C3576\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"ERBB2 Overexpressing Subtype of Breast Carcinoma\", \"HER2 Overexpressing Breast Carcinoma\", \"HER2 Overexpressing Subtype of Breast Carcinoma\", \"HER2 Positive Breast Cancer\", \"HER2 Positive Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C53556\", \"name\": \"HER2-Positive Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C53553\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Unresectable Malignant Tumor\"], \"nci_thesaurus_concept_id\": \"C27359\", \"name\": \"Unresectable Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162648\", \"name\": \"Advanced Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153171\", \"C153238\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153238\", \"name\": \"Metastatic Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C3482\", \"C170728\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Triple-Negative Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C71732\", \"name\": \"Triple-Negative Breast Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C53553\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v8 Anatomic Stage\"], \"nci_thesaurus_concept_id\": \"C139533\", \"name\": \"Breast Cancer by AJCC v8 Anatomic Stage\", \"type\": [\"stage\"], \"parents\": [\"C139532\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153348\", \"name\": \"Metastatic Triple-Negative Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C165698\", \"C71732\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer by AJCC v8 Prognostic Stage Group\", \"Breast Carcinoma by AJCC v8 Prognostic Stage\"], \"nci_thesaurus_concept_id\": \"C139554\", \"name\": \"Breast Cancer by AJCC v8 Prognostic Stage\", \"type\": [\"stage\"], \"parents\": [\"C139532\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C53553\", \"name\": \"Breast Carcinoma by Gene Expression Profile\", \"type\": [\"subtype\"], \"parents\": [\"C5214\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma of Breast\", \"Adenocarcinoma of the Breast\", \"Mammary adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C5214\", \"name\": \"Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Cancer\", \"advanced cancer\"], \"nci_thesaurus_concept_id\": \"C9270\", \"name\": \"Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165700\", \"name\": \"Advanced Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C159556\", \"C162648\", \"C165698\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Tumor\"], \"nci_thesaurus_concept_id\": \"C7628\", \"name\": \"Refractory Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170728\", \"name\": \"Metastatic Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9335\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C159563\", \"name\": \"Refractory Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C8511\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148124\", \"name\": \"Unresectable Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C159556\", \"name\": \"Advanced Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153171\", \"C4124\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hormone Receptor Positive Breast Adenocarcinoma\", \"Hormone Receptor-Positive Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C157056\", \"name\": \"Hormone Receptor Positive Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C5214\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Chest Wall Disease\"], \"nci_thesaurus_concept_id\": \"C35745\", \"name\": \"Chest Wall Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165698\", \"name\": \"Metastatic Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C5214\", \"C4124\", \"C153238\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C147965\", \"name\": \"Refractory Breast Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C8511\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Advanced Cancer\", \"advanced cancer\"], \"nci_thesaurus_concept_id\": \"C9270\", \"name\": \"Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v8 Stage\"], \"nci_thesaurus_concept_id\": \"C139532\", \"name\": \"Breast Cancer by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153171\", \"name\": \"Advanced Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170728\", \"name\": \"Metastatic Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9335\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Prognostic Stage III Breast Cancer AJCC v8\", \"Prognostic Stage III Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139582\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139554\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C8511\", \"name\": \"Refractory Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C120186\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165703\", \"name\": \"Refractory Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C5214\", \"C159563\", \"C147965\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage III Breast Cancer AJCC v8\", \"Anatomic Stage III Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139541\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C139533\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Cancer\", \"clinical resistance\", \"refractory cancer\", \"resistant cancer\"], \"nci_thesaurus_concept_id\": \"C120186\", \"name\": \"Refractory Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C7628\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C4124\", \"name\": \"Metastatic Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153171\", \"name\": \"Advanced Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153238\", \"name\": \"Metastatic Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C3482\", \"C170728\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Chest Wall Tumor\", \"Neoplasm of Chest Wall\", \"Neoplasm of the Chest Wall\", \"Tumor of Chest Wall\", \"Tumor of the Chest Wall\"], \"nci_thesaurus_concept_id\": \"C4929\", \"name\": \"Chest Wall Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35745\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"157521\", \"active_sites_count\": 8, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"nci_thesaurus_concept_id\": \"C106432\", \"name\": \"Pembrolizumab\", \"description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Blastocarb\", \"Carboplat\", \"Carbosin\", \"Carbosol\", \"Carbotec\", \"Displata\", \"Ercar\", \"Nealorin\", \"Novoplatinum\", \"Paraplatin AQ\", \"Paraplatine\", \"Platinwas\", \"Ribocarbo\", \"Carboplatin\"], \"nci_thesaurus_concept_id\": \"C1282\", \"name\": \"Carboplatin\", \"description\": \"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1450\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Laboratory Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C64263\", \"name\": \"Laboratory Biomarker Analysis\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C63333\", \"C74957\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Herceptin\", \"Herzuma\", \"Kanjinti\", \"Ogivri\", \"Ontruzant\", \"Trazimera\", \"Trastuzumab\"], \"nci_thesaurus_concept_id\": \"C1647\", \"name\": \"Trastuzumab\", \"description\": \"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C155711\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Platinum Agents\", \"Platinum-Based Chemotherapy\", \"Platinum Compound\"], \"nci_thesaurus_concept_id\": \"C1450\", \"name\": \"Platinum Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1590\", \"C2163\", \"C798\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"nci_thesaurus_concept_id\": \"C1590\", \"name\": \"Antineoplastic Alkylating Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2842\", \"name\": \"DNA Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2163\", \"name\": \"DNA Adduct Forming Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiation Sensitizers\", \"Radiation-Sensitizing Agents\", \"Radiation-Sensitizing Drugs\", \"Radiosensitizers\", \"Radiosensitizing Drugs\"], \"nci_thesaurus_concept_id\": \"C798\", \"name\": \"Radiosensitizing Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C63333\", \"name\": \"Biomarker Analysis\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C74957\", \"name\": \"Mixed Category Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25294\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lab Test\", \"Lab Tests\", \"Laboratory Test\", \"Test\", \"Tests\", \"Laboratory Procedure\"], \"nci_thesaurus_concept_id\": \"C25294\", \"name\": \"Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-ErbB2 Monoclonal Antibody\", \"Anti-HER-2 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C155711\", \"name\": \"Anti-HER2 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129822\", \"C163760\", \"C20401\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"HER2-targeting Agent\"], \"nci_thesaurus_concept_id\": \"C163760\", \"name\": \"HER2-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C163758\"]}], \"name\": \"Arm A (carboplatin, pembrolizumab)\", \"description\": \"Patients receive carboplatin IV and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients may discontinue carboplatin and receive pembrolizumab alone. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"intervention_name\": \"Pembrolizumab\", \"category\": \"agent\", \"intervention_code\": \"C106432\", \"intervention_description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C128037\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Blastocarb\", \"Carboplat\", \"Carbosin\", \"Carbosol\", \"Carbotec\", \"Displata\", \"Ercar\", \"Nealorin\", \"Novoplatinum\", \"Paraplatin AQ\", \"Paraplatine\", \"Platinwas\", \"Ribocarbo\", \"Carboplatin\"], \"intervention_name\": \"Carboplatin\", \"category\": \"agent\", \"intervention_code\": \"C1282\", \"intervention_description\": \"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C1450\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Laboratory Biomarker Analysis\"], \"intervention_name\": \"Laboratory Biomarker Analysis\", \"category\": \"other\", \"intervention_code\": \"C64263\", \"intervention_description\": null, \"parents\": [\"C63333\", \"C74957\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Herceptin\", \"Herzuma\", \"Kanjinti\", \"Ogivri\", \"Ontruzant\", \"Trazimera\", \"Trastuzumab\"], \"intervention_name\": \"Trastuzumab\", \"category\": \"agent\", \"intervention_code\": \"C1647\", \"intervention_description\": \"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C155711\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"intervention_name\": \"Anti-PD1 Monoclonal Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C128037\", \"intervention_description\": \"\", \"parents\": [\"C20401\", \"C124946\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"intervention_name\": \"Monoclonal Antibody Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C20401\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"intervention_name\": \"PD1 Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C124946\", \"intervention_description\": \"\", \"parents\": [\"C143250\", \"C163758\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"intervention_name\": \"Immune Checkpoint Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C143250\", \"intervention_description\": \"\", \"parents\": [\"C141144\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immune Checkpoint Modulator\", \"category\": \"agent category\", \"intervention_code\": \"C141144\", \"intervention_description\": \"\", \"parents\": [\"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"intervention_name\": \"Targeted Therapy Agent\", \"category\": \"agent category\", \"intervention_code\": \"C163758\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Platinum Agents\", \"Platinum-Based Chemotherapy\", \"Platinum Compound\"], \"intervention_name\": \"Platinum Compound\", \"category\": \"agent category\", \"intervention_code\": \"C1450\", \"intervention_description\": \"\", \"parents\": [\"C1590\", \"C2163\", \"C798\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"intervention_name\": \"Antineoplastic Alkylating Agent\", \"category\": \"agent category\", \"intervention_code\": \"C1590\", \"intervention_description\": \"\", \"parents\": [\"C2842\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"DNA Binding Agent\", \"category\": \"agent category\", \"intervention_code\": \"C2842\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"DNA Adduct Forming Agent\", \"category\": \"agent category\", \"intervention_code\": \"C2163\", \"intervention_description\": \"\", \"parents\": [\"C2842\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiation Sensitizers\", \"Radiation-Sensitizing Agents\", \"Radiation-Sensitizing Drugs\", \"Radiosensitizers\", \"Radiosensitizing Drugs\"], \"intervention_name\": \"Radiosensitizing Agent\", \"category\": \"agent category\", \"intervention_code\": \"C798\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biomarker Analysis\"], \"intervention_name\": \"Biomarker Analysis\", \"category\": \"none\", \"intervention_code\": \"C63333\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Intervention or Procedure\", \"category\": \"none\", \"intervention_code\": \"C25218\", \"intervention_description\": \"\", \"parents\": [\"C16203\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Clinical or Research Activity\", \"category\": \"none\", \"intervention_code\": \"C16203\", \"intervention_description\": \"\", \"parents\": [\"C43431\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Activity\", \"category\": \"none\", \"intervention_code\": \"C43431\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Mixed Category Laboratory Procedure\", \"category\": \"none\", \"intervention_code\": \"C74957\", \"intervention_description\": \"\", \"parents\": [\"C25294\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lab Test\", \"Lab Tests\", \"Laboratory Test\", \"Test\", \"Tests\", \"Laboratory Procedure\"], \"intervention_name\": \"Laboratory Procedure\", \"category\": \"none\", \"intervention_code\": \"C25294\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-ErbB2 Monoclonal Antibody\", \"Anti-HER-2 Monoclonal Antibody\"], \"intervention_name\": \"Anti-HER2 Monoclonal Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C155711\", \"intervention_description\": \"\", \"parents\": [\"C129822\", \"C163760\", \"C20401\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"intervention_name\": \"Antineoplastic Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C129822\", \"intervention_description\": \"\", \"parents\": [\"C129821\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"intervention_name\": \"Antineoplastic Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C129821\", \"intervention_description\": \"\", \"parents\": [\"C274\", \"C307\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"HER2-targeting Agent\"], \"intervention_name\": \"HER2-targeting Agent\", \"category\": \"agent category\", \"intervention_code\": \"C163760\", \"intervention_description\": \"\", \"parents\": [\"C163758\"]}], \"name\": \"Arm B (carboplatin, pembrolizumab)\", \"description\": \"Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Patients may also receive carboplatin IV on day 1 at the discretion of the investigator. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.\", \"type\": \"ACTIVE_COMPARATOR\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2018-00010\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies the effect of carboplatin with or without pembrolizumab in treating patients with breast cancer that has spread to other places in the body (advanced) with chest wall disease that has come back (locally recurrent) and cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.\", \"brief_title\": \"Carboplatin with or without Pembrolizumab in Treating Patients with Advanced Breast Cancer with Locally Recurrent Chest Wall Disease That Cannot Be Removed by Surgery\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 84, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2017-09-07\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Breast\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Hope S. Rugo\", \"study_source\": \"Institutional\", \"completion_date\": \"2022-09-30\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"ETCTN10030\"}], \"amendment_date\": \"2021-03-11T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"JHU Sidney Kimmel Comprehensive Cancer Center LAO\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"PRE-REGISTRATION ELIGIBILITY CRITERIA\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Patients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be 60 years of age or older\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Bone marrow and/or peripheral blood specimens will be submitted for correlative studies; patients who have a dry tap will still be eligible\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"REGISTRATION ELIGIBILITY CRITERIA\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Patients must have histologically or cytologically confirmed by the local institution CD19+ precursor B-acute lymphoblastic leukemia (pre-B cell ALL) OR CD19+ mixed phenotype acute leukemia (MPAL): a) with relapse following or refractory to at least one prior line of therapy if older than 21 years; b) in second or higher relapse or refractory to at least two prior lines of therapy if 21 years old and younger (16-21); c) or they must have a new diagnosis of pre-B cell ALL or CD19+ MPAL but are >= 60 years old and are either not a candidate for or do not wish to receive traditional induction chemotherapy\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"The evidence of CD19+ expression on leukemia cells must be confirmed by pathology review of the bone marrow and/or peripheral blood specimens (flow cytometry and/or immunohistochemistry) collected at the time of current relapse and prior to the initiation of therapy\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Patients with Philadelphia chromosome (Ph) positive (+) pre-B cell ALL OR Ph+ MPAL will be eligible if they have been refractory to or intolerant of treatment with at least 1 second-generation or third-generation tyrosine kinase inhibitor (TKI)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Patients who were treated with blinatumomab in the past will be allowed on the study as long as they have persistent CD19 expression on leukemia cells and did not experience unacceptable toxicities with prior blinatumomab administration; patients who were treated with chimeric antigen receptor (CAR)-modified T cells targeting CD19 in the past will be allowed on the study as long as they have persistent CD19 expression on leukemia cells\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT) will be eligible if they are more than 90 days removed from the date of stem cell infusion, have no evidence of acute graft-versus-host disease (GVHD) or active chronic (grade 2-4) GVHD, and are off of all transplant-related immunosuppression for at least 2 weeks\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0-2 (Karnofsky >= 60%)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Life expectancy of greater than 12 weeks\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Total bilirubin =< 2.0 mg/dL (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x upper limit of normal (ULN)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"The effects of nivolumab, ipilimumab, and blinatumomab on the developing human fetus are unknown; for this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of treatment on the study; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab +/- ipilimumab and blinatumomab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\\r\\n* Note: Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\\r\\n* Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Adequate pulmonary function as assessed by oxygen saturation >= 90% when ambulating and not requiring supplemental oxygen\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:\\r\\n* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months\\r\\n* They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts\\r\\n* They have an undetectable viral load on standard assays\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Patients with a known history of hepatitis C (HCV) will be eligible if they have an undetectable viral load; if the patient received treatment for HCV, then that treatment must have been completed at least three weeks prior to enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Ability to understand and the willingness to sign a written informed consent document\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Patients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows: chemotherapy, radiotherapy or surgery =< 3 weeks prior to entering the study, targeted therapy (e.g., TKI) =< 1 week prior to entering the study; autologous HSCT =< 6 weeks prior to entering the study; investigational drug or immunotherapy (e.g. rituximab) =< 4 weeks prior to entering the study; prophylactic intrathecal chemotherapy within one week of enrollment allowed; patients will be allowed to receive cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone, prednisone or similar) or cyclophosphamide provided that it is discontinued at least 24 hours prior to the initiation of study treatment; pre-phase treatment with dexamethasone 10 mg/m^2 (maximum total 24 mg per day) for up to 5 days is required for patients with bone marrow blasts more than 50%, peripheral blood blasts of 15,000/uL or higher, or elevated lactate dehydrogenase suggesting rapidly progressing disease as per investigator\\u2019s assessment; pre-phase treatment must be stopped at least 24 hours prior to the initiation of blinatumomab\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Patients who are receiving any other investigational agents\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Patients with active central nervous system leukemia are excluded from this clinical trial because they may develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible; the absence of CNS disease must be confirmed by flow cytometric and cytologic examination of the cerebrospinal fluid (CSF) within 7 days of study enrollment\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Active leukemia in the testes or isolated extramedullary relapse; patients with a history of treated leukemia in testes but no active disease at the time of enrollment are eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomab\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"History of severe hypersensitivity reaction to any monoclonal antibody\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Uncontrolled intercurrent illness including, but not limited to, active, uncontrolled infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements; patients with infection under treatment and controlled with antibiotics are eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Pregnant women are excluded from this study because nivolumab and ipilimumab have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab and ipilimumab, breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"History of any chronic hepatitis including alcoholic, non-alcoholic steatohepatitis (NASH), drug related, autoimmune, chronic viral positive tests for hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antibody (anti-HBs), or a positive hepatitis C (HCV) viral load; these patients are excluded due to the risk for autoimmune hepatitis with immune checkpoint inhibitors exacerbating their known liver disease as well as the unknown risk for hepatitis B and/or C reactivation with blinatumomab and immune checkpoint inhibitors\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Subjects with active autoimmune disease, a history of known or suspected autoimmune disease or a history of a syndrome requiring systemic corticosteroids (> 10 mg daily of prednisone equivalent) except for the treatment of malignancy with the exception of:\\r\\n* Isolated vitiligo\\r\\n* Resolved childhood atopy\\r\\n* History of a positive antinuclear antibody (ANA) titer without associated symptoms or history of symptoms of an autoimmune disorder\\r\\n* Controlled thyroid disorders\\r\\n* Type I diabetes mellitus\\r\\n* Psoriasis, Sjogren\\u2019s syndrome, and arthropathies not requiring systemic treatment\\r\\n* Autoimmune diseases: these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, autoimmune vasculitis, inflammatory bowel disease (IBD), Crohn\\u2019s, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen), or as pre-phase treatment for cytoreduction; patients will receive steroids with blinatumomab to reduce cytokine release syndrome (CRS) as specified in the protocol\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Patients who have a history of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson\\u2019s disease, cerebellar disease, psychosis, or other significant CNS abnormalities; a history of treated CNS leukemia will be allowed if recent CNS studies confirm the absence of active CNS disease at the time of study entry (screening)\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Patients with a known concurrent malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or carcinoma in situ of the cervix\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"16 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 16, \"min_age_in_years\": 16}}, \"sites\": [{\"org_state_or_province\": \"CT\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"203-785-5702\", \"recruitment_status_date\": \"2019-03-15\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"333 Cedar Street\", \"org_tty\": null, \"org_family\": \"Yale Cancer Center\", \"org_postal_code\": \"06520\", \"contact_email\": \"canceranswers@yale.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"New Haven\", \"org_email\": \"canceranswers@yale.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"203-785-5702\", \"org_name\": \"Yale University\", \"org_coordinates\": {\"lon\": -72.9291, \"lat\": 41.31}}, {\"org_state_or_province\": \"KY\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"859-257-3379\", \"recruitment_status_date\": \"2020-03-19\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"800 Rose Street\", \"org_tty\": null, \"org_family\": \"University of Kentucky - Markey Cancer Center\", \"org_postal_code\": \"40536\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Lexington\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"859-257-3379\", \"org_name\": \"University of Kentucky/Markey Cancer Center\", \"org_coordinates\": {\"lon\": -84.5089, \"lat\": 38.0316}}, {\"org_state_or_province\": \"MA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"877-442-3324\", \"recruitment_status_date\": \"2017-10-05\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"450 Brookline Avenue\", \"org_tty\": null, \"org_family\": \"Dana-Farber/Harvard Cancer Center\", \"org_postal_code\": \"02215\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Boston\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"617-632-3000\", \"org_name\": \"Dana-Farber Cancer Institute\", \"org_coordinates\": {\"lon\": -71.1025, \"lat\": 42.3469}}, {\"org_state_or_province\": \"MD\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"410-955-8804\", \"recruitment_status_date\": \"2017-09-27\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"600 North Wolfe Street\", \"org_tty\": null, \"org_family\": \"Sidney Kimmel Comprehensive Cancer Center\", \"org_postal_code\": \"21287\", \"contact_email\": \"jhcccro@jhmi.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Baltimore\", \"org_email\": \"jhcccro@jhmi.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"410-955-8804\", \"org_name\": \"Johns Hopkins University/Sidney Kimmel Cancer Center\", \"org_coordinates\": {\"lon\": -76.5621, \"lat\": 39.3021}}, {\"org_state_or_province\": \"OH\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"800-293-5066\", \"recruitment_status_date\": \"2017-10-31\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"410 West Tenth Avenue\", \"org_tty\": null, \"org_family\": \"Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute\", \"org_postal_code\": \"43210\", \"contact_email\": \"Jamesline@osumc.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Columbus\", \"org_email\": \"Jamesline@osumc.edu\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"866-627-7616\", \"org_name\": \"Ohio State University Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -83.0218, \"lat\": 40.0051}}, {\"org_state_or_province\": \"PA\", \"contact_name\": \"Site Public Contact\", \"contact_phone\": \"412-647-8073\", \"recruitment_status_date\": \"2019-07-19\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5150 Centre Avenue\", \"org_tty\": null, \"org_family\": \"University of Pittsburgh Cancer Institute\", \"org_postal_code\": \"15232\", \"contact_email\": null, \"recruitment_status\": \"CLOSED_TO_ACCRUAL\", \"org_city\": \"Pittsburgh\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"412-647-8073\", \"org_name\": \"University of Pittsburgh Cancer Institute (UPCI)\", \"org_coordinates\": {\"lon\": -79.9323, \"lat\": 40.4529}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To evaluate the safety and tolerability of the blinatumomab given in combination with nivolumab alone, or in combination with both nivolumab and ipilimumab in subjects with poor-risk, relapsed or refractory CD19+ pre-B cell acute lymphoblastic leukemia (ALL) or CD19+ mixed phenotype acute leukemia (MPAL).\\r\\nII. To determine the maximum tolerated dose (MTD) of the combination of blinatumomab plus nivolumab, and blinatumomab plus both nivolumab and ipilimumab and to further confirm the safety of the combination therapy in subjects with poor-risk, relapsed or refractory CD19+ pre-B cell ALL or CD19+ mixed phenotype acute leukemia (MPAL).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To observe and record anti-leukemia activity of blinatumomab and nivolumab, and blinatumomab plus both nivolumab and ipilimumab, including the effects on minimal residual disease (MRD).\\r\\nII. To assess preliminary anti-leukemia activity in expansion cohorts of patients with poor-risk, relapsed or refractory CD19+ precursor B-lymphoblastic leukemia, or CD19+ mixed phenotype acute leukemia (MPAL).\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To examine changes in absolute lymphocyte count and distribution of T cell subsets (CD4+, CD8+, regulatory T cells [Tregs], effector T cells [Teffs]) and their differentiation status, natural killer (NK) cells, and B cells before and post-blinatumomab, and immune checkpoint inhibitor(s) therapy in both peripheral blood and the bone marrow microenvironment. \\r\\nII. To explore changes in T cell co-signaling receptors expression in defined T cell subpopulations and their canonic transcription factor expression in both peripheral blood and bone marrow before and post-blinatumomab, and immune checkpoint inhibitor(s) therapy.\\r\\nIII. To examine changes in expression of co-signaling molecules on leukemia blasts (CD10+/CD19+/CD34+) before and after treatment with blinatumomab and checkpoint inhibitors.\\r\\nIV. To examine the serum levels of cytokines before and after treatment with blinatumomab and checkpoint inhibitors, including the levels of sCTLA-4.\\r\\nV. To perform immune profiling of T cell repertoire and characterize T cell transcriptional signature before and after treatment.\\r\\n\\r\\nOUTLINE: This is a dose-escalation study of blinatumomab.\\r\\n\\r\\nPatients receive blinatumomab intravenously (IV) continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up every 3 months for up to 2 years.\", \"official_title\": \"A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia\", \"_phase_sort_order\": 4, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 2 years\", \"name\": \"Anti-leukemia activity\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 2 years\", \"name\": \"Changes in absolute lymphocyte count\", \"description\": null, \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 2 years\", \"name\": \"Changes in cytokines levels in serum\", \"description\": \"Will be summarized using descriptive statistics and either Wilcoxon rank sum tests or paired t tests, as appropriate for a single time point, or using the mixed effects linear regression models previously described for simultaneously modelling data from multiple time points for the T cell population data.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 2 years\", \"name\": \"Changes in distribution of T cell subsets and differentiation status, natural killer (NK) cells, and B cells\", \"description\": \"Will be assessed by flow cytometry. The analyses of pre- and post-treatment peripheral blood and bone marrow specimens for immune parameters will be descriptive and graphical in nature. Data will be summarized for each patient group separately. Flow values at each time point will be summarized using geometric means and standard deviation. Differences in baseline values between patient subgroups will be explored using linear regression models.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Changes in expression of co-signaling molecules on leukemia blasts\", \"description\": \"Will be summarized using descriptive statistics and either Wilcoxon rank sum tests or paired t tests, as appropriate for a single time point, or using the mixed effects linear regression models for simultaneously modelling data from multiple time points as previously described for analyzing the T cell population data. The changes in blasts in terms of expression of co-signaling molecules over time will be explored and summarize any correlation in the pattern of blast changes over time using the regression models and interaction tests.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 2 years\", \"name\": \"Changes in T cell co-signaling receptors expression\", \"description\": null, \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Characterization of T cell transcriptional signature\", \"description\": \"Expression levels will be summarized at pre-treatment and post-treatment using standard descriptive statistics. Differentially-expressed genes and corresponding fold-changes will be analyzed using standard statistics and through the use of Ingenuity pathway analysis.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Complete remission\", \"description\": \"The frequency distribution of responses, including complete remission, complete remission with incomplete blood count recovery or progressive disease will be reported by treatment arm and dose level for all patients on study and reported with exact 95% confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Complete remission with incomplete blood count recovery\", \"description\": \"The frequency distribution of responses, including complete remission, complete remission with incomplete blood count recovery or progressive disease will be reported by treatment arm and dose level for all patients on study and reported with exact 95% confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time from measured response to progressive disease, death, or study end, assessed up to 2 years\", \"name\": \"Duration of response\", \"description\": \"Will be analyzed using the Kaplan Meier method. A sensitivity analysis may be performed to evaluate duration of response while excluding patients who go on to have an allogeneic-hematopoietic stem cell transplantation.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Incidence of adverse events\", \"description\": \"Incidence of adverse events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All adverse events and toxicities will be tabulated and reported by type and grade for all dose levels of all treatment combinations and the proportions reported with exact 95% binomial confidence intervals.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Maximum tolerated dose\", \"description\": \"Maximum tolerated dose will be defined as the maximum dose level in the absence of dose limiting toxicity in each patient assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The maximum tolerated dose of the combination of blinatumomab plus nivolumab, and blinatumomab plus both nivolumab and ipilimumab will be determined in subjects with poor-risk, relapsed or refractory CD19+ Pre-B cell acute lymphoblastic leukemia or CD19+ mixed phenotype acute leukemia.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Minimal residual disease\", \"description\": \"Will be assessed by flow cytometry. For patients who have a clinical response, the frequency of minimal residual disease positive versus minimal residual disease negative responses will be reported by treatment arm and dose level for all patients on study.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From the first day of treatment on the study until death or last known follow up, assessed up to 2 years\", \"name\": \"Overall survival\", \"description\": \"Will be measured using the Kaplan Meier method.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Progressive disease\", \"description\": \"The frequency distribution of responses, including complete remission, complete remission with incomplete blood count recovery or progressive disease will be reported by treatment arm and dose level for all patients on study and reported with exact 95% confidence intervals.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"I\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT02879695\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Ph Positive\", \"Ph+\"], \"nci_thesaurus_concept_id\": \"C128843\", \"name\": \"Philadelphia Chromosome Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C158948\", \"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C158948\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"B4 Positive\", \"CD19 Antigen Positive\", \"CD19 Molecule Positive\", \"CD19+\"], \"nci_thesaurus_concept_id\": \"C129255\", \"name\": \"CD19 Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C177692\", \"C20921\", \"C25997\", \"C3367\", \"C35682\", \"C36292\", \"C38886\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C177692\", \"C38886\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"CD19\", \"CD19 Antigen Gene\", \"CD19 Molecule Gene\"], \"nci_thesaurus_concept_id\": \"C38886\", \"name\": \"CD19 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20921\", \"C25997\"], \"parents\": [\"C25997\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chromosomal Rearrangement Detected\", \"Chromosome Rearrangement Detected\", \"Cytogenetic Rearrangement Detected\", \"Cytogenetic Rearrangement Positive\", \"Cytogenetic Rearrangement Present\", \"Rearrangement Positive\", \"Rearrangement Present\", \"Rearrangement identified\"], \"nci_thesaurus_concept_id\": \"C158948\", \"name\": \"Rearrangement Detected\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Adapter Protein Gene\", \"Adapter Signaling Protein Gene\", \"Adaptor Protein Gene\"], \"nci_thesaurus_concept_id\": \"C25997\", \"name\": \"Adaptor Signaling Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20921\"], \"parents\": [\"C20921\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Signaling Factor\", \"Signaling Gene\"], \"nci_thesaurus_concept_id\": \"C20921\", \"name\": \"Signaling Pathway Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Expressed\", \"Expression Detected\"], \"nci_thesaurus_concept_id\": \"C177692\", \"name\": \"Expression Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": \"SAFETY\", \"current_trial_status_date\": \"2017-05-05\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent B-Cell Acute Lymphoblastic Leukemia\"], \"nci_thesaurus_concept_id\": \"C142811\", \"name\": \"Recurrent B Acute Lymphoblastic Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C8644\", \"C142810\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory B-Cell Acute Lymphoblastic Leukemia\"], \"nci_thesaurus_concept_id\": \"C142812\", \"name\": \"Refractory B Acute Lymphoblastic Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C8644\", \"C136488\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148423\", \"name\": \"Recurrent Mixed Phenotype Acute Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C82179\", \"C172626\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148430\", \"name\": \"Refractory Mixed Phenotype Acute Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C82179\", \"C172630\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Leukemia\"], \"nci_thesaurus_concept_id\": \"C148426\", \"name\": \"Advanced Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C3161\", \"C27357\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Hematologic Cancer\", \"Recurrent Hematologic Malignancy\", \"Relapsed Hematologic Cancer\", \"Relapsed Hematologic Malignancy\"], \"nci_thesaurus_concept_id\": \"C27358\", \"name\": \"Recurrent Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C27134\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Cancer\", \"clinical resistance\", \"refractory cancer\", \"resistant cancer\"], \"nci_thesaurus_concept_id\": \"C120186\", \"name\": \"Refractory Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C7628\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148425\", \"name\": \"Recurrent Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C3161\", \"C27358\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148425\", \"name\": \"Recurrent Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C3161\", \"C27358\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"ALL\", \"ALL - Acute Lymphocytic Leukemia\", \"ALL_TYPE\", \"Acute Lymphoblastic Leukemia\", \"Acute Lymphocytic Leukaemia\", \"Acute Lymphocytic Leukemia\", \"Acute Lymphocytic Leukemias\", \"Acute Lymphogenous Leukemia\", \"Acute Lymphoid Leukemia\", \"Acute lymphatic leukemia\", \"Acute lymphoblastic leukemia\", \"Acute lymphoblastic leukemia (ALL)\", \"Acute lymphoblastic leukemia, NOS\", \"Acute lymphoblastic leukemia, precursor cell type\", \"Acute lymphocytic leukemia\", \"Acute lymphoid leukemia\", \"LEUKEMIA, LYMPHOBLASTIC, MALIGNANT\", \"Lymphoblastic Leukemia\", \"Lymphoblastic leukemia, NOS\", \"Precursor Cell Lymphoblastic Leukemia\", \"Precursor Lymphoblasic Leukemia\", \"Precursor Lymphoblastic Leukemia\", \"Precursor cell lymphoblastic leukemia, NOS\", \"acute lymphoblastic leukemia\", \"acute lymphocytic leukemia\"], \"nci_thesaurus_concept_id\": \"C3167\", \"name\": \"Acute Lymphoblastic Leukemia (ALL)\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9300\", \"C7539\", \"C7055\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"ALL\", \"ALL - Acute Lymphocytic Leukemia\", \"ALL_TYPE\", \"Acute Lymphoblastic Leukemia\", \"Acute Lymphocytic Leukaemia\", \"Acute Lymphocytic Leukemia\", \"Acute Lymphocytic Leukemias\", \"Acute Lymphogenous Leukemia\", \"Acute Lymphoid Leukemia\", \"Acute lymphatic leukemia\", \"Acute lymphoblastic leukemia\", \"Acute lymphoblastic leukemia (ALL)\", \"Acute lymphoblastic leukemia, NOS\", \"Acute lymphoblastic leukemia, precursor cell type\", \"Acute lymphocytic leukemia\", \"Acute lymphoid leukemia\", \"LEUKEMIA, LYMPHOBLASTIC, MALIGNANT\", \"Lymphoblastic Leukemia\", \"Lymphoblastic leukemia, NOS\", \"Precursor Cell Lymphoblastic Leukemia\", \"Precursor Lymphoblasic Leukemia\", \"Precursor Lymphoblastic Leukemia\", \"Precursor cell lymphoblastic leukemia, NOS\", \"acute lymphoblastic leukemia\", \"acute lymphocytic leukemia\"], \"nci_thesaurus_concept_id\": \"C3167\", \"name\": \"Acute Lymphoblastic Leukemia (ALL)\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9300\", \"C7539\", \"C7055\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Precursor B Lymphoblastic Leukemia/Lymphoma\", \"Precursor B-Lymphoblastic Lymphoma/Leukemia\"], \"nci_thesaurus_concept_id\": \"C8936\", \"name\": \"B Lymphoblastic Leukemia/Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C27907\", \"C7055\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Acute Lymphoblastic Leukemia\"], \"nci_thesaurus_concept_id\": \"C136488\", \"name\": \"Refractory Acute Lymphoblastic Leukemia (ALL)\", \"type\": [\"subtype\"], \"parents\": [\"C3167\", \"C148431\", \"C172280\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Precursor B Lymphoblastic Leukemia/Lymphoma\", \"Precursor B-Lymphoblastic Lymphoma/Leukemia\"], \"nci_thesaurus_concept_id\": \"C8936\", \"name\": \"B Lymphoblastic Leukemia/Lymphoma\", \"type\": [\"subtype\"], \"parents\": [\"C27907\", \"C7055\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172626\", \"name\": \"Recurrent Acute Leukemia of Ambiguous Lineage\", \"type\": [\"stage\"], \"parents\": [\"C7464\", \"C148429\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172630\", \"name\": \"Refractory Acute Leukemia of Ambiguous Lineage\", \"type\": [\"subtype\"], \"parents\": [\"C7464\", \"C148431\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172280\", \"name\": \"Refractory Malignant Lymphoid Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7065\", \"C27357\", \"C157686\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148431\", \"name\": \"Refractory Acute Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C9300\", \"C148426\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27907\", \"name\": \"B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C179052\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Precursor Lymphoblastic Leukemia/Lymphoma\", \"Precursor Lymphoblastic Lymphoma/Leukemia\"], \"nci_thesaurus_concept_id\": \"C7055\", \"name\": \"Precursor Lymphoid Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7065\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27907\", \"name\": \"B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C179052\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Precursor Lymphoblastic Leukemia/Lymphoma\", \"Precursor Lymphoblastic Lymphoma/Leukemia\"], \"nci_thesaurus_concept_id\": \"C7055\", \"name\": \"Precursor Lymphoid Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7065\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C142810\", \"name\": \"Recurrent Acute Lymphoblastic Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C3167\", \"C148429\", \"C172133\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Blood (Leukemia)\", \"LEUKEMIA, MALIGNANT\", \"Leukemia NOS\", \"Leukemia, Disease\", \"Leukemia, NOS\", \"Leukemias\", \"Leukemias, General\", \"leukemia\"], \"nci_thesaurus_concept_id\": \"C3161\", \"name\": \"Leukemia\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C27134\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Blood (Leukemia)\", \"LEUKEMIA, MALIGNANT\", \"Leukemia NOS\", \"Leukemia, Disease\", \"Leukemia, NOS\", \"Leukemias\", \"Leukemias, General\", \"leukemia\"], \"nci_thesaurus_concept_id\": \"C3161\", \"name\": \"Leukemia\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C27134\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157686\", \"name\": \"Refractory Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"MPAL\", \"Mixed phenotype (biphenotypic) acute leukemia\"], \"nci_thesaurus_concept_id\": \"C82179\", \"name\": \"Mixed Phenotype Acute Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C7464\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Acute Leukemia of Ambiguous Lineage (ALAL)\", \"Acute Leukemia of Indeterminate Lineage\", \"Acute Leukemia, ambiguous lineage (mixed or biphenotypic)\"], \"nci_thesaurus_concept_id\": \"C7464\", \"name\": \"Acute Leukemia of Ambiguous Lineage\", \"type\": [\"subtype\"], \"parents\": [\"C9300\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"acute leukemia\"], \"nci_thesaurus_concept_id\": \"C9300\", \"name\": \"Acute Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C3161\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"acute leukemia\"], \"nci_thesaurus_concept_id\": \"C9300\", \"name\": \"Acute Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C3161\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"LEUKEMIA, LYMPHOCYTIC, MALIGNANT\", \"Lymphocytic Leukemia\", \"Lymphogenous Leukemia\", \"Lymphoid leukemia, NOS\", \"lymphocytic leukemia\"], \"nci_thesaurus_concept_id\": \"C7539\", \"name\": \"Lymphoid Leukemia\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C3161\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148429\", \"name\": \"Recurrent Acute Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C9300\", \"C148425\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"LEUKEMIA, LYMPHOCYTIC, MALIGNANT\", \"Lymphocytic Leukemia\", \"Lymphogenous Leukemia\", \"Lymphoid leukemia, NOS\", \"lymphocytic leukemia\"], \"nci_thesaurus_concept_id\": \"C7539\", \"name\": \"Lymphoid Leukemia\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C3161\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148429\", \"name\": \"Recurrent Acute Leukemia\", \"type\": [\"stage\"], \"parents\": [\"C9300\", \"C148425\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Hematologic Cancer\"], \"nci_thesaurus_concept_id\": \"C27357\", \"name\": \"Refractory Hematologic Malignancy\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C120186\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179052\", \"name\": \"B-Cell Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179052\", \"name\": \"B-Cell Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Acute B Cell Lymphocytic Leukemia\", \"Acute B-Cell Lymphocytic Leukemia\", \"B Cell Acute Lymphocytic Leukemia\", \"B Cell Precursor Type Acute Leukemia\", \"B-ALL\", \"B-Cell ALL\", \"B-Cell Acute Lymphoblastic Leukemia\", \"B-Cell Acute Lymphocytic Leukemia\", \"B-Cell Lymphoblastic Leukemia\", \"B-Cell Precursor Type Acute Leukemia\", \"B-Cell Type Acute Leukemia\", \"B-cell acute lymphoblastic leukemia\", \"B-cell acute lymphocytic leukemia\", \"B-precursor ALL\", \"Precursor B-Lymphoblastic Leukemia\", \"Precursor B-cell lymphoblastic leukemia\", \"Precursor B-lymphoblastic leukemia (B-precursor ALL)\", \"precursor B-lymphoblastic leukemia\"], \"nci_thesaurus_concept_id\": \"C8644\", \"name\": \"B Acute Lymphoblastic Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C3167\", \"C8936\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Acute B Cell Lymphocytic Leukemia\", \"Acute B-Cell Lymphocytic Leukemia\", \"B Cell Acute Lymphocytic Leukemia\", \"B Cell Precursor Type Acute Leukemia\", \"B-ALL\", \"B-Cell ALL\", \"B-Cell Acute Lymphoblastic Leukemia\", \"B-Cell Acute Lymphocytic Leukemia\", \"B-Cell Lymphoblastic Leukemia\", \"B-Cell Precursor Type Acute Leukemia\", \"B-Cell Type Acute Leukemia\", \"B-cell acute lymphoblastic leukemia\", \"B-cell acute lymphocytic leukemia\", \"B-precursor ALL\", \"Precursor B-Lymphoblastic Leukemia\", \"Precursor B-cell lymphoblastic leukemia\", \"Precursor B-lymphoblastic leukemia (B-precursor ALL)\", \"precursor B-lymphoblastic leukemia\"], \"nci_thesaurus_concept_id\": \"C8644\", \"name\": \"B Acute Lymphoblastic Leukemia\", \"type\": [\"subtype\"], \"parents\": [\"C3167\", \"C8936\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Tumor\"], \"nci_thesaurus_concept_id\": \"C7628\", \"name\": \"Refractory Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C147861\", \"name\": \"Recurrent Lymphoproliferative Disorder\", \"type\": [\"stage\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172133\", \"name\": \"Recurrent Malignant Lymphoid Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7065\", \"C27358\", \"C147861\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Hematologic Cancer\", \"Recurrent Hematologic Malignancy\", \"Relapsed Hematologic Cancer\", \"Relapsed Hematologic Malignancy\"], \"nci_thesaurus_concept_id\": \"C27358\", \"name\": \"Recurrent Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C27134\", \"C4813\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"10030\", \"active_sites_count\": 5, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Yervoy\", \"Ipilimumab\"], \"nci_thesaurus_concept_id\": \"C2654\", \"name\": \"Ipilimumab\", \"description\": \"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128036\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"nci_thesaurus_concept_id\": \"C68814\", \"name\": \"Nivolumab\", \"description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Blincyto\", \"Blinatumomab\"], \"nci_thesaurus_concept_id\": \"C62528\", \"name\": \"Blinatumomab\", \"description\": \"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of  T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129822\", \"C1454\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-CTLA4 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128036\", \"name\": \"Anti-CTLA-4 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\", \"C20401\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Bispecific Antibodies\"], \"nci_thesaurus_concept_id\": \"C1454\", \"name\": \"Bispecific Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}], \"name\": \"Treatment (blinatumomab, nivolumab, ipilimumab)\", \"description\": \"Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2016-01300\", \"why_study_stopped\": null, \"brief_summary\": \"This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treatment (refractory). Immunotherapy with monoclonal antibodies, such as blinatumomab, nivolumab, and ipilimumab, may help the body\\u2019s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.\", \"brief_title\": \"Blinatumomab and Nivolumab with or without Ipilimumab in Treating Patients with Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 30, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2017-05-05\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": \"10030\", \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": \"OPEN\", \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lymphoid Leukemia\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Ivana Gojo\", \"study_source\": \"National\", \"completion_date\": \"2021-11-05\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"17-23309\"}], \"amendment_date\": \"2021-04-23T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"University of California San Francisco\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically or cytologically confirmed NSCLC, performed on a biopsy that occurred within the last 90 days\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Documented activating EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples by Clinical Laboratory Improvement Amendments (CLIA)-approved test\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Brain magnetic resonance imaging (MRI) (or CT if contraindication to MRI) within the last 60 days showing no evidence of metastatic disease\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Documentation that the patient is a candidate for surgical resection of their lung cancer by an American Board of Thoracic Surgery certified surgeon\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"The patient must have a tumor size >= 1 cm in its longest diameter\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum therapy\\u2013related neuropathy is allowed\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Bilirubin =< 1.5 x ULN, (Patients with documented Gilbert\\u2019s syndrome and conjugated bilirubin within the normal range may be allowed into the study; in this event, it will be documented that the patient was eligible based on conjugated bilirubin levels)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Potassium, magnesium, and calcium within normal range, patients may receive supplements to meet this requirement\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Leukocytes > 3,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Hemoglobin >= 9 g/dL, with no blood transfusions in the 28 days prior to study entry\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Absolute neutrophil count > 1,500/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Platelets > 100,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels =< 1.5 x upper limit above institutional normal\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Ability to swallow oral medications\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose of study treatment and agree to use highly effective contraception, during the study and for 90 days following the last dose of osimertinib\\r\\n* Women of childbearing potential (WoCBP): women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation\\r\\n* Women NOT of childbearing potential: women who are permanently or surgically sterilized or postmenopausal\\r\\n** Permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion; tubal occlusion is considered a highly effective method of birth control but does not absolutely exclude possibility of pregnancy; (the term occlusion refers to both occluding and ligating techniques that do not physically remove the oviducts)\\r\\n* Women who have undergone tubal occlusion should be managed on trials as if they are WoCBP (e.g. undergo pregnancy testing etc., as required by the study protocol)\\r\\n* Women will be considered postmenopausal if they are amenorrhoeic for 12 months without an alternative medical cause; the following age-specific requirements apply:\\r\\n** Women under 50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range\\r\\n** Women over 50 years of age will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments\\r\\n* Acceptable contraception methods are:\\r\\n** Total sexual abstinence (abstinence must be for the total duration of the trial and the follow-up period)\\r\\n** Vasectomized sexual partner plus male condom (with participant assurance that partner received post-vasectomy confirmation of azoospermia)\\r\\n** Tubal occlusion plus male condom\\r\\n** Intra-uterine device \\u2013 provided coils are copper-banded, plus male condom\\r\\n** Intra-uterine system (IUS) levonorgestrel IUS (e.g., Mirena), plus male condom\\r\\n** Medroxyprogesterone injections (Depo-Provera) plus male condom\\r\\n** Etonogestrel implants (e.g., Implanon, Norplan) plus male condom\\r\\n** Normal and low dose combined oral contraceptive pills, plus male condom\\r\\n** Norelgestromin / ethinylestradiol transdermal system plus male condom\\r\\n** Intravaginal device (e.g., ethinylestradiol and etonogestrel) plus male condom\\r\\n** Cerazette (desogestrel) plus male condom (Cerazette is currently the only highly efficacious progesterone based pill)\\r\\n* Unacceptable Contraception Methods\\r\\nThe following methods are considered not to be highly effective and are therefore not acceptable contraceptive methods:\\r\\n** Triphasic combined oral contraceptives\\r\\n** All progesterone only pills except, Cerazette\\r\\n** All barrier methods, if intended to be used alone\\r\\n** Non-copper containing intra-uterine devices\\r\\n** Fertility awareness methods\\r\\n** Coitus interruptus\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Men with a female partner of childbearing potential must have either had a prior vasectomy agree to use effective contraception as described in the full protocol for at least 14 days prior to administration of the first dose of study treatment, during the study, and for 120 days following the last dose of osimertinib; men also can not donate sperm within this time period\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Leptomeningeal carcinomatosis or other central nervous system (CNS) metastases\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or biopsy (PET abnormalities that are negative for malignancy on biopsy will be considered on a case by case basis)\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Patients who are known to be serologically positive for human immunodeficiency virus (HIV)\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > 12 months prior and/or bone marrow transplant > 2 years prior\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Patients who are currently receiving treatment with contraindicated corrected QT interval (QTc) prolonging medications or potent CYP3A4 inducers, if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatment; all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects.\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Any of the following cardiac abnormalities or history:\\r\\n* Mean resting corrected QT interval (QTc) > 470 msec, obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value\\r\\n* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block\\r\\n* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium < lower limit of normal (LLN); Serum/plasma magnesium < LLN; Serum/plasma calcium < LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Prior treatment with osimertinib or other drugs that target EGFR mutant NSCLC (including erlotinib, afatinib, gefitinib, rocelitinib)\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterol acetate], or immunotherapy) =< 14 days prior to treatment with osimertinib\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator\\u2019s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or known active infection including chronic active hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Active tuberculosis\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Signs or symptoms of infection within 2 weeks prior to first day of study\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment:\\r\\n* Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Class II to IV heart failure as defined by the New York Heart Association functional classification system\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction (LVEF) < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate, to be eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous 3 months; coronary angioplasty, or stenting or bypass grafting within the past 6 months; cardiac ventricular arrhythmias requiring medication; any history of second (2nd) or third (3rd) degree atrioventricular conduction defects)\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Females who are pregnant or breastfeeding\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"Participation in another clinical study with an investigational product (IP) during the last 3 months or within five half-lives of the compound, whichever is longer\"}, {\"inclusion_indicator\": false, \"display_order\": 41, \"description\": \"Uncontrolled medical, psychological, familial, sociological, or geographical conditions that interfere with the patient\\u2019s safety, ability to provide informed consent, or ability to comply with the protocol\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"CA\", \"contact_name\": \"Collin Michael Blakely\", \"contact_phone\": \"415-885-3882\", \"recruitment_status_date\": \"2018-06-04\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": \"collin.blakely@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Jonathan W. Riess\", \"contact_phone\": \"916-734-3772\", \"recruitment_status_date\": \"2019-11-07\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"4501 X Street\", \"org_tty\": null, \"org_family\": \"UC Davis Comprehensive Cancer Center\", \"org_postal_code\": \"95817\", \"contact_email\": \"jwriess@ucdavis.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Sacramento\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"916-734-3089\", \"org_name\": \"University of California Davis Comprehensive Cancer Center\", \"org_coordinates\": {\"lon\": -121.4572, \"lat\": 38.5503}}, {\"org_state_or_province\": \"CO\", \"contact_name\": \"Robert Charles Doebele\", \"contact_phone\": \"303-724-2980\", \"recruitment_status_date\": \"2020-02-14\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1665 Aurora Court\", \"org_tty\": null, \"org_family\": \"University of Colorado Cancer Center\", \"org_postal_code\": \"80045\", \"contact_email\": \"robert.doebele@ucdenver.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Aurora\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"720-848-0650\", \"org_name\": \"University of Colorado Hospital\", \"org_coordinates\": {\"lon\": -104.837, \"lat\": 39.7462}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Collin Michael Blakely\", \"contact_phone\": \"415-885-3882\", \"recruitment_status_date\": \"2018-06-04\", \"org_address_line_2\": \"Floor 6\", \"org_va\": false, \"org_address_line_1\": \"490 Illinois Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"collin.blakely@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"University of California San Francisco\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To evaluate the efficacy of osimertinib as neoadjuvant therapy in patients with surgically resectable EGFR-mutant non-small cell lung cancer (NSCLC).\\r\\n\\r\\nSECONDARY OBJECTIVES: \\r\\nI. To evaluate the safety of osimertinib given as neoadjuvant therapy in early stage EGFR-mutant NSCLC participants.\\r\\nII. To evaluate whether neoadjuvant osimertinib treatment increases the frequency of tumors that are unresectable due to adverse events (AEs) or progressive disease (PD).\\r\\nIII. To evaluate secondary measures of clinical efficacy in early stage EGFR-mutant NSCLC patients treated with osimertinib induction therapy.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To evaluate long-term measures of efficacy in patients treated with osimertinib neoadjuvant therapy.\\r\\nII. To explore tissue and cell-free biomarkers that may be predictive of response or primary resistance to osimertinib neoadjuvant therapy.\\r\\n\\r\\nOUTLINE:\\r\\nPatients receive osimertinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of their cancer.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 30 days, every 3 months for 1 year, and then every 6 months for up to 5 years post-surgery.\", \"official_title\": \"A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"From date of surgical resection to documented radiographic relapse/progression or death due to any cause, assessed up to 5 years\", \"name\": \"5 year disease-free survival (DFS)\", \"description\": \"The Kaplan-Meier analysis will be used to calculate the mean DFS with 95% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From surgical resection to death due to any cause, assessed up to 5 years\", \"name\": \"5 year overall survival (OS)\", \"description\": \"The Kaplan-Meier analysis will be used to calculate the mean OS with 95% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Adverse pathologic outcomes\", \"description\": \"Rates of adverse pathologic features including rates of positive margins, lymphovascular invasion (LVI), and pathologic upstaging (e.g. by T or N status) as compared to clinical staging based on pre-operative scans, for comparison to historical controls will be recorded.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 5 years\", \"name\": \"Changes in circulating tumor deoxyribonucleic acid (ctDNA)\", \"description\": \"Descriptive statistics and graphical methods will be used to analyze the data.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 5 years\", \"name\": \"Changes in immune cell infiltration\", \"description\": null, \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 5 years\", \"name\": \"Depth of response (DpR)\", \"description\": \"Will be defined as the percentage change in tumor burden by RECIST criteria at best response versus baseline imaging. Depth of response will be summarized using descriptive statistics and correlated with patient outcomes using hazard ratios via the Cox proportional hazards model.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 5 years\", \"name\": \"Genomic and transcriptional changes\", \"description\": null, \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Major pathological response rate (MPR)\", \"description\": \"Will be defined as =< 10% viable tumor present histologically in the resected tumor specimen. Tumors that exhibit =< 10% viable tumor will meet the criteria for a major pathological response. The major pathological response rate will be reported with 95% confidence intervals.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"From start of treatment until time of surgery\", \"name\": \"Objective response rate (ORR)\", \"description\": \"Will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria when evaluable. The frequency and percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined. The ORR will be reported with 95% confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Pathologic complete response rate (pCR)\", \"description\": \"Will be defined as absence of (0%) viable tumor present histologically in the resected tumor specimen.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Rate of inability to undergo surgical resection\", \"description\": \"Rate of conversion from operable to non-operative will be recorded as rate of patients initially assessed as surgically resectable, who are subsequently unable to undergo surgical resection due to either treatment-related AEs or disease progression.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Rate of surgical complications occurring prior to the end of treatment visit\", \"description\": \"Rate of surgical complications occurring prior to the end of treatment visit will be recorded.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Serial peripheral blood collection\", \"description\": null, \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Treatment-emergent adverse events (AEs), laboratory abnormalities and electrocardiogram (ECG) abnormalities\", \"description\": \"Will be assessed per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. AE terms recorded on the case report forms (CRFs) will be mapped to preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA). Seriousness, severity grade and relationship to study treatment will be assessed by the investigator.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03433469\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"BCR-ABL\", \"BCR-ABL Fusion Gene\", \"BCR-ABL Oncogene\", \"BCR-ABL Rearrangement\", \"BCR-ABL Translocation Mutation\", \"BCR-ABL fusion gene\", \"BCR-ABL1 Fusion Gene\", \"BCR-ABL1 Translocation\", \"BCR/ABL Translocation\"], \"nci_thesaurus_concept_id\": \"C94600\", \"name\": \"BCR/ABL1 Fusion Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17346\", \"C18455\", \"C20921\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C25873\", \"C25971\", \"C28510\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C28510\", \"C17346\", \"C18455\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"NP_006209.2:p.Glu545Lys\", \"PI3Kalpha E545K\", \"PIK3CA E545K\", \"PIK3CA Glu545Lys\", \"PIK3CA NP_006209.2:p.Glu545Lys\", \"PIK3CA p.E545K\", \"PIK3CA p.Glu545Lys\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545K\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545K\", \"Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545K\", \"p110alpha E545K\"], \"nci_thesaurus_concept_id\": \"C98468\", \"name\": \"PIK3CA NP_006209.2:p.E545K\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C107481\", \"C16612\", \"C21220\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C26072\", \"C3910\", \"C97926\", \"C97928\", \"C98460\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C107481\", \"C21220\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"EGFR G719A\", \"EGFR Gly719Ala\", \"EGFR NP_005219.2:p.Gly719Ala\", \"EGFR p.G719A\", \"EGFR p.Gly719Ala\", \"Epidermal Growth Factor Receptor G719A\", \"NP_005219.2:p.Gly719Ala\", \"Proto-Oncogene c-ErbB-1 G719A\", \"Receptor Tyrosine-Protein Kinase erbB-1 G719A\"], \"nci_thesaurus_concept_id\": \"C98520\", \"name\": \"EGFR NP_005219.2:p.G719A\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C107154\", \"C16612\", \"C17757\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3910\", \"C97926\", \"C97928\", \"C98356\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C107154\", \"C17757\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Tyrosine-Kinase\"], \"nci_thesaurus_concept_id\": \"C25971\", \"name\": \"Non-Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BCR\", \"BCR, RhoGEF and GTPase Activating Protein Gene\"], \"nci_thesaurus_concept_id\": \"C18455\", \"name\": \"BCR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20921\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C25873\"], \"parents\": [\"C25873\", \"C20921\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chromosomal, Gene, or Protein Abnormality\", \"Cytogenetic or Molecular Genetic Abnormality\", \"Genetic Abnormality\", \"MOLECULAR_ABNORMALITY\", \"Molecular Alteration\"], \"nci_thesaurus_concept_id\": \"C3910\", \"name\": \"Molecular Abnormality\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"EGFR\", \"Epidermal Growth Factor Receptor Gene\"], \"nci_thesaurus_concept_id\": \"C17757\", \"name\": \"EGFR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PIK3CA\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene\"], \"nci_thesaurus_concept_id\": \"C21220\", \"name\": \"PIK3CA Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C26072\"], \"parents\": [\"C26072\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Phosphatidylinositol Kinase Family Gene\", \"Phosphatidylinositol Kinase Gene\", \"Phosphoinositol Kinase Gene\"], \"nci_thesaurus_concept_id\": \"C26072\", \"name\": \"Phosphoinositol Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"STK\", \"Serine/Threonine Kinase Gene\", \"Serine/Threonine-Protein Kinase Gene\"], \"nci_thesaurus_concept_id\": \"C25873\", \"name\": \"Serine/Threonine Protein Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"AA_MUTATION\", \"amino acid change\", \"amino_acid_change\"], \"nci_thesaurus_concept_id\": \"C97928\", \"name\": \"Gene Product Sequence Variation\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3910\", \"C97926\"], \"parents\": [\"C97926\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PI3Kalpha Protein Variant\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha Protein Variant\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform Protein Variant\", \"Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide Protein Variant\", \"p110alpha Protein Variant\"], \"nci_thesaurus_concept_id\": \"C98460\", \"name\": \"PIK3CA Protein Variant\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21220\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C26072\", \"C3910\", \"C97926\", \"C97928\"], \"parents\": [\"C97928\", \"C21220\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Epidermal Growth Factor Receptor Protein Variant\", \"Proto-Oncogene c-ErbB-1 Protein Variant\", \"Receptor Tyrosine-Protein Kinase erbB-1 Protein Variant\"], \"nci_thesaurus_concept_id\": \"C98356\", \"name\": \"EGFR Protein Variant\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17757\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3910\", \"C97926\", \"C97928\"], \"parents\": [\"C97928\", \"C17757\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Signaling Factor\", \"Signaling Gene\"], \"nci_thesaurus_concept_id\": \"C20921\", \"name\": \"Signaling Pathway Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Activating G719X Mutation\", \"EGFR G719 Mutation\", \"EGFR G719X\", \"EGFR Gly719Xxx\", \"EGFR NP_005219.2:p.Gly719Xxx\", \"EGFR exon 18 G719X\", \"EGFR p.G719X\", \"Epidermal Growth Factor Receptor G719X\", \"Exon 18 Gly719\", \"NP_005219.2:p.G719X\", \"NP_005219.2:p.Gly719Xxx\", \"Proto-Oncogene c-ErbB-1 G719X\", \"Receptor Tyrosine-Protein Kinase erbB-1 G719X\"], \"nci_thesaurus_concept_id\": \"C107154\", \"name\": \"EGFR NP_005219.2:p.G719X\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17757\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3910\", \"C97926\", \"C97928\", \"C98356\"], \"parents\": [\"C98356\", \"C17757\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ABL\", \"ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene\", \"ABL1\", \"v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene\"], \"nci_thesaurus_concept_id\": \"C17346\", \"name\": \"ABL1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C25971\"], \"parents\": [\"C25971\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"fusion gene\"], \"nci_thesaurus_concept_id\": \"C28510\", \"name\": \"Fusion Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"VARIANT_TYPE\", \"molecular consequence\", \"molecular_consequence\"], \"nci_thesaurus_concept_id\": \"C97926\", \"name\": \"Molecular Sequence Variation\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3910\"], \"parents\": [\"C3910\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"NP_006209.2:p.Glu545Xxx\", \"PI3Kalpha E545X\", \"PIK3CA E545 Mutation\", \"PIK3CA E545X\", \"PIK3CA Glu545Xxx\", \"PIK3CA NP_006209.2:p.Glu545Xxx\", \"PIK3CA p.E545X\", \"PIK3CA p.Glu545Xxx\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545X\", \"Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545X\", \"Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545X\", \"p110alpha E545X\"], \"nci_thesaurus_concept_id\": \"C107481\", \"name\": \"PIK3CA NP_006209.2:p.E545X\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21220\", \"C21281\", \"C25870\", \"C25871\", \"C25872\", \"C26072\", \"C3910\", \"C97926\", \"C97928\", \"C98460\"], \"parents\": [\"C98460\", \"C21220\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2018-06-04\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IA Lung Non-Small Cell Carcinoma AJCC v7\", \"Stage IA Non-Oat Cell Carcinoma of Lung\", \"Stage IA Non-Oat Cell Carcinoma of the Lung\", \"Stage IA Non-Oat Cell Lung Carcinoma\", \"Stage IA Non-Small Cell Carcinoma of Lung\", \"Stage IA Non-Small Cell Carcinoma of the Lung\", \"Stage IA Non-Small Cell Lung Carcinoma\", \"Stage IA Non-Small Cell Lung Carcinoma AJCC v7\", \"stage IA non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C5652\", \"name\": \"Stage IA Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C6671\", \"C5642\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IB Lung Non-Small Cell Carcinoma AJCC v7\", \"Stage IB Non-Oat Cell Carcinoma of Lung\", \"Stage IB Non-Oat Cell Carcinoma of the Lung\", \"Stage IB Non-Oat Cell Lung Carcinoma\", \"Stage IB Non-Small Cell Carcinoma of Lung\", \"Stage IB Non-Small Cell Carcinoma of the Lung\", \"Stage IB Non-Small Cell Lung Carcinoma\", \"Stage IB Non-Small Cell Lung Carcinoma AJCC v7\", \"stage IB non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C5653\", \"name\": \"Stage IB Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C6671\", \"C5643\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIB Lung Non-Small Cell Carcinoma AJCC v7\", \"Stage IIB Non-Oat Cell Carcinoma of Lung\", \"Stage IIB Non-Oat Cell Carcinoma of the Lung\", \"Stage IIB Non-Oat Cell Lung Carcinoma\", \"Stage IIB Non-Small Cell Carcinoma of Lung\", \"Stage IIB Non-Small Cell Carcinoma of the Lung\", \"Stage IIB Non-Small Cell Lung Carcinoma\", \"Stage IIB Non-Small Cell Lung Carcinoma AJCC v7\", \"stage IIB non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C5654\", \"name\": \"Stage IIB Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C7777\", \"C5645\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIA Lung Non-Small Cell Carcinoma AJCC v7\", \"Stage IIA Non-Oat Cell Carcinoma of Lung\", \"Stage IIA Non-Oat Cell Carcinoma of the Lung\", \"Stage IIA Non-Oat Cell Lung Carcinoma\", \"Stage IIA Non-Small Cell Carcinoma of Lung\", \"Stage IIA Non-Small Cell Carcinoma of the Lung\", \"Stage IIA Non-Small Cell Lung Carcinoma\", \"Stage IIA Non-Small Cell Lung Carcinoma AJCC v7\", \"stage IIA non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C5655\", \"name\": \"Stage IIA Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C7777\", \"C5644\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Stage I Lung Non-Small Cell Cancer AJCC v7\", \"Stage I NSCLC\", \"Stage I Non-Oat Cell Carcinoma of Lung\", \"Stage I Non-Oat Cell Carcinoma of the Lung\", \"Stage I Non-Oat Cell Lung Carcinoma\", \"Stage I Non-Small Cell Carcinoma of Lung\", \"Stage I Non-Small Cell Carcinoma of the Lung\", \"Stage I Non-Small Cell Lung Cancer AJCC v7\", \"Stage I Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6671\", \"name\": \"Stage I Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88888\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Non -Small Cell Lung Cancer Stage II\", \"Non Small Cell Lung Cancer Stage II\", \"Stage II Lung Non-Small Cell Cancer AJCC v7\", \"Stage II Non-Oat Cell Carcinoma of Lung\", \"Stage II Non-Oat Cell Carcinoma of the Lung\", \"Stage II Non-Oat Cell Lung Carcinoma\", \"Stage II Non-Small Cell Carcinoma of Lung\", \"Stage II Non-Small Cell Carcinoma of the Lung\", \"Stage II Non-Small Cell Lung Cancer AJCC v7\", \"Stage II Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7777\", \"name\": \"Stage II Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88889\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Non Small Cell Lung Cancer Stage IIIA\", \"Non Small Cell Lung Cancer, Stage IIIA\", \"Stage IIIA Lung Non-Small Cell Cancer AJCC v7\", \"Stage IIIA NSCLC\", \"Stage IIIA Non-Oat Cell Carcinoma of Lung\", \"Stage IIIA Non-Oat Cell Carcinoma of the Lung\", \"Stage IIIA Non-Oat Cell Lung Carcinoma\", \"Stage IIIA Non-Small Cell Carcinoma of Lung\", \"Stage IIIA Non-Small Cell Carcinoma of the Lung\", \"Stage IIIA Non-Small Cell Lung Cancer AJCC v7\", \"Stage IIIA Non-Small Cell Lung Carcinoma\", \"stage IIIA non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C9102\", \"name\": \"Stage IIIA Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C7778\", \"C5646\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIA Carcinoma of Lung\", \"Stage IIIA Carcinoma of the Lung\", \"Stage IIIA Lung Cancer AJCC v7\", \"Stage IIIA Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5646\", \"name\": \"Stage IIIA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136491\", \"name\": \"Lung Non-Small Cell Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C91232\", \"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Non-Small Cell Cancer AJCC v7\", \"Stage III NSCLC\", \"Stage III Non-Oat Cell Carcinoma of Lung\", \"Stage III Non-Oat Cell Carcinoma of the Lung\", \"Stage III Non-Oat Cell Lung Carcinoma\", \"Stage III Non-Small Cell Carcinoma of Lung\", \"Stage III Non-Small Cell Carcinoma of the Lung\", \"Stage III Non-Small Cell Lung Cancer AJCC v7\", \"Stage III Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7778\", \"name\": \"Stage III Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IB Carcinoma of Lung\", \"Stage IB Carcinoma of the Lung\", \"Stage IB Lung Cancer AJCC v7\", \"Stage IB Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5643\", \"name\": \"Stage IB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88888\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91232\", \"name\": \"Lung Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage I Lung Non-Small Cell Cancer AJCC v7\", \"Stage I NSCLC\", \"Stage I Non-Oat Cell Carcinoma of Lung\", \"Stage I Non-Oat Cell Carcinoma of the Lung\", \"Stage I Non-Oat Cell Lung Carcinoma\", \"Stage I Non-Small Cell Carcinoma of Lung\", \"Stage I Non-Small Cell Carcinoma of the Lung\", \"Stage I Non-Small Cell Lung Cancer AJCC v7\", \"Stage I Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6671\", \"name\": \"Stage I Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88888\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIB Carcinoma of Lung\", \"Stage IIB Carcinoma of the Lung\", \"Stage IIB Lung Cancer AJCC v7\", \"Stage IIB Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5645\", \"name\": \"Stage IIB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88889\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage I Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88888\", \"name\": \"Stage I Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Stage I Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88888\", \"name\": \"Stage I Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage II Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88889\", \"name\": \"Stage II Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88890\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIA Carcinoma of Lung\", \"Stage IIA Carcinoma of the Lung\", \"Stage IIA Lung Cancer AJCC v7\", \"Stage IIA Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5644\", \"name\": \"Stage IIA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88889\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91232\", \"name\": \"Lung Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136491\", \"name\": \"Lung Non-Small Cell Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C91232\", \"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IA Carcinoma of Lung\", \"Stage IA Carcinoma of the Lung\", \"Stage IA Lung Cancer AJCC v7\", \"Stage IA Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5642\", \"name\": \"Stage IA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88888\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non -Small Cell Lung Cancer Stage II\", \"Non Small Cell Lung Cancer Stage II\", \"Stage II Lung Non-Small Cell Cancer AJCC v7\", \"Stage II Non-Oat Cell Carcinoma of Lung\", \"Stage II Non-Oat Cell Carcinoma of the Lung\", \"Stage II Non-Oat Cell Lung Carcinoma\", \"Stage II Non-Small Cell Carcinoma of Lung\", \"Stage II Non-Small Cell Carcinoma of the Lung\", \"Stage II Non-Small Cell Lung Cancer AJCC v7\", \"Stage II Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7777\", \"name\": \"Stage II Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88889\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"17658\", \"active_sites_count\": 4, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Therapeutic Conventional Surgery\"], \"nci_thesaurus_concept_id\": \"C65008\", \"name\": \"Therapeutic Conventional Surgery\", \"description\": null, \"category\": \"other\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C16079\", \"C64982\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Tagrisso\", \"Osimertinib\"], \"nci_thesaurus_concept_id\": \"C116377\", \"name\": \"Osimertinib\", \"description\": \"A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, AZD9291 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. AZD9291 preferentially inhibits mutated forms of EGFR including T790M, a secondarily-acquired resistance mutation, and may have enhanced anti-tumor effects in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGF\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C129825\", \"C2167\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Conventional Surgery\"], \"nci_thesaurus_concept_id\": \"C16079\", \"name\": \"Conventional Surgery\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C49165\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49165\", \"name\": \"Surgical Procedure by Method\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15329\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C15329\", \"name\": \"Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Therapeutic Surgical Procedure\"], \"nci_thesaurus_concept_id\": \"C64982\", \"name\": \"Therapeutic Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15329\", \"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Enzyme Inhibitor\"], \"nci_thesaurus_concept_id\": \"C129825\", \"name\": \"Antineoplastic Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129824\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Protein Inhibitor\", \"Antineoplastic Protein Antagonist\"], \"nci_thesaurus_concept_id\": \"C129824\", \"name\": \"Antineoplastic Protein Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2189\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Signal Transduction Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2189\", \"name\": \"Signal Transduction Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"EGFR Blocker\", \"EGFR Inhibitor\", \"EGFR Tyrosine Kinase Inhibitor\", \"EGFR Tyrosine Kinase Inhibitors\", \"EGFR-TK Inhibitor\", \"Epidermal Growth Factor Receptor Inhibitor\", \"Epidermal Growth-Factor Receptor Inhibitors\"], \"nci_thesaurus_concept_id\": \"C2167\", \"name\": \"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163952\", \"C1967\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C163952\", \"name\": \"EGFR-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PTK Inhibitors\", \"Protein Tyrosine Kinase Inhibitors\", \"TK Inhibitors\", \"Tyrosine Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1967\", \"name\": \"Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protein Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1404\", \"name\": \"Protein Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}], \"name\": \"Treatment (osimertinib)\", \"description\": \"Patients receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of their cancer.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2018-00019\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies the effect of osimertinib in treating patients with stage I-IIIA EGFR-mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.\", \"brief_title\": \"Osimertinib in Treating Patients with Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer before Surgery\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 27, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2018-06-04\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lung\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Collin Michael Blakely\", \"study_source\": \"Institutional\", \"completion_date\": \"2026-05-31\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"17-22178\"}], \"amendment_date\": \"2020-06-16T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"University of California San Francisco\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization [WHO] type 2a and 2b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"No distant metastasis as verified by one of the study investigators\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Documentation that the patient is a candidate for chemoradiation of their nasopharyngeal cancer by one of the study investigators\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Measurable disease as defined by RECIST v1.1\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Lack of contraindications to systemic immunotherapy (see list of exclusions below)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Resolution of all acute toxic effects of any prior chemotherapy, radiotherapy or surgical procedures to National Cancer Institute (NCI) CTCAE version 5.0 grade 1\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Total bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"White blood cell (WBC) >= 2000/uL within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Neutrophils >= 1500/uL within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Platelet >= 100 x 10^3/uL within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Hemoglobin > 9.0 g/dL within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Serum creatinine =< 1.5 x upper limit of normal (ULN) or creatinine clearance > 40 mL/min (or >= 50 mL/min for Singapore sites only) (if using the Cockcroft-Gault formula) within 14 days of registration\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Women of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the first dose of study treatment and agree to use appropriate highly effective methods of contraception, during the study and for 5 months following completion of study treatment;\\r\\n* A \\u201cwoman of childbearing potential\\u201d is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL\\r\\n* Female subjects: women of child bearing potential are expected to use one of the highly effective methods of contraception\\r\\n* Male subjects: male subjects must inform their female partners who are women of child bearing potential of the contraceptive requirements and are expected to adhere to using contraception with their partner; female partners of male subjects, who are women of child bearing potential, are expected to use one of the highly effective methods of contraception; in addition, male subjects are expected to use a condom\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Men with a female partner of childbearing potential must agree to use highly effective methods of contraception or any contraceptive method with a failure rate of less than 1% per year during the study and for 7 months following completion of study treatment\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Ability to sign informed consent\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Active second malignancy, i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment; patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll in this trial; for example, patients with early-stage skin cancers, prostate cancer under surveillance with non-rising PSA, or meningioma or thyroid papillary cancers which are under surveillance are eligible; for determinations of a specific clinical condition, please consult with the principal investigator\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Active, untreated central nervous system (CNS) metastases\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD ligand-1 (PD-L1) or PD ligand-2 (PD-L2), anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, or cancer vaccine\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Prior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery within 28 days of first dose of study medication\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Severe hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Has received a live-virus vaccination within 30 days of planned treatment start\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Active, known, or suspected autoimmune disease or any autoimmune condition that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed); subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Signs or symptoms of infection within 2 weeks prior to first day of study treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Patients with active tuberculosis (clinical evaluation in line with local practice), or a known history of active tuberculosis that in the opinion of the treating investigator has a high risk of reactivation\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment:\\r\\n* Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Known positive test for human immunodeficiency virus (HIV)\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Known active hepatitis B or hepatitis C virus (HBV or HCV):\\r\\n* Patients with past or resolved HBV infection (defined by a negative hepatitis B surface antigen [HBsAg] test and a positive anti-hepatitis B core antigen [anti-HBc] antibody test) are eligible; HBV DNA must be obtained in these patients prior to first day of study treatment\\r\\n* Patients who have been recently discovered to have HBV with positive HBsAg test and positive anti-HBc antibody test but who have been started on antiretroviral treatment with non-detectable HBV DNA are eligible; HBV DNA must be obtained in these patients prior to first day of study treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Patients with known active hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection:\\r\\n* Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Prior radiation therapy of any type within 7 days of first dose of study medication\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Prior radiation therapy to head and neck region that would overlap with intended radiation treatment for nasopharyngeal carcinoma\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate]) =< 14 days prior to treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study\"}, {\"inclusion_indicator\": false, \"display_order\": 41, \"description\": \"Active, uncontrolled psychiatric disorders or substance (drug/alcohol) abuse that interfere with patient\\u2019s safety, ability to provide informed consent, or ability to comply with the protocol\"}, {\"inclusion_indicator\": false, \"display_order\": 42, \"description\": \"Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": null, \"contact_name\": \"Boon Cher Goh\", \"contact_phone\": \"65 6773 7888 \", \"recruitment_status_date\": \"2020-04-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"5 Lower Kent Ridge Road\", \"org_tty\": null, \"org_family\": null, \"org_postal_code\": \"119074\", \"contact_email\": \"ncis@nuhs.edu.sg\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Singapore\", \"org_email\": null, \"org_country\": \"Singapore\", \"org_fax\": null, \"org_phone\": null, \"org_name\": \"National University Hospital Singapore\"}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Sue Sun Yom\", \"contact_phone\": \"415-353-7175\", \"recruitment_status_date\": \"2017-12-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1001 Potrero Avenue\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94110\", \"contact_email\": \"sue.yom@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"Zuckerberg San Francisco General Hospital\", \"org_coordinates\": {\"lon\": -122.4153, \"lat\": 37.7496}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Sue Sun Yom\", \"contact_phone\": \"415-353-7175\", \"recruitment_status_date\": \"2017-12-12\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": \"sue.yom@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Sue Sun Yom\", \"contact_phone\": \"415-353-7175\", \"recruitment_status_date\": \"2017-12-12\", \"org_address_line_2\": \"Floor 6\", \"org_va\": false, \"org_address_line_1\": \"490 Illinois Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"sue.yom@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"University of California San Francisco\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To establish the feasibility of treatment completion of a combined chemoradiation-nivolumab regimen followed by adjuvant nivolumab.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To determine the clinical response as judged by the investigator.\\r\\nII. To determine the overall response rate at 1 year from completion of therapy, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.\\r\\nIII. To determine the locoregional control rate at 1 year post-treatment.\\r\\nIV. To determine the distant metastasis rate at 1 year post-treatment.\\r\\nV. To determine the overall survival rate at 1 year post-treatment.\\r\\nVI. To determine the rate of Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year post-treatment.\\r\\nVII. To determine the acute and late toxicity rates according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0, including immune-related adverse events (AEs).\\r\\nVIII. To assess patients\\u2019 quality of life from baseline through 1 year post-treatment.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To determine whether PDL1-positive immunohistochemistry and novel quantitative assays correlate to clinical outcome.\\r\\nII. To determine if the density of infiltrating CD3+ T cells/um2 correlates to clinical outcome.\\r\\nIII. To monitor immune changes by flow cytometry in the circulating T cell response to EBV antigens.\\r\\nIV. To compare the change in the circulating T-cell repertoire by T-cell receptor (TCR) sequencing and single-cell T-cell profiling.\\r\\nV. To quantify treatment-induced changes over time in the circulating T cell immune response to EBV using TCR sequencing and enzyme-linked immunospot (ELISPOT) assays.\\r\\n\\r\\nOUTLINE:\\r\\nPatients receive nivolumab intravenously (IV) over 60 minutes on day 1 of cycles 1-5 and 7-12. Treatment repeats every 14 days for 11 cycles in the absence of disease progression or unacceptable toxicity. Beginning at cycle 2, patients undergo radiation therapy once daily (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 100 days, at 1, 3, 6 and 12 months for up to 1 year, and then every 3 months for 1 year.\", \"official_title\": \"Nivolumab in Combination with Chemoradiation for Patients with Stage II-IVB Nasopharyngeal Carcinoma, a Phase II Study with Correlative Biomarkers\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"Bristol-Myers Squibb\", \"functional_role\": \"FUNDING_SOURCE\"}, {\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 1 year\", \"name\": \"Acute and late toxicity rates\", \"description\": \"Will be graded according to CTCAE version 5, including immune-related AEs.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 1 year post-treatment\", \"name\": \"Changes in T-cell response to Epstein-Barr virus (EBV) antigens\", \"description\": \"Assessed by flow cytometry.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 1 year post-treatment\", \"name\": \"Changes in the circulating T-cell repertoire\", \"description\": \"Assessed by T-cell receptor (TCR) sequencing and single-cell T-cell profiling.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 1 year post-treatment\", \"name\": \"Changes over time in the circulating T-cell immune response to EBV\", \"description\": \"Assessed using TCR sequencing and enzyme-linked immunospot (ELISPOT) assays.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Clinical response as judged by the investigator\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 1 year post-treatment\", \"name\": \"Density of infiltrating CD3+ T cells/um2\", \"description\": \"Will be correlated with clinical outcomes.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"At 1 year post-treatment\", \"name\": \"Distant metastasis (DM) rate\", \"description\": \"Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with 95% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Incidence of adverse events\", \"description\": \"Will be determined by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0 by investigator assessment. Safety will be assessed by evaluation of adverse events (AEs). All safety analyses will be performed using the safety population. Adverse event terms recorded on the case report forms (CRFs) will be mapped to preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA). Seriousness, severity grade and relationship to study treatment will be assessed by the investigator. Severity grade will be defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Listings of AEs will be provided.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At 1 year post-treatment\", \"name\": \"Locoregional control (LRC) rate\", \"description\": \"Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with 95% confidence interval.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Overall response rate (ORR)\", \"description\": \"Will be determined by investigator\\u2019s assessment and Response Evaluation Criteria in Solid Tumors 1.1 criteria. The ORR is based on the best overall response recorded from the first day of treatment until time of assessment. The frequency and percentages of patients with a best overall response rate of complete response, partial response, stable disease, or progressive disease will be determined.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At 1 year post-treatment\", \"name\": \"Overall survival rate\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 4 weeks\", \"name\": \"PDL1-positive immunohistochemistry and novel quantitative assays\", \"description\": \"Will be correlated with clinical outcomes.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Baseline up to 1 year post-treatment\", \"name\": \"Quality of life\", \"description\": \"Will be assessed by patient reported outcomes (Functional Assessment of Cancer Therapy-Nasopharyngeal Cancer [FACT-NP], FACT-Taxane, Hearing Handicap Inventory for the Elderly, Screening, and European Quality of Life Five Dimension).\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Rate of completion of adjuvant immunotherapy\", \"description\": \"Will be compared to the rate of completion of a standard adjuvant cisplatin-based platform. Will be determined in patients who receive the study drug for a minimum of 1 cycle (or 14 days) at the maximum tolerated dose schedule based on the ability to complete all prescribed concurrent and/or adjuvant nivolumab without discontinuation for disease progression or toxicity.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 1 year post-treatment\", \"name\": \"Rate of Epstein-Barr virus deoxyribonucleic acid clearance assessed in plasma\", \"description\": null, \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03267498\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2017-12-12\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphoepithelial Carcinoma\", \"Lymphoepithelial carcinoma\", \"Lymphoepithelioma\", \"Lymphoepithelioma-Like Carcinoma\", \"Lymphoepithelioma-like carcinoma\", \"Nasopharyngeal Type Undifferentiated Carcinoma\", \"Schmincke Tumor\", \"lymphoepithelioma\"], \"nci_thesaurus_concept_id\": \"C4107\", \"name\": \"Nasopharyngeal-Type Undifferentiated Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3780\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IVC Carcinoma of Nasopharynx\", \"Stage IVC Carcinoma of the Nasopharynx\", \"Stage IVC Nasopharyngeal Carcinoma\", \"Stage IVC Nasopharyngeal Carcinoma AJCC v7\", \"Stage IVC Nasopharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5995\", \"name\": \"Stage IVC Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88984\", \"C6002\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IVB Carcinoma of Nasopharynx\", \"Stage IVB Carcinoma of the Nasopharynx\", \"Stage IVB Nasopharyngeal Carcinoma\", \"Stage IVB Nasopharyngeal Carcinoma AJCC v7\", \"Stage IVB Nasopharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5996\", \"name\": \"Stage IVB Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88984\", \"C6001\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IVA Carcinoma of Nasopharynx\", \"Stage IVA Carcinoma of the Nasopharynx\", \"Stage IVA Nasopharyngeal Carcinoma\", \"Stage IVA Nasopharyngeal Carcinoma AJCC v7\", \"Stage IVA Nasopharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C5997\", \"name\": \"Stage IVA Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88984\", \"C6000\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"EBV positive nasopharyngeal carcinoma\", \"Nasopharyngeal Non-Keratinizing Carcinoma\", \"Nasopharyngeal Nonkeratinizing Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7373\", \"name\": \"Nasopharyngeal Throat Nonkeratinizing Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C27690\", \"C167265\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Nasopharyngeal Undifferentiated Carcinoma Stage II\", \"Stage II Lymphoepithelioma of Nasopharynx\", \"Stage II Lymphoepithelioma of the Nasopharynx\", \"Stage II Nasopharyngeal Lymphoepithelioma\", \"Stage II Nasopharyngeal Undifferentiated Carcinoma\", \"Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C8225\", \"name\": \"Stage II Undifferentiated Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8023\", \"C88982\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Nasopharyngeal Undifferentiated Carcinoma Stage III\", \"Stage III Lymphoepithelioma of Nasopharynx\", \"Stage III Lymphoepithelioma of the Nasopharynx\", \"Stage III Nasopharyngeal Lymphoepithelioma\", \"Stage III Nasopharyngeal Undifferentiated Carcinoma\", \"Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C8227\", \"name\": \"Stage III Undifferentiated Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8023\", \"C88983\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Nasopharyngeal Undifferentiated Carcinoma Stage IV\", \"Stage IV Lymphoepithelioma of Nasopharynx\", \"Stage IV Lymphoepithelioma of the Nasopharynx\", \"Stage IV Nasopharyngeal Lymphoepithelioma\", \"Stage IV Nasopharyngeal Undifferentiated Carcinoma\", \"Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C8229\", \"name\": \"Stage IV Undifferentiated Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8023\", \"C88984\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage II Nasopharyngeal Carcinoma\", \"Stage II Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88982\", \"name\": \"Stage II Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8769\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Nasopharyngeal Carcinoma\", \"Stage III Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88983\", \"name\": \"Stage III Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8770\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Nasopharyngeal Carcinoma\", \"Stage IV Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88984\", \"name\": \"Stage IV Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8771\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"EBV Related Carcinoma\", \"Epstein-Barr Virus Related Carcinoma\", \"Epstein-Barr Virus-Related Carcinoma\"], \"nci_thesaurus_concept_id\": \"C27690\", \"name\": \"EBV-Related Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C27689\", \"C27698\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Virus Related Cancer\", \"Virus Related Malignancy\", \"Virus-Related Cancer\", \"Virus-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27673\", \"name\": \"Virus-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27223\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Pharynx\", \"Neoplasm of the Pharynx\", \"Pharyngeal Neoplasms\", \"Pharyngeal Tumor\", \"Pharynx Neoplasm\", \"Pharynx Tumor\", \"Tumor of Pharynx\", \"Tumor of the Pharynx\"], \"nci_thesaurus_concept_id\": \"C3325\", \"name\": \"Pharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3260\", \"C26850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neck Disease\"], \"nci_thesaurus_concept_id\": \"C27648\", \"name\": \"Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27571\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphoepithelioma of Nasopharynx\", \"Lymphoepithelioma of the Nasopharynx\", \"Nasopharyngeal Lymphoepithelial Carcinoma\", \"Nasopharyngeal Lymphoepithelioma\", \"Nasopharyngeal Nonkeratinizing Undifferentiated Carcinoma\", \"Nasopharyngeal Undifferentiated Carcinoma\", \"Undifferentiated Carcinoma of Nasopharynx\", \"Undifferentiated Carcinoma of the Nasopharynx\"], \"nci_thesaurus_concept_id\": \"C8023\", \"name\": \"Undifferentiated Nasopharyngeal Throat Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C7373\", \"C4107\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Nasopharyngeal Neoplasms\", \"Nasopharyngeal Tumor\", \"Neoplasm of Nasopharynx\", \"Neoplasm of the Nasopharynx\", \"Tumor of Nasopharynx\", \"Tumor of the Nasopharynx\"], \"nci_thesaurus_concept_id\": \"C3257\", \"name\": \"Nasopharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35723\", \"C3325\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Head and Neck\", \"Cancer of the Head and Neck\", \"Head and Neck Cancer\", \"Head and neck cancer, NOS\", \"Malignant Head and Neck Tumor\", \"Malignant Neoplasm of Head and Neck\", \"Malignant Neoplasm of the Head and Neck\", \"Malignant Tumor of Head and Neck\", \"Malignant Tumor of the Head and Neck\", \"head and neck cancer\"], \"nci_thesaurus_concept_id\": \"C4013\", \"name\": \"Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Neck\", \"Cancer of the Neck\", \"Malignant Neck Tumor\", \"Malignant Neoplasm of Neck\", \"Malignant Neoplasm of the Neck\", \"Malignant Tumor of Neck\", \"Malignant Tumor of the Neck\", \"Neck Cancer\"], \"nci_thesaurus_concept_id\": \"C4940\", \"name\": \"Malignant Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4013\", \"C3260\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26850\", \"name\": \"Pharyngeal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27648\", \"C118420\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Pharyngeal Tumor\", \"Malignant Pharynx Neoplasm\", \"Malignant Pharynx Tumor\", \"Malignant Tumor of Pharynx\", \"Malignant Tumor of the Pharynx\"], \"nci_thesaurus_concept_id\": \"C7545\", \"name\": \"Malignant Pharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4940\", \"C3325\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"EBV Related Malignancy\", \"EBV-Related Malignancy\", \"Epstein-Barr Virus Related Malignancy\", \"Epstein-Barr Virus-Related Malignancy\", \"Epstein-Barr Virus-Related Malignant Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27689\", \"name\": \"EBV-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Pharynx\", \"Cancer of the Pharynx\", \"Carcinoma of Pharynx\", \"Carcinoma of the Pharynx\", \"Pharyngeal Cancer\", \"Pharyngeal Carcinoma\", \"Pharynx Cancer\", \"Pharynx Carcinoma\", \"pharyngeal cancer\"], \"nci_thesaurus_concept_id\": \"C9466\", \"name\": \"Pharyngeal Throat Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C7545\", \"C35506\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Throat Cancer\", \"throat cancer\"], \"nci_thesaurus_concept_id\": \"C35506\", \"name\": \"Throat Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C6077\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C118420\", \"name\": \"Otolaryngologic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27571\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal (including Hypopharyngeal and Oropharyngeal) squamous cell carcinoma\", \"Pharyngeal Squamous Cell Carcinoma\", \"Pharyngeal squam. cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C102872\", \"name\": \"Pharyngeal Throat Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm by Etiology\"], \"nci_thesaurus_concept_id\": \"C27933\", \"name\": \"Neoplasm by Cause\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Virus Related Carcinoma\"], \"nci_thesaurus_concept_id\": \"C27698\", \"name\": \"Virus-Related Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV Nasopharyngeal Carcinoma\", \"Stage IV Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88984\", \"name\": \"Stage IV Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8771\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Head and Neck\", \"Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C35850\", \"name\": \"Head and Neck Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C4013\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma, Large Cell\", \"large cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C3780\", \"name\": \"Large Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage IVB\", \"Stage IVB Carcinoma of Pharynx\", \"Stage IVB Carcinoma of the Pharynx\", \"Stage IVB Pharyngeal Carcinoma\", \"Stage IVB Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6001\", \"name\": \"Stage IVB Pharyngeal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8771\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C35723\", \"name\": \"Nasopharyngeal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphoepithelial Carcinoma\", \"Lymphoepithelial carcinoma\", \"Lymphoepithelioma\", \"Lymphoepithelioma-Like Carcinoma\", \"Lymphoepithelioma-like carcinoma\", \"Nasopharyngeal Type Undifferentiated Carcinoma\", \"Schmincke Tumor\", \"lymphoepithelioma\"], \"nci_thesaurus_concept_id\": \"C4107\", \"name\": \"Nasopharyngeal-Type Undifferentiated Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3780\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Neck\", \"Cancer of the Neck\", \"Malignant Neck Tumor\", \"Malignant Neoplasm of Neck\", \"Malignant Neoplasm of the Neck\", \"Malignant Tumor of Neck\", \"Malignant Tumor of the Neck\", \"Neck Cancer\"], \"nci_thesaurus_concept_id\": \"C4940\", \"name\": \"Malignant Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4013\", \"C3260\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Nasopharyngeal Carcinoma\", \"Stage III Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88983\", \"name\": \"Stage III Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8770\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage II Nasopharyngeal Carcinoma\", \"Stage II Nasopharyngeal Carcinoma AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88982\", \"name\": \"Stage II Nasopharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91244\", \"C8769\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"EBV Related Malignancy\", \"EBV-Related Malignancy\", \"Epstein-Barr Virus Related Malignancy\", \"Epstein-Barr Virus-Related Malignancy\", \"Epstein-Barr Virus-Related Malignant Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27689\", \"name\": \"EBV-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C167265\", \"name\": \"Nasopharyngeal Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3871\", \"C102872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C118420\", \"name\": \"Otolaryngologic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27571\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm by Etiology\"], \"nci_thesaurus_concept_id\": \"C27933\", \"name\": \"Neoplasm by Cause\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C91244\", \"name\": \"Nasopharyngeal Carcinoma by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C3871\", \"C91252\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27571\", \"name\": \"Head and Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Head and Neck Neoplasm (Excluding Central Nervous System)\", \"Head and Neck Tumor\", \"Neoplasm of Head and Neck\", \"Neoplasm of the Head and Neck\", \"Tumor of Head and Neck\", \"Tumor of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C3077\", \"name\": \"Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27571\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"EBV positive nasopharyngeal carcinoma\", \"Nasopharyngeal Non-Keratinizing Carcinoma\", \"Nasopharyngeal Nonkeratinizing Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7373\", \"name\": \"Nasopharyngeal Throat Nonkeratinizing Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C27690\", \"C167265\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neck Neoplasms (Including All Pharyngeal Related Neoplasms)\", \"Neck Tumor\", \"Neoplasm of Neck\", \"Neoplasm of the Neck\", \"Tumor of Neck\", \"Tumor of the Neck\"], \"nci_thesaurus_concept_id\": \"C3260\", \"name\": \"Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C27648\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma of Head and Neck\", \"Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C35850\", \"name\": \"Head and Neck Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C4013\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Nasopharyngeal Tumor\", \"Malignant Neoplasm of Nasopharynx\", \"Malignant Neoplasm of the Nasopharynx\", \"Malignant Tumor of Nasopharynx\", \"Malignant Tumor of the Nasopharynx\"], \"nci_thesaurus_concept_id\": \"C9321\", \"name\": \"Malignant Nasopharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7545\", \"C3257\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma, Large Cell\", \"large cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C3780\", \"name\": \"Large Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C35723\", \"name\": \"Nasopharyngeal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage II\", \"Stage II Carcinoma of Pharynx\", \"Stage II Carcinoma of the Pharynx\", \"Stage II Pharyngeal Cancer\", \"Stage II Pharyngeal Carcinoma\", \"Stage II Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C8769\", \"name\": \"Stage II Pharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27224\", \"name\": \"Infection-Related Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27933\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C167265\", \"name\": \"Nasopharyngeal Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3871\", \"C102872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HNSCC\", \"Head and neck squamous cell carcinoma, NOS\", \"SCCHN\", \"Squamous Cell Carcinoma of Head and Neck\", \"Squamous Cell Carcinoma of the Head and Neck\", \"squamous cell carcinoma of the head and neck\"], \"nci_thesaurus_concept_id\": \"C34447\", \"name\": \"Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage IV\", \"Stage IV Carcinoma of Pharynx\", \"Stage IV Carcinoma of the Pharynx\", \"Stage IV Pharyngeal Cancer\", \"Stage IV Pharyngeal Carcinoma\", \"Stage IV Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C8771\", \"name\": \"Stage IV Pharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Nasopharynx\", \"Cancer of the Nasopharynx\", \"Carcinoma of Nasopharynx\", \"Carcinoma of the Nasopharynx\", \"NPC\", \"Nasopharyngeal Cancer\", \"Nasopharyngeal Carcinoma\", \"Nasopharyngeal carcinoma\", \"Nasopharynx Cancer\", \"nasopharyngeal cancer\"], \"nci_thesaurus_concept_id\": \"C3871\", \"name\": \"Nasopharyngeal Throat Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9321\", \"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage III\", \"Stage III Carcinoma of Pharynx\", \"Stage III Carcinoma of the Pharynx\", \"Stage III Pharyngeal Cancer\", \"Stage III Pharyngeal Carcinoma\", \"Stage III Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C8770\", \"name\": \"Stage III Pharyngeal Throat Cancer\", \"type\": [\"stage\"], \"parents\": [\"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma of Neck\", \"Carcinoma of the Neck\"], \"nci_thesaurus_concept_id\": \"C6077\", \"name\": \"Neck Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C4940\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27571\", \"name\": \"Head and Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Head and Neck Neoplasm (Excluding Central Nervous System)\", \"Head and Neck Tumor\", \"Neoplasm of Head and Neck\", \"Neoplasm of the Head and Neck\", \"Tumor of Head and Neck\", \"Tumor of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C3077\", \"name\": \"Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27571\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Infection Related Cancer\", \"Infection Related Malignancy\", \"Infection-Related Cancer\", \"Infection-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27223\", \"name\": \"Infection-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27224\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neck Neoplasms (Including All Pharyngeal Related Neoplasms)\", \"Neck Tumor\", \"Neoplasm of Neck\", \"Neoplasm of the Neck\", \"Tumor of Neck\", \"Tumor of the Neck\"], \"nci_thesaurus_concept_id\": \"C3260\", \"name\": \"Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C27648\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C91252\", \"name\": \"Pharyngeal Carcinoma by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"EBV Related Carcinoma\", \"Epstein-Barr Virus Related Carcinoma\", \"Epstein-Barr Virus-Related Carcinoma\"], \"nci_thesaurus_concept_id\": \"C27690\", \"name\": \"EBV-Related Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C27689\", \"C27698\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Virus Related Cancer\", \"Virus Related Malignancy\", \"Virus-Related Cancer\", \"Virus-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27673\", \"name\": \"Virus-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27223\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Pharynx\", \"Neoplasm of the Pharynx\", \"Pharyngeal Neoplasms\", \"Pharyngeal Tumor\", \"Pharynx Neoplasm\", \"Pharynx Tumor\", \"Tumor of Pharynx\", \"Tumor of the Pharynx\"], \"nci_thesaurus_concept_id\": \"C3325\", \"name\": \"Pharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3260\", \"C26850\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Nasopharyngeal Tumor\", \"Malignant Neoplasm of Nasopharynx\", \"Malignant Neoplasm of the Nasopharynx\", \"Malignant Tumor of Nasopharynx\", \"Malignant Tumor of the Nasopharynx\"], \"nci_thesaurus_concept_id\": \"C9321\", \"name\": \"Malignant Nasopharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7545\", \"C3257\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage IVA\", \"Stage IVA Carcinoma of Pharynx\", \"Stage IVA Carcinoma of the Pharynx\", \"Stage IVA Pharyngeal Carcinoma\", \"Stage IVA Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6000\", \"name\": \"Stage IVA Pharyngeal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8771\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neck Disease\"], \"nci_thesaurus_concept_id\": \"C27648\", \"name\": \"Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27571\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Nasopharyngeal Neoplasms\", \"Nasopharyngeal Tumor\", \"Neoplasm of Nasopharynx\", \"Neoplasm of the Nasopharynx\", \"Tumor of Nasopharynx\", \"Tumor of the Nasopharynx\"], \"nci_thesaurus_concept_id\": \"C3257\", \"name\": \"Nasopharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35723\", \"C3325\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Head and Neck\", \"Cancer of the Head and Neck\", \"Head and Neck Cancer\", \"Head and neck cancer, NOS\", \"Malignant Head and Neck Tumor\", \"Malignant Neoplasm of Head and Neck\", \"Malignant Neoplasm of the Head and Neck\", \"Malignant Tumor of Head and Neck\", \"Malignant Tumor of the Head and Neck\", \"head and neck cancer\"], \"nci_thesaurus_concept_id\": \"C4013\", \"name\": \"Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27224\", \"name\": \"Infection-Related Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27933\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26850\", \"name\": \"Pharyngeal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27648\", \"C118420\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Pharyngeal Tumor\", \"Malignant Pharynx Neoplasm\", \"Malignant Pharynx Tumor\", \"Malignant Tumor of Pharynx\", \"Malignant Tumor of the Pharynx\"], \"nci_thesaurus_concept_id\": \"C7545\", \"name\": \"Malignant Pharyngeal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4940\", \"C3325\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pharyngeal Cancer Stage IVC\", \"Stage IVC Carcinoma of Pharynx\", \"Stage IVC Carcinoma of the Pharynx\", \"Stage IVC Pharyngeal Carcinoma\", \"Stage IVC Pharynx Carcinoma\"], \"nci_thesaurus_concept_id\": \"C6002\", \"name\": \"Stage IVC Pharyngeal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C8771\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Pharynx\", \"Cancer of the Pharynx\", \"Carcinoma of Pharynx\", \"Carcinoma of the Pharynx\", \"Pharyngeal Cancer\", \"Pharyngeal Carcinoma\", \"Pharynx Cancer\", \"Pharynx Carcinoma\", \"pharyngeal cancer\"], \"nci_thesaurus_concept_id\": \"C9466\", \"name\": \"Pharyngeal Throat Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C7545\", \"C35506\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HNSCC\", \"Head and neck squamous cell carcinoma, NOS\", \"SCCHN\", \"Squamous Cell Carcinoma of Head and Neck\", \"Squamous Cell Carcinoma of the Head and Neck\", \"squamous cell carcinoma of the head and neck\"], \"nci_thesaurus_concept_id\": \"C34447\", \"name\": \"Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Throat Cancer\", \"throat cancer\"], \"nci_thesaurus_concept_id\": \"C35506\", \"name\": \"Throat Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C6077\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Nasopharynx\", \"Cancer of the Nasopharynx\", \"Carcinoma of Nasopharynx\", \"Carcinoma of the Nasopharynx\", \"NPC\", \"Nasopharyngeal Cancer\", \"Nasopharyngeal Carcinoma\", \"Nasopharyngeal carcinoma\", \"Nasopharynx Cancer\", \"nasopharyngeal cancer\"], \"nci_thesaurus_concept_id\": \"C3871\", \"name\": \"Nasopharyngeal Throat Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9321\", \"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Neck\", \"Carcinoma of the Neck\"], \"nci_thesaurus_concept_id\": \"C6077\", \"name\": \"Neck Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C4940\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Pharyngeal (including Hypopharyngeal and Oropharyngeal) squamous cell carcinoma\", \"Pharyngeal Squamous Cell Carcinoma\", \"Pharyngeal squam. cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C102872\", \"name\": \"Pharyngeal Throat Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C9466\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Infection Related Cancer\", \"Infection Related Malignancy\", \"Infection-Related Cancer\", \"Infection-Related Malignancy\"], \"nci_thesaurus_concept_id\": \"C27223\", \"name\": \"Infection-Related Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27224\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Virus Related Carcinoma\"], \"nci_thesaurus_concept_id\": \"C27698\", \"name\": \"Virus-Related Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C27673\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"162010\", \"active_sites_count\": 4, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Abiplatin\", \"Blastolem\", \"Briplatin\", \"Cisplatyl\", \"Citoplatino\", \"Citosin\", \"Lederplatin\", \"Metaplatin\", \"Neoplatin\", \"Placis\", \"Plastistil\", \"Platamine\", \"Platiblastin\", \"Platiblastin-S\", \"Platinex\", \"Platinol\", \"Platinol- AQ\", \"Platinol-AQ\", \"Platinol-AQ VHA Plus\", \"Platiran\", \"Platistin\", \"Platosin\", \"Cisplatin\"], \"nci_thesaurus_concept_id\": \"C376\", \"name\": \"Cisplatin\", \"description\": \"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1450\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"nci_thesaurus_concept_id\": \"C68814\", \"name\": \"Nivolumab\", \"description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Platinum Agents\", \"Platinum-Based Chemotherapy\", \"Platinum Compound\"], \"nci_thesaurus_concept_id\": \"C1450\", \"name\": \"Platinum Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1590\", \"C2163\", \"C798\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"nci_thesaurus_concept_id\": \"C1590\", \"name\": \"Antineoplastic Alkylating Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2842\", \"name\": \"DNA Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2163\", \"name\": \"DNA Adduct Forming Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiation Sensitizers\", \"Radiation-Sensitizing Agents\", \"Radiation-Sensitizing Drugs\", \"Radiosensitizers\", \"Radiosensitizing Drugs\"], \"nci_thesaurus_concept_id\": \"C798\", \"name\": \"Radiosensitizing Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": []}], \"name\": \"Treatment (nivolumab, radiation therapy, cisplatin)\", \"description\": \"Patients receive nivolumab IV over 60 minutes on day 1 of cycles 1-5 and 7-12. Treatment repeats every 14 days for 11 cycles in the absence of disease progression or unacceptable toxicity. Beginning at cycle 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2017-02291\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.\", \"brief_title\": \"Nivolumab and Chemoradiotherapy in Treating Patients with Stage II-IVB Nasopharyngeal Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 40, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2017-12-12\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lip, Oral Cavity and Pharynx\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Sue Sun Yom\", \"study_source\": \"Institutional\", \"completion_date\": \"2022-12-01\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"18-26851\"}], \"amendment_date\": \"2021-03-18T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"University of California San Francisco\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Participants must have histologically or cytological confirmed stage IIIB/IV NSCLC\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Documented ALK-rearrangement (or ROS1- rearrangement) break-apart fluorescence in situ hybridization (FISH) (in >= 15% or tumor cells), or next generation sequencing assay performed on tumor sample or cell free DNA in a Clinical Laboratory Improvement Act (CLIA)-approved laboratory\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Dose Escalation Phase Only: At least one prior ALK or ROS1 targeted tyrosine kinase inhibitor (TKI). With progression or intolerance of most recent regimen\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Dose Expansion Phase Only: In addition to the criteria in exclusion criteria, ALK+ patients with no prior chemotherapy, immunotherapy, radiation therapy or other systemic therapy are also allowed\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Measurable or evaluable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Life expectancy of at least 3 months\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Leukocytes >= 3,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Absolute neutrophil count >=1,500/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Platelets >= 75,000/mcL\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Hemoglobin (Hgb) >= 9 gm/dL\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Total bilirubin within normal institutional limits\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 5 x institutional upper limit of normal\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x institutional upper limit of normal if there are liver metastases\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Creatinine within normal institutional limits OR\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Creatinine clearance >= 50 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Female participants who:\\r\\n* Are postmenopausal for at least 1 year before the screening visit, OR\\r\\n* Are surgically sterile, OR\\r\\n* If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of the study drugs, or\\r\\n* Agree to completely abstain from heterosexual intercourse\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Male participants, even if surgically sterilized (i.e., status post-vasectomy), who:\\r\\n* Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of the study drugs, or\\r\\n* Agree to completely abstain from heterosexual intercourse\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Negative pregnancy testing required at screening and cycle 1 day 1 for women of childbearing potential\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"Ability to understand a written informed consent document, and willingness to sign it\"}, {\"inclusion_indicator\": true, \"display_order\": 21, \"description\": \"Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels\"}, {\"inclusion_indicator\": true, \"display_order\": 22, \"description\": \"Participant is deemed by the investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up)\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 7 days for prior TKI and 14 days for chemotherapy or radiation and 30 days for prior immunotherapy before the first dose of treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Prior treatment with either study drug as most recent treatment or prior discontinuation of either study drug due to toxicity\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Known hypersensitivity to any study drug components\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Known history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Known history of myositis\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"History of pancreatitis\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"History or current evidence of retinal vein occlusion (RVO) or current risk factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\\r\\n* Symptomatic chronic heart failure grade >= 2, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.\\r\\n* Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\\r\\n** Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib\\r\\n** Unstable angina within 6 months prior to first dose\\r\\n** Symptomatic congestive heart failure requiring treatment (New York Heart Association grade >= 2), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality =< 6 months prior to Screening except atrial fibrillation and paroxysmal supraventricular tachycardia\\r\\n** Congestive heart failure requiring treatment (New York Heart Association grade >= 2)\\r\\n** Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO)\\r\\n**QT interval corrected for heart rate using the Fridericia formula (QTcF) > 480 msec;\\r\\n** History of clinically significant atrial arrhythmia\\r\\n** Any history of ventricular arrhythmia\\r\\n** Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Uncontrolled hypertension defined as persistent elevation of systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite current therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"History of chronic inflammatory bowel disease or Crohn\\u2019s disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =< 12 months prior to first dose of study treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Impaired gastrointestinal (GI) function or disease that may significantly alter the absorption of binimetinib or brigatinib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"History of thromboembolic or cerebrovascular events =< 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Current neuromuscular disorder(s) associated with elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Major surgery =< 3 weeks prior to starting study drugs, or persistent/ongoing side effects of major surgery\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Pregnant or nursing (lactating) women\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with ability to participate actively in the study\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"History of another malignancy. Participants with fully resected non-melanoma skin cancer, indolent early stage second malignancies, or who have been disease free for > three years may be eligible following discussion with study principal investigator (PI)\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"Any symptomatic brain metastasis\\r\\n* Note: Participants previously treated or untreated for this condition who are asymptomatic in the absence of corticosteroid and anti-epileptic therapy are allowed. Brain metastases must be stable for >= 2 weeks, with imaging (e.g., magnetic resonance imaging [MRI] or computed tomography [CT]) demonstrating no current evidence of progressive brain metastases at screening)\"}, {\"inclusion_indicator\": false, \"display_order\": 41, \"description\": \"Participants receiving any medications or substances that are inhibitors or inducers of CYP3A enzyme(s) and CYP2C8 within 14 days of enrollment are ineligible\"}, {\"inclusion_indicator\": false, \"display_order\": 42, \"description\": \"Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"CA\", \"contact_name\": \"Matthew A. Gubens\", \"contact_phone\": null, \"recruitment_status_date\": \"2019-12-06\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1600 Divisadero Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94115\", \"contact_email\": \"matthew.gubens@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"UCSF Medical Center-Mount Zion\", \"org_coordinates\": {\"lon\": -122.4376, \"lat\": 37.7858}}, {\"org_state_or_province\": \"CA\", \"contact_name\": \"Collin Michael Blakely\", \"contact_phone\": \"415-502-6959\", \"recruitment_status_date\": \"2019-12-06\", \"org_address_line_2\": \"Floor 6\", \"org_va\": false, \"org_address_line_1\": \"490 Illinois Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"Collin.Blakely@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"University of California San Francisco\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To determine the safety and tolerability of brigatinib in combination with binimetinib in stage IIIB or IV ALK or ROS1 rearranged non-small cell lung cancer (NSCLC) and the recommended phase 2 dose.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To determine preliminary efficacy of brigatinib in combination with binimetinib in any line of treatment.\\r\\nII. To characterize the pharmacokinetic parameters of brigatinib in combination with binimetinib.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To assess circulating tumor deoxyribonucleic acid (DNA) (ctDNA) utility in evaluating treatment response.\\r\\nII. To evaluate the blockade of downstream signaling indicating response or resistance to treatment of immunohistochemistry (IHC) for PI3K/AKT/MAPK pathway activity evaluation.\\r\\n\\r\\nOUTLINE: This a dose-escalation study.\\r\\n\\r\\nPatients receive brigatinib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up for 30 days and then every 6 months for 12 months.\", \"official_title\": \"A Phase I Study of Brigatinib with Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)\", \"_phase_sort_order\": 4, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 12 months\", \"name\": \"Depth of response\", \"description\": \"Will be defined as maximal reduction in tumor size based on Response Evaluation Criteria in Solid Tumors (RECIST) measurement. Median and inter-quartile range will be used to describe the depth of response (the maximal reduction in tumor size based on RECIST measurement).\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 12 months\", \"name\": \"Immunohistochemistry (IHC) pathway analyses\", \"description\": \"Immunohistochemistry pathway analyses will be used to evaluate signaling pathway activity. Analyses performed for this study include ctDNA monitoring while on treatment and IHC assessment of associated signaling pathways.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 12 months\", \"name\": \"Measurement of circulating tumor deoxyribonucleic acid (ctDNA)\", \"description\": \"Measurement of ctDNA at each time point will be summarized by descriptive statistics.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"At pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose on days 1 and 15 of cycle 1\", \"name\": \"Measurement of pharmacokinetic parameters\", \"description\": \"Plasma concentration assessment (pharmacokinetic data) of brigatinib during coadministration with binimetinib will be determine by assay at the timepoints described above. The assay will be done by Takeda / their designated vendor. These results will be presented in graph form as a function of time.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 12 months\", \"name\": \"Objective response rate (ORR)\", \"description\": \"Point estimate and 95% exact binomial confidence interval (CI) will be obtained for ORR.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At 12 months\", \"name\": \"Overall survival (OS)\", \"description\": \"Kaplan-Meier method will be used to describe the describe OS at 12 months with their median and 95% CI.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time from start of treatment to time of progression, assessed at 6 months\", \"name\": \"Progression free survival (PFS)\", \"description\": \"Kaplan-Meier method will be used to describe the describe PFS at 6 months \\r\\nmonths with their median and 95% CI.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 12 months\", \"name\": \"Recommended phase 2 dose of brigatinib in combination with binimetinib\", \"description\": \"Will be measured by evaluating the number and frequency of adverse events as determined by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version (v)5.0 by investigator\\u2019s assessment and to determine the recommended phase 2 dose for future studies.\", \"type_code\": \"PRIMARY\"}], \"phase\": \"I\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT04005144\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ALK Rearrangement\", \"Anaplastic Lymphoma Kinase Gene Rearrangement\", \"Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement\", \"CD246 Gene Rearrangement\", \"Rearrangement identified\"], \"nci_thesaurus_concept_id\": \"C129574\", \"name\": \"ALK Gene Rearrangement\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C133155\", \"C156028\", \"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C2950\", \"C36327\", \"C36391\", \"C36541\", \"C38184\", \"C3910\", \"C97926\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C156028\", \"C38184\", \"C20719\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"MCF3 Gene Rearrangement\", \"ROS Gene Rearrangement\", \"ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement\", \"ROS1 Rearrangement\", \"Rearrangement identified\", \"c-ros-1 Gene Rearrangement\"], \"nci_thesaurus_concept_id\": \"C130236\", \"name\": \"ROS1 Gene Rearrangement\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C133155\", \"C156028\", \"C16612\", \"C18399\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C2950\", \"C36327\", \"C36391\", \"C36541\", \"C3910\", \"C97926\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C156028\", \"C20719\", \"C18399\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ALK\", \"ALK Receptor Tyrosine Kinase Gene\"], \"nci_thesaurus_concept_id\": \"C38184\", \"name\": \"ALK Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anomaly\", \"DNA Sequence Variation\", \"Genetic Abnormality\", \"Genetic Alteration\", \"Genetic Anomaly\", \"Molecular Abnormality\", \"Molecular Anomaly\", \"Molecular Genetic Abnormality\", \"Molecular Genetic Anomaly\"], \"nci_thesaurus_concept_id\": \"C36391\", \"name\": \"Molecular Genetic Variation\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3910\", \"C97926\"], \"parents\": [\"C97926\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"VARIANT_TYPE\", \"molecular consequence\", \"molecular_consequence\"], \"nci_thesaurus_concept_id\": \"C97926\", \"name\": \"Molecular Sequence Variation\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3910\"], \"parents\": [\"C3910\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene\", \"ROS1\"], \"nci_thesaurus_concept_id\": \"C18399\", \"name\": \"ROS1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Aberrant Chromosome\", \"Chromosomal Aberration\", \"Chromosomal Abnormalities\", \"Chromosomal Abnormality\", \"Chromosomal Alterations\", \"Chromosome Aberration\", \"Chromosome Abnormality\", \"Chromosome Alterations\", \"Chromosome Anomalies\", \"Cytogenetic Aberration\", \"Cytogenetic Analysis Abnormality Type\"], \"nci_thesaurus_concept_id\": \"C2950\", \"name\": \"Cytogenetic Abnormality\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3910\"], \"parents\": [\"C3910\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C36327\", \"name\": \"Gene Abnormality\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C36391\", \"C3910\", \"C97926\"], \"parents\": [\"C36391\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chromosomal Rearrangements\", \"Rearrangement\", \"Structural Chromosomal Abnormality\", \"Structural Chromosome Aberration\", \"Structural Chromosome Anomalies\"], \"nci_thesaurus_concept_id\": \"C36541\", \"name\": \"Chromosomal Rearrangement\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C2950\", \"C3910\"], \"parents\": [\"C2950\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"RTK Family Gene Rearrangement\", \"RTK Family Rearrangement\", \"RTK Gene Rearrangement\", \"RTK Rearrangement\", \"Receptor Tyrosine Kinase Family Gene Rearrangement\", \"Receptor Tyrosine Kinase Rearrangement\", \"Tyrosine Kinase Receptor Family Rearrangement\", \"Tyrosine Kinase Receptor Gene Rearrangement\", \"Tyrosine Kinase Receptor Rearrangement\"], \"nci_thesaurus_concept_id\": \"C156028\", \"name\": \"Receptor Tyrosine Kinase Gene Rearrangement\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C133155\", \"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C2950\", \"C36327\", \"C36391\", \"C36541\", \"C3910\", \"C97926\"], \"parents\": [\"C133155\", \"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chromosomal, Gene, or Protein Abnormality\", \"Cytogenetic or Molecular Genetic Abnormality\", \"Genetic Abnormality\", \"MOLECULAR_ABNORMALITY\", \"Molecular Alteration\"], \"nci_thesaurus_concept_id\": \"C3910\", \"name\": \"Molecular Abnormality\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Abnormal Gene Rearrangement\", \"Abnormal Rearrangement\", \"Gene Rearrangement\"], \"nci_thesaurus_concept_id\": \"C133155\", \"name\": \"Gene Rearrangement Abnormality\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C2950\", \"C36327\", \"C36391\", \"C36541\", \"C3910\", \"C97926\"], \"parents\": [\"C36541\", \"C36327\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2019-12-06\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIB\", \"Stage IIIB Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136480\", \"name\": \"Stage IIIB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136478\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136481\", \"name\": \"Stage IIIC Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136478\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV\", \"Stage IV Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136482\", \"name\": \"Stage IV Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136467\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IVA Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136483\", \"name\": \"Stage IVA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136482\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IVB Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136484\", \"name\": \"Stage IVB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136482\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III\", \"Stage III Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136478\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV\", \"Stage IV Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136482\", \"name\": \"Stage IV Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Stage (Pathological)\"], \"nci_thesaurus_concept_id\": \"C136467\", \"name\": \"Lung Cancer by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"186517\", \"active_sites_count\": 2, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Mektovi\", \"Binimetinib\"], \"nci_thesaurus_concept_id\": \"C84865\", \"name\": \"Binimetinib\", \"description\": \"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C129825\", \"C69145\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Alunbrig\", \"Brigatinib\"], \"nci_thesaurus_concept_id\": \"C98831\", \"name\": \"Brigatinib\", \"description\": \"An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Dual ALK/EGFR inhibitor AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C141136\", \"C129825\", \"C2167\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Enzyme Inhibitor\"], \"nci_thesaurus_concept_id\": \"C129825\", \"name\": \"Antineoplastic Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129824\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Protein Inhibitor\", \"Antineoplastic Protein Antagonist\"], \"nci_thesaurus_concept_id\": \"C129824\", \"name\": \"Antineoplastic Protein Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2189\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Signal Transduction Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2189\", \"name\": \"Signal Transduction Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"MAP2K Inhibitor\", \"MAPK/ERK Kinase Inhibitor\", \"MAPKK Inhibitor\", \"MEK Inhibitor\", \"MKK Inhibitor\", \"Mitogen-Activated Protein Kinase Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C69145\", \"name\": \"Mitogen-Activated Protein Kinase Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protein Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1404\", \"name\": \"Protein Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anaplastic Lymphoma Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C141136\", \"name\": \"ALK Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163758\", \"C1967\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PTK Inhibitors\", \"Protein Tyrosine Kinase Inhibitors\", \"TK Inhibitors\", \"Tyrosine Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1967\", \"name\": \"Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"EGFR Blocker\", \"EGFR Inhibitor\", \"EGFR Tyrosine Kinase Inhibitor\", \"EGFR Tyrosine Kinase Inhibitors\", \"EGFR-TK Inhibitor\", \"Epidermal Growth Factor Receptor Inhibitor\", \"Epidermal Growth-Factor Receptor Inhibitors\"], \"nci_thesaurus_concept_id\": \"C2167\", \"name\": \"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163952\", \"C1967\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C163952\", \"name\": \"EGFR-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163758\"]}], \"name\": \"Treatment (brigatinib, binimetinib)\", \"description\": \"Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2019-02315\", \"why_study_stopped\": null, \"brief_summary\": \"This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\", \"brief_title\": \"Brigatinib and Binimetinib in Treating Patients with Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 18, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2019-12-06\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lung\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Collin Michael Blakely\", \"study_source\": \"Institutional\", \"completion_date\": \"2024-08-01\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": \"2019-12-17T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"University of Miami Miller School of Medicine-Sylvester Cancer Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Prostate cancer patients with a PSA after prostatectomy of at least 0.1 ng/mL and up to 4.0 ng/mL within 3 months prior to enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Patients with or without palpable abnormalities on digital rectal exam (DRE) are eligible\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Minimum of 3 months since prostatectomy to allow for return of urinary continence and healing\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Imaging detectable lesion or lesions in prostate bed or regional lymph nodes (LN). Each lesion should be at least 0.4 cc and a maximum of 6 cc and was obtained =< 3 months prior to protocol entry or enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"No evidence of metastatic (distant) disease (pelvic nodes are allowed up to common iliac)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Negative bone scan if deemed necessary by treating physician obtained =< 4 months prior to protocol entry or enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"No previous pelvic radiotherapy\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Serum total testosterone taken within 3 months prior to enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for >= 3 years then the patient is eligible\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Ability to understand and the willingness to sign a written informed consent document\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Zubrod performance status < 2\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Patients must agree to fill out quality of life/psychosocial questionnaires\"}, {\"inclusion_indicator\": false, \"display_order\": 13, \"description\": \"Prior androgen deprivation therapy is not permitted if it was within 6 months previous to signing consent form. (NOTE: Therapy given as part of the planned course of radiation is allowed)\"}], \"structured\": {\"max_age\": \"85 Years\", \"max_age_number\": 85, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 85, \"gender\": \"MALE\", \"min_age\": \"35 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 35, \"min_age_in_years\": 35}}, \"sites\": [{\"org_state_or_province\": \"FL\", \"contact_name\": \"Matthew Charles Abramowitz\", \"contact_phone\": \"305-243-4319\", \"recruitment_status_date\": \"2011-06-01\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1475 Northwest 12th Avenue\", \"org_tty\": null, \"org_family\": \"Sylvester Comprehensive Cancer Center\", \"org_postal_code\": \"33136\", \"contact_email\": \"MAbramowitz@med.miami.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Miami\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"305-243-2647\", \"org_name\": \"University of Miami Miller School of Medicine-Sylvester Cancer Center\", \"org_coordinates\": {\"lon\": -80.2039, \"lat\": 25.7869}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To determine the effect of radiation boost to the imaging detected lesions on initial complete biochemical response.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To determine the impact of salvage radiation therapy (SRT) boost to the MRI-identified lesion on toxicity, health-related quality of life (HRQOL), prostate cancer-specific anxiety, and prostate cancer-specific quality of life (QOL).\\r\\nII. To evaluate biochemical and clinical failure, failure-free survival, and overall survival.\\r\\nIII. To determine the distribution and degree of expression of tissue biomarkers by ultrasound (US)-directed biopsies for patients who choose to undergo the optional biopsies.\\r\\nIV. Compare positron emission tomography (PET) and MRI detected lesions.\\r\\nV. To determine the incidence and relationship of circulating deoxyribonucleic acid (DNA) and tumor cells to tissue biomarkers and initial complete biochemical response.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM I: Patients undergo standard SRT (SSRT) in the form of intensity-modulated radiation therapy 5 times per week over 7-8 weeks in the absence of disease progression or unacceptable toxicity. (CLOSED)\\r\\n\\r\\nARM II: Patients undergo mapped tumor salvage radiation therapy (MTSRT) 5 times per week over 7-8 weeks in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 6 weeks, 3 months, 9 months, and every 6 months for 5.25 years.\", \"official_title\": \"A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial\", \"_phase_sort_order\": 1, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Impact of protocol therapy on study participant Health-Related Quality of Life (HRQOL)\", \"description\": \"The impact of protocol therapy on study participant health-related quality of life (HRQOL), will be measured and scored via the Expanded Prostate Cancer Index Composite Questionnaire-short form (SF)12 quality of life questionnaire.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Impact of protocol therapy on study participant prostate cancer-specific anxiety\", \"description\": \"The impact of protocol therapy on study participant prostate cancer-specific anxiety will be measured and scored via the Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Impact of protocol therapy on study participant prostate cancer-specific Quality of Life (QOL)\", \"description\": \"The impact of protocol therapy on study participant prostate cancer-specific QOL will be measured and scored via the International Prostate Symptom Score (IPSS) quality of life questionnaire.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Incidence and relationship of circulating deoxyribonucleic acid (DNA) and tumor cells to tissue biomarkers\", \"description\": \"To determine the incidence and relationship of circulating DNA and tumor cells to tissue biomarkers and initial complete biochemical response.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Measurement of tissue biomarker expression\", \"description\": \"The distribution and degree of expression of tissue biomarkers by ultrasound-directed biopsies for patients who choose to undergo the optional biopsies. Quantification of the amount of the biomarker specific immunohistochemical staining in the area of tumor.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Rate of acute and late toxicity\", \"description\": \"The impact of protocol therapy on toxicity in study participants: Acute toxicity: Toxicity occurring during treatment and within three months of completing treatment. Late toxicity: Toxicity occurring more than three months after treatment completion.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Rate of biochemical and clinical failure\", \"description\": \"The cumulative incidence of biochemical or clinical failure allowing for competing risk as needed. Clinical failure is defined as at least a 25% increase in the size of the tumor relative to the smallest volume recorded, or new extension of tumor beyond the capsule, or re-extension of tumor beyond the capsule after initial regression, or urinary obstructive symptoms with carcinoma found at transurethral resection of the prostate (TURP). Biochemical failure is defined as PSA >= nadir + 2 ng/mL.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Rate of failure-free survival (FFS)\", \"description\": \"Rate of failure-free survival in study participants. Failure-free survival is defined as the elapsed time from start of radiotherapy to first documented evidence of biochemical or clinical failure or death from any cause, whichever occurs first. In the absence of any event defining failure, follow-up time will be censored at the date of last documented failure-free status.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 5.25 years post-protocol therapy\", \"name\": \"Rate of overall survival (OS)\", \"description\": \"Rate of overall survival in study participants. Overall survival is defined as the elapsed time from start of radiotherapy to death from any cause. For surviving patients, follow-up will be censored at the date of last contact.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"21 months post-completion of protocol therapy\", \"name\": \"Rate of prostate specific antigen (PSA) response to protocol therapy\", \"description\": \"The primary objective is to determine the effect of radiation boost to the magnetic resonance imaging (MRI) lesion on initial complete biochemical response. Rate of PSA response is defined as the proportion of study patients with PSA < 0.1 ng/mL at 21 months after completion of study treatment.\", \"type_code\": \"PRIMARY\"}], \"phase\": \"II_III\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 2, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT01411345\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"PSA Level 0.1 or Greater\"], \"nci_thesaurus_concept_id\": \"C138940\", \"name\": \"PSA Level Greater than or Equal to 0.1\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C138961\", \"C16612\", \"C21281\", \"C25804\", \"C26003\", \"C26585\", \"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C138961\", \"C26585\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"PSA Level 4 or Less\", \"PSA Level Four or Less\", \"PSA Level Less than or Equal to 4\"], \"nci_thesaurus_concept_id\": \"C156007\", \"name\": \"PSA Level Less than or Equal to Four\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C138961\", \"C16612\", \"C21281\", \"C25804\", \"C26003\", \"C26585\", \"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C138961\", \"C26585\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"KLK3\", \"Kallikrein 3, (Prostate Specific Antigen) Gene\", \"PSA\"], \"nci_thesaurus_concept_id\": \"C26585\", \"name\": \"KLK3 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C21281\", \"C25804\", \"C26003\"], \"parents\": [\"C26003\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C138961\", \"name\": \"PSA Level Finding\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25804\", \"C26003\", \"C26585\", \"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\", \"C26585\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protease Gene\", \"Proteinase Gene\"], \"nci_thesaurus_concept_id\": \"C26003\", \"name\": \"Peptidase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25804\"], \"parents\": [\"C25804\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Hydrolase Family Gene\"], \"nci_thesaurus_concept_id\": \"C25804\", \"name\": \"Hydrolase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2011-06-01\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Prostate\", \"Cancer of the Prostate\", \"Carcinoma of Prostate\", \"Carcinoma of the Prostate\", \"Prostate Carcinoma\", \"Prostate cancer, NOS\", \"prostate cancer\"], \"nci_thesaurus_concept_id\": \"C4863\", \"name\": \"Prostate Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C181196\", \"C7378\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Reproductive System\", \"Neoplasm of the Reproductive System\", \"Reproductive Neoplasm\", \"Reproductive System Tumor\", \"Reproductive Tumor\", \"Tumor of Reproductive System\", \"Tumor of the Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3674\", \"name\": \"Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Urogenital Disease\"], \"nci_thesaurus_concept_id\": \"C156660\", \"name\": \"Genitourinary System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Prostate Disease\"], \"nci_thesaurus_concept_id\": \"C26865\", \"name\": \"Prostate Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27019\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C36076\", \"name\": \"Malignant Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156484\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Male Reproductive System\", \"Male Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C27019\", \"name\": \"Male Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Reproductive System\", \"Genital Disorders\", \"Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C4875\", \"name\": \"Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C156660\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Genitourinary Cancer\", \"Genitourinary System Cancer\", \"Malignant Genitourinary Neoplasm\"], \"nci_thesaurus_concept_id\": \"C156484\", \"name\": \"Malignant Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Male Reproductive System Tumor\", \"Neoplasm of Male Reproductive System\", \"Neoplasm of the Male Reproductive System\", \"Tumor of Male Reproductive System\", \"Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3054\", \"name\": \"Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27019\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Prostate\", \"Neoplasm of the Prostate\", \"Prostate Tumor\", \"Tumor of Prostate\", \"Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C3343\", \"name\": \"Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C26865\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C164141\", \"name\": \"Genitourinary System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C156484\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Prostate\", \"Malignant Neoplasm of the Prostate\", \"Malignant Prostate Tumor\", \"Malignant Tumor of Prostate\", \"Malignant Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C7378\", \"name\": \"Malignant Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8561\", \"C3343\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C181196\", \"name\": \"Male Reproductive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C164141\", \"C8561\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Male reprod. system cancer, NOS\", \"Male reproductive system cancer, NOS\", \"Malignant Male Reproductive System Tumor\", \"Malignant Neoplasm of Male Reproductive System\", \"Malignant Neoplasm of the Male Reproductive System\", \"Malignant Tumor of Male Reproductive System\", \"Malignant Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C8561\", \"name\": \"Malignant Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C36076\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156482\", \"name\": \"Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156660\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"20101056\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Questionnaire Administration\"], \"nci_thesaurus_concept_id\": \"C64253\", \"name\": \"Questionnaire Administration\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C64255\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Informational Intervention\"], \"nci_thesaurus_concept_id\": \"C64255\", \"name\": \"Informational Intervention\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C63474\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Behavioral, Psychological or Informational Intervention\"], \"nci_thesaurus_concept_id\": \"C63474\", \"name\": \"Behavioral, Psychological or Informational Intervention\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}], \"name\": \"Arm II (MTSRT)\", \"description\": \"Patients undergo MTSRT 5 times per week over 7-8 weeks in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Questionnaire Administration\"], \"intervention_name\": \"Questionnaire Administration\", \"category\": \"other\", \"intervention_code\": \"C64253\", \"intervention_description\": null, \"parents\": [\"C64255\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"IMRT\", \"Intensity Modulated RT\", \"Intensity-Modulated Radiotherapy\", \"Intensity-Modulated Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C16135\", \"name\": \"Intensity-Modulated Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C16035\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Informational Intervention\"], \"intervention_name\": \"Informational Intervention\", \"category\": \"none\", \"intervention_code\": \"C64255\", \"intervention_description\": \"\", \"parents\": [\"C63474\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Behavioral, Psychological or Informational Intervention\"], \"intervention_name\": \"Behavioral, Psychological or Informational Intervention\", \"category\": \"none\", \"intervention_code\": \"C63474\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Intervention or Procedure\", \"category\": \"none\", \"intervention_code\": \"C25218\", \"intervention_description\": \"\", \"parents\": [\"C16203\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Clinical or Research Activity\", \"category\": \"none\", \"intervention_code\": \"C16203\", \"intervention_description\": \"\", \"parents\": [\"C43431\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Activity\", \"category\": \"none\", \"intervention_code\": \"C43431\", \"intervention_description\": \"\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"3D-CRT\", \"Conformal Therapy\", \"Radiation Conformal Therapy\", \"3-Dimensional Conformal Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C16035\", \"name\": \"3-Dimensional Conformal Radiation Therapy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C15313\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"intervention_name\": \"Radiation Therapy\", \"category\": \"none\", \"intervention_code\": \"C15313\", \"intervention_description\": \"\", \"parents\": [\"C49236\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Therapeutic Procedure\", \"category\": \"none\", \"intervention_code\": \"C49236\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}], \"name\": \"Arm I (SSRT)\", \"description\": \"Patients undergo SSRT in the form of intensity-modulated radiation therapy 5 times per week over 7-8 weeks in the absence of disease progression or unacceptable toxicity. (CLOSED)\", \"type\": \"ACTIVE_COMPARATOR\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2019-06901\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II/III trial studies how well magnetic resonance imaging (MRI)-mapped dose-escalated salvage radiotherapy works after surgery in treating patients with prostate cancer. A very focused treatment of high dose boost of radiation delivered to the regions of the prostate bed indicated to have a tumor based on MRI scans may be more effective and create less side effects than standard radiation therapy.\", \"brief_title\": \"MRI-Mapped Dose-Escalated Salvage Radiotherapy for the Treatment of Prostate Cancer after Surgery, the MAPS Study\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 80, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2011-06-01\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Prostate\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Matthew Charles Abramowitz\", \"study_source\": \"Institutional\", \"completion_date\": \"2028-06-30\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": null, \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"M D Anderson Cancer Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Hematopoietic cell transplant recipients OR hematological malignancy patients\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Diagnosed with influenza\\r\\n* A positive multiplex polymerase chain reaction (PCR) for influenza is required to confirm a diagnosis of influenza infection\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Evidence of LRTI or high risk upper respiratory tract infection (URTI)\\r\\n* LRTI will be defined as influenza cases that have evidence of disease below the level of the trachea on either imaging only (possible LRTI), imaging and microbiological evidence of lower airway disease with a bronchoscopy (probable LRTD) or pathological evidence of disease via biopsy (proven LRTI)\\r\\n* High risk URI will be defined as those cases of influenza that do not have microbiological nor radiological evidence of LRTI, yet they have an immunodeficiency scoring index (ISI) of 3 or greater as defined by Shah D et al (19) for HCT recipients or severe neutropenia (absolute neutrophil count [ANC] =< 500 cells/ml) and/or lymphopenia (absolute blood lymphocyte count [ALC] =< 200 cells/ml) for HM patients.\"}, {\"inclusion_indicator\": false, \"display_order\": 4, \"description\": \"Patient requires mechanical ventilation at time of enrollment\"}, {\"inclusion_indicator\": false, \"display_order\": 5, \"description\": \"Patient is younger than the age of 12 years old\"}, {\"inclusion_indicator\": false, \"display_order\": 6, \"description\": \"The patient is unable to tolerate oral therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 7, \"description\": \"The patient is pregnant\"}, {\"inclusion_indicator\": false, \"display_order\": 8, \"description\": \"The patient is on a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine) and herbal therapies\"}, {\"inclusion_indicator\": false, \"display_order\": 9, \"description\": \"The patient is unable to consent will be excluded\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"12 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 12, \"min_age_in_years\": 12}}, \"sites\": [{\"org_state_or_province\": \"TX\", \"contact_name\": \"Roy F Chemaly\", \"contact_phone\": \"713-792-6830\", \"recruitment_status_date\": \"2021-10-11\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1515 Holcombe Boulevard\", \"org_tty\": null, \"org_family\": \"MD Anderson Cancer Center\", \"org_postal_code\": \"77030\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Houston\", \"org_email\": \"askmdanderson@mdanderson.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-632-6789\", \"org_name\": \"M D Anderson Cancer Center\", \"org_coordinates\": {\"lon\": -95.4026, \"lat\": 29.7059}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To compare the efficacy of baloxavir marboxil (baloxavir) in combination with oseltamivir to oseltamivir monotherapy as measured by changes in influenza viral loads at day 1 from baseline for treatment of severe influenza infections in immunocompromised hosts (such as hematopoietic cell transplant [HCT] recipients and hematological malignancy [HM] patients) and compare the main clinical outcome, complicated hospital stay between the intervention arm and control arm.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To compare the efficacy of baloxavir in combination with oseltamivir to oseltamivir monotherapy as measured by changes in influenza viral loads at day 3, 7, 14 and 30 from baseline.\\r\\nII. To measure the incidence of baloxavir and oseltamivir resistance, development of lower respiratory tract infections (LRTI), oxygen requirement, respiratory failure, changes in microbiome of the upper airway, length of hospital stay and all-cause mortality at day 30 while on baloxavir and/or oseltamivir in these immunocompromised hosts.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM I: Patients receive oseltamivir orally (PO) twice daily (BID) for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity. \\r\\n\\r\\nARM II: Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study, patients are followed up at 30 days.\", \"official_title\": \"Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts\", \"_phase_sort_order\": 2, \"collaborators\": null, \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"At 30 days\", \"name\": \"30-day mortality\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"On day 0, 1, 3, 7, 14, and 30\", \"name\": \"Changes in microbiome diversity\", \"description\": \"Analysis of alpha and beta diversity of microbiome will be assessed using Agile Toolkit for Incisive Microbial Analyses. Using Shannon index, we will quantify the alpha diversity of the microbiome. Changes in microbiome diversity will be made by comparing alpha diversity at each time point of sample collection (days 0, 1, 3, 7, 14 and 30).\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"On day 0, 1, 3, 7, 14, and 30\", \"name\": \"Changes in viral loads\", \"description\": \"Will be measured via repeat nasopharyngeal swabs at each follow up on day 0, 1, 3, 7, 14 and 30 for influenza quantification.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Incidence of complicated hospital stay\", \"description\": \"Defined as a hospital admission that was either prolonged (greater than 7 days), requiring intensive care unit level of care or death at day 30 as a result of influenza infection.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Length of hospital stay\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Oxygen requirement\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Progression to lower respiratory tract infections\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Rate of resistance to antiviral agents\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Rate of respiratory failure\", \"description\": \"Will compare variables between the interventional and control groups using Fischer\\u2019s exact test or Wilcoxon rank sum test when appropriate.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 2, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT04712539\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Influenza Type B Virus Positive\"], \"nci_thesaurus_concept_id\": \"C167117\", \"name\": \"Influenza B Virus Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C35682\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Influenza Type A Virus Positive\"], \"nci_thesaurus_concept_id\": \"C167118\", \"name\": \"Influenza A Virus Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C35682\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2021-10-11\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Flu\"], \"nci_thesaurus_concept_id\": \"C53482\", \"name\": \"Influenza\", \"type\": [\"subtype\"], \"parents\": [\"C3439\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-Neoplastic Disease by Special Category\"], \"nci_thesaurus_concept_id\": \"C53547\", \"name\": \"Non-Neoplastic Disorder by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C53529\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Inflammatory Disease\", \"Inflammatory_Disease\"], \"nci_thesaurus_concept_id\": \"C93210\", \"name\": \"Inflammatory Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C53547\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"NON-NEOPLASTIC\", \"Non-Neoplastic Disease\", \"Non-neoplastic Disorder\", \"Non-neoplastic condition, NOS\", \"Non-neoplastic disorder, NOS\"], \"nci_thesaurus_concept_id\": \"C53529\", \"name\": \"Non-Neoplastic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Clinical Infection\", \"ID\", \"INFECTION\", \"Infection\", \"Infectious\", \"Infectious Disease\", \"Infectious Diseases and Manifestations\", \"Unspecified Infection\", \"infection\"], \"nci_thesaurus_concept_id\": \"C26726\", \"name\": \"Infectious Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C93210\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Viral Disease\", \"Viral Disorder\"], \"nci_thesaurus_concept_id\": \"C3439\", \"name\": \"Viral Infection\", \"type\": [\"subtype\"], \"parents\": [\"C26726\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"2020-0919\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Oseltamivir\"], \"nci_thesaurus_concept_id\": \"C62061\", \"name\": \"Oseltamivir\", \"description\": null, \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C281\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antiviral\", \"Antivirals\"], \"nci_thesaurus_concept_id\": \"C281\", \"name\": \"Antiviral Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C254\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Infective Agents\", \"Anti-Infective Drugs\", \"Anti-Infectives\", \"AntiInfective Agents\", \"AntiInfective Drugs\", \"AntiInfectives\"], \"nci_thesaurus_concept_id\": \"C254\", \"name\": \"Anti-Infective Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}], \"name\": \"Arm II (oseltamivir)\", \"description\": \"Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.\", \"type\": \"ACTIVE_COMPARATOR\"}, {\"interventions\": [{\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Oseltamivir\"], \"intervention_name\": \"Oseltamivir\", \"category\": \"agent\", \"intervention_code\": \"C62061\", \"intervention_description\": null, \"parents\": [\"C281\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Xofluza\", \"Baloxavir Marboxil\"], \"nci_thesaurus_concept_id\": \"C166177\", \"name\": \"Baloxavir Marboxil\", \"description\": null, \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C281\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antiviral\", \"Antivirals\"], \"intervention_name\": \"Antiviral Agent\", \"category\": \"agent category\", \"intervention_code\": \"C281\", \"intervention_description\": \"\", \"parents\": [\"C254\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Infective Agents\", \"Anti-Infective Drugs\", \"Anti-Infectives\", \"AntiInfective Agents\", \"AntiInfective Drugs\", \"AntiInfectives\"], \"intervention_name\": \"Anti-Infective Agent\", \"category\": \"agent category\", \"intervention_code\": \"C254\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}], \"name\": \"Arm I (oseltamivir, baloxavir marboxil)\", \"description\": \"Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2020-13918\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral drug that inhibits the growth of influenza virus, reduces viral load and prevents further influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of influenza viruses, interfering with cell release of complete viral particles. Giving baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza infection compared to oseltamivir alone.\", \"brief_title\": \"Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 60, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2021-10-11\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Roy F Chemaly\", \"study_source\": \"Institutional\", \"completion_date\": \"2023-03-31\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": \"2021-04-09T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Wake Forest University Health Sciences\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Advanced, recurrent or metastatic head and neck squamous cell carcinoma, as defined by clinical or pathological diagnosis of any of the following:\\r\\n* Locally advanced head and neck squamous cell carcinoma not suitable for curative local treatment\\r\\n* Locally recurrent head and neck squamous cell carcinoma not suitable for curative local treatment within or outside a previously irradiated tissue\\r\\n* Metastatic head and neck squamous cell carcinoma\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Target site in the head and neck region amenable to quad-shot palliative radiotherapy, for which palliative radiotherapy is recommended, as determined by the treating radiation oncologist\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Willingness to provide blood and saliva samples for exploratory research purposes\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Absolute neutrophil count (ANC) >= 1.5 x 10^9/L\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Platelet count >= 100 x 10^9/L\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Hemoglobin >= 9.0 g/dL\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Serum bilirubin =< 1.5 x ULN (institutional upper limit of normal)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (institutional upper limit of normal)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Serum creatinine clearance (CL) > 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance\"}, {\"inclusion_indicator\": false, \"display_order\": 13, \"description\": \"Radiation therapy to the head and neck region within 30 days of registration\"}, {\"inclusion_indicator\": false, \"display_order\": 14, \"description\": \"Prior radiotherapy to the head and neck that precludes safe delivery of study radiotherapy, as determined by the treating radiation oncologist\"}, {\"inclusion_indicator\": false, \"display_order\": 15, \"description\": \"Active medical conditions that are contraindications to study radiotherapy (i.e. scleroderma), as determined by the treating radiation oncologist\"}, {\"inclusion_indicator\": false, \"display_order\": 16, \"description\": \"Pregnant or lactating women are excluded from this study because radiotherapy is contraindicated in pregnancy and because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with immunotherapy\"}, {\"inclusion_indicator\": false, \"display_order\": 17, \"description\": \"Participation in another clinical study with an investigational product during the last 3 months\"}, {\"inclusion_indicator\": false, \"display_order\": 18, \"description\": \"Any previous treatment with a PD1 or PD-L1 inhibitor\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Any anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within the last 30 days\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Mean QT interval corrected for heart rate (corrected QT [QTc]) >= 470 ms except for patients with pacemaker who have a paced ventricular rhythm\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Current or prior use of immunosuppressive medication within 30 days, with exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Any unresolved toxicity (> Common Terminology Criteria for Adverse Events [CTCAE] grade > 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Active or prior documented autoimmune disease within the past 2 years\\r\\n* NOTE: Subjects with vitiligo, Grave\\u2019s disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Active or prior documented inflammatory bowel disease (e.g., Crohn\\u2019s disease, ulcerative colitis)\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"History of primary immunodeficiency\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"History of allogeneic organ transplant\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"History of hypersensitivity to any excipient in pembrolizumab\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"History of pneumonitis or interstitial lung disease\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Subjects with uncontrolled seizures\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses, evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Known history of active tuberculosis\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving pembrolizumab\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Mercedes Porosnicu\", \"contact_phone\": \"336-713-5440\", \"recruitment_status_date\": \"2020-09-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"Medical Center Boulevard\", \"org_tty\": null, \"org_family\": \"Wake Forest Baptist Comprehensive Cancer Center\", \"org_postal_code\": \"27157\", \"contact_email\": \"mporosni@wakehealth.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Winston-Salem\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"336-713-6771\", \"org_name\": \"Wake Forest University Health Sciences\", \"org_coordinates\": {\"lon\": -80.2096, \"lat\": 36.0964}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. Measure the overall response rate for immunotherapy given with quad-shot radiotherapy.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. Measure the response rate at the target lesion.\\r\\nII. Measure the response rate at non-target sites in patients with non-target sites.\\r\\nIII. Evaluate the durability of response at the target lesion.\\r\\nIV. Evaluate progression-free survival.\\r\\nV. Evaluate overall survival.\\r\\nVI. Assess the tolerability of the combination of quad-shot radiotherapy with immunotherapy in order to assess the feasibility of this treatment regimen.\\r\\n\\r\\nEXPLORATORY OBJECTIVE:\\r\\nI. Evaluate the effect of quad- shot administration on increasing the immune activation by treatment with pembrolizumab and investigate possible mechanisms.\\r\\n\\r\\nOUTLINE:\\r\\nPatients receive standard of care pembrolizumab intravenously (IV) over 30 minutes every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo quad-shot radiation therapy twice daily (BID) on 2 consecutive days between cycles 2-3 or 3-4, 6-7, and 11-12 of pembrolizumab treatment and in the last week of pembrolizumab treatment.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 1 and 2 months for adverse events monitoring. Patients will be followed until death for monitoring survival study endpoints. Frequency of visits will be established by the treating physician and will be done in person or over the phone.\", \"official_title\": \"Quad-Shot Radiotherapy in Combination with Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 2 years\", \"name\": \"Duration of response at the target lesion\", \"description\": \"Will estimate both the mean and median duration and the corresponding 95% confidence intervals for the mean and inter-quartile range for the median.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Incidence of adverse events (AEs)\", \"description\": \"Will estimate the percent of patients with different AEs assessed using the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events and corresponding 95% Clopper Pearson exact confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Overall response rate\", \"description\": \"Will measure according to Response Evaluation Criteria in Solid Tumors criteria and determine the percentage of patients with either a partial or complete response (PR or CR) and the corresponding 95% Clopper Pearson exact confidence interval.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"At 6 months and 1 year post treatment\", \"name\": \"Overall survival (OS)\", \"description\": \"Will estimate Kaplan Meier survival curves and estimate the median time to event times as well as the percent OS at 6 months and 1 year post treatment\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At 6 months and 1 year post treatment\", \"name\": \"Progression free survival (PFS)\", \"description\": \"Will estimate Kaplan Meier survival curves and estimate the median time to event times as well as the percent PFS at 6 months and 1 year post treatment\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Response rate in non-target lesions\", \"description\": \"Will estimate the percent of responders (PR or CR) and the corresponding 95% Clopper Pearson exact confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Response rate in the target lesion\", \"description\": \"Will estimate the percent of responders (PR or CR) and the corresponding 95% Clopper Pearson exact confidence intervals.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT04454489\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2020-09-28\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III\", \"Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8\"], \"nci_thesaurus_concept_id\": \"C133258\", \"name\": \"Stage III Head and Neck Squamous Cell Cancer\", \"type\": [\"stage\"], \"parents\": [\"C133253\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IV\", \"Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8\"], \"nci_thesaurus_concept_id\": \"C133259\", \"name\": \"Stage IV Head and Neck Squamous Cell Cancer\", \"type\": [\"stage\"], \"parents\": [\"C133253\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Head and Neck Squamous Cell Carcinoma\", \"Recurrent Squamous Cell Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C133709\", \"name\": \"Recurrent Head and Neck Squamous Cell Cancer\", \"type\": [\"stage\"], \"parents\": [\"C34447\", \"C7624\", \"C162652\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Head and Neck Squamous Cell Carcinoma\"], \"nci_thesaurus_concept_id\": \"C139291\", \"name\": \"Advanced Head and Neck Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C129861\", \"C162653\", \"C148153\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Head and Neck Squamous Cell Carcinoma\"], \"nci_thesaurus_concept_id\": \"C148153\", \"name\": \"Metastatic Head and Neck Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C126465\", \"C4104\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162758\", \"name\": \"Locally Advanced Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153213\", \"C154321\", \"C148153\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C176682\", \"name\": \"Locally Recurrent Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C94796\", \"C133709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C154321\", \"name\": \"Locally Advanced Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C148130\", \"C4104\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170467\", \"name\": \"Metastatic Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4013\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Head and Neck Squamous Cell Carcinoma\", \"Recurrent Squamous Cell Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C133709\", \"name\": \"Recurrent Head and Neck Squamous Cell Cancer\", \"type\": [\"stage\"], \"parents\": [\"C34447\", \"C7624\", \"C162652\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Head and Neck Squamous Cell Carcinoma\"], \"nci_thesaurus_concept_id\": \"C148153\", \"name\": \"Metastatic Head and Neck Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C126465\", \"C4104\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162652\", \"name\": \"Recurrent Squamous Cell Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C7619\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Advanced Cancer\", \"Locally Metastatic Malignant Neoplasm\", \"Locally advanced\", \"locally advanced cancer\", \"regional cancer\"], \"nci_thesaurus_concept_id\": \"C8524\", \"name\": \"Locally Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Head and Neck Neoplasm (Excluding Central Nervous System)\", \"Head and Neck Tumor\", \"Neoplasm of Head and Neck\", \"Neoplasm of the Head and Neck\", \"Tumor of Head and Neck\", \"Tumor of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C3077\", \"name\": \"Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27571\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153171\", \"name\": \"Advanced Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cutaneous Disorder\", \"Disorder of Skin\", \"Skin Diseases and Manifestations\", \"Skin Disorders\"], \"nci_thesaurus_concept_id\": \"C3371\", \"name\": \"Skin Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Head and Neck\", \"Cancer of the Head and Neck\", \"Head and Neck Cancer\", \"Head and neck cancer, NOS\", \"Malignant Head and Neck Tumor\", \"Malignant Neoplasm of Head and Neck\", \"Malignant Neoplasm of the Head and Neck\", \"Malignant Tumor of Head and Neck\", \"Malignant Tumor of the Head and Neck\", \"head and neck cancer\"], \"nci_thesaurus_concept_id\": \"C4013\", \"name\": \"Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148130\", \"name\": \"Locally Advanced Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Skin\", \"Malignant Neoplasm of the Skin\", \"Malignant Skin Tumor\", \"Malignant Tumor of Skin\", \"Malignant Tumor of the Skin\", \"Melanoma and Non-Melanoma Skin Cancer\", \"Skin Cancer\", \"Skin Cancer, Including Melanoma\", \"Skin Neoplasm, Malignant\", \"Skin cancer, NOS\", \"skin cancer\"], \"nci_thesaurus_concept_id\": \"C2920\", \"name\": \"Malignant Skin Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3372\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C133252\", \"name\": \"Cutaneous Squamous Cell Carcinoma of the Head and Neck\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C4819\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Head and Neck Cancer\"], \"nci_thesaurus_concept_id\": \"C152077\", \"name\": \"Recurrent Malignant Head and Neck Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C4013\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Skin\", \"Carcinoma of the Skin\", \"Non-Melanoma Cancer of Skin\", \"Non-Melanoma Cancer of the Skin\", \"Non-melanoma Skin Cancer\", \"Skin Cancer, Non-Melanoma\", \"Skin Carcinoma\", \"nonmelanoma skin cancer\"], \"nci_thesaurus_concept_id\": \"C4914\", \"name\": \"Non-Melanoma Skin Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7342\", \"C2920\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Head and Neck\", \"Cancer of the Head and Neck\", \"Head and Neck Cancer\", \"Head and neck cancer, NOS\", \"Malignant Head and Neck Tumor\", \"Malignant Neoplasm of Head and Neck\", \"Malignant Neoplasm of the Head and Neck\", \"Malignant Tumor of Head and Neck\", \"Malignant Tumor of the Head and Neck\", \"head and neck cancer\"], \"nci_thesaurus_concept_id\": \"C4013\", \"name\": \"Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3077\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7624\", \"name\": \"Recurrent Head and Neck Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C35850\", \"C7619\", \"C152077\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Squamous cell carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C4104\", \"name\": \"Metastatic Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3482\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma of Head and Neck\", \"Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C35850\", \"name\": \"Head and Neck Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C4013\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HNSCC\", \"Head and neck squamous cell carcinoma, NOS\", \"SCCHN\", \"Squamous Cell Carcinoma of Head and Neck\", \"Squamous Cell Carcinoma of the Head and Neck\", \"squamous cell carcinoma of the head and neck\"], \"nci_thesaurus_concept_id\": \"C34447\", \"name\": \"Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170470\", \"name\": \"Locally Advanced Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C170467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Recurrent Cancer\", \"Loco-Regional\", \"Locoregional Recurrence\", \"locally recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C94796\", \"name\": \"Locally Recurrent Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Skin\", \"Neoplasm of the Skin\", \"Skin Neoplasm\", \"Skin Neoplasms\", \"Tumor of Skin\", \"Tumor of the Skin\"], \"nci_thesaurus_concept_id\": \"C3372\", \"name\": \"Skin Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C3371\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153213\", \"name\": \"Locally Advanced Head and Neck Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C148130\", \"C170470\", \"C126465\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Cancer\", \"Relapsed Cancer\", \"Relapsed Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7619\", \"name\": \"Recurrent Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C2916\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Head and Neck Carcinoma\"], \"nci_thesaurus_concept_id\": \"C126465\", \"name\": \"Metastatic Head and Neck Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C3482\", \"C170467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27571\", \"name\": \"Head and Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Squamous cell carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C4104\", \"name\": \"Metastatic Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3482\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170467\", \"name\": \"Metastatic Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4013\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Head and Neck\", \"Carcinoma of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C35850\", \"name\": \"Head and Neck Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C4013\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HNSCC\", \"Head and neck squamous cell carcinoma, NOS\", \"SCCHN\", \"Squamous Cell Carcinoma of Head and Neck\", \"Squamous Cell Carcinoma of the Head and Neck\", \"squamous cell carcinoma of the head and neck\"], \"nci_thesaurus_concept_id\": \"C34447\", \"name\": \"Head and Neck Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Head and Neck Squamous Cell Carcinoma\"], \"nci_thesaurus_concept_id\": \"C148153\", \"name\": \"Metastatic Head and Neck Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C34447\", \"C126465\", \"C4104\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162653\", \"name\": \"Advanced Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153171\", \"C4104\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Stage (Pathological)\"], \"nci_thesaurus_concept_id\": \"C133253\", \"name\": \"Cutaneous Squamous Cell Carcinoma of the Head and Neck by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C133252\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170469\", \"name\": \"Advanced Malignant Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C170467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Head and Neck Carcinoma\"], \"nci_thesaurus_concept_id\": \"C129861\", \"name\": \"Advanced Head and Neck Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C153171\", \"C170469\", \"C126465\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Head and Neck Carcinoma\"], \"nci_thesaurus_concept_id\": \"C126465\", \"name\": \"Metastatic Head and Neck Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C35850\", \"C3482\", \"C170467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Head and Neck Neoplasm (Excluding Central Nervous System)\", \"Head and Neck Tumor\", \"Neoplasm of Head and Neck\", \"Neoplasm of the Head and Neck\", \"Tumor of Head and Neck\", \"Tumor of the Head and Neck\"], \"nci_thesaurus_concept_id\": \"C3077\", \"name\": \"Head and Neck Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27571\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Advanced Cancer\", \"advanced cancer\"], \"nci_thesaurus_concept_id\": \"C9270\", \"name\": \"Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Skin Tumor\", \"Skin Epithelium Neoplasm\", \"Skin Epithelium Tumor\"], \"nci_thesaurus_concept_id\": \"C7342\", \"name\": \"Epithelial Skin Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\", \"C3372\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27571\", \"name\": \"Head and Neck Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cutaneous Squamous Cell Carcinoma\", \"Epidermoid Carcinoma of Skin\", \"Epidermoid Carcinoma of the Skin\", \"Epidermoid Skin Carcinoma\", \"Skin Squamous Cell Carcinoma\", \"Squamous Cell Carcinoma of Skin\", \"Squamous Cell Carcinoma of the Skin\", \"Squamous Cell Skin Carcinoma\", \"Squamous cell carcinoma - skin\", \"Squamous cell carcinoma of the skin\"], \"nci_thesaurus_concept_id\": \"C4819\", \"name\": \"Skin Squamous Cell Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C4914\", \"C2929\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"WFBCCC 60320\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"nci_thesaurus_concept_id\": \"C106432\", \"name\": \"Pembrolizumab\", \"description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Questionnaire Administration\"], \"nci_thesaurus_concept_id\": \"C64253\", \"name\": \"Questionnaire Administration\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C64255\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Quad Shot\", \"Quad Shot RT\", \"Quad Shot Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C172159\", \"name\": \"Quad Shot Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C62726\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Informational Intervention\"], \"nci_thesaurus_concept_id\": \"C64255\", \"name\": \"Informational Intervention\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C63474\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Behavioral, Psychological or Informational Intervention\"], \"nci_thesaurus_concept_id\": \"C63474\", \"name\": \"Behavioral, Psychological or Informational Intervention\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Hypofractionated Radiotherapy\", \"Hypofractionated Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C62726\", \"name\": \"Hypofractionated Radiation Therapy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C15654\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Fractionation Radiotherapy\"], \"nci_thesaurus_concept_id\": \"C15654\", \"name\": \"Fractionation\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C15313\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C25218\"]}], \"name\": \"Treatment (pembrolizumab, quad-shot radiation therapy)\", \"description\": \"Patients receive standard of care pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo quad-shot radiation therapy BID on 2 consecutive days between cycles 2-3 or 3-4, 6-7, and 11-12 of pembrolizumab treatment and in the last week of pembrolizumab treatment.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2020-07332\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well quad-shot radiation therapy works in combination with pembrolizumab in treating head and neck cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced), has come back at or near the same place as the original tumor (locally recurrent), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body\\u2019s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy can trigger faster cancer destruction in the area of radiation treatment, and this can activate the immune system to further attack the cancer and stop it from growing. Quad-shot radiation therapy is a standard of care treatment that involves radiation at a larger dose per fraction but using shorter treatment courses than conventional radiotherapy and commonly used for relieving symptoms of cancer, also called palliative radiation therapy. Giving quad-shot radiation therapy in combination with pembrolizumab immunotherapy may be more effective than each treatment alone in treating locally advanced, locally recurrent, or metastatic head and neck cancer.\", \"brief_title\": \"Quad-Shot Radiation Therapy in Combination with Pembrolizumab for the Treatment of Locally Advanced, Locally Recurrent, or Metastatic Head and Neck Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 15, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2020-09-28\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Mercedes Porosnicu\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"19-29438\"}], \"amendment_date\": \"2021-01-07T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"University of California San Francisco\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Patients must have a known diagnosis of multiple myeloma with evidence of measurable disease, AND have evidence of disease progression based on IMWG criteria:\\r\\n* Serum M-protein >= 0.5 g/dL, or urine M-protein >= 200 mg/24 hours. OR \\r\\n* In the absence of measurable M-protein, serum immunoglobulin free light chain >= 10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Relapsed from or refractory to 2 or more different prior therapies, including immunomodulatory drugs (IMiDs; e.g., thalidomide, lenalidomide) and proteasome inhibitors, chemotherapy-based regimens, monoclonal antibodies, or autologous stem cell transplantation (ASCT)\\r\\n* Relapse is defined as progression of disease after an initial response (minimal response [MR] or better) to previous treatment, more than 60 days after cessation of treatment\\r\\n* Refractory disease is defined as < 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Prior exposure to daratumumab, with most recent dose being at least 6 months prior to trial enrollment\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%)\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Absolute neutrophil count >= 1,500/mcL (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Platelets >= 75,000/mcL (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Total bilirubin within normal institutional limits, unless elevated due to Gilbert\\u2019s syndrome and direct bilirubin is within normal limits (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x institutional upper limit of normal (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Creatinine =< 1.5 x within institutional upper limit or normal OR creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2, calculated using the Cockcroft-Gault equation, unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 (within 7 days of first dose of drug)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Life expectancy of at least 3 months\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Women of childbearing potential must have at least one negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening, within one week prior to the first dose of any component of study treatment\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Before enrollment, a woman must be either:\\r\\n* Not of childbearing potential defined as:\\r\\n** Postmenopausal:\\r\\n*** A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level (> 40 IU/L or mIU/mL in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy, however in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient\\r\\n** Permanently sterile\\r\\n*** Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy OR\\r\\n* Of childbearing potential and\\r\\n** Practicing 2 highly effective user-independent methods of contraception (failure rate of < 1% per year when used consistently and correctly\\r\\n*** Examples of highly effective user-independent methods of contraception include:\\r\\n**** Implantable progesterone-only hormone contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); vasectomized partner; sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the subject.)\\r\\n*** Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies\\r\\n*** Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraceptive method\\r\\n*** Agrees to remain on a highly effective method for 4 weeks before the first dose of any component of study treatment, throughout the study (including during dose interruptions), and for 4 weeks following discontinuation of azacitidine, and for 3 months after last daratumumab dose\\r\\n**** Note: If the risk of pregnancy changes (e.g., a woman who is not heterosexually active becomes active), a woman must begin a highly effective method of contraception, as described throughout the inclusion criteria\\r\\n***** If reproductive status is questionable, additional evaluation should be considered\\r\\n*** Agrees to not breast feed for the duration of the study (including during dose interruptions), and for 4 weeks following discontinuation of azacitidine, and for 3 months after last daratumumab dose\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study (including during dose interruptions), and for 4 weeks following discontinuation of azacitidine, and if receiving daratumumab, for 3 months after the last dose\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Due to the teratogenicity of azacitidine and the lack of adequate reproductive toxicity data for daratumumab, in addition to the user independent highly effective method of contraception, a male or female condom with or without spermicide, diaphragm, or cervical cap is required. Male condom and female condom should not be used together (due to risk of failure with friction)\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"During the study (including during dose interruptions), and for 4 weeks following discontinuation of azacitidine, and for 3 months after the last daratumumab dose, in addition to the user independent highly effective method of contraception (even if he has undergone a successful vasectomy), a man\\r\\n* Who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (i.e., latex or synthetic condom with spermicidal foam/gel/film/cream/suppository)\\r\\n* Who is sexually active with a woman who is pregnant must use a latex or synthetic condom\\r\\n* Must agree not to donate sperm\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Willing and able to adhere to the prohibitions and restrictions specified in this protocol and referenced in the informed consent form (ICF)\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Must sign an ICF (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Diagnosed or treated for malignancy (either solid tumor or hematologic) other than multiple myeloma, except:\\r\\n* Malignancy treated with curative intent and with no known active disease at enrollment\\r\\n** Adequately treated non-melanoma skin cancer, lentigo maligna or in situ malignancies (including but not limited to, cervical, breast) with no evidence of disease\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Received daratumumab therapy less than 6 months prior to trial enrollment\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Primary refractory to prior daratumumab\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Subject is:\\r\\n* Seropositive for human immunodeficiency virus (HIV)\\r\\n* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\\r\\n* Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal to minimize daratumumab-related pulmonary toxicities\\r\\n* Note: FEV1 testing is required for subjects suspected of having chronic obstructive pulmonary disease and asthma. Subjects must be excluded if FEV1 < 50% of predicted normal\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Known moderate or severe persistent asthma within the past 2 year or currently has uncontrolled asthma of any classification\\r\\n* Note: Subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study. FEV1 testing is required for subjects suspected of having asthma\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Concurrent medical condition or disease (e.g., active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Clinically significant cardiac disease, including:\\r\\n* Myocardial infarction within 6 months before cycle 1, day -7, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association class III-IV)\\r\\n* Uncontrolled cardiac arrhythmia (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities\\r\\n* Screening 12-lead electrocardiogram (ECG) showing a baseline corrected QT interval (QTc) > 470 msec.\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, daratumumab or its excipients (refer to investigator\\u2019s brochure), or known sensitivity to mammalian-derived products\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Concurrent plasma cell leukemia, Waldenstrom\\u2019s macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and/or skin changes), or light chain amyloidosis\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Known or suspected of not being able to comply with the study protocol (e.g., because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Contraindications to the use of daratumumab, azacitidine or dexamethasone per local prescribing information\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Taken any disallowed therapies before the planned first dose of study drug\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Received any therapy to treat cancer (including radiation, chemotherapy, biologics, cellular therapies, and/or steroids at doses > 20 mg) or undergone a major surgical procedure within 14 days, or within 5 half-lives of an anticancer drug, prior to the first dose of study treatment, whichever is longer (with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma)\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Participated in an interventional clinical trial(s) and received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before cycle 1, day -7 or 5 pharmacokinetic half-lives, whichever is longer\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Had major surgery within 2 weeks before cycle 1, day -7, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration\\r\\n* Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty is not considered a major surgery\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"CA\", \"contact_name\": \"Nina Shah\", \"contact_phone\": \"415-353-2737\", \"recruitment_status_date\": \"2020-11-04\", \"org_address_line_2\": \"Floor 6\", \"org_va\": false, \"org_address_line_1\": \"490 Illinois Street\", \"org_tty\": null, \"org_family\": \"UCSF Helen Diller Family Comprehensive Cancer Center\", \"org_postal_code\": \"94143\", \"contact_email\": \"Nina.Shah@ucsf.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"San Francisco\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"877-827-3222\", \"org_name\": \"University of California San Francisco\", \"org_coordinates\": {\"lon\": -122.4584, \"lat\": 37.7616}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To evaluate the efficacy of adding azacitidine to daratumumab and dexamethasone, as measured by the overall response rate in patients with relapsed refractory multiple myeloma (RRMM) previously treated with daratumumab.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To evaluate the duration of response per International Myeloma Working Group (IMWG) criteria.\\r\\nII. To evaluate the safety and tolerability of azacitidine in combination with daratumumab and dexamethasone.\\r\\nIII. To evaluate progression free and overall survival in patients treated with azacitidine in combination with daratumumab and dexamethasone.\\r\\nIV. To assess the changes in CD38 expression on plasma cells after treatment with azacitidine and correlate this change with the depth and duration of response of azacitidine in combination with daratumumab and dexamethasone.\\r\\n\\r\\nOUTLINE:\\r\\n\\r\\nPRE-INDUCTION (CYCLE 0): Patients receive azacitidine intravenously (IV) on days -7 to -3 in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nINDUCTION PHASE (CYCLES 1-2): Patients receive azacitidine IV on days 22-26 and dexamethasone IV or orally (PO) and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION PHASE (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6 and dexamethasone IV or PO and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nMAINTENANCE PHASE (CYCLES 7+): Patients receive azacitidine IV on days 1-5 and dexamethasone IV or PO and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up every 4 weeks for up to 1 year.\", \"official_title\": \"Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Baseline up to cycle 1, day 1 (each cycle is 28 days)\", \"name\": \"Bone marrow tumor microenvironment changes\", \"description\": \"Mass cytometry (time-of-flight mass cytometry [CyTOF]) will be used to report the changes in bone marrow tumor microenvironment before and after treatment with azacitidine, one of the exploratory endpoints of the study.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Change in CD38 expression after azacitidine treatment\", \"description\": \"Will be correlated to response, including depth of response and duration of response using logistic regression, linear regression methods, and Spearman\\u2019s correlation coefficient, as appropriate.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From day -7 up to end of first cycle of azacitidine treatment (day 28) (each cycle is 28 days)\", \"name\": \"Change in CD38 surface expression of plasma cells\", \"description\": \"Change in CD38 surface expression will be summarized using descriptive statistics and tested using the one-sample t-test. Two-sided p-value less than 0.05 will be considered statistically significant.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to cycle 1, day 1 (each cycle is 28 days)\", \"name\": \"Deoxyribonucleic acid (DNA) methylation pattern changes\", \"description\": \"Paired t-tests will be used to compare the DNA methylation levels between the samples. Analysis will be corrected for multiple hypothesis testing by controlling the false discovery rate (FDR). The distribution of uncorrected p values will be analyzed and an FDR will be inferred for each differentially methylated region (DMR). The inference will be made using the q value method available in R/Bioconductor. Hierarchical models will be used to minimize small standard deviations that frequently arise by chance. Standard deviation of a given CpG or genomic region will be estimated as the average of observed and expected values to obtain more robust p values for DNA methylation comparisons. A ranked list of DMRs will be established by incorporating p values as well as the relative and absolute differences in DNA methylation between samples pre and post azacitidine treatment.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"From the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria or death due to progressive disease whichever occurred first, assessed up to 1 year\", \"name\": \"Duration of response\", \"description\": \"Will be summarized using the Kaplan-Meier estimator. Median even-free survival will be reported and the corresponding 95% confidence interval will be calculated using Brookmeyer and Crowley method.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From the initiation of study treatment until discontinuation of treatment, assessed up to 30 days\", \"name\": \"Incidence of adverse events\", \"description\": \"Will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. For each adverse event, the percentage of subjects who experience at least 1 occurrence of the given event will be summarized.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 1 cycle of treatment (each cycle is 28 days)\", \"name\": \"Number of patients who achieve at least 1.5 fold increase in their CD38 expression\", \"description\": \"Will be assessed by flow cytometry and based on a one-sample t-test at a two-sided type I error rate of 0.05.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From the date of first dose of study treatment to the date of death due to any cause or censored based on the date of last encounter if patient is alive or lost to follow-up, assessed up to 1 year\", \"name\": \"Overall survival\", \"description\": \"Will be summarized using the Kaplan-Meier estimator. Median even-free survival will be reported and the corresponding 95% confidence interval will be calculated using Brookmeyer and Crowley method.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From the date of first dose of study treatment to the date of first documented evidence of progressive disease or death, whichever occurs first, assessed up to 1 year\", \"name\": \"Progression-free survival\", \"description\": \"Will be summarized using the Kaplan-Meier estimator. Median even-free survival will be reported and the corresponding 95% confidence interval will be calculated using Brookmeyer and Crowley method.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From initiation of study treatment until discontinuation of treatment, assessed up to 1 year\", \"name\": \"Rate of overall response\", \"description\": \"Will be defined as stringent complete response + complete response + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria. Will calculate the uniformly minimum-variance unbiased estimator, p-value and 95% confidence interval for the response rates to account for the adaptive nature of Simon\\u2019s two-stage design.\", \"type_code\": \"PRIMARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT04407442\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2020-11-04\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Multiple Myeloma\", \"Refractory Plasma Cell Myeloma\"], \"nci_thesaurus_concept_id\": \"C7024\", \"name\": \"Refractory Multiple Myeloma/Plasma Cell Myeloma\", \"type\": [\"subtype\"], \"parents\": [\"C3242\", \"C7813\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Multiple Myeloma\", \"Recurrent Plasma Cell Myeloma\"], \"nci_thesaurus_concept_id\": \"C7025\", \"name\": \"Recurrent Multiple Myeloma/Plasma Cell Myeloma\", \"type\": [\"stage\"], \"parents\": [\"C3242\", \"C172289\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7813\", \"name\": \"Refractory Plasma Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4665\", \"C172280\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphoproliferative disease, NOS\", \"Lymphoproliferative disorder, NOS\", \"lymphoproliferative disorder\"], \"nci_thesaurus_concept_id\": \"C9308\", \"name\": \"Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26323\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172133\", \"name\": \"Recurrent Malignant Lymphoid Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7065\", \"C27358\", \"C147861\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Disease\"], \"nci_thesaurus_concept_id\": \"C35814\", \"name\": \"Hematopoietic and Lymphoid System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157686\", \"name\": \"Refractory Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"HEMOLYMPHORETICULAR TUMOR, MALIGNANT\", \"Hematologic Cancer\", \"Hematologic Malignancy\", \"Hematologic Neoplasm\", \"Hematological Neoplasm\", \"Hematopoietic Cancer\", \"Hematopoietic Neoplasm\", \"Hematopoietic Neoplasms Including Lymphomas\", \"Hematopoietic and Lymphoid Neoplasm\", \"Hematopoietic malignancy, NOS\", \"Malignant Hematologic Neoplasm\", \"Malignant Hematopoietic Neoplasm\", \"hematologic cancer\"], \"nci_thesaurus_concept_id\": \"C27134\", \"name\": \"Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C26323\", \"C35813\", \"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179052\", \"name\": \"B-Cell Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"PLASMA CELL TUMOR, MALIGNANT\", \"Plasma Cell Dyscrasia\", \"Plasma Cell Neoplasm\", \"Plasma Cell Tumors\", \"Plasma cell tumor\", \"Plasmacytic Neoplasm\", \"Plasmacytic Tumor\", \"Plasmacytic Tumour\", \"plasma cell tumor\"], \"nci_thesaurus_concept_id\": \"C4665\", \"name\": \"Plasma Cell Tumor\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C27910\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179052\", \"name\": \"B-Cell Lymphoproliferative Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"PLASMA CELL TUMOR, MALIGNANT\", \"Plasma Cell Dyscrasia\", \"Plasma Cell Neoplasm\", \"Plasma Cell Tumors\", \"Plasma cell tumor\", \"Plasmacytic Neoplasm\", \"Plasmacytic Tumor\", \"Plasmacytic Tumour\", \"plasma cell tumor\"], \"nci_thesaurus_concept_id\": \"C4665\", \"name\": \"Plasma Cell Tumor\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C27910\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172280\", \"name\": \"Refractory Malignant Lymphoid Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7065\", \"C27357\", \"C157686\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27907\", \"name\": \"B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C179052\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27907\", \"name\": \"B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C179052\", \"C7065\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Mature B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27910\", \"name\": \"Mature B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27907\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Cancer\", \"clinical resistance\", \"refractory cancer\", \"resistant cancer\"], \"nci_thesaurus_concept_id\": \"C120186\", \"name\": \"Refractory Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C7628\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Hematologic Cancer\"], \"nci_thesaurus_concept_id\": \"C27357\", \"name\": \"Refractory Hematologic Malignancy\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C120186\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Mature B-Cell Lymphocytic Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27910\", \"name\": \"Mature B-Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27907\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Tumor\"], \"nci_thesaurus_concept_id\": \"C7628\", \"name\": \"Refractory Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Kahler disease\", \"MYELOMA, PLASMA CELL, MALIGNANT\", \"Multiple Myeloma\", \"Multiple myeloma\", \"Myeloma\", \"Myeloma, NOS\", \"Myelomatosis\", \"Plasma Cell Myeloma\", \"Plasma cell myeloma\", \"multiple myeloma\", \"myeloma\", \"myelomatosis\", \"plasma cell myeloma\"], \"nci_thesaurus_concept_id\": \"C3242\", \"name\": \"Multiple Myeloma/Plasma Cell Myeloma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9305\", \"C4665\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C147861\", \"name\": \"Recurrent Lymphoproliferative Disorder\", \"type\": [\"stage\"], \"parents\": [\"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Kahler disease\", \"MYELOMA, PLASMA CELL, MALIGNANT\", \"Multiple Myeloma\", \"Multiple myeloma\", \"Myeloma\", \"Myeloma, NOS\", \"Myelomatosis\", \"Plasma Cell Myeloma\", \"Plasma cell myeloma\", \"multiple myeloma\", \"myeloma\", \"myelomatosis\", \"plasma cell myeloma\"], \"nci_thesaurus_concept_id\": \"C3242\", \"name\": \"Multiple Myeloma/Plasma Cell Myeloma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C9305\", \"C4665\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172289\", \"name\": \"Recurrent Plasma Cell Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C4665\", \"C172133\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lymphocytic Tumor\", \"Lymphocytic and Plasma Cell Neoplasm\", \"Lymphocytic and Plasma Cell Tumor\", \"Lymphocytic and Plasma Cell Tumour\", \"Lymphocytic and Plasmacytic Neoplasm\", \"Lymphoid Neoplasm\", \"Lymphoid Tumor\", \"Lymphoid and Plasma Cell Tumor\", \"Lymphoid and Plasma Cell Tumour\", \"Lymphoid and Plasmacytic Neoplasm\", \"Lymphoid and Plasmacytic Tumor\", \"Lymphoid and Plasmacytic Tumour\"], \"nci_thesaurus_concept_id\": \"C7065\", \"name\": \"Lymphocytic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27134\", \"C9308\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Recurrent Hematologic Cancer\", \"Recurrent Hematologic Malignancy\", \"Relapsed Hematologic Cancer\", \"Relapsed Hematologic Malignancy\"], \"nci_thesaurus_concept_id\": \"C27358\", \"name\": \"Recurrent Hematopoietic and Lymphoid Cell Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C27134\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Blood Disease\", \"Blood Disorder\", \"Hematologic Disorder\", \"Hematological Disorder\"], \"nci_thesaurus_concept_id\": \"C26323\", \"name\": \"Hematologic and Lymphocytic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C35814\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Hematopoietic and Lymphoid System Tumor\"], \"nci_thesaurus_concept_id\": \"C35813\", \"name\": \"Hematopoietic and Lymphoid System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35814\", \"C3263\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"20251\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Aacidexam\", \"Adexone\", \"Aknichthol Dexa\", \"Alba-Dex\", \"Alin\", \"Alin Depot\", \"Alin Oftalmico\", \"Amplidermis\", \"Anemul mono\", \"Auricularum\", \"Auxiloson\", \"Baycadron\", \"Baycuten\", \"Baycuten N\", \"Cortidexason\", \"Cortisumman\", \"Decacort\", \"Decadrol\", \"Decadron\", \"Decadron DP\", \"Decalix\", \"Decameth\", \"Decasone R.p.\", \"Dectancyl\", \"Dekacort\", \"Deltafluorene\", \"Deronil\", \"Desameton\", \"Dexa-Mamallet\", \"Dexa-Rhinosan\", \"Dexa-Scheroson\", \"Dexa-sine\", \"Dexacortal\", \"Dexacortin\", \"Dexafarma\", \"Dexafluorene\", \"Dexalocal\", \"Dexamecortin\", \"Dexameth\", \"Dexamethasone Intensol\", \"Dexamonozon\", \"Dexapos\", \"Dexinoral\", \"Dexone\", \"Dinormon\", \"Dxevo\", \"Fluorodelta\", \"Fortecortin\", \"Gammacorten\", \"Hemady\", \"Hexadrol\", \"Lokalison-F\", \"Loverine\", \"Millicorten\", \"Mymethasone\", \"Orgadrone\", \"Spersadex\", \"TaperDex\", \"Visumetazone\", \"ZoDex\", \"Dexamethasone\"], \"nci_thesaurus_concept_id\": \"C422\", \"name\": \"Dexamethasone\", \"description\": \"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C267\", \"C521\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Onureg\", \"Vidaza\", \"Azacitidine\"], \"nci_thesaurus_concept_id\": \"C288\", \"name\": \"Azacitidine\", \"description\": \"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C2083\", \"C1557\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Darzalex\", \"Daratumumab\"], \"nci_thesaurus_concept_id\": \"C74007\", \"name\": \"Daratumumab\", \"description\": \"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of daratumumab to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells,  triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).     CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C155321\", \"C129822\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-emetic Agent\", \"Antiemetic Drugs\", \"Antiemetics\"], \"nci_thesaurus_concept_id\": \"C267\", \"name\": \"Antiemetic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C78272\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C78272\", \"name\": \"Agent Affecting Nervous System\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Glucocorticoid\"], \"nci_thesaurus_concept_id\": \"C521\", \"name\": \"Therapeutic Glucocorticoid\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C211\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Corticosteroids\"], \"nci_thesaurus_concept_id\": \"C211\", \"name\": \"Therapeutic Corticosteroid\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2364\", \"C574\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Adrenal Drugs\"], \"nci_thesaurus_concept_id\": \"C2364\", \"name\": \"Adrenal Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1636\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Steroid Hormone\", \"Synthetic Steroids\"], \"nci_thesaurus_concept_id\": \"C1636\", \"name\": \"Therapeutic Steroid Hormone\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C548\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Synthetic Hormone\", \"Therapeutic Hormone\"], \"nci_thesaurus_concept_id\": \"C548\", \"name\": \"Therapeutic Hormone\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C147908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Hormonal Therapy Agent\", \"Hormone Therapy\"], \"nci_thesaurus_concept_id\": \"C147908\", \"name\": \"Hormone Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immunosuppressive Agents\"], \"nci_thesaurus_concept_id\": \"C574\", \"name\": \"Immunosuppressant\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"DNMT Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2083\", \"name\": \"DNA Methyltransferase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C132686\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"DNA Methylation Inhibitor\"], \"nci_thesaurus_concept_id\": \"C132686\", \"name\": \"Demethylating Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1557\", \"name\": \"Pyrimidine Antagonist\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C272\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antimetabolites\"], \"nci_thesaurus_concept_id\": \"C272\", \"name\": \"Antimetabolite\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-CD38 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C155321\", \"name\": \"Anti-CD38 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C164008\", \"C20401\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C164008\", \"name\": \"CD38-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}], \"name\": \"Treatment (azacitidine, dexamethasone, daratumumab)\", \"description\": \"See Detailed Description.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2020-02985\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and was previously treated with daratumumab. Daratumumab is an antibody made up of immune cells that attaches to a protein on myeloma cells, called CD38. CD38 is found in higher levels on tumor cells than on normal cells. Daratumumab prevents the growth of tumors who have high levels of CD38 by causing those cells to die. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is a steroid that helps decrease inflammation and lowers the body's normal immune response to help reduce the effect of any infusion-related reactions. Giving azacitidine may help increase the levels of CD38 on the tumor cells to increase the function of daratumumab to attach to those tumor cells to help destroy them.\", \"brief_title\": \"Daratumumab, Azacitidine, and Dexamethasone for the Treatment of Patients with Recurrent or Refractory Multiple Myeloma Previously Treated with Daratumumab\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 23, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2020-11-04\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple Myeloma\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Nina Shah\", \"study_source\": \"Externally Peer Reviewed\", \"completion_date\": \"2023-06-30\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": null, \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Fred Hutch/University of Washington Cancer Consortium\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically or cytologically documented non-small cell lung cancer (NSCLC)\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Stage III NSCLC according to American Joint Committee on Cancer (AJCC) staging version (v)8\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"At least one mediastinal site of disease that is discontiguous from all other visible sites of disease and can be excluded from primary tumor site radiation (i.e. at least 10 mm separation between tumors)\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"A maximum of 20 patients with bulky mediastinal disease will be allowed on this trial, defined as at least one contiguous mediastinal mass with minimum diameter > 2 cm, that is not contiguous with the primary tumor (and therefore would not be irradiated during radiation to the primary tumor)\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"No surgery for lung cancer for at least 3 years\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"No other malignancies for at least 3 years, excluding low grade or non-invasive malignancies such as skin cancers, prostate cancers, and ductal breast carcinoma in situ (DCIS)\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Life expectancy of >= at least 3 months\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Body weight > 30 kg\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Hemoglobin >= 9.0 g/dL\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Absolute neutrophil count (ANC) 1.5 (or 1.0) x (>= 1500 per mm^3)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Platelet count >= 100,000 per mm^3\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert\\u2019s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x upper limit of normal (ULN)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Measured creatinine clearance (CL) > 60 mL/min or calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\\r\\n* Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)\\r\\n* Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Prior anti-CTLA-4, PD-1 or PD-L1 antibodies including durvalumab\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Prior chemotherapy in the past 3 years from consent\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Any unresolved toxicity National Cancer Institute (NCI) CTCAE grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\\r\\n* Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician\\r\\n* Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Prior thoracic radiation that would preclude curative-intent radiation dose as outlined in this study\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"History of allogenic organ transplantation\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:\\r\\n* Patients with vitiligo or alopecia\\r\\n* Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\\r\\n* Any chronic skin condition that does not require systemic therapy\\r\\n* Patients without active disease in the last 5 years may be included but only after consultation with the study physician\\r\\n* Patients with celiac disease controlled by diet alone\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"History of leptomeningeal carcinomatosis\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"History of active primary immunodeficiency\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (hepatitis C virus [HCV]) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\\r\\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\\r\\n* Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent\\r\\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational product (IP). Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"WA\", \"contact_name\": \"Ramesh Rengan\", \"contact_phone\": null, \"recruitment_status_date\": \"2021-09-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1100 Fairview Avenue North\", \"org_tty\": null, \"org_family\": \"Fred Hutchinson/University of Washington Cancer Consortium\", \"org_postal_code\": \"98109\", \"contact_email\": \"rengan@uw.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Seattle\", \"org_email\": \"CRScustomerservice@fredhutch.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"206-667-4520\", \"org_name\": \"Fred Hutch/University of Washington Cancer Consortium\", \"org_coordinates\": {\"lon\": -122.3461, \"lat\": 47.6307}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To compare the 1-year progression free survival (PFS) rate in patients treated with concurrent chemotherapy, durvalumab and hypofractionated radiation therapy to the primary lung tumor followed by response adaptive mediastinal radiation and durvalumab relative to historical data on durvalumab maintenance therapy (PACIFIC-2 trial).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. Evaluation of the frequency and severity of pneumonitis.\\r\\nII. To evaluate overall survival (OS).\\r\\nIII. To evaluate the pathologic response rate of the mediastinum to chemo-immunotherapy plus primary lung tumor radiation.\\r\\nIV. To evaluate the objective response rate (complete response [CR] or partial response [PR], confirmed and unconfirmed) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\\r\\nV. To evaluate the frequency and severity of toxicities graded with Common Terminology Criteria for Adverse Events (CTCAE), version 5.\\r\\n\\r\\nOUTLINE:\\r\\nPatients will receive platinum doublet chemotherapy per standard of care with durvalumab for 8 weeks, concurrent with a short course of radiation to the primary lung tumor. Patients will then undergo repeat evaluation of the mediastinal lymph nodes. If there is no cancer in the lymph nodes, patients will receive 2 years of adjuvant durvalumab. If there is still cancer in the lymph nodes, patients will receive 6 weeks of radiation to the mediastinal lymph nodes, and 2 years of adjuvant durvalumab.\\r\\n\\r\\nAfter the completion of study treatment, patients are followed up for 12 months.\", \"official_title\": \"Adaptive-Dose to Mediastinum with Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 12 months after treatment\", \"name\": \"Frequency and severity of pneumonitis\", \"description\": \"The primary toxicity of interest is grade 3 or higher pneumonitis. The incidence of grade 3 or worse pneumonitis attributable to treatment will be evaluated and compared against the PACIFIC trial results. All toxicities of all grades will be monitored on study and reported. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as toxicity.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 12 months after treatment\", \"name\": \"Incidence of adverse events\", \"description\": \"Frequency and severity of toxicities will be graded with Common Terminology Criteria for Adverse Events (CTCAE), version 5. Toxicities will be summarized as the proportion of patients with such toxicities, in addition to total number of toxicities (allowing for multiple toxicities within a patient) among all patients. All toxicities of all grades will be monitored on study and reported. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as toxicity.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From study registration to death due to any cause, assessed up to 12 months after treatment\", \"name\": \"Overall survival (OS)\", \"description\": \"Will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood\\u2019s formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From study registration to progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, symptomatic deterioration, or death due to any cause, whichever comes first, assessed at 1 year after treatment\", \"name\": \"Progression-free survival rate (PFS)\", \"description\": \"Will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood\\u2019s formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 12 months after treatment\", \"name\": \"Response rate\", \"description\": \"Will be evaluated using the method of Kaplan-Meier. Confidence intervals for median times will be determined using the Brookmeyer-Crowley method. Confidence intervals around landmark times will be determined using Greenwood\\u2019s formula for the variance and based on a log-log transformation applied on the survival function. Binary proportions will be calculated with associated confidence intervals for binary outcomes, such as response. Means and/or medians will be calculated for continuous outcomes. Confidence bounds will be provided for means and quartiles and ranges for median values. All confidence bounds will be presented as 95% bounds.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT04372927\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2021-09-28\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III\", \"Stage III Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136478\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136467\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIA\", \"Stage IIIA Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136479\", \"name\": \"Stage IIIA Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136478\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIB\", \"Stage IIIB Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136480\", \"name\": \"Stage IIIB Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136478\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136481\", \"name\": \"Stage IIIC Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136478\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C160783\", \"name\": \"Locally Advanced Lung Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C153206\", \"C156094\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153206\", \"name\": \"Locally Advanced Lung Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C148130\", \"C153202\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165537\", \"name\": \"Metastatic Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C3482\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C148130\", \"name\": \"Locally Advanced Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C3482\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153202\", \"name\": \"Metastatic Lung Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4878\", \"C3482\", \"C176862\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Stage (Pathological)\"], \"nci_thesaurus_concept_id\": \"C136467\", \"name\": \"Lung Cancer by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156094\", \"name\": \"Metastatic Lung Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2926\", \"C153202\", \"C165537\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Locally Advanced Cancer\", \"Locally Metastatic Malignant Neoplasm\", \"Locally advanced\", \"locally advanced cancer\", \"regional cancer\"], \"nci_thesaurus_concept_id\": \"C8524\", \"name\": \"Locally Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III\", \"Stage III Lung Cancer AJCC v8\"], \"nci_thesaurus_concept_id\": \"C136478\", \"name\": \"Stage III Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136467\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C176862\", \"name\": \"Metastatic Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3576\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"RG1007190\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Lastet\", \"Etoposide\"], \"nci_thesaurus_concept_id\": \"C491\", \"name\": \"Etoposide\", \"description\": \"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1331\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Abiplatin\", \"Blastolem\", \"Briplatin\", \"Cisplatyl\", \"Citoplatino\", \"Citosin\", \"Lederplatin\", \"Metaplatin\", \"Neoplatin\", \"Placis\", \"Plastistil\", \"Platamine\", \"Platiblastin\", \"Platiblastin-S\", \"Platinex\", \"Platinol\", \"Platinol- AQ\", \"Platinol-AQ\", \"Platinol-AQ VHA Plus\", \"Platiran\", \"Platistin\", \"Platosin\", \"Cisplatin\"], \"nci_thesaurus_concept_id\": \"C376\", \"name\": \"Cisplatin\", \"description\": \"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1450\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Imfinzi\", \"Durvalumab\"], \"nci_thesaurus_concept_id\": \"C103194\", \"name\": \"Durvalumab\", \"description\": \"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, MEDI4736 binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128057\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Pemfexy\", \"Pemetrexed\"], \"nci_thesaurus_concept_id\": \"C61614\", \"name\": \"Pemetrexed\", \"description\": null, \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C511\", \"C2021\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Hypofractionated Radiotherapy\", \"Hypofractionated Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C62726\", \"name\": \"Hypofractionated Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C15654\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1331\", \"name\": \"Epipodophyllotoxin Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1931\", \"C1968\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1931\", \"name\": \"Antineoplastic Plant Product\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\", \"C1907\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Drug Derived from Natural Products\"], \"nci_thesaurus_concept_id\": \"C1907\", \"name\": \"Drug, Natural Product\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Topoisomerase-II Inhibitors\"], \"nci_thesaurus_concept_id\": \"C1968\", \"name\": \"Topoisomerase-II Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1748\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"DNA Topoisomerase Inhibitors\", \"Topoisomerase Inhibitors\"], \"nci_thesaurus_concept_id\": \"C1748\", \"name\": \"Topoisomerase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129825\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Enzyme Inhibitor\"], \"nci_thesaurus_concept_id\": \"C129825\", \"name\": \"Antineoplastic Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129824\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Protein Inhibitor\", \"Antineoplastic Protein Antagonist\"], \"nci_thesaurus_concept_id\": \"C129824\", \"name\": \"Antineoplastic Protein Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2189\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Signal Transduction Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2189\", \"name\": \"Signal Transduction Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Platinum Agents\", \"Platinum-Based Chemotherapy\", \"Platinum Compound\"], \"nci_thesaurus_concept_id\": \"C1450\", \"name\": \"Platinum Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1590\", \"C2163\", \"C798\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"nci_thesaurus_concept_id\": \"C1590\", \"name\": \"Antineoplastic Alkylating Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2842\", \"name\": \"DNA Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2163\", \"name\": \"DNA Adduct Forming Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiation Sensitizers\", \"Radiation-Sensitizing Agents\", \"Radiation-Sensitizing Drugs\", \"Radiosensitizers\", \"Radiosensitizing Drugs\"], \"nci_thesaurus_concept_id\": \"C798\", \"name\": \"Radiosensitizing Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-L1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128057\", \"name\": \"Anti-PD-L1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C156893\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Ligand-targeting Agent\", \"PD-1 Ligands Inhibitor\", \"PD-1 Ligand Inhibitor\"], \"nci_thesaurus_concept_id\": \"C156893\", \"name\": \"PD-1 Ligand Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antifolates\", \"Folate Analog\", \"Folate Inhibitors\", \"Folic Acid Analog\", \"Folic Acid Antagonist\", \"Folic Acid Antagonists\", \"Folic Acid Inhibitors\"], \"nci_thesaurus_concept_id\": \"C511\", \"name\": \"Folate Antagonist\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C272\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antimetabolites\"], \"nci_thesaurus_concept_id\": \"C272\", \"name\": \"Antimetabolite\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Thymidylate Synthetase Inhibitors\"], \"nci_thesaurus_concept_id\": \"C2021\", \"name\": \"Thymidylate Synthase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Fractionation Radiotherapy\"], \"nci_thesaurus_concept_id\": \"C15654\", \"name\": \"Fractionation\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C15313\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": []}], \"name\": \"Treatment (chemotherapy, durvalumab, radiation therapy)\", \"description\": \"Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 21, and 42. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiationin the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2020-02417\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment with durvalumab, is it possible to avoid mediastinal radiation to decrease side effects, without decreasing cancer control?\", \"brief_title\": \"ADMIRAL Trial: Adaptive Mediastinal Radiation with Chemo-Immunotherapy\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 40, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2021-09-28\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lung\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Ramesh Rengan\", \"study_source\": \"Institutional\", \"completion_date\": \"2026-11-30\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": null, \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Karnofsky performance status (KPS) of >= 70\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Histologic evidence of adenocarcinoma of the prostate who are deemed candidates for curative radical prostatectomy\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Planned robotic or laparoscopic prostatectomy technique\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Low risk for conversion to open prostatectomy, in the opinion of the treating surgeon\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Intermediate-high or high risk, clinically localized disease by the following criteria:\\r\\n* Gleason score >= 4+3 and greater than or equal to 2 cores\\r\\n* No definite evidence of metastasis, in the opinion of the investigator\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x local laboratory upper limit of normal (ULN) (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Total serum bilirubin =< 1.5 x ULN, (for subjects with Gilbert\\u2019s disease =< 3 x ULN) (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Absolute neutrophil count (ANC) >= 1500/L without granulocyte colony-stimulating factor support (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"White blood cell count >= 2500/mm^3 (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Serum albumin >= 2.8 g/dl (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Platelets >= 100,000/mm^3 (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Hemoglobin >= 9.0 g/dL (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Serum calcium =< 12.0 mg/dL (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Serum creatinine =< 2.0 x ULN or calculated creatinine clearance >= 30mL/min. (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol) (within 14 days prior to first dose of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Written Authorization for Use and Release of Health and Research Study Information (Health Insurance Portability and Accountability Act [HIPAA] authorization per institutional requirements)\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Willing/able to adhere to the prohibitions and restrictions specified in this protocol\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Agrees to use a condom (even men with vasectomies) and another effective method of birth control if subject is having sex with a woman who is pregnant or a woman of childbearing potential while on study drug and for 4 months following the last dose of study drug\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Prior treatment for prostate cancer\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Major surgery or radiation therapy within 4 weeks of day 1 on study\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Planned radiation therapy until at least 4 weeks after prostatectomy\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 grade 3 hemorrhage within 4 weeks of day 1 on study\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before day 1 on study\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel). However, low-dose aspirin for cardio protection is allowed (per local applicable guidelines)\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"History of or known metastatic prostate cancer\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"QT interval by Fridericia (QTcF) interval > 500 msec on baseline electrocardiogram (EKG)\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\\r\\n* Cardiovascular disorders:\\r\\n** Symptomatic congestive heart failure (CHF) New York Heart Association class 3 or 4, unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade >= 2 coronary/peripheral artery bypass graft (CABG), within 6 months prior to screening\\r\\n** Stroke (including transient ischemic attack [TIA]), cerebrovascular accident (CVA), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism [PE]) within 6 months prior to screening\\r\\n* Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\\r\\n** Evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn\\u2019s disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction\\r\\n** Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose\\r\\n*** Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose\\r\\n* Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose\\r\\n* Serious non-healing wound/ulcer/bone fracture\\r\\n* Other clinically significant disorders that would preclude safe study participation\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Hypertension that cannot be controlled by medications (> 140/90 mm Hg despite optimal medical therapy)\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Inability to swallow tablets\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"MALE\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Michael R. Harrison\", \"contact_phone\": \"919-668-4667\", \"recruitment_status_date\": \"2020-01-28\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"michael.harrison@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To compare pathologic apoptotic indices in prostatectomy specimens from patients who undergo immediate prostatectomy versus those treated with cabozantinib followed by prostatectomy.\\r\\n\\r\\nSECONDARY OBJECTIVE:\\r\\nI. To conduct immune phenotypic profiling on the peripheral blood and tumor microenvironment in prostatectomy specimens from patients who undergo immediate prostatectomy versus those treated with cabozantinib prior to prostatectomy.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To estimate the pathologic complete response rate (pCR) and =< pathologic T2 (=< pT2) rate in each arm. \\r\\nII. To evaluate relapse-free survival in each arm.\\r\\nIII. To compare apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]), proliferation (Ki-67), and microvessel density (CD31) indices in prostatectomy specimens from patients who undergo immediate prostatectomy versus those treated with cabozantinib prior to prostatectomy.\\r\\nIV. To measure expression levels of c-MET, VEGF, and HGF, as well as activation status of cMET in prostate tissue.\\r\\nV. To describe changes in plasticity signaling markers associated with prostate tumors, including vimentin, AR, SNAIL, AXL, and N-cadherin, with cabozantinib exposure.\\r\\nVI. To evaluate PTEN and p53 genomic and protein expression status in tumor tissue.\\r\\nVII. To demonstrate that cabozantinib is safe and tolerable in patients undergoing radical prostatectomy.\\r\\nVIII. To demonstrate that surgery is safe and feasible in patients undergoing treatment with cabozantinib.\\r\\nIX. To collect plasma angiome samples (multiplex enzyme-linked immunosorbent assay [ELISA]) for analysis and correlation with primary and key secondary endpoints.\\r\\nX. To describe gene expression patterns (in particular those associated with apoptosis, androgen receptor signaling, c-MET activation, and a cMET-specific endocytosis panel) correlated with cabozantinib administration using RNA sequencing analysis. \\r\\nXI. To explore changes in serum and intratumoral androgen concentrations related to cabozantinib treatment. \\r\\nXII. To collect cell-free DNA (cfDNA) for analysis and correlation with primary and key secondary endpoints.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM A: Patients receive cabozantinib orally (PO) once daily (QD) on days 1-28 in the absence of disease progression or unacceptable toxicity. After a 2 week washout period, patients then undergo radical prostatectomy on day 43.\\r\\n\\r\\nARM B: Patients undergo radical prostatectomy on day 1.\\r\\n\\r\\nAfter completion of study, patients in Arm A are followed up on days 57-85, and all patients are followed up for 3 years.\", \"official_title\": \"A Phase II, Open-Label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men with High-Risk Prostate Cancer (SPARC)\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Apoptotic index in prostatectomy specimens from patients who undergo immediate prostatectomy (Arm B) versus those treated with cabozantinib followed by prostatectomy (Arm A)\", \"description\": \"Apoptotic index as measured by cleaved caspase-3 levels in tumor tissue.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Description of the MDSC-promoting cytokine CCL12\", \"description\": \"Percentage of MDSC-promoting cytokine CCL12 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Description of the MDSC-promoting cytokine CCL5\", \"description\": \"Percentage of MDSC-promoting cytokine CCL5 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Description of the MDSC-promoting cytokine CD40\", \"description\": \"Percentage of MDSC-promoting cytokine CD40 cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Description of the neutrophil chemotactic factor CXCL12\", \"description\": \"Percentage of neutrophil chemotactic factor CXCL12 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Description of the neutrophil chemotactic factor HMGB1\", \"description\": \"Percentage of neutrophil chemotactic factor HMGB1 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Arm A: Screening, Day 29, Day 43, Day 57-85; Arm B: Screening, Day 1\", \"name\": \"Immune phenotyping of M1 macrophages\", \"description\": \"Percentage of M1 macrophages in peripheral blood and tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Arm A: Screening, Day 29, Day 43, Day 57-85; Arm B: Screening, Day 1\", \"name\": \"Immune phenotyping of M2 macrophages\", \"description\": \"Percentage of M2 macrophages in peripheral blood and tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Arm A: Screening, Day 29, Day 43, Day 57-85; Arm B: Screening, Day 1\", \"name\": \"Immune phenotyping of Myeloid-derived suppressor cells (MDSCs)\", \"description\": \"Percentage of MDSCs in peripheral blood and tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Arm A: Screening, Day 29, Day 43, Day 57-85; Arm B: Screening, Day 1\", \"name\": \"Immune phenotyping of neutrophils\", \"description\": \"Percentage of neutrophils in peripheral blood and tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Immunohistochemical (IHC) analysis of CD8 positive (+)\", \"description\": \"Percentage of CD8+ positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Immunohistochemical (IHC) analysis of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)\", \"description\": \"Percentage of CTLA-4 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Immunohistochemical (IHC) analysis of interleukin-1 receptor antagonist (IL-1RA)\", \"description\": \"Percentage of IL-1RA positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At prostatectomy (Arm A: Day 43, Arm B: Day 1)\", \"name\": \"Immunohistochemical (IHC) analysis of programmed death ligand-1 (PD-L1)\", \"description\": \"Percentage of PD-L1 positive cells in tumor tissue.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 2, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03964337\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2020-01-28\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"IIC\", \"Stage IIC Prostate Cancer AJCC v8\", \"Stage IIC Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140168\", \"name\": \"Stage IIC Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140165\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Prostate Cancer AJCC v8\", \"Stage III Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140169\", \"name\": \"Stage III Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140163\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"IIIA\", \"Stage IIIA Prostate Cancer AJCC v8\", \"Stage IIIA Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140170\", \"name\": \"Stage IIIA Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140169\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"IIIB\", \"Stage IIIB Prostate Cancer AJCC v8\", \"Stage IIIB Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140171\", \"name\": \"Stage IIIB Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140169\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"IIIC\", \"Stage IIIC Prostate Cancer AJCC v8\", \"Stage IIIC Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140172\", \"name\": \"Stage IIIC Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140169\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Adenocarcinoma of Prostate\", \"Adenocarcinoma of the Prostate\", \"PRAD\"], \"nci_thesaurus_concept_id\": \"C2919\", \"name\": \"Prostate Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C48596\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C181196\", \"name\": \"Male Reproductive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C164141\", \"C8561\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C181196\", \"name\": \"Male Reproductive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C164141\", \"C8561\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Male Reproductive System Tumor\", \"Neoplasm of Male Reproductive System\", \"Neoplasm of the Male Reproductive System\", \"Tumor of Male Reproductive System\", \"Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3054\", \"name\": \"Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27019\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Male Reproductive System Tumor\", \"Neoplasm of Male Reproductive System\", \"Neoplasm of the Male Reproductive System\", \"Tumor of Male Reproductive System\", \"Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3054\", \"name\": \"Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27019\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C9480\", \"name\": \"Invasive Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C8505\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Infiltrating Malignant Neoplasm\", \"infiltrating cancer\", \"invasive cancer\"], \"nci_thesaurus_concept_id\": \"C8505\", \"name\": \"Invasive Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Infiltrating Prostate Carcinoma\", \"Invasive Prostate Carcinoma\"], \"nci_thesaurus_concept_id\": \"C48596\", \"name\": \"Invasive Prostate Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C9480\", \"C4863\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Prostate Cancer AJCC v8\", \"Stage III Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140169\", \"name\": \"Stage III Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140163\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C164141\", \"name\": \"Genitourinary System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C156484\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156482\", \"name\": \"Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156660\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C36076\", \"name\": \"Malignant Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156484\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156482\", \"name\": \"Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156660\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Male reprod. system cancer, NOS\", \"Male reproductive system cancer, NOS\", \"Malignant Male Reproductive System Tumor\", \"Malignant Neoplasm of Male Reproductive System\", \"Malignant Neoplasm of the Male Reproductive System\", \"Malignant Tumor of Male Reproductive System\", \"Malignant Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C8561\", \"name\": \"Malignant Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C36076\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C36076\", \"name\": \"Malignant Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156484\", \"C3674\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C164141\", \"name\": \"Genitourinary System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C156484\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Male reprod. system cancer, NOS\", \"Male reproductive system cancer, NOS\", \"Malignant Male Reproductive System Tumor\", \"Malignant Neoplasm of Male Reproductive System\", \"Malignant Neoplasm of the Male Reproductive System\", \"Malignant Tumor of Male Reproductive System\", \"Malignant Tumor of the Male Reproductive System\"], \"nci_thesaurus_concept_id\": \"C8561\", \"name\": \"Malignant Male Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C36076\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Prostate\", \"Malignant Neoplasm of the Prostate\", \"Malignant Prostate Tumor\", \"Malignant Tumor of Prostate\", \"Malignant Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C7378\", \"name\": \"Malignant Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8561\", \"C3343\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Prostate\", \"Malignant Neoplasm of the Prostate\", \"Malignant Prostate Tumor\", \"Malignant Tumor of Prostate\", \"Malignant Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C7378\", \"name\": \"Malignant Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8561\", \"C3343\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Male Reproductive System\", \"Male Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C27019\", \"name\": \"Male Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Male Reproductive System\", \"Male Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C27019\", \"name\": \"Male Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Prostate Carcinoma by AJCC v8 Stage\", \"Tumor Stage (Pathologic)\"], \"nci_thesaurus_concept_id\": \"C140163\", \"name\": \"Prostate Cancer by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4863\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Urogenital Disease\"], \"nci_thesaurus_concept_id\": \"C156660\", \"name\": \"Genitourinary System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Urogenital Disease\"], \"nci_thesaurus_concept_id\": \"C156660\", \"name\": \"Genitourinary System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Prostate\", \"Neoplasm of the Prostate\", \"Prostate Tumor\", \"Tumor of Prostate\", \"Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C3343\", \"name\": \"Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C26865\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Prostate Disease\"], \"nci_thesaurus_concept_id\": \"C26865\", \"name\": \"Prostate Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27019\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Prostate\", \"Neoplasm of the Prostate\", \"Prostate Tumor\", \"Tumor of Prostate\", \"Tumor of the Prostate\"], \"nci_thesaurus_concept_id\": \"C3343\", \"name\": \"Prostate Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3054\", \"C26865\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Prostate Disease\"], \"nci_thesaurus_concept_id\": \"C26865\", \"name\": \"Prostate Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27019\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Reproductive System\", \"Neoplasm of the Reproductive System\", \"Reproductive Neoplasm\", \"Reproductive System Tumor\", \"Reproductive Tumor\", \"Tumor of Reproductive System\", \"Tumor of the Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3674\", \"name\": \"Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Reproductive System\", \"Neoplasm of the Reproductive System\", \"Reproductive Neoplasm\", \"Reproductive System Tumor\", \"Reproductive Tumor\", \"Tumor of Reproductive System\", \"Tumor of the Reproductive System\"], \"nci_thesaurus_concept_id\": \"C3674\", \"name\": \"Reproductive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C4875\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Genitourinary Cancer\", \"Genitourinary System Cancer\", \"Malignant Genitourinary Neoplasm\"], \"nci_thesaurus_concept_id\": \"C156484\", \"name\": \"Malignant Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Genitourinary Cancer\", \"Genitourinary System Cancer\", \"Malignant Genitourinary Neoplasm\"], \"nci_thesaurus_concept_id\": \"C156484\", \"name\": \"Malignant Genitourinary System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C156482\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Prostate\", \"Cancer of the Prostate\", \"Carcinoma of Prostate\", \"Carcinoma of the Prostate\", \"Prostate Carcinoma\", \"Prostate cancer, NOS\", \"prostate cancer\"], \"nci_thesaurus_concept_id\": \"C4863\", \"name\": \"Prostate Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C181196\", \"C7378\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Prostate\", \"Cancer of the Prostate\", \"Carcinoma of Prostate\", \"Carcinoma of the Prostate\", \"Prostate Carcinoma\", \"Prostate cancer, NOS\", \"prostate cancer\"], \"nci_thesaurus_concept_id\": \"C4863\", \"name\": \"Prostate Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C181196\", \"C7378\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Reproductive System\", \"Genital Disorders\", \"Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C4875\", \"name\": \"Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C156660\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Reproductive System\", \"Genital Disorders\", \"Reproductive System Disease\"], \"nci_thesaurus_concept_id\": \"C4875\", \"name\": \"Reproductive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C156660\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage II Prostate Cancer AJCC v8\", \"Stage II Prostate Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C140165\", \"name\": \"Stage II Prostate Cancer\", \"type\": [\"stage\"], \"parents\": [\"C140163\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00101042\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cabometyx\", \"Cometriq\", \"Cabozantinib S-malate\"], \"nci_thesaurus_concept_id\": \"C97938\", \"name\": \"Cabozantinib S-malate\", \"description\": \"The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C159438\", \"C93259\", \"C143099\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Prostatovesiculectomy\", \"Radical Prostatectomy\"], \"nci_thesaurus_concept_id\": \"C15399\", \"name\": \"Radical Prostatectomy\", \"description\": null, \"category\": \"other\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15307\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cabozantinib\"], \"nci_thesaurus_concept_id\": \"C52200\", \"name\": \"Cabozantinib\", \"description\": null, \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C159438\", \"C93259\", \"C143099\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Rearranged During Transfection Inhibitor\", \"Rearranged During Transfection Kinase Inhibitor\", \"c-RET Inhibitor\"], \"nci_thesaurus_concept_id\": \"C159438\", \"name\": \"RET Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129825\", \"C163758\", \"C1967\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Enzyme Inhibitor\"], \"nci_thesaurus_concept_id\": \"C129825\", \"name\": \"Antineoplastic Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129824\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Protein Inhibitor\", \"Antineoplastic Protein Antagonist\"], \"nci_thesaurus_concept_id\": \"C129824\", \"name\": \"Antineoplastic Protein Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2189\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Signal Transduction Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2189\", \"name\": \"Signal Transduction Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PTK Inhibitors\", \"Protein Tyrosine Kinase Inhibitors\", \"TK Inhibitors\", \"Tyrosine Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1967\", \"name\": \"Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protein Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1404\", \"name\": \"Protein Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C93259\", \"name\": \"VEGFR Tyrosine Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1742\", \"C1967\", \"C163953\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Angiogenesis Antagonists\", \"Angiogenesis Blockers\", \"Anti-Angiogenic Agents\", \"Antiangiogenesis Agents\", \"Antiangiogenic Agent\", \"Angiogenesis Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1742\", \"name\": \"Angiogenesis Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C163953\", \"name\": \"VEGFR-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"HGFR Inhibitor\", \"Hepatocyte Growth Factor Receptor Inhibitor\", \"MET Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143099\", \"name\": \"c-Met Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1967\", \"C164000\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C164000\", \"name\": \"c-Met-targeting Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Prostatectomy\"], \"nci_thesaurus_concept_id\": \"C15307\", \"name\": \"Prostatectomy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15334\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Urinary Tract Surgery\", \"Urologic Surgery\", \"Urological Surgical Procedure\"], \"nci_thesaurus_concept_id\": \"C15334\", \"name\": \"Urologic Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15333\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genitourinary System Surgical Procedure\", \"Surgery, Genitourinary\", \"Urogenital Surgery\"], \"nci_thesaurus_concept_id\": \"C15333\", \"name\": \"Urogenital Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C49163\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49163\", \"name\": \"Surgical Procedure by Site or System\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15329\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C15329\", \"name\": \"Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": []}], \"name\": \"Arm A (cabozantinib, radical prostatectomy)\", \"description\": \"Patients receive cabozantinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. After a 2 week washout period, patients then undergo radical prostatectomy on day 43.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Prostatovesiculectomy\", \"Radical Prostatectomy\"], \"intervention_name\": \"Radical Prostatectomy\", \"category\": \"other\", \"intervention_code\": \"C15399\", \"intervention_description\": null, \"parents\": [\"C15307\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Prostatectomy\"], \"intervention_name\": \"Prostatectomy\", \"category\": \"none\", \"intervention_code\": \"C15307\", \"intervention_description\": \"\", \"parents\": [\"C15334\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Urinary Tract Surgery\", \"Urologic Surgery\", \"Urological Surgical Procedure\"], \"intervention_name\": \"Urologic Surgical Procedure\", \"category\": \"none\", \"intervention_code\": \"C15334\", \"intervention_description\": \"\", \"parents\": [\"C15333\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genitourinary System Surgical Procedure\", \"Surgery, Genitourinary\", \"Urogenital Surgery\"], \"intervention_name\": \"Urogenital Surgical Procedure\", \"category\": \"none\", \"intervention_code\": \"C15333\", \"intervention_description\": \"\", \"parents\": [\"C49163\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Surgical Procedure by Site or System\", \"category\": \"none\", \"intervention_code\": \"C49163\", \"intervention_description\": \"\", \"parents\": [\"C15329\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Surgical Procedure\", \"category\": \"none\", \"intervention_code\": \"C15329\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Intervention or Procedure\", \"category\": \"none\", \"intervention_code\": \"C25218\", \"intervention_description\": \"\", \"parents\": [\"C16203\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Clinical or Research Activity\", \"category\": \"none\", \"intervention_code\": \"C16203\", \"intervention_description\": \"\", \"parents\": [\"C43431\"]}, {\"intervention_type\": \"Procedure/Surgery\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Activity\", \"category\": \"none\", \"intervention_code\": \"C43431\", \"intervention_description\": \"\", \"parents\": []}], \"name\": \"Arm B (radical prostatectomy)\", \"description\": \"Patients undergo radical prostatectomy on day 1.\", \"type\": \"ACTIVE_COMPARATOR\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2020-00761\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies different biomarkers to gain a better understanding of how cabozantinib affects prostate cancer and the immune system in patients with intermediate-high or high-risk prostate cancer undergoing radical prostatectomy. Radical prostatectomy is a surgical procedure to remove the entire prostate and some of the tissue surrounding it. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Biomarkers, obtained from blood and prostate tissue, include proteins (building blocks of the body, cells, and organs) involved in tumor growth and immune system activation, as well as genetic changes. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose of this study is to determine the effect that cabozantinib has on these biomarkers and prostate cancer by comparing prostatectomy tissue and blood samples from patients who received cabozantinib to those who did not receive cabozantinib prior to prostatectomy. This study will also evaluate the safety and efficacy of cabozantinib in subjects with prostate cancer who are undergoing prostatectomy.\", \"brief_title\": \"Immediate Prostatectomy versus Cabozantinib Followed by Prostatectomy in Patients with Intermediate-High or High-Risk Prostate Cancer, The SPARC Study\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 30, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2020-01-28\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Prostate\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Michael R. Harrison\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": [{\"name\": \"Study Protocol Other Identifier\", \"value\": \"I3Y-US-I007\"}], \"amendment_date\": \"2020-02-05T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Fred Hutch/University of Washington Cancer Consortium\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically confirmed GEP NET, radiographically progressed on at least one line of standard therapy within the past 12 months\\r\\n* Primary tumors may be in: pancreas, foregut (esophagus, stomach, duodenum), midgut (small intestine, appendix), hindgut (large intestine, rectum), or unknown origin\\r\\n* Tumors may be functional (associated with clinical symptoms of hormone secretion) or non-functional\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Well-differentiated low grade (Ki67 index < 3% or mitotic index < 2 mitoses/10 high power fields [HPF]), or intermediate grade (Ki67 index 3-20% or mitotic index 2-20 mitoses/10 HPF) NETs\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Metastatic or locally advanced unresectable disease\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Prior or concurrent therapy with somatostatin analogs (SSAs) is allowed. If concurrent therapy, dose must be stable for at least 2 months\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Patients with carcinoid syndrome must have symptoms controlled with stable doses of SSAs for at least 2 months\\r\\n* Telotristat is not allowed\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Able to swallow oral medications\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Absolute neutrophil count >= 1500/uL\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Platelet count >= 100,000/uL (without platelet transfusion for at least two weeks)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Hemoglobin >= 8 g/dL (blood transfusion is not allowed the day before or on the day of study treatment)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Total bilirubin =< 1.5 times upper limit of normal (ULN)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) =< 3 x upper limit of normal (ULN) (=< 5 x ULN if liver metastases)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Patients with Gilbert\\u2019s syndrome with a total bilirubin =< 2.0 times ULN and direct bilirubin within normal limits are permitted\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Creatinine > 30 mL/min\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Ability to understand and sign the consent form\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Women of child-bearing potential must:\\r\\n* Have a negative serum pregnancy test within 7 days prior to initiation of treatment, and\\r\\n* Agree to use a highly effective method of contraception during the study and for at least 3 weeks following the last dose of study drug\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Men must be sterile or agree to use a highly effective method of contraception during the study and for at least 3 weeks following the last dose of study drug\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Poorly differentiated or high-grade GEP NETs (Ki67 index > 20% or mitotic index > 20 mitoses/10 HPF)\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Prior treatment with abemaciclib or other CDK4/6 inhibitors\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Known hypersensitivity to abemaciclib or its components\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Receipt of any therapy or investigational agent within 4 weeks prior to study registration, except SSAs\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Any surgery, radiation, or embolization within 4 weeks\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Peptide receptor radionuclide therapy (PRRT) within 6 weeks\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Patients receiving other investigational agents\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Patients who have not recovered from adverse events of prior therapy to =< grade 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5), except for alopecia or grade =< 2 peripheral neuropathy prior to study treatment initiation.  Subjects must have fully recovered from the acute effects of any prior radiotherapy\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Patients with untreated or symptomatic brain metastases (must be off corticosteroids for >= 4 weeks)\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Uncontrolled or untreated intercurrent illness including, but not limited to, active bacterial or fungal infection, congestive heart failure, severe/unstable angina, syncope of cardiac etiology, ventricular arrythmia (including but not limited to ventricular tachycardia, ventricular fibrillation), history of cardiac arrest, interstitial lung disease, severe dyspnea at rest or requiring oxygen supplementation, arterial or venous thrombotic event, pre-existing chronic condition resulting in baseline grade >= 2 diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures involving stomach or small bowel in the last 28 days, active peptic ulcer disease, Crohn\\u2019s disease or ulcerative colitis\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Known history of infection with human immunodeficiency virus (HIV)\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Active untreated infection with hepatitis B virus (i.e. hepatitis B surface antigen positive) or hepatitis C virus (i.e. hepatitis C antibody and ribonucleic acid [RNA] positive)\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Other malignancy diagnosed or recurrent in the past 3 years (except non-melanoma skin cancer and in-situ cervical cancer)\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Pregnancy or breast-feeding\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"CO\", \"contact_name\": \"Stephen Leong\", \"contact_phone\": \"303-724-3837\", \"recruitment_status_date\": \"2019-03-04\", \"org_address_line_2\": \"PO Box 173364 Campus Box 167\", \"org_va\": false, \"org_address_line_1\": \"1380 Lawrence Street\", \"org_tty\": null, \"org_family\": \"University of Colorado Cancer Center\", \"org_postal_code\": \"80217-3364\", \"contact_email\": null, \"recruitment_status\": \"IN_REVIEW\", \"org_city\": \"Denver\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"720-848-0650\", \"org_name\": \"University of Colorado\"}, {\"org_state_or_province\": \"WA\", \"contact_name\": \"Kaylyn Kit Man Wong\", \"contact_phone\": \"206-606-2038\", \"recruitment_status_date\": \"2020-01-24\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"1100 Fairview Avenue North\", \"org_tty\": null, \"org_family\": \"Fred Hutchinson/University of Washington Cancer Consortium\", \"org_postal_code\": \"98109\", \"contact_email\": null, \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Seattle\", \"org_email\": \"CRScustomerservice@fredhutch.org\", \"org_country\": \"United States\", \"org_fax\": null, \"org_phone\": \"206-667-4520\", \"org_name\": \"Fred Hutch/University of Washington Cancer Consortium\", \"org_coordinates\": {\"lon\": -122.3461, \"lat\": 47.6307}}], \"completion_date_type_code\": \"ANTICIPATED\", \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. Evaluate the objective response rate (ORR) with abemaciclib in patients with advanced and refractory well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. Assess the progression-free survival (PFS) and overall survival (OS) rates at one year in GEP NETs overall.\\r\\nII. Assess the antitumor activity of abemaciclib (ORR, 1-year PFS and OS rates) separately in carcinoid tumors and PNETs.\\r\\nIII. Assess the safety of abemaciclib in patients with advanced and refractory GEP NETs.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. Evaluate the genomic and molecular biomarkers related to the CDK4/6 pathway that may predict abemaciclib efficacy in well-differentiated GEP NETs.\\r\\n\\r\\nOUTLINE:\\r\\nPatients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 30 days and then every 4 months for up to 1 year.\", \"official_title\": \"A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients with Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Baseline\", \"name\": \"Genomic and molecular biomarkers related to the CDK4/6 pathway\", \"description\": \"Will be explored. Available archival tumors from consented patients (optional) will be analyzed by immunohistochemistry for Ki67 index and RB1 expression. Available next-generation sequencing results will be reviewed by a molecular pathologist. The association between biomarker expression or mutational status and ORR will be evaluated using a Cox Proportional hazards regression model.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 30 days\", \"name\": \"Incidence of adverse events\", \"description\": \"Safety will be evaluated by assessing the adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 1 year\", \"name\": \"Objective response rate (ORR)\", \"description\": \"ORR defined as complete or partial response as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, will be represented by a waterfall plot.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Time from study registration to death of any cause, assessed up to 1 year\", \"name\": \"Overall survival\", \"description\": \"The distribution for survival times will be estimated using the method of Kaplan-Meier; associated landmark time percentages and the median value will be based on this. Confidence intervals for median values will use the Brookmeyer-Crowley method. Survival outcomes between\\r\\ncarcinoid tumors and PNETs will be compared using a log-rank test.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From study registration to radiographic progression per RECIST v1.1 (investigator assessment), clinical progression, or death of any cause, assessed up to 1 year\", \"name\": \"Progression-free survival\", \"description\": \"The distribution for survival times will be estimated using the method of Kaplan-Meier; associated landmark time percentages and the median value will be based on this. Confidence intervals for median values will use the Brookmeyer-Crowley method. Survival outcomes between\\r\\ncarcinoid tumors and pancreatic neuroendocrine tumor (PNET)s will be compared using a log-rank test.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03891784\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2020-01-24\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C156492\", \"name\": \"Metastatic Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27721\", \"C162255\", \"C156485\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Digestive System Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C158088\", \"name\": \"Refractory Gastroenteropancreatic Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27721\", \"C157131\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Advanced Gastroenteropancreatic Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C158089\", \"name\": \"Advanced Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C175547\", \"C156486\", \"C156492\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C158090\", \"name\": \"Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C178271\", \"C153278\", \"C165455\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Islet Cell Tumor\", \"Islet cell tumors - pancreas\", \"Islet cell tumors of the pancreas\", \"PanNET\", \"Pancreatic NET\", \"Well Differentiated Pancreatic Endocrine Neoplasm\", \"Well Differentiated Pancreatic Endocrine Tumor\", \"islet cell tumor\"], \"nci_thesaurus_concept_id\": \"C27720\", \"name\": \"Pancreatic Neuroendocrine Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C95404\", \"C27031\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C6421\", \"name\": \"Foregut Carcinoid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C2915\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Midgut Carcinoid Tumor\"], \"nci_thesaurus_concept_id\": \"C6422\", \"name\": \"Midgut Neuroendocrine Tumor G1\", \"type\": [\"subtype\"], \"parents\": [\"C2915\", \"C167327\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C6423\", \"name\": \"Hindgut Carcinoid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C2915\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive System NET\", \"Digestive System Well Differentiated Neuroendocrine Tumor\", \"Gastroenteropancreatic NET\", \"Gastroenteropancreatic Neuroendocrine Tumor\", \"Gastrointestinal NET\", \"Gastrointestinal Neuroendocrine Tumor\", \"Gastrointestinal System Neuroendocrine Tumor\"], \"nci_thesaurus_concept_id\": \"C95404\", \"name\": \"Digestive System Neuroendocrine Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C27721\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Pancreas\", \"Neoplasm of the Pancreas\", \"Pancreas Neoplasm\", \"Pancreas Tumor\", \"Pancreatic Tumor\", \"Tumor of Pancreas\", \"Tumor of the Pancreas\"], \"nci_thesaurus_concept_id\": \"C3305\", \"name\": \"Pancreatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C26842\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157131\", \"name\": \"Refractory Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3809\", \"C7628\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Endocrine System Neoplasm\", \"Endocrine System Tumor\", \"Endocrine Tumor\"], \"nci_thesaurus_concept_id\": \"C3010\", \"name\": \"Endocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3009\", \"C3709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Advanced Cancer\", \"advanced cancer\"], \"nci_thesaurus_concept_id\": \"C9270\", \"name\": \"Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162845\", \"name\": \"Unresectable Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Endocrine System Neoplasm\", \"Endocrine System Tumor\", \"Endocrine Tumor\"], \"nci_thesaurus_concept_id\": \"C3010\", \"name\": \"Endocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3009\", \"C3709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Advanced Unresectable Malignant Tumor\"], \"nci_thesaurus_concept_id\": \"C153278\", \"name\": \"Locally Advanced Unresectable Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C153279\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Endocrine System\", \"Endocrine Disease\", \"Endocrine Disorder\", \"Endocrinopathy\", \"Thyroid or other glandular disorders\"], \"nci_thesaurus_concept_id\": \"C3009\", \"name\": \"Endocrine System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Endocrine System\", \"Endocrine Disease\", \"Endocrine Disorder\", \"Endocrinopathy\", \"Thyroid or other glandular disorders\"], \"nci_thesaurus_concept_id\": \"C3009\", \"name\": \"Endocrine System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Pancreatic Endocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27031\", \"name\": \"Pancreatic Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27721\", \"C27067\", \"C3305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C168973\", \"name\": \"Unresectable Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3809\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156485\", \"name\": \"Metastatic Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26842\", \"name\": \"Pancreatic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C167332\", \"name\": \"Locally Advanced Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C156485\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C179181\", \"name\": \"Locally Advanced Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C8524\", \"C162255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastroenteropancreatic Neuroendocrine Neoplasm\", \"Gastrointestinal Neuroendocrine Neoplasm\", \"Gastrointestinal System Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27721\", \"name\": \"Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Gastroenteropancreatic Neuroendocrine Neoplasm\", \"Gastrointestinal Neuroendocrine Neoplasm\", \"Gastrointestinal System Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C27721\", \"name\": \"Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Unresectable Malignant Tumor\"], \"nci_thesaurus_concept_id\": \"C27359\", \"name\": \"Unresectable Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"NEN\", \"Neuroendocrine Neoplasm\", \"neuroendocrine tumor\"], \"nci_thesaurus_concept_id\": \"C3809\", \"name\": \"Neuroendocrine Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C3010\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"NEN\", \"Neuroendocrine Neoplasm\", \"neuroendocrine tumor\"], \"nci_thesaurus_concept_id\": \"C3809\", \"name\": \"Neuroendocrine Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C3010\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Advanced Cancer\", \"Locally Metastatic Malignant Neoplasm\", \"Locally advanced\", \"locally advanced cancer\", \"regional cancer\"], \"nci_thesaurus_concept_id\": \"C8524\", \"name\": \"Locally Advanced Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Unresectable Malignant Tumor\"], \"nci_thesaurus_concept_id\": \"C153279\", \"name\": \"Metastatic Unresectable Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C27359\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Locally Advanced Gastroenteropancreatic Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C178271\", \"name\": \"Locally Advanced Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C179181\", \"C167332\", \"C156492\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C167327\", \"name\": \"Midgut Neuroendocrine Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C95404\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm\"], \"nci_thesaurus_concept_id\": \"C156492\", \"name\": \"Metastatic Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27721\", \"C162255\", \"C156485\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C162255\", \"name\": \"Metastatic Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4890\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoid\", \"Carcinoid tumor\", \"Enterochromaffin cell carcinoid\", \"carcinoid\"], \"nci_thesaurus_concept_id\": \"C2915\", \"name\": \"Carcinoid Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C3809\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C175547\", \"name\": \"Advanced Malignant Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C162255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C156486\", \"name\": \"Advanced Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9270\", \"C156485\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Refractory Tumor\"], \"nci_thesaurus_concept_id\": \"C7628\", \"name\": \"Refractory Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C165455\", \"name\": \"Unresectable Digestive System Neuroendocrine Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C27721\", \"C162845\", \"C168973\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Endocrine Pancreas Disease\"], \"nci_thesaurus_concept_id\": \"C27067\", \"name\": \"Endocrine Pancreas Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C3009\", \"C26842\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive System NET\", \"Digestive System Well Differentiated Neuroendocrine Tumor\", \"Gastroenteropancreatic NET\", \"Gastroenteropancreatic Neuroendocrine Tumor\", \"Gastrointestinal NET\", \"Gastrointestinal Neuroendocrine Tumor\", \"Gastrointestinal System Neuroendocrine Tumor\"], \"nci_thesaurus_concept_id\": \"C95404\", \"name\": \"Digestive System Neuroendocrine Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C27721\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"RG1004456\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Verzenio\"], \"nci_thesaurus_concept_id\": \"C97660\", \"name\": \"Abemaciclib\", \"description\": \"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C129825\", \"C2185\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Enzyme Inhibitor\"], \"nci_thesaurus_concept_id\": \"C129825\", \"name\": \"Antineoplastic Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C129824\", \"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Protein Inhibitor\", \"Antineoplastic Protein Antagonist\"], \"nci_thesaurus_concept_id\": \"C129824\", \"name\": \"Antineoplastic Protein Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2189\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Signal Transduction Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2189\", \"name\": \"Signal Transduction Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Enzyme Antagonist\", \"Enzyme Inhibitor Agent\", \"Enzyme Inhibitor Drug\"], \"nci_thesaurus_concept_id\": \"C471\", \"name\": \"Enzyme Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"CDK Inhibitor\"], \"nci_thesaurus_concept_id\": \"C2185\", \"name\": \"Cyclin-Dependent Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1404\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Protein Kinase Inhibitor\"], \"nci_thesaurus_concept_id\": \"C1404\", \"name\": \"Protein Kinase Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C471\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}], \"name\": \"Treatment (abemaciclib)\", \"description\": \"Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2019-01490\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\", \"brief_title\": \"Abemaciclib in Treating Patients with Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 37, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2019-10-31\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Kaylyn Kit Man Wong\", \"study_source\": \"Institutional\", \"completion_date\": \"2024-09-30\", \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": null, \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Glioblastoma with definitive resection prior to enrollment, with residual radiographic contrast enhancing disease on the post-operative computed tomography (CT) or magnetic resonance imaging (MRI) of < 1 cm in maximal diameter in any axial plane\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Enough tumor tissue available for determination of MGMT gene promoter status\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Cytomegalovirus (CMV) seropositive\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Karnofsky performance status (KPS) of >= 80%\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Hemoglobin >= 9.0 g/dl\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Absolute neutrophil count (ANC) >= 1,500 cells/ul\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Platelets >= 100,000 cells/ul\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Serum creatinine =< 1.5 mg/dl\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Serum glutamic-oxaloacetic transaminase (SGOT) =< 1.5 times upper limit of normal\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Serum bilirubin =< 1.5 times upper limit of normal\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Signed informed consent approved by the Institutional Review Board\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, [i.e. with a failure rate of < 1% per year] are implants, injectables, combined oral contraceptives, intra-uterine device [IUD; only hormonal], sexual abstinence or vasectomized partner) during the trial and for a period of > 6 months following the last administration of trial drug(s). Female patients with an intact uterus (unless amenorrhea for the last 24 months) must have a negative serum pregnancy test within 48 hours prior to first study treatment\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a period of > 6 months following the last administration of trial drugs\"}, {\"inclusion_indicator\": false, \"display_order\": 14, \"description\": \"Pregnant or breast-feeding\"}, {\"inclusion_indicator\": false, \"display_order\": 15, \"description\": \"Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"}, {\"inclusion_indicator\": false, \"display_order\": 16, \"description\": \"Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylene triamine pentaacetic acid (DTPA)\"}, {\"inclusion_indicator\": false, \"display_order\": 17, \"description\": \"Patients who cannot undergo MRI or single photon emission computed tomography (SPECT) due to obesity or to having certain metal in their bodies (specifically pacemakers, infusion pumps, metal aneurysm clips, metal prostheses, joints, rods, or plates)\"}, {\"inclusion_indicator\": false, \"display_order\": 18, \"description\": \"Patients with evidence of tumor in the brainstem, cerebellum, or spinal cord, radiological evidence of (actively growing) multifocal disease, or leptomeningeal disease\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Severe, active comorbidity, including any of the following:\\r\\n* Unstable angina and/or congestive heart failure requiring hospitalization;\\r\\n* Transmural myocardial infarction within the last 6 months;\\r\\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study initiation;\\r\\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy;\\r\\n* Known hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;\\r\\n* Known human immunodeficiency virus (HIV) and hepatitis C positive status;\\r\\n* Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy;\\r\\n* Active connective tissue disorders, such as lupus or scleroderma that, in the opinion of the treating physician, may put the patient at high risk for radiation toxicity\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin. (Treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment)\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Patients are not permitted to have had any other conventional therapeutic intervention other than steroids prior to enrollment outside of standard of care chemoradiation and tumor-treating fields during chemoradiation. Patients who receive previous inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies will be excluded\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Current, recent (within 4 weeks of the administration of this study agent), or planned participation in an experimental drug study\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Known history of autoimmune disease (with the exceptions of medically-controlled hypothyroidism and type I diabetes mellitus)\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Annick Desjardins\", \"contact_phone\": \"919-684-6173\", \"recruitment_status_date\": \"2019-07-22\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"annick.desjardins@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To confirm that tetanus and diphtheria toxoids adsorbed (Td) preconditioning of autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine (pp65 loaded DC vaccination) extends overall survival.\\r\\nII. To assess the safety of administering varlilumab in conjunction with pp65 loaded DC vaccination and Td preconditioning.\\r\\nIII. To examine the effect of adding varlilumab on regulatory T-cells (TReg) depletion among glioblastoma (GBM) patients treated with pp65 loaded DC vaccination and Td pre-conditioning.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To describe the survival of patients treated with pp65-loaded DC vaccine, varlilumab, and Td preconditioning.\\r\\nII. To examine the impact of Td preconditioning with and without varlilumab on progression-free survival.\\r\\nIII. To confirm previous findings that Td pre-conditioning and DC vaccination increase DC migration to the draining lymph nodes.\\r\\nIV. To confirm previous findings that Td pre-conditioning increases serum CCL3.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To assess whether functional vaccine-induced pp65-specific CD4+ T cells and CD8+ are increased by varlilumab.\\r\\nII. To assess the impact of varlilumab on Td-specific memory T cells, and to examine intracellular levels of CCL3 from peripheral blood mononuclear cells (PBMC) collected before and after Td pre-conditioning.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 3 groups.\\r\\n\\r\\nAll patients undergo standard of care radiation therapy and receive temozolomide intravenously (IV). Treatment continues for 4 weeks (as 1 cycle) for patients with unmethylated MGMT, and repeats every 4 weeks for up to 12 cycles for patients with methylated MGMT in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nGROUP I: Patients receive pp65 loaded DC vaccine intradermally (ID) every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive saline intradermally. Patients then receive indium (In) 111-autologous CMV-pp65-LAMP mRNA loaded dendritic cells (111 In labeled DCs) ID as the 4th vaccine.\\r\\n\\r\\nGROUP II: Patients receive pp65 loaded DC vaccine ID every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive a single dose of tetanus and diphtheria toxoids adsorbed ID and saline ID. Patients then receive 111 In labeled DCs ID as the 4th vaccine.\\r\\n\\r\\nGROUP III: Patients receive varlilumab IV 7 days before vaccines except the 2nd vaccine. Patients also receive pp65 loaded DC vaccine ID every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive a single dose of tetanus and diphtheria toxoids adsorbed ID and saline ID. Patients then receive 111 In labeled DCs ID as the 4th vaccine.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up periodically.\", \"official_title\": \"DERIVe: DC Migration Study to Evaluate TReg Depletion in GBM Patients with and without Varlilumab\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"2 days\", \"name\": \"Median chemokine (C-C motif) ligand 3 (CCL3) levels in serum at 24, 48, and 72 hours after pre-conditioning\", \"description\": \"CCL3 levels in serum 24, 48, and 72 hours after pre-conditioning by multiplex. The median CCL3 level will be presented.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"5 years\", \"name\": \"Median overall survival (OS) of subjects receiving DC vaccines, varlilumab, and Td pre-conditioning\", \"description\": \"OS is defined as the time in months between randomization and death, or last follow-up if alive (Group 3). Kaplan-Meier methods will be used to estimate median OS.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"5 years\", \"name\": \"Median overall survival (OS) of subjects receiving tetanus and diphtheria toxoids adsorbed (Td) pre-conditioning\", \"description\": \"OS is defined as the time in months between randomization and death, or last follow-up if alive (Groups 1 and 2). Kaplan-Meier methods will be used to estimate median OS.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"2 days\", \"name\": \"Median percentage of 111In-labeled DCs reaching inguinal nodes\", \"description\": \"The percentage of 111In-labeled DCs reaching inguinal nodes calculated from the initial signal at the injections site in the groin at 1 and 2 days after the 4th vaccination base upon single photon emission computed tomography (SPECT)/computed tomography (CT). The median percentage at each time point will be presented.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"50 days\", \"name\": \"Median percent change between baseline, assessed on day 14, and nadir levels of regulatory T-cells (TReg) before the time that the second cycle of adjuvant temozolomide (TMZ) would be administered\", \"description\": \"Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+). Change between baseline and nadir before the 2nd cycle of TMZ (Combined Groups 1 and 2, Group 3)\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"5 years\", \"name\": \"Median progression-free survival (PFS)\", \"description\": \"PFS is defined as the time between randomization and initial failure (disease progression or death) (all Groups). If the patient remains alive without disease progression, PFS will be censored at the time of last follow-up. Kaplan-Meier methods will be used to estimate median PFS.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"5 years\", \"name\": \"Safety of administering varlilumab to glioblastoma (GBM) patients receiving temozolomide and dendritic cell vaccines +/- Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution\", \"description\": \"Percentage of patients with unacceptable toxicity (all Groups).\", \"type_code\": \"PRIMARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 3, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03688178\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"CMV Positive\", \"HHV-5 Positive\", \"Human Herpesvirus 5 Positive\"], \"nci_thesaurus_concept_id\": \"C131328\", \"name\": \"Cytomegalovirus Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C35682\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2019-07-22\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"CNS, glioblastoma (GBM)\", \"GBM\", \"GBM (Glioblastoma)\", \"Glioblastoma Multiforme\", \"Glioblastoma multiforme\", \"Grade IV Astrocytic Neoplasm\", \"Grade IV Astrocytic Tumor\", \"Spongioblastoma Multiforme\", \"Spongioblastoma multiforme\", \"WHO Grade IV Glioma\", \"glioblastoma\", \"glioblastoma multiforme\"], \"nci_thesaurus_concept_id\": \"C3058\", \"name\": \"Glioblastoma\", \"type\": [\"grade\", \"maintype\", \"subtype\"], \"parents\": [\"C36025\", \"C129325\", \"C102897\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Astrocytic Neoplasm\", \"Astroglioma\"], \"nci_thesaurus_concept_id\": \"C6958\", \"name\": \"Astrocytic Tumor\", \"type\": [\"subtype\"], \"parents\": [\"C3059\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neural Neoplasm\", \"Neural Tumor\"], \"nci_thesaurus_concept_id\": \"C35562\", \"name\": \"Neuroepithelial, Perineurial, and Schwann Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\", \"C3268\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Central Nervous System Disease\", \"Disorder of Central Nervous System\"], \"nci_thesaurus_concept_id\": \"C2934\", \"name\": \"Central Nervous System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26835\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Nervous System\", \"Malignant Neoplasm of the Nervous System\", \"Malignant Nervous System Tumor\", \"Malignant Tumor of Nervous System\", \"Malignant Tumor of the Nervous System\", \"Nervous System Neoplasms, Malignant\"], \"nci_thesaurus_concept_id\": \"C4788\", \"name\": \"Malignant Nervous System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3268\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Nervous System\", \"Neoplasm of the Nervous System\", \"Nervous System Neoplasm\", \"Nervous System Neoplasms\", \"Nervous System Tumour\", \"Tumor of Nervous System\", \"Tumor of the Nervous System\"], \"nci_thesaurus_concept_id\": \"C3268\", \"name\": \"Nervous System Tumor\", \"type\": [\"maintype\"], \"parents\": [\"C3263\", \"C26835\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CNS Cancer\", \"CNS Malignant Neoplasms\", \"CNS Neoplasms, Malignant\", \"Cancer of CNS\", \"Cancer of Central Nervous System\", \"Cancer of the CNS\", \"Cancer of the Central Nervous System\", \"Central Nervous System Cancer\", \"Central Nervous System Neoplasms, Malignant\", \"Malignant CNS Neoplasm\", \"Malignant CNS Neoplasms\", \"Malignant CNS Tumor\", \"Malignant Central Nervous System Tumor\", \"Malignant Neoplasm of CNS\", \"Malignant Neoplasm of Central Nervous System\", \"Malignant Neoplasm of the CNS\", \"Malignant Neoplasm of the Central Nervous System\", \"Malignant Tumor of CNS\", \"Malignant Tumor of Central Nervous System\", \"Malignant Tumor of the CNS\", \"Malignant Tumor of the Central Nervous System\"], \"nci_thesaurus_concept_id\": \"C4627\", \"name\": \"Malignant Central Nervous System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9293\", \"C4788\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Nervous System\", \"Neurologic Disorder\", \"Neurological Disorder\", \"Unspecified Nervous System Problem\"], \"nci_thesaurus_concept_id\": \"C26835\", \"name\": \"Nervous System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CNS Neoplasm\", \"CNS Tumor\", \"CNS tumor\", \"Central Nervous System Neoplasm\", \"Central Nervous System Tumor\", \"Neoplasm of CNS\", \"Neoplasm of Central Nervous System\", \"Neoplasm of the Central Nervous System\", \"Tumor of CNS\", \"Tumor of Central Nervous System\", \"Tumor of the CNS\", \"Tumor of the Central Nervous System\", \"central nervous system tumor\"], \"nci_thesaurus_concept_id\": \"C9293\", \"name\": \"Brain/Spinal Cord Tumor\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C2934\", \"C3268\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Neuroepithelial Tissue\", \"Neoplasm of Neuroepithelium\", \"Neoplasm of the Neuroepithelium\", \"Neuroepithelial Neoplasms\", \"Neuroepithelial Tissue Neoplasm\", \"Neuroepithelial Tissue Tumor\", \"Neuroepithelial Tumor\", \"Neuroepithelial Tumors\", \"Neuroepitheliomatous Neoplasms\", \"Tumor of Neuroepithelial Tissue\", \"Tumor of Neuroepithelium\", \"Tumor of the Neuroepithelium\"], \"nci_thesaurus_concept_id\": \"C3787\", \"name\": \"Neuroepithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C35562\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CNS primary tumor, NOS\"], \"nci_thesaurus_concept_id\": \"C102871\", \"name\": \"Primary Central Nervous System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9293\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"GLIOMA, MALIGNANT\", \"Glioma, malignant\", \"High Grade Glioma\", \"High-Grade Glioma\", \"Malignant Glial Neoplasm\", \"Malignant Glial Tumor\", \"Malignant Neuroglial Neoplasm\", \"Malignant Neuroglial Tumor\"], \"nci_thesaurus_concept_id\": \"C4822\", \"name\": \"Malignant Glioma\", \"type\": [\"grade\", \"subtype\"], \"parents\": [\"C3059\", \"C4627\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Glial Neoplasm\", \"Glial Tumor\", \"Glioma, NOS\", \"Neoplasm of Neuroglia\", \"Neoplasm of the Neuroglia\", \"Neuroglial Neoplasm\", \"Neuroglial Tumor\", \"Tumor of Neuroglia\", \"Tumor of the Neuroglia\", \"glial tumor\", \"glioma\"], \"nci_thesaurus_concept_id\": \"C3059\", \"name\": \"Glioma\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C3787\", \"C102871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"High Grade Astrocytic Neoplasm\", \"High-Grade Astrocytic Neoplasm\", \"High-Grade Astrocytic Tumor\"], \"nci_thesaurus_concept_id\": \"C102897\", \"name\": \"High Grade Astrocytic Tumor\", \"type\": [\"grade\"], \"parents\": [\"C6958\", \"C4822\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C129325\", \"name\": \"Diffuse Glioma\", \"type\": [\"subtype\"], \"parents\": [\"C3059\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C36025\", \"name\": \"Anaplastic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00082570\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\"], \"nci_thesaurus_concept_id\": \"C162641\", \"name\": \"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\", \"description\": null, \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1511\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Varlilumab\"], \"nci_thesaurus_concept_id\": \"C99127\", \"name\": \"Varlilumab\", \"description\": \"A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of CDX-1127, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Hea\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C20401\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Methazolastone\", \"Temcad\", \"Temodal\", \"Temodar\", \"Temozolomide\"], \"nci_thesaurus_concept_id\": \"C1244\", \"name\": \"Temozolomide\", \"description\": \"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C902\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\"], \"nci_thesaurus_concept_id\": \"C156067\", \"name\": \"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\", \"description\": null, \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C28310\", \"C181141\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Sodium Chloride 0.9%\", \"Saline\"], \"nci_thesaurus_concept_id\": \"C821\", \"name\": \"Saline\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C45678\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"DECAVAC\", \"Tetanus and Diphtheria Toxoids Adsorbed\"], \"nci_thesaurus_concept_id\": \"C96405\", \"name\": \"Tetanus and Diphtheria Toxoids Adsorbed\", \"description\": null, \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C96398\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiolabeled Antibodies\"], \"nci_thesaurus_concept_id\": \"C1511\", \"name\": \"Radioimmunoconjugate\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1512\", \"C2124\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1512\", \"name\": \"Immunoconjugate\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radio Conjugates\"], \"nci_thesaurus_concept_id\": \"C2124\", \"name\": \"Radioconjugate\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1446\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radioactive Pharmaceutical\", \"Radiochemical\", \"Radiopharmaceuticals\", \"Radiopharmaceutical Compound\"], \"nci_thesaurus_concept_id\": \"C1446\", \"name\": \"Radiopharmaceutical Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Triazene Compounds\"], \"nci_thesaurus_concept_id\": \"C902\", \"name\": \"Triazene Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1590\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"nci_thesaurus_concept_id\": \"C1590\", \"name\": \"Antineoplastic Alkylating Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C2842\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C2842\", \"name\": \"DNA Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Dendritic Cell-based Cancer Vaccine\"], \"nci_thesaurus_concept_id\": \"C28310\", \"name\": \"Dendritic Cell Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C28308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C28308\", \"name\": \"APC Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1663\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Vaccine\", \"Neoplasm Vaccine\", \"Tumor Vaccine\"], \"nci_thesaurus_concept_id\": \"C1663\", \"name\": \"Antineoplastic Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C923\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Vaccine Therapy\"], \"nci_thesaurus_concept_id\": \"C923\", \"name\": \"Vaccine Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"mRNA Antineoplastic Vaccine\", \"mRNA-based Cancer Vaccine\", \"mRNA-derived Cancer Vaccine\"], \"nci_thesaurus_concept_id\": \"C181141\", \"name\": \"mRNA Cancer Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1663\", \"C172787\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C172787\", \"name\": \"mRNA Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C923\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Industrial Additive\"], \"nci_thesaurus_concept_id\": \"C45678\", \"name\": \"Industrial Aid\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C96398\", \"name\": \"Toxoid Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C96390\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C96390\", \"name\": \"Bacterial Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C923\"]}], \"name\": \"Group III (varlilumab,vaccine, Td, 111 In labeled DC, TMZ, RT)\", \"description\": \"Patients receive varlilumab IV 7 days before vaccines except the 2nd vaccine. Patients also receive pp65 loaded DC vaccine ID every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive a single dose of tetanus and diphtheria toxoids adsorbed ID and saline ID. Patients then receive 111 In labeled DCs ID as the 4th vaccine. All patients undergo standard of care radiation therapy and receive temozolomide IV. Treatment continues for 4 weeks (as 1 cycle) for patients with unmethylated MGMT, and repeats every 4 weeks for up to 12 cycles for patients with methylated MGMT in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"DECAVAC\", \"Tetanus and Diphtheria Toxoids Adsorbed\"], \"intervention_name\": \"Tetanus and Diphtheria Toxoids Adsorbed\", \"category\": \"agent\", \"intervention_code\": \"C96405\", \"intervention_description\": null, \"parents\": [\"C96398\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"intervention_name\": \"Radiation Therapy\", \"category\": \"other\", \"intervention_code\": \"C15313\", \"intervention_description\": null, \"parents\": [\"C49236\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Methazolastone\", \"Temcad\", \"Temodal\", \"Temodar\", \"Temozolomide\"], \"intervention_name\": \"Temozolomide\", \"category\": \"agent\", \"intervention_code\": \"C1244\", \"intervention_description\": \"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C902\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\"], \"intervention_name\": \"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\", \"category\": \"agent\", \"intervention_code\": \"C156067\", \"intervention_description\": null, \"parents\": [\"C28310\", \"C181141\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Sodium Chloride 0.9%\", \"Saline\"], \"intervention_name\": \"Saline\", \"category\": \"other\", \"intervention_code\": \"C821\", \"intervention_description\": null, \"parents\": [\"C45678\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\"], \"intervention_name\": \"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\", \"category\": \"agent\", \"intervention_code\": \"C162641\", \"intervention_description\": null, \"parents\": [\"C1511\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Toxoid Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C96398\", \"intervention_description\": \"\", \"parents\": [\"C96390\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Bacterial Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C96390\", \"intervention_description\": \"\", \"parents\": [\"C923\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Vaccine Therapy\"], \"intervention_name\": \"Vaccine Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C923\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Therapeutic Procedure\", \"category\": \"none\", \"intervention_code\": \"C49236\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Intervention or Procedure\", \"category\": \"none\", \"intervention_code\": \"C25218\", \"intervention_description\": \"\", \"parents\": [\"C16203\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Clinical or Research Activity\", \"category\": \"none\", \"intervention_code\": \"C16203\", \"intervention_description\": \"\", \"parents\": [\"C43431\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Activity\", \"category\": \"none\", \"intervention_code\": \"C43431\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Triazene Compounds\"], \"intervention_name\": \"Triazene Compound\", \"category\": \"agent category\", \"intervention_code\": \"C902\", \"intervention_description\": \"\", \"parents\": [\"C1590\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"intervention_name\": \"Antineoplastic Alkylating Agent\", \"category\": \"agent category\", \"intervention_code\": \"C1590\", \"intervention_description\": \"\", \"parents\": [\"C2842\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"DNA Binding Agent\", \"category\": \"agent category\", \"intervention_code\": \"C2842\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Dendritic Cell-based Cancer Vaccine\"], \"intervention_name\": \"Dendritic Cell Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C28310\", \"intervention_description\": \"\", \"parents\": [\"C28308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"APC Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C28308\", \"intervention_description\": \"\", \"parents\": [\"C1663\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Vaccine\", \"Neoplasm Vaccine\", \"Tumor Vaccine\"], \"intervention_name\": \"Antineoplastic Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C1663\", \"intervention_description\": \"\", \"parents\": [\"C274\", \"C923\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"mRNA Antineoplastic Vaccine\", \"mRNA-based Cancer Vaccine\", \"mRNA-derived Cancer Vaccine\"], \"intervention_name\": \"mRNA Cancer Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C181141\", \"intervention_description\": \"\", \"parents\": [\"C1663\", \"C172787\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"mRNA Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C172787\", \"intervention_description\": \"\", \"parents\": [\"C923\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Industrial Additive\"], \"intervention_name\": \"Industrial Aid\", \"category\": \"none\", \"intervention_code\": \"C45678\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiolabeled Antibodies\"], \"intervention_name\": \"Radioimmunoconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C1511\", \"intervention_description\": \"\", \"parents\": [\"C1512\", \"C2124\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immunoconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C1512\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radio Conjugates\"], \"intervention_name\": \"Radioconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C2124\", \"intervention_description\": \"\", \"parents\": [\"C1446\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radioactive Pharmaceutical\", \"Radiochemical\", \"Radiopharmaceuticals\", \"Radiopharmaceutical Compound\"], \"intervention_name\": \"Radiopharmaceutical Compound\", \"category\": \"agent category\", \"intervention_code\": \"C1446\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}], \"name\": \"Group II (vaccine, Td, 111 In labeled DC, TMZ, RT)\", \"description\": \"Patients receive pp65 loaded DC vaccine ID every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive a single dose of tetanus and diphtheria toxoids adsorbed ID and saline ID. Patients then receive 111 In labeled DCs ID as the 4th vaccine. All patients undergo standard of care radiation therapy and receive temozolomide IV. Treatment continues for 4 weeks (as 1 cycle) for patients with unmethylated MGMT, and repeats every 4 weeks for up to 12 cycles for patients with methylated MGMT in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}, {\"interventions\": [{\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Sodium Chloride 0.9%\", \"Saline\"], \"intervention_name\": \"Saline\", \"category\": \"other\", \"intervention_code\": \"C821\", \"intervention_description\": null, \"parents\": [\"C45678\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\"], \"intervention_name\": \"Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine\", \"category\": \"agent\", \"intervention_code\": \"C156067\", \"intervention_description\": null, \"parents\": [\"C28310\", \"C181141\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Methazolastone\", \"Temcad\", \"Temodal\", \"Temodar\", \"Temozolomide\"], \"intervention_name\": \"Temozolomide\", \"category\": \"agent\", \"intervention_code\": \"C1244\", \"intervention_description\": \"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C902\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\"], \"intervention_name\": \"Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells\", \"category\": \"agent\", \"intervention_code\": \"C162641\", \"intervention_description\": null, \"parents\": [\"C1511\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"intervention_name\": \"Radiation Therapy\", \"category\": \"other\", \"intervention_code\": \"C15313\", \"intervention_description\": null, \"parents\": [\"C49236\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Industrial Additive\"], \"intervention_name\": \"Industrial Aid\", \"category\": \"none\", \"intervention_code\": \"C45678\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Other\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"none\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Dendritic Cell-based Cancer Vaccine\"], \"intervention_name\": \"Dendritic Cell Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C28310\", \"intervention_description\": \"\", \"parents\": [\"C28308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"APC Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C28308\", \"intervention_description\": \"\", \"parents\": [\"C1663\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Vaccine\", \"Neoplasm Vaccine\", \"Tumor Vaccine\"], \"intervention_name\": \"Antineoplastic Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C1663\", \"intervention_description\": \"\", \"parents\": [\"C274\", \"C923\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Vaccine Therapy\"], \"intervention_name\": \"Vaccine Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C923\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"mRNA Antineoplastic Vaccine\", \"mRNA-based Cancer Vaccine\", \"mRNA-derived Cancer Vaccine\"], \"intervention_name\": \"mRNA Cancer Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C181141\", \"intervention_description\": \"\", \"parents\": [\"C1663\", \"C172787\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"mRNA Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C172787\", \"intervention_description\": \"\", \"parents\": [\"C923\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Triazene Compounds\"], \"intervention_name\": \"Triazene Compound\", \"category\": \"agent category\", \"intervention_code\": \"C902\", \"intervention_description\": \"\", \"parents\": [\"C1590\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Chemotherapy Alkylating Agents\", \"Chemotherapy Alkylators\"], \"intervention_name\": \"Antineoplastic Alkylating Agent\", \"category\": \"agent category\", \"intervention_code\": \"C1590\", \"intervention_description\": \"\", \"parents\": [\"C2842\"]}, {\"intervention_type\": \"Drug\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"DNA Binding Agent\", \"category\": \"agent category\", \"intervention_code\": \"C2842\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radiolabeled Antibodies\"], \"intervention_name\": \"Radioimmunoconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C1511\", \"intervention_description\": \"\", \"parents\": [\"C1512\", \"C2124\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immunoconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C1512\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radio Conjugates\"], \"intervention_name\": \"Radioconjugate\", \"category\": \"agent category\", \"intervention_code\": \"C2124\", \"intervention_description\": \"\", \"parents\": [\"C1446\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Radioactive Pharmaceutical\", \"Radiochemical\", \"Radiopharmaceuticals\", \"Radiopharmaceutical Compound\"], \"intervention_name\": \"Radiopharmaceutical Compound\", \"category\": \"agent category\", \"intervention_code\": \"C1446\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Therapeutic Procedure\", \"category\": \"none\", \"intervention_code\": \"C49236\", \"intervention_description\": \"\", \"parents\": [\"C25218\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Intervention or Procedure\", \"category\": \"none\", \"intervention_code\": \"C25218\", \"intervention_description\": \"\", \"parents\": [\"C16203\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Clinical or Research Activity\", \"category\": \"none\", \"intervention_code\": \"C16203\", \"intervention_description\": \"\", \"parents\": [\"C43431\"]}, {\"intervention_type\": \"Radiation\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Activity\", \"category\": \"none\", \"intervention_code\": \"C43431\", \"intervention_description\": \"\", \"parents\": []}], \"name\": \"Group I (pp65 loaded DC vaccine, 111 IN labeled DC, TMZ, RT)\", \"description\": \"Patients receive pp65 loaded DC vaccine ID every 2 weeks for up to 20 vaccinations in the absence of disease progression or unacceptable toxicity. The day prior to the 4th vaccine, patients receive saline intradermally. Patients then receive 111 In labeled DCs ID as the 4th vaccine.\\r\\n\\r\\nAll patients undergo standard of care radiation therapy and receive temozolomide IV. Treatment continues for 4 weeks (as 1 cycle) for patients with unmethylated MGMT, and repeats every 4 weeks for up to 12 cycles for patients with methylated MGMT in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2019-05126\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well a vaccine (pp65 loaded DC vaccine) with or without varlilumab works in treating patients with glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Pre-conditioning the vaccination site with varlilumab may help the pp65 loaded DC vaccine stimulate the immune system to kill tumor cells and extend survival in patients with glioblastoma.\", \"brief_title\": \"A Vaccine (pp65 Loaded DC Vaccine) with or without Varlilumab in Treating Patients with Glioblastoma\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 112, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2019-07-22\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": \"CAREGIVER\", \"masking\": null, \"role_investigator\": \"INVESTIGATOR\", \"role_outcome_assessor\": null, \"role_subject\": \"SUBJECT\", \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Brain and Nervous System\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Annick Desjardins\", \"study_source\": \"Externally Peer Reviewed\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": null, \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Parallel\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically-confirmed breast cancer that is metastatic or locally recurrent (7th edition of the American Joint Committee on Cancer [AJCC] TNM system) with HER2/neu overexpression by immunohistochemistry (2+, 3+) or fluorescence in situ hybridization (FISH)+ per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines and receiving trastuzumab plus pertuzumab (determined by their physician)\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Have undergone treatment with trastuzumab plus pertuzumab (as selected by their attending physician) for at least 3 weeks prior to initiation on this study\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Be willing and able to provide written informed consent/assent for the trial. Informed consent will be obtained from the patient prior to performing any study-related procedures, including screening visits. Available computed tomography (CT) scans and bone scans performed as standard of care prior to signing consent can be used to fulfill eligibility requirements if they were performed within 4 weeks of the first dose of study drug(s). Available multigated acquisition scan (MUGA), echocardiogram, and electrocardiogram (EKG) performed as standard of care prior to signing consent can be used to fulfill eligibility requirements if they were performed within 8 weeks of the first dose of study drug(s)\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Resolution of all toxic side effects of prior chemotherapy, radiotherapy or surgical procedures to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) grade =< 1 (with the exception of grade 2 alopecia, grade 2 neuropathy and grade 2 fatigue)\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the sponsor\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Normal cardiac function defined as either a MUGA or echocardiogram (ECHO) with left ventricular ejection fraction (LVEF) in normal institutional range (MUGA 50%; ECHO 55%)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Absolute neutrophil count (ANC) >= 1,500 /mcL (performed within 7 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Platelets >= 100,000/mcL (performed within 7 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (performed within 7 days of treatment initiation) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (performed within 7 days of treatment initiation) (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN (performed within 7 days of treatment initiation) for subjects with total bilirubin levels > 1.5 ULN\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases (performed within 7 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Albumin >= 2.5 mg/dL (performed within 7 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (performed within 7 days of treatment initiation) unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 7 days of treatment initiation) unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\"}, {\"inclusion_indicator\": true, \"display_order\": 17, \"description\": \"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\"}, {\"inclusion_indicator\": true, \"display_order\": 18, \"description\": \"Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\\r\\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject\"}, {\"inclusion_indicator\": true, \"display_order\": 19, \"description\": \"Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\\r\\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject\"}, {\"inclusion_indicator\": true, \"display_order\": 20, \"description\": \"Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Patients in this study, may not receive cytotoxic chemotherapy, anti-estrogen therapy, targeted small molecule therapy, or radiation therapy in the 3 weeks before the first infusion of pembrolizumab, during the injection period for VRP-HER2 and infusion period for pembrolizumab or for at least 2 weeks after booster immunization with VRP-HER2 (arm 1) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\\r\\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\\r\\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Has estrogen receptor (ER) and or progesterone receptor (PR) positive breast cancer\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Patients may have received prior radiation including for brain metastases\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Prior history of autoimmune thyroiditis or vitiligo is permitted\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Has a known history of active TB (Bacillus tuberculosis)\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Hypersensitivity to pembrolizumab or any of its excipients\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirements of steroid treatment for at least 14 days prior to the first dose of study treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Has history of (non-infectious) pneumonitis that required steroids or active, noninfectious pneumonitis\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Has an active infection requiring systemic therapy or systemic use of antimicrobials within 72 hours prior to the first study treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject\\u2019s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\"}, {\"inclusion_indicator\": false, \"display_order\": 39, \"description\": \"Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)\"}, {\"inclusion_indicator\": false, \"display_order\": 40, \"description\": \"Has received a live vaccine within 30 days of planned start of study therapy\\r\\n* Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Michael A. Morse\", \"contact_phone\": \"919-684-5705\", \"recruitment_status_date\": \"2019-04-04\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"michael.morse@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To determine whether pembrolizumab increases the tumor infiltrating (T cell) and peripheral blood (T cell and antibody) immune response to the HER2 ECD+TM virus-like replicon particles vaccine AVX901 (VRP-HER2) vaccine.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To determine whether the administration of pembrolizumab is safe in patients with recurrent or metastatic HER2 positive (+) cancers who are receiving the anti-HER2 vaccine VRP-HER2.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To collect preliminary data on the clinical response rates to this concurrent therapy of agents in subjects with assessable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 3 arms.\\r\\n\\r\\nARM A: Patients receive HER2 ECD+TM virus-like replicon particles vaccine AVX901 intramuscularly (IM) on days 1 and 15 of cycle 1, day 8 of cycle 2, and a booster on day 1 of cycle 5 in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nARM B: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for 5 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nARM C: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive HER2 ECD+TM virus-like replicon particles vaccine AVX901 IM on days 1 and 15 of cycle 1, day 8 of cycle 2, and a booster on day 1 of cycle 5 in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 30 days, 24 weeks, and then every 12 weeks.\", \"official_title\": \"A Phase II Randomized Study to Evaluate the Immunologic and Antitumor Activity of Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients with Advanced HER2-Overexpressing Breast Cancer\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"36 months\", \"name\": \"Clinical response rate\", \"description\": \"To collect preliminary data on the clinical response rates to this concurrent therapy of agents in subjects with assessable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"24 months\", \"name\": \"Number of tumor infiltrating lymphocytes and HER2 specific antibodies\", \"description\": \"The objective is to determine whether pembrolizumab increases the tumor infiltrating and HER2 specific antibodies resulting from the HER2 ECD+TM virus-like replicon particles vaccine AVX901 (VRP-HER2) vaccine.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"24 months\", \"name\": \"Rate and severity of adverse events\", \"description\": \"Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 3, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03632941\", \"biomarkers\": [{\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER Alpha Positive\", \"ER Positive\", \"ER+\", \"ER-Alpha Positive\", \"ERA Positive\", \"ESR Positive\", \"ESR1 Positive\", \"ESRA Positive\", \"ESTRR Positive\", \"Estrogen Receptor 1 Positive\", \"Estrogen Receptor Alpha Positive\", \"NR3A1 Positive\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Positive\", \"Positive\", \"Positive Estrogen Receptor\", \"estrogen receptor positive\"], \"nci_thesaurus_concept_id\": \"C15492\", \"name\": \"Estrogen Receptor Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C101267\", \"C16150\", \"C16612\", \"C177692\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35682\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\", \"parents\": [\"C16150\", \"C101267\", \"C38349\"]}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"PGR Positive\", \"PR Positive\", \"PR+\", \"Positive\", \"progesterone receptor positive\"], \"nci_thesaurus_concept_id\": \"C15496\", \"name\": \"Progesterone Receptor Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C101267\", \"C16149\", \"C16612\", \"C177692\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35682\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\", \"parents\": [\"C101267\", \"C16149\", \"C28656\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Erb-B2 Receptor Tyrosine Kinase Overexpression\", \"HER2 Overexpression\", \"HER2/neu Overexpression\", \"NEU Overexpression\", \"Proto-Oncogene Neu Overexpression\", \"Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Overexpression\", \"Tyrosine Kinase-Type Cell Surface Receptor HER2 Overexpression\", \"v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Overexpression\"], \"nci_thesaurus_concept_id\": \"C150634\", \"name\": \"ERBB2 Overexpression\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16152\", \"C16612\", \"C17756\", \"C177692\", \"C177693\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C26683\", \"C3367\", \"C35682\", \"C36292\", \"C68748\", \"C7057\", \"C77140\", \"C81326\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C177693\", \"C68748\", \"C17756\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER\", \"ESR1\", \"Estrogen Receptor 1 Gene\"], \"nci_thesaurus_concept_id\": \"C38349\", \"name\": \"ESR1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER Alpha Status\", \"ER Status\", \"ER-Alpha Status\", \"ERA Status\", \"ESR Status\", \"ESR1 Status\", \"ESRA Status\", \"ESTRR Status\", \"Estrogen Receptor\", \"Estrogen Receptor 1 Status\", \"Estrogen Receptor Alpha Status\", \"NR3A1 Status\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Status\"], \"nci_thesaurus_concept_id\": \"C16150\", \"name\": \"Estrogen Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C38349\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"High Expression\"], \"nci_thesaurus_concept_id\": \"C177693\", \"name\": \"Elevated Expression\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C26683\", \"C3367\", \"C36292\", \"C7057\", \"C77140\", \"C81326\"], \"parents\": [\"C81326\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Abnormal Lab Test Result\", \"Abnormal Laboratory Test\", \"Abnormal, NOS\"], \"nci_thesaurus_concept_id\": \"C26683\", \"name\": \"Abnormal Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER and/or PR +\", \"ER and/or PR Positive\", \"Estrogen Receptor and/or Progesterone Receptor Positive\"], \"nci_thesaurus_concept_id\": \"C101267\", \"name\": \"Hormone Receptor Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C177692\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35682\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C177692\", \"C94299\", \"C38349\", \"C28656\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2 Positive\", \"HER-2 Positive\", \"HER2 Positive\"], \"nci_thesaurus_concept_id\": \"C68748\", \"name\": \"HER2/Neu Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16152\", \"C16612\", \"C17756\", \"C177692\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C177692\", \"C16152\", \"C17756\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Expressed\", \"Expression Detected\"], \"nci_thesaurus_concept_id\": \"C177692\", \"name\": \"Expression Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PGR\", \"PR\", \"Progesterone Receptor Gene\"], \"nci_thesaurus_concept_id\": \"C28656\", \"name\": \"PGR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C94299\", \"name\": \"Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C94299\", \"name\": \"Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C81326\", \"name\": \"Elevated Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C26683\", \"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C26683\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Transcription Factor\"], \"nci_thesaurus_concept_id\": \"C20420\", \"name\": \"Transcription Factor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C54362\"], \"parents\": [\"C54362\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2\", \"Erb-b2 Receptor Tyrosine Kinase 2 Gene\", \"HER2\", \"HER2/Neu\", \"NEU\"], \"nci_thesaurus_concept_id\": \"C17756\", \"name\": \"ERBB2 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C54362\", \"name\": \"Transcription Regulation Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PgR Status\", \"Progesterone Receptor\"], \"nci_thesaurus_concept_id\": \"C16149\", \"name\": \"Progesterone Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C36292\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C28656\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2 Status\", \"Her2/Neu Value\"], \"nci_thesaurus_concept_id\": \"C16152\", \"name\": \"HER2/Neu Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17756\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C17756\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Expressed\", \"Expression Detected\"], \"nci_thesaurus_concept_id\": \"C177692\", \"name\": \"Expression Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}, {\"eligibility_criterion\": \"exclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20709\", \"name\": \"Nuclear Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C21295\", \"C54362\"], \"parents\": [\"C20103\", \"C20420\"], \"assay_purpose\": \"Eligibility Criterion - Exclusion\"}], \"classification_code\": null, \"current_trial_status_date\": \"2019-04-04\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C153238\", \"name\": \"Metastatic Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C3482\", \"C170728\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IV\", \"Breast Carcinoma Stage IV\", \"Stage IV Breast Cancer AJCC v6\", \"Stage IV Breast Cancer AJCC v6 and v7\", \"Stage IV Breast Cancer AJCC v7\", \"Stage IV Breast Carcinoma\", \"stage IV breast cancer\"], \"nci_thesaurus_concept_id\": \"C3995\", \"name\": \"Stage IV Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C90513\", \"C91230\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IIIA\", \"Breast Carcinoma Stage IIIA\", \"Stage IIIA Breast Cancer AJCC v7\", \"Stage IIIA Breast Carcinoma\", \"stage IIIA breast cancer\"], \"nci_thesaurus_concept_id\": \"C7770\", \"name\": \"Stage IIIA Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer, Recurrent\", \"Recurrent Breast Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7771\", \"name\": \"Recurrent Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C4872\", \"C7619\", \"C170726\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage IIIB\", \"Breast Carcinoma Stage IIIB\", \"Stage IIIB Breast Cancer AJCC v7\", \"Stage IIIB Breast Carcinoma\", \"stage IIIB breast cancer\"], \"nci_thesaurus_concept_id\": \"C7782\", \"name\": \"Stage IIIB Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Breast Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88376\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91230\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Breast Cancer AJCC v7\", \"stage IIIC breast cancer\"], \"nci_thesaurus_concept_id\": \"C88377\", \"name\": \"Stage IIIC Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88376\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170726\", \"name\": \"Recurrent Malignant Breast Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9335\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma, metastatic, NOS\"], \"nci_thesaurus_concept_id\": \"C3482\", \"name\": \"Metastatic Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C36263\", \"C36310\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary Cancer\", \"Secondary Malignancy\", \"secondary cancer\"], \"nci_thesaurus_concept_id\": \"C4968\", \"name\": \"Secondary Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C36255\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91230\", \"name\": \"Breast Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Cancer\", \"Relapsed Cancer\", \"Relapsed Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7619\", \"name\": \"Recurrent Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C2916\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastasis\", \"Metastatic\", \"Metastatic Disease\", \"Metastatic Tumor\", \"Neoplasm, metastatic\", \"Tumor, metastatic\", \"metastasis\"], \"nci_thesaurus_concept_id\": \"C3261\", \"name\": \"Metastatic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v6 Stage\"], \"nci_thesaurus_concept_id\": \"C90513\", \"name\": \"Breast Cancer by AJCC v6 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Metastatic Cancer\"], \"nci_thesaurus_concept_id\": \"C36263\", \"name\": \"Metastatic Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3261\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C170728\", \"name\": \"Metastatic Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9335\", \"C36263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm, secondary\", \"Secondary Tumor\", \"Tumor, secondary\", \"secondary tumor\"], \"nci_thesaurus_concept_id\": \"C36255\", \"name\": \"Secondary Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Secondary carcinoma\"], \"nci_thesaurus_concept_id\": \"C36310\", \"name\": \"Secondary Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4968\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Breast Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88376\", \"name\": \"Stage III Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91230\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00100093\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901\"], \"nci_thesaurus_concept_id\": \"C99903\", \"name\": \"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901\", \"description\": \"A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent.Healt\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1572\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1572\", \"name\": \"Recombinant Viral Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C96404\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C96404\", \"name\": \"Viral Vaccine\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C923\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Vaccine Therapy\"], \"nci_thesaurus_concept_id\": \"C923\", \"name\": \"Vaccine Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}], \"name\": \"Arm A (VRP-HER2)\", \"description\": \"Patients receive HER2 ECD+TM virus-like replicon particles vaccine AVX901 IM on days 1 and 15 of cycle 1, day 8 of cycle 2, and a booster on day 1 of cycle 5 in the absence of disease progression or unacceptable toxicity.\", \"type\": \"ACTIVE_COMPARATOR\"}, {\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"nci_thesaurus_concept_id\": \"C106432\", \"name\": \"Pembrolizumab\", \"description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}], \"name\": \"Arm B (pembrolizumab)\", \"description\": \"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 5 cycles in the absence of disease progression or unacceptable toxicity.\", \"type\": \"ACTIVE_COMPARATOR\"}, {\"interventions\": [{\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901\"], \"intervention_name\": \"HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901\", \"category\": \"agent\", \"intervention_code\": \"C99903\", \"intervention_description\": \"A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent.Healt\", \"parents\": [\"C1572\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"intervention_name\": \"Pembrolizumab\", \"category\": \"agent\", \"intervention_code\": \"C106432\", \"intervention_description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"parents\": [\"C128037\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Recombinant Viral Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C1572\", \"intervention_description\": \"\", \"parents\": [\"C96404\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Viral Vaccine\", \"category\": \"agent category\", \"intervention_code\": \"C96404\", \"intervention_description\": \"\", \"parents\": [\"C923\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Vaccine Therapy\"], \"intervention_name\": \"Vaccine Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C923\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"intervention_name\": \"Biological Agent\", \"category\": \"agent category\", \"intervention_code\": \"C307\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Pharmacologic Substance\", \"category\": \"agent category\", \"intervention_code\": \"C1909\", \"intervention_description\": \"\", \"parents\": [\"C1908\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Drug, Food, Chemical or Biomedical Material\", \"category\": \"agent category\", \"intervention_code\": \"C1908\", \"intervention_description\": \"\", \"parents\": []}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"intervention_name\": \"Immunotherapy\", \"category\": \"agent category\", \"intervention_code\": \"C308\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"intervention_name\": \"Anti-PD1 Monoclonal Antibody\", \"category\": \"agent category\", \"intervention_code\": \"C128037\", \"intervention_description\": \"\", \"parents\": [\"C20401\", \"C124946\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"intervention_name\": \"Monoclonal Antibody Therapy\", \"category\": \"agent category\", \"intervention_code\": \"C20401\", \"intervention_description\": \"\", \"parents\": [\"C307\", \"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"intervention_name\": \"PD1 Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C124946\", \"intervention_description\": \"\", \"parents\": [\"C143250\", \"C163758\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"intervention_name\": \"Immune Checkpoint Inhibitor\", \"category\": \"agent category\", \"intervention_code\": \"C143250\", \"intervention_description\": \"\", \"parents\": [\"C141144\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"intervention_name\": \"Immune Checkpoint Modulator\", \"category\": \"agent category\", \"intervention_code\": \"C141144\", \"intervention_description\": \"\", \"parents\": [\"C308\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"intervention_name\": \"Targeted Therapy Agent\", \"category\": \"agent category\", \"intervention_code\": \"C163758\", \"intervention_description\": \"\", \"parents\": [\"C274\"]}, {\"intervention_type\": \"Biological/Vaccine\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"intervention_name\": \"Antineoplastic Agent\", \"category\": \"agent category\", \"intervention_code\": \"C274\", \"intervention_description\": \"\", \"parents\": [\"C1909\"]}], \"name\": \"Arm C (pembrolizumab, VRP-HER2)\", \"description\": \"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive HER2 ECD+TM virus-like replicon particles vaccine AVX901 IM on days 1 and 15 of cycle 1, day 8 of cycle 2, and a booster on day 1 of cycle 5 in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2019-02411\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well a vaccine (VRP-HER2) and pembrolizumab work in treating patients with  breast cancer where the HER2 gene is overactive and produces extra HER2 protein, and has come back at or near the same place or has spread to other places in the body. Vaccines made by inserting a laboratory-treated gene into a person\\u2019s tumor cells may help the body build an effective immune response to kill tumor cells that overexpress HER2. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving VRP-HER2 and pembrolizumab may work better in treating patients with HER2-overexpressing breast cancer compared to VRP-HER2 alone.\", \"brief_title\": \"A Vaccine (VRP-HER2) and Pembrolizumab in Treating Patients with Locally Recurrent or Metastatic HER2-Overexpressing Breast Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 39, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2019-04-04\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"Randomized Controlled Trial\"}, \"acronym\": null, \"anatomic_sites\": [\"Breast\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Michael A. Morse\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": \"2020-02-12T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Histologically confirmed stage IV or recurrent non-small cell lung cancer squamous or non-squamous histology (stage IV as diagnosed using the 7th edition of Lung Cancer Stage Classification), with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease. Prior adjuvant chemotherapy, neoadjuvant chemotherapy, or chemoradiotherapy is permitted as long as the last administration of the prior regimen occurred at least 6 months prior to study enrollment. Patients with known EGFR, ALK, or ROS1 alterations must have received one prior TKI. If ROS1 not known for any reason, subject meets eligibility. (Greater than or equal to 1 week washout for those patients on a TKI).\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Archival tumor tissue will be used for exploratory analysis. Archival samples must come from a core needle biopsy, surgical tissue, or fine needle aspiration (FNA) 19 gauge needle or larger. Available tumor tissue is not required for eligibility. There is no protocol violation if submitted specimen is not adequate for analysis. Note: a bone biopsy is not an acceptable sample.\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Negative pregnancy test done =< 72 hours (or per institutional policy) prior to treatment, for women of childbearing potential only. Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\\r\\n* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\\r\\n* Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.\\r\\n* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Men and women of childbearing potential must agree to use medically accepted barrier methods of contraception (e.g. male or female condom) at the time of pregnancy test (women of childbearing potential only), during the course of the study and for 7 months after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of study and for 7 months after the last dose of study drug.\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"A concurrent diagnosis of a separate malignancy is allowed if clinically stable and does not require tumor-directed therapy.\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Provision of written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines prior to any study-specific procedures.\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Patients must agree to research blood sampling to participate in study.\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Creatinine clearance >= 50 cc/min or serum creatinine (Cr) =< 1.5 x institutional upper limit of normal (ULN).\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Total bilirubin =< 1.5 x upper limit of normal (ULN).\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN without liver metastasis; =< 5 x ULN with liver metastasis.\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"Absolute neutrophil count (ANC) >= 1500 ul.\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Hemoglobin (Hgb) >= 9 g/dL.\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Platelets >= 100,000/ul.\"}, {\"inclusion_indicator\": false, \"display_order\": 16, \"description\": \"Subjects with known EGFR mutations which are sensitive to available targeted inhibitor therapy and must have received treatment with at least one prior tyrosine kinase inhibitor (TKI). (Greater than or equal to 1 week washout for those patients on a TKI).\"}, {\"inclusion_indicator\": false, \"display_order\": 17, \"description\": \"Subjects with known ALK or ROS1 translocations which are sensitive to available targeted inhibitor therapy must have received treatment with at least one prior TKI. (Greater than or equal to 1 week washout for those patients on a TKI).\"}, {\"inclusion_indicator\": false, \"display_order\": 18, \"description\": \"Radiation therapy within 14 days prior to day 1 of study drug.\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Experimental agents within 28 days prior to day 1 of study drug.\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Intolerance of nivolumab or other PD-1/PD-L1 axis drug(s), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including prior therapy with anti-tumor vaccines or other immune-stimulatory anti-tumor agents.\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Known auto-immune conditions requiring systemic immune suppression therapy other than prednisone =< 10 mg daily (or equivalent).\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"History of interstitial pneumonitis from any cause.\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Concurrent severe and/or uncontrolled medical conditions which may compromise participation in the study, including impaired heart function or clinically significant heart disease.\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Pregnant or breast feeding.\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Not willing to use an effective method of birth control medically accepted barrier methods of contraception (e.g. male or female condom) at the time of pregnancy test (women of childbearing potential only), during the course of the study and for 7 months after the last dose of study drug.\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Current use of medications specified by the protocol as prohibited for administration in combination with the study drugs. This includes patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to day 1 of study drug. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment on day 1 of study drug. Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible.\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Known active central nervous system (CNS) metastases which are symptomatic. Eligible if metastases have been locally treated 14 days prior to cycle 1 day 1, are clinically controlled, or asymptomatic on cycle 1 day.\\r\\n* Steroid dose must be equivalent of =< 2 mg decadron daily or equivalent dose steroid. Untreated, asymptomatic brain metastases allowed if subject does not require corticosteroids or anticonvulsant therapy.\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"History of myocardial infarction, New York Heart Association (NYHA) class III or IV congestive heart failure, or unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 6 months prior to study enrollment.\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Known history of human immunodeficiency virus (HIV) seropositivity or known acquired immunodeficiency syndrome (AIDS), hepatitis C virus (allowed if received curative therapy), acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment.\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Inability to comply with protocol or study procedures.\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Jeffrey Melson Clarke\", \"contact_phone\": \"919-681-9509\", \"recruitment_status_date\": \"2018-09-25\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"jeffrey.clarke@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVE:\\r\\nI. To estimate the progression free survival for the combination nivolumab, ipilimumab, and paclitaxel in untreated, metastatic non-small cell lung cancer (NSCLC).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To describe the safety and adverse events of combination nivolumab, ipilimumab, and paclitaxel in untreated, metastatic NSCLC.\\r\\nII. To estimate the overall response rate with the study combination.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To explore correlation between baseline and treatment related changes in immune correlates and clinical outcome.\\r\\nII. To explore any correlation between molecular/ histopathologic alterations and clinical outcome.\\r\\nIII. To estimate the objective response rate and median progression free survival (PFS) to the study combination in PDL1 positive tumors.\\r\\n\\r\\nOUTLINE:\\r\\nPatients receive nivolumab intravenously (IV) over 30 minutes every 3 weeks and ipilimumab IV over 30 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 60 minutes on days 1 and 8. Treatment of paclitaxel repeats every 21 days for up to 4-6 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 35, 80, and 100 days, and then up to 2 years.\", \"official_title\": \"A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 2 years\", \"name\": \"Biomarker analysis assessed in tumor and peripheral blood specimens via multiplex flow cytometric analysis and enzyme-linked immunosorbent assay based testing\", \"description\": \"For analysis of the immune monitoring data from the 2 polychromatic flow cytometry panels, will perform initial analysis using statistical graphics (e.g. box-plots) of the cell subset relative frequencies and trend over time. To assess the impact of cell subsets of interest (listed above) at baseline and on-treatment and on treatment outcome, we will perform a Kruskal\\u2013Wallis one-way analysis of variance with cell subset relative frequency as dependent variable and the Response Evaluation Criteria in Solid Tumors 1.1 response categories as independent factors to identify the cell subsets whose unadjusted p-values are statistically significant. Given the exploratory aim of research, no correction for the number of independent variables will be performed, and a ranked list of cell subsets with uncorrected p-values will be tabulated. Will perform step-wise Cox regression against survival time using the adjusted R-squared value to evaluate goodness-of-fit.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 30 days after last dose\", \"name\": \"Incidence of immune-mediated adverse events assessed by Common Terminology Criteria for Adverse Events version 4.03\", \"description\": \"The toxicity associated with the treatment regimen will be summarized. For each type of toxicity, a patient\\u2019s worst treatment-related toxic episode will be used to summarize distribution of toxicity grade experienced.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 2 years\", \"name\": \"Overall response rate\", \"description\": \"Will be defined as the number and percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR). BOR is defined as the best response designation, recorded between the date of first dose and the date of the initial objectively documented tumor progression per RECIST version 1.1 or the date of subsequent therapy, whichever occurs first.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"From the date of registration to the date of progression or death from any cause, whichever comes first, assessed up to 2 years\", \"name\": \"Progression-free survival (PFS)\", \"description\": \"Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST). Kaplan and Meier will be used. The median PFS and the rate of PFS at 6 months will be estimated. The proportion of patients who respond (completely or partially) to the combination regimen will be estimated and exact binomial confidence intervals will be computed for the estimate. One-sample log rank test will be used to compare survival of the combination regimen against that of similar population treated with nivolumab and ipilimumab.\", \"type_code\": \"PRIMARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03573947\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2018-09-25\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Non-Squamous Non-Small Cell Lung Cancer\", \"Recurrent Non-Squamous Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C128797\", \"name\": \"Recurrent Lung Non-Squamous Non-Small Cell Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C135017\", \"C7783\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Squamous Carcinoma\", \"Non-Small Cell Squamous Lung Carcinoma\", \"Squamous Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C133254\", \"name\": \"Non-Small Cell Squamous Lung Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C2926\", \"C3493\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Stage IV Lung Non-Small Cell Cancer AJCC v7\", \"Stage IV NSCLC\", \"Stage IV Non-Oat Cell Carcinoma of Lung\", \"Stage IV Non-Oat Cell Carcinoma of the Lung\", \"Stage IV Non-Oat Cell Lung Carcinoma\", \"Stage IV Non-Small Cell Carcinoma of Lung\", \"Stage IV Non-Small Cell Carcinoma of the Lung\", \"Stage IV Non-Small Cell Lung Cancer AJCC v7\", \"Stage IV Non-Small Cell Lung Carcinoma\", \"stage IV non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C4012\", \"name\": \"Stage IV Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C136491\", \"C88891\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Non Small Cell Lung Cancer Recurrent\", \"Non Small Cell Lung Cancer, Recurrent\", \"Recurrent Lung Non-Small Cell Carcinoma\", \"Recurrent NSCLC\", \"Recurrent Non-Small Cell Cancer of Lung\", \"Recurrent Non-Small Cell Cancer of the Lung\", \"Recurrent Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7783\", \"name\": \"Recurrent Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C2926\", \"C8953\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Lung Carcinoma\", \"Recurrent Unspecified Carcinoma of Lung\", \"Recurrent Unspecified Carcinoma of the Lung\", \"Recurrent Unspecified Lung Carcinoma\", \"Relapsed Unspecified Carcinoma of Lung\", \"Relapsed Unspecified Carcinoma of the Lung\", \"Relapsed Unspecified Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C8953\", \"name\": \"Recurrent Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C4878\", \"C7619\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, SQUAMOUS CELL, MALIGNANT\", \"Epidermoid Carcinoma\", \"Epidermoid Cell Cancer\", \"Epidermoid carcinoma, NOS\", \"Malignant Epidermoid Cell Neoplasm\", \"Malignant Epidermoid Cell Tumor\", \"Malignant Squamous Cell Neoplasm\", \"Malignant Squamous Cell Tumor\", \"Squamous Carcinoma\", \"Squamous Cell Cancer\", \"Squamous Cell Carcinoma, NOS\", \"Squamous Cell Carcinoma, Not Otherwise Specified\", \"Squamous Cell Carcinoma, conventional\", \"Squamous Cell Epithelioma\", \"Squamous carcinoma\", \"Squamous cell carcinoma, NOS\", \"Squamous cell epithelioma\", \"epidermoid carcinoma\", \"squamous cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C2929\", \"name\": \"Squamous Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C3792\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Squamous Non-Small Cell Carcinoma\", \"Non-Squamous Non-Small Cell Lung Carcinoma\", \"Non-squamous\"], \"nci_thesaurus_concept_id\": \"C135017\", \"name\": \"Non-Squamous Non-Small Cell Lung Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm of Thorax\", \"Neoplasm of the Thorax\", \"Thoracic Tumor\", \"Tumor of Thorax\", \"Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3406\", \"name\": \"Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C136491\", \"name\": \"Lung Non-Small Cell Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C91232\", \"C2926\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91232\", \"name\": \"Lung Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4878\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Non-small cell carcinoma\"], \"nci_thesaurus_concept_id\": \"C65151\", \"name\": \"Non-Small Cell Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Thoracic Disease\"], \"nci_thesaurus_concept_id\": \"C35742\", \"name\": \"Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrence\", \"Recurrent Cancer\", \"Recurrent Malignant Tumor\", \"recurrence\", \"recurrent cancer\"], \"nci_thesaurus_concept_id\": \"C4813\", \"name\": \"Recurrent Malignant Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C9305\", \"C4798\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Neoplasm of Thorax\", \"Malignant Neoplasm of the Thorax\", \"Malignant Thoracic Tumor\", \"Malignant Tumor of Thorax\", \"Malignant Tumor of the Thorax\"], \"nci_thesaurus_concept_id\": \"C3576\", \"name\": \"Malignant Thoracic Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4571\", \"name\": \"Malignant Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\", \"C3355\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Non-Small Cell Carcinoma\", \"NSCLC\", \"NSCLC - Non-Small Cell Lung Cancer\", \"Non Small Cell Lung Cancer NOS\", \"Non-Small Cell Cancer of Lung\", \"Non-Small Cell Cancer of the Lung\", \"Non-Small Cell Carcinoma of Lung\", \"Non-Small Cell Carcinoma of the Lung\", \"Non-Small Cell Lung Carcinoma\", \"Non-small cell lung cancer, NOS\", \"non-small cell lung cancer\"], \"nci_thesaurus_concept_id\": \"C2926\", \"name\": \"Non-Small Cell Lung Cancer\", \"type\": [\"maintype\", \"subtype\"], \"parents\": [\"C4878\", \"C65151\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasm Recurrence\", \"Recurrence\", \"Recurrent\", \"Recurrent Tumor\", \"recurrence\"], \"nci_thesaurus_concept_id\": \"C4798\", \"name\": \"Recurrent Neoplasm\", \"type\": [\"stage\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Lung Neoplasms\", \"Lung Tumor\", \"Neoplasm of Lung\", \"Neoplasm of the Lung\", \"Tumor of Lung\", \"Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C3200\", \"name\": \"Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3198\", \"C3355\", \"C3406\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Respiratory System\", \"Respiratory Disorder\", \"Unspecified Respiratory Problem\"], \"nci_thesaurus_concept_id\": \"C26871\", \"name\": \"Respiratory System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27669\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epidermoid Cell Carcinoma of Lung\", \"Epidermoid Cell Carcinoma of the Lung\", \"Epidermoid Cell Lung Carcinoma\", \"LSCC\", \"LUSC\", \"Lung Squamous Cell Carcinoma\", \"Squamous Cell Carcinoma of Lung\", \"Squamous Cell Carcinoma of the Lung\", \"Squamous Cell Lung Carcinoma\", \"Squamous cell lung carcinoma\"], \"nci_thesaurus_concept_id\": \"C3493\", \"name\": \"Squamous Cell Lung Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C4878\", \"C2929\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epidermoid Cell Neoplasm\", \"Epidermoid Cell Tumor\", \"Squamous Cell Neoplasms\", \"Squamous Cell Tumor\"], \"nci_thesaurus_concept_id\": \"C3792\", \"name\": \"Squamous Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Respiratory and Thoracic Disease\", \"Respiratory, Thoracic, and Mediastinal Disease\", \"Respiratory, Thoracic, and Mediastinal Disorder\"], \"nci_thesaurus_concept_id\": \"C27669\", \"name\": \"Respiratory and Thoracic Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Stage IV Lung Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88891\", \"name\": \"Stage IV Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91232\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Non Small Cell Lung Cancer Recurrent\", \"Non Small Cell Lung Cancer, Recurrent\", \"Recurrent Lung Non-Small Cell Carcinoma\", \"Recurrent NSCLC\", \"Recurrent Non-Small Cell Cancer of Lung\", \"Recurrent Non-Small Cell Cancer of the Lung\", \"Recurrent Non-Small Cell Lung Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7783\", \"name\": \"Recurrent Non-Small Cell Lung Cancer\", \"type\": [\"stage\"], \"parents\": [\"C2926\", \"C8953\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Recurrent Cancer\", \"Relapsed Cancer\", \"Relapsed Carcinoma\"], \"nci_thesaurus_concept_id\": \"C7619\", \"name\": \"Recurrent Carcinoma\", \"type\": [\"stage\"], \"parents\": [\"C2916\", \"C4813\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disorder of Lung\", \"Lung Disorders\", \"Pulmonary Disease\", \"Pulmonary Diseases\", \"Pulmonary Disorder\", \"Pulmonary Disorders\"], \"nci_thesaurus_concept_id\": \"C3198\", \"name\": \"Lung Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C26871\", \"C35742\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Lung Tumor\", \"Malignant Neoplasm of Lung\", \"Malignant Neoplasm of the Lung\", \"Malignant Tumor of Lung\", \"Malignant Tumor of the Lung\"], \"nci_thesaurus_concept_id\": \"C7377\", \"name\": \"Malignant Lung Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3200\", \"C4571\", \"C3576\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Lung\", \"Cancer of the Lung\", \"Carcinoma of Lung\", \"Carcinoma of the Lung\", \"Lung Cancer (all types)\", \"Lung Carcinoma\", \"Lung cancer, NOS\", \"lung cancer\"], \"nci_thesaurus_concept_id\": \"C4878\", \"name\": \"Lung Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C7377\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Respiratory Tract Neoplasm\"], \"nci_thesaurus_concept_id\": \"C3355\", \"name\": \"Respiratory System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3263\", \"C26871\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00092210\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Opdivo\", \"Nivolumab\"], \"nci_thesaurus_concept_id\": \"C68814\", \"name\": \"Nivolumab\", \"description\": \"A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Yervoy\", \"Ipilimumab\"], \"nci_thesaurus_concept_id\": \"C2654\", \"name\": \"Ipilimumab\", \"description\": \"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128036\", \"C129822\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Anzatax\", \"Asotax\", \"Bristaxol\", \"Praxel\", \"Taxol Konzentrat\", \"Paclitaxel\"], \"nci_thesaurus_concept_id\": \"C1411\", \"name\": \"Paclitaxel\", \"description\": \"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Drug\", \"parents\": [\"C1490\", \"C67437\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Antibody\", \"Anticancer Antibody\", \"Antineoplastic Ab\"], \"nci_thesaurus_concept_id\": \"C129822\", \"name\": \"Antineoplastic Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C129821\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-cancer Biological Agent\", \"Anticancer Biological\", \"Antineoplastic Biological\", \"Antineoplastic Biotherapeutic\", \"Antineoplastic Biological Agent\"], \"nci_thesaurus_concept_id\": \"C129821\", \"name\": \"Antineoplastic Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\", \"C307\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-CTLA4 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128036\", \"name\": \"Anti-CTLA-4 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\", \"C20401\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Taxanes\"], \"nci_thesaurus_concept_id\": \"C1490\", \"name\": \"Taxane Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C860\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Terpenes\"], \"nci_thesaurus_concept_id\": \"C860\", \"name\": \"Terpene Compound\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C552\", \"C616\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Hydrocarbons\"], \"nci_thesaurus_concept_id\": \"C552\", \"name\": \"Hydrocarbon\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C718\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C718\", \"name\": \"Organic Chemical\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1913\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1913\", \"name\": \"Drug or Chemical by Structure\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lipids\"], \"nci_thesaurus_concept_id\": \"C616\", \"name\": \"Lipid\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C718\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Taxane-Site Binding Agent\"], \"nci_thesaurus_concept_id\": \"C67437\", \"name\": \"Taxane-Pocket Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C25974\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Tubulin Binding Agents\"], \"nci_thesaurus_concept_id\": \"C25974\", \"name\": \"Tubulin Binding Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C273\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Antimitotic Drugs\", \"Antimitotics\", \"Microtubular Function Inhibitors\", \"Mitosis Inhibitor Agents\", \"Mitosis Inhibitor Drugs\", \"Mitosis Inhibitors\", \"Mitotic Inhibitor Agents\", \"Mitotic Inhibitor Drugs\", \"Mitotic Inhibitors\"], \"nci_thesaurus_concept_id\": \"C273\", \"name\": \"Antimitotic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Drug\", \"parents\": [\"C274\"]}], \"name\": \"Treatment (nivolumab, ipilimumab, paclitaxel)\", \"description\": \"Patients receive nivolumab IV over 30 minutes every 3 weeks and ipilimumab IV over 30 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 60 minutes on days 1 and 8. Treatment of paclitaxel repeats every 21 days for up to 4-6 cycles in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2018-02288\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well nivolumab, ipilimumab, and paclitaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body\\u2019s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as paclitaxel, use substances made from living organisms that may kill tumor cells by blocking blood flow to the tumor. Giving nivolumab, ipilimumab, and paclitaxel may work better in treating patients with non-small cell lung cancer.\", \"brief_title\": \"Nivolumab, Ipilimumab, and Paclitaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 49, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2018-09-25\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Lung\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Jeffrey Melson Clarke\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": \"2019-07-26T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Be willing and able to provide written informed consent for the trial\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Has a pathologic diagnosis of invasive esophageal, gastroesophageal or gastric adenocarcinoma\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Staging computed tomography (CT) chest, abdomen, pelvis (CAP) or positron emission tomography (PET)/CT shows no evidence of metastatic disease\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Plan for neoadjuvant chemoradiation\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Absolute neutrophil count (ANC) >= 1,500/mcL (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"Platelets >= 100,000/mcL (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (within 14 days of treatment initiation); creatinine clearance should be calculated per institutional standard\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 12, \"description\": \"Albumin >= 2.5 mg/dL (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 13, \"description\": \"International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 14, \"description\": \"Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)\"}, {\"inclusion_indicator\": true, \"display_order\": 15, \"description\": \"Female subject of childbearing potential should have a negative serum pregnancy within 48 hours prior to receiving the first dose of study medication\"}, {\"inclusion_indicator\": true, \"display_order\": 16, \"description\": \"Female and male subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in the Duke Contraception Policy\"}, {\"inclusion_indicator\": false, \"display_order\": 17, \"description\": \"Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 18, \"description\": \"Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Has a known history of active TB (Bacillus tuberculosis)\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Hypersensitivity to pembrolizumab or any of its excipients\"}, {\"inclusion_indicator\": false, \"display_order\": 21, \"description\": \"Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\"}, {\"inclusion_indicator\": false, \"display_order\": 22, \"description\": \"Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current diagnosis of EGC\"}, {\"inclusion_indicator\": false, \"display_order\": 23, \"description\": \"Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer; (all patients with prior radiotherapy must be reviewed by the principal investigator [PI] to determine if patient is eligible)\"}, {\"inclusion_indicator\": false, \"display_order\": 24, \"description\": \"Has known metastatic disease; staging CT C/A/P or PET/CT will be mandatory no more than 45 days prior to enrollment to evaluate for the presence of metastatic disease\"}, {\"inclusion_indicator\": false, \"display_order\": 25, \"description\": \"Has unresectable disease or is medically inoperable\"}, {\"inclusion_indicator\": false, \"display_order\": 26, \"description\": \"Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with chronic use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 27, \"description\": \"Has known history of, or any evidence of active, non-infectious pneumonitis\"}, {\"inclusion_indicator\": false, \"display_order\": 28, \"description\": \"Has an active infection requiring systemic therapy\"}, {\"inclusion_indicator\": false, \"display_order\": 29, \"description\": \"Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator\"}, {\"inclusion_indicator\": false, \"display_order\": 30, \"description\": \"Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\"}, {\"inclusion_indicator\": false, \"display_order\": 31, \"description\": \"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\"}, {\"inclusion_indicator\": false, \"display_order\": 32, \"description\": \"Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\"}, {\"inclusion_indicator\": false, \"display_order\": 33, \"description\": \"Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)\"}, {\"inclusion_indicator\": false, \"display_order\": 34, \"description\": \"Has known, active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)\"}, {\"inclusion_indicator\": false, \"display_order\": 35, \"description\": \"Has received a live vaccine within 30 days of planned start of study therapy; Note: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, are not allowed\"}, {\"inclusion_indicator\": false, \"display_order\": 36, \"description\": \"Has a diagnosis of scleroderma\"}, {\"inclusion_indicator\": false, \"display_order\": 37, \"description\": \"Has a known history of allogenic stem cell transplant\"}, {\"inclusion_indicator\": false, \"display_order\": 38, \"description\": \"Has received a solid organ transplant\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"BOTH\", \"min_age\": \"18 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 18, \"min_age_in_years\": 18}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Manisha Palta\", \"contact_phone\": \"919-668-5640\", \"recruitment_status_date\": \"2017-07-07\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"manisha.palta@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. To investigate whether neoadjuvant chemoradiotherapy combined with pembrolizumab followed by resection improves pathologic complete response (pCR) compared to historical control with standard of care neoadjuvant chemoradiotherapy followed by resection (23%).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. To assess the safety of neoadjuvant pembrolizumab administered with conventionally fractionated chemoradiotherapy in esophageal and gastric cancers (EGC).\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\nI. To identify immune related biomarkers as predictors of clinical response to pembrolizumab and chemoradiotherapy.\\r\\nII. To estimate the distribution of time to local recurrence (TTLR), time to distant recurrence (TTDR), progression free survival (PFS), and overall survival (OS).\\r\\n\\r\\nOUTLINE:\\r\\nBeginning 14 days before standard of care radiation therapy, patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive standard of care radiation therapy daily for 25 fractions. Patients also receive standard of care carboplatin IV and paclitaxel IV weekly during radiation therapy. Treatment repeats every 3 weeks for a minimum of 4 cycles in the absence of disease progression or unacceptable toxicity. Within 6-16 weeks after completing chemoradiotherapy, patients undergo surgical resection per standard of care. Patients then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 3 cycles in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 30 days, every 3-6 months for 2 years and every 6-12 months for 3 years.\", \"official_title\": \"Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-Gastric Diseases (PROCEED)\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Up to 5 years\", \"name\": \"Immune correlates\", \"description\": \"Using categorical predictors of clinical interest, pCR rates with their 80% confidence intervals will be presented according to the level of the predictors.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0\", \"description\": \"Toxicity by type and grade will be tabulated. Toxicity rates of interest will be calculated with their 80% confidence intervals.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time from enrollment to death due to any cause, assessed up to 5 years\", \"name\": \"Overall survival\", \"description\": \"The Kaplan Meier method will be used to estimate the distributions.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Pathologic complete response (pCR) rate\", \"description\": \"The observed pCR rate will be estimated with its exact 80% confidence interval.\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Time from enrollment to local recurrence, distant recurrence, or death due to any cause, whichever comes first, assessed up to 5 years\", \"name\": \"Progression free survival\", \"description\": \"The Kaplan Meier method will be used to estimate the distributions.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Up to 5 years\", \"name\": \"Time to distant recurrence (TTDR)\", \"description\": \"Distant recurrences will be ignored and deaths will be censored. TTDR will be defined analogously. The Kaplan Meier method will be used to estimate the distributions.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}, {\"time_frame\": \"Time from enrollment to local recurrence, assessed up to 5 years\", \"name\": \"Time to local recurrence\", \"description\": \"The Kaplan Meier method will be used to estimate the distributions.\", \"type_code\": \"OTHER_PRE_SPECIFIED\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT03064490\", \"biomarkers\": null, \"classification_code\": null, \"current_trial_status_date\": \"2017-07-07\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIA Esophageal Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C115119\", \"name\": \"Stage IIIA Esophageal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89795\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIB Esophageal Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C115120\", \"name\": \"Stage IIIB Esophageal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89795\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Esophageal Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C115121\", \"name\": \"Stage IIIC Esophageal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89795\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Adenocarcinoma\", \"Adenocarcinoma - stomach\", \"Adenocarcinoma of Stomach\", \"Adenocarcinoma of the Stomach\", \"Adenocarcinoma of the stomach\", \"Gastric Adenocarcinoma\", \"Gastric Adenocarcinoma, NOS\", \"STAD\", \"Stomach Adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C4004\", \"name\": \"Gastric (Stomach) Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C4911\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Adenocarcinoma\", \"Adenocarcinoma - esophagus\", \"Adenocarcinoma of Esophagus\", \"Adenocarcinoma of the Esophagus\", \"Adenocarcinoma of the esophagus\", \"Esophagus Adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C4025\", \"name\": \"Esophageal Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C3513\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Stomach Stage IIIB\", \"Carcinoma of the Stomach Stage IIIB\", \"Gastric Cancer Stage IIIB\", \"Gastric Carcinoma Stage IIIB\", \"Stage IIIB Carcinoma of Stomach\", \"Stage IIIB Carcinoma of the Stomach\", \"Stage IIIB Gastric Cancer\", \"Stage IIIB Gastric Cancer AJCC v7\", \"Stage IIIB Gastric Carcinoma\", \"Stage IIIB Stomach Carcinoma\", \"Stomach Carcinoma Stage IIIB\"], \"nci_thesaurus_concept_id\": \"C5470\", \"name\": \"Stage IIIB Gastric (Stomach) Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89860\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of Stomach Stage IIIA\", \"Carcinoma of the Stomach Stage IIIA\", \"Gastric Cancer Stage IIIA\", \"Gastric Carcinoma Stage IIIA\", \"Stage IIIA Carcinoma of Stomach\", \"Stage IIIA Carcinoma of the Stomach\", \"Stage IIIA Gastric Cancer\", \"Stage IIIA Gastric Cancer AJCC v7\", \"Stage IIIA Gastric Carcinoma\", \"Stage IIIA Stomach Carcinoma\", \"Stomach Carcinoma Stage IIIA\"], \"nci_thesaurus_concept_id\": \"C5471\", \"name\": \"Stage IIIA Gastric (Stomach) Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89860\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IIIC Gastric Cancer\", \"Stage IIIC Gastric Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C87777\", \"name\": \"Stage IIIC Gastric (Stomach) Cancer\", \"type\": [\"stage\"], \"parents\": [\"C89860\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Esophageal Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C89795\", \"name\": \"Stage III Esophageal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91221\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Gastric Cancer\", \"Stage III Gastric Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C89860\", \"name\": \"Stage III Gastric (Stomach) Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91222\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma - GEJ\", \"Adenocarcinoma of Cardioesophageal Junction\", \"Adenocarcinoma of Gastroesophageal Junction\", \"Adenocarcinoma of the Cardioesophageal Junction\", \"Adenocarcinoma of the EG Junction\", \"Adenocarcinoma of the Esophagogastric Junction\", \"Adenocarcinoma of the GE Junction\", \"Adenocarcinoma of the Gastroesophageal Junction\", \"Adenocarcinoma of the gastroesophageal junction\"], \"nci_thesaurus_concept_id\": \"C9296\", \"name\": \"Gastroesophageal Junction Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C96963\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Neoplasm\", \"Digestive System Tumor\", \"Digestive Tumor\", \"GI Neoplasm\", \"GI System Neoplasm\", \"GI System Tumor\", \"GI Tumor\", \"Gastrointestinal Neoplasm\", \"Gastrointestinal System Neoplasm\", \"Gastrointestinal System Tumor\", \"Gastrointestinal Tumor\", \"Neoplasm of Digestive System\", \"Neoplasm of GI System\", \"Neoplasm of Gastrointestinal System\", \"Neoplasm of the Digestive System\", \"Neoplasm of the GI System\", \"Neoplasm of the Gastrointestinal System\", \"Tumor of Digestive System\", \"Tumor of GI System\", \"Tumor of Gastrointestinal System\", \"Tumor of the Digestive System\", \"Tumor of the GI System\", \"Tumor of the Gastrointestinal System\"], \"nci_thesaurus_concept_id\": \"C3052\", \"name\": \"Digestive System Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2990\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Digestive Disease\", \"Digestive System Disease\", \"Disorder of Digestive System\", \"Gastrointestinal Disorder\", \"Gastrointestinal System Disease\", \"Gastrointestinal System Disorder\", \"Unspecified Gastrointestinal Problem\", \"stomach or intestinal disorder\"], \"nci_thesaurus_concept_id\": \"C2990\", \"name\": \"Digestive System Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastric Tumor\", \"Neoplasm of Stomach\", \"Neoplasm of the Stomach\", \"Stomach Neoplasm\", \"Stomach Tumor\", \"Tumor of Stomach\", \"Tumor of the Stomach\"], \"nci_thesaurus_concept_id\": \"C3387\", \"name\": \"Gastric Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C26886\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Gastric Tumor\", \"Neoplasm of Stomach\", \"Neoplasm of the Stomach\", \"Stomach Neoplasm\", \"Stomach Tumor\", \"Tumor of Stomach\", \"Tumor of the Stomach\"], \"nci_thesaurus_concept_id\": \"C3387\", \"name\": \"Gastric Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C26886\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Esophageal Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91221\", \"name\": \"Esophageal Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C3513\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Esophageal Neoplasms, Benign and Malignant\", \"Esophageal Tumor\", \"Esophageal Tumors\", \"Esophagus Neoplasm\", \"Esophagus Tumor\", \"Neoplasm of Esophagus\", \"Neoplasm of the Esophagus\", \"Tumor of Esophagus\", \"Tumor of the Esophagus\"], \"nci_thesaurus_concept_id\": \"C3028\", \"name\": \"Esophageal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C3027\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Esophageal Neoplasms, Benign and Malignant\", \"Esophageal Tumor\", \"Esophageal Tumors\", \"Esophagus Neoplasm\", \"Esophagus Tumor\", \"Neoplasm of Esophagus\", \"Neoplasm of the Esophagus\", \"Tumor of Esophagus\", \"Tumor of the Esophagus\"], \"nci_thesaurus_concept_id\": \"C3028\", \"name\": \"Esophageal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C3027\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Esophagus\", \"Cancer of the Esophagus\", \"Carcinoma of Esophagus\", \"Carcinoma of the Esophagus\", \"ESCA\", \"Esophageal Carcinoma\", \"Esophageal cancer, NOS\", \"Esophagus Carcinoma\", \"esophageal cancer\"], \"nci_thesaurus_concept_id\": \"C3513\", \"name\": \"Esophageal Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C7478\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Esophagus\", \"Cancer of the Esophagus\", \"Carcinoma of Esophagus\", \"Carcinoma of the Esophagus\", \"ESCA\", \"Esophageal Carcinoma\", \"Esophageal cancer, NOS\", \"Esophagus Carcinoma\", \"esophageal cancer\"], \"nci_thesaurus_concept_id\": \"C3513\", \"name\": \"Esophageal Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C7478\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Esophageal Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C89795\", \"name\": \"Stage III Esophageal Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91221\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Gastrointestinal System Cancer\", \"Gastrointestinal cancer, NOS\", \"Malignant Digestive System Neoplasm\", \"Malignant Gastrointestinal System Neoplasm\"], \"nci_thesaurus_concept_id\": \"C4890\", \"name\": \"Malignant Gastrointestinal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3052\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Esophageal Tumor\", \"Malignant Esophagus Tumor\", \"Malignant Neoplasm of Esophagus\", \"Malignant Neoplasm of the Esophagus\", \"Malignant Tumor of Esophagus\", \"Malignant Tumor of the Esophagus\"], \"nci_thesaurus_concept_id\": \"C7478\", \"name\": \"Malignant Esophageal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3028\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Esophageal Tumor\", \"Malignant Esophagus Tumor\", \"Malignant Neoplasm of Esophagus\", \"Malignant Neoplasm of the Esophagus\", \"Malignant Tumor of Esophagus\", \"Malignant Tumor of the Esophagus\"], \"nci_thesaurus_concept_id\": \"C7478\", \"name\": \"Malignant Esophageal Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3028\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26886\", \"name\": \"Stomach Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C26886\", \"name\": \"Stomach Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Carcinoma of the Gastrointestinal System\", \"Gastrointestinal System Carcinoma\"], \"nci_thesaurus_concept_id\": \"C96963\", \"name\": \"Digestive System Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage III Gastric Cancer\", \"Stage III Gastric Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C89860\", \"name\": \"Stage III Gastric (Stomach) Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91222\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Gastric Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91222\", \"name\": \"Gastric Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4911\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer of Stomach\", \"Cancer of the Stomach\", \"Carcinoma of Stomach\", \"Carcinoma of the Stomach\", \"Gastric Cancer\", \"Gastric Carcinoma\", \"Gastric cancer, NOS\", \"Stomach Cancer\", \"Stomach Carcinoma\", \"gastric cancer\", \"stomach cancer\"], \"nci_thesaurus_concept_id\": \"C4911\", \"name\": \"Gastric (Stomach) Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C9331\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Gastric Tumor\", \"Malignant Neoplasm of Stomach\", \"Malignant Neoplasm of the Stomach\", \"Malignant Tumor of Stomach\", \"Malignant Tumor of the Stomach\"], \"nci_thesaurus_concept_id\": \"C9331\", \"name\": \"Malignant Gastric Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3387\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Cancer of Stomach\", \"Cancer of the Stomach\", \"Carcinoma of Stomach\", \"Carcinoma of the Stomach\", \"Gastric Cancer\", \"Gastric Carcinoma\", \"Gastric cancer, NOS\", \"Stomach Cancer\", \"Stomach Carcinoma\", \"gastric cancer\", \"stomach cancer\"], \"nci_thesaurus_concept_id\": \"C4911\", \"name\": \"Gastric (Stomach) Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C96963\", \"C9331\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Gastric Tumor\", \"Malignant Neoplasm of Stomach\", \"Malignant Neoplasm of the Stomach\", \"Malignant Tumor of Stomach\", \"Malignant Tumor of the Stomach\"], \"nci_thesaurus_concept_id\": \"C9331\", \"name\": \"Malignant Gastric Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3387\", \"C4890\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3027\", \"name\": \"Esophageal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3027\", \"name\": \"Esophageal Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C2990\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00081010\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Keytruda\", \"Pembrolizumab\"], \"nci_thesaurus_concept_id\": \"C106432\", \"name\": \"Pembrolizumab\", \"description\": \"A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional\", \"category\": \"agent\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C128037\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Laboratory Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C64263\", \"name\": \"Laboratory Biomarker Analysis\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C63333\", \"C74957\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-PD-1 Monoclonal Antibody\"], \"nci_thesaurus_concept_id\": \"C128037\", \"name\": \"Anti-PD1 Monoclonal Antibody\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C20401\", \"C124946\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Monoclonal Antibodies\", \"Monoclonal Antibody Therapy\"], \"nci_thesaurus_concept_id\": \"C20401\", \"name\": \"Monoclonal Antibody Therapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C307\", \"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biological Products\", \"Biologicals\", \"Biologics\", \"Biopharmaceuticals\", \"Immunologic, Immunochemical\", \"Immunologics\"], \"nci_thesaurus_concept_id\": \"C307\", \"name\": \"Biological Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1909\", \"name\": \"Pharmacologic Substance\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1908\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C1908\", \"name\": \"Drug, Food, Chemical or Biomedical Material\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BRM\", \"Biological Response Modifier\", \"Biomodulators\", \"Immune Mediators\", \"Immune Modulators\", \"Immune Regulators\", \"Immunomodulating Agent\", \"Immunomodulators\", \"Immunomodulatory Agent\", \"Immunopotentiators\", \"Immunotherapy Agent\", \"Immunotherapy\"], \"nci_thesaurus_concept_id\": \"C308\", \"name\": \"Immunotherapy\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PD-1 Inhibitor\", \"PD-1-targeting Agent\", \"Programmed Cell Death Protein 1 Inhibitor\", \"Protein PD-1 Inhibitor\", \"PD1 Inhibitor\"], \"nci_thesaurus_concept_id\": \"C124946\", \"name\": \"PD1 Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C143250\", \"C163758\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Immune Checkpoint Inhibitor\"], \"nci_thesaurus_concept_id\": \"C143250\", \"name\": \"Immune Checkpoint Inhibitor\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C141144\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C141144\", \"name\": \"Immune Checkpoint Modulator\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C308\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-tumor Targeted Therapy Agent\", \"Molecularly Targeted Therapy Agent\", \"Targeted Agent\", \"Targeted Therapeutic Agent\"], \"nci_thesaurus_concept_id\": \"C163758\", \"name\": \"Targeted Therapy Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C274\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Anti-Cancer Agents\", \"Anti-Tumor Agents\", \"Anti-Tumor Drugs\", \"Antineoplastic Drugs\", \"Antineoplastics\", \"Antiproliferative Agents\", \"Antiproliferative Drugs\", \"Cancer Drug\", \"Chemotherapeutic Agents, Neoplastic Disease\", \"Tumor-Specific Treatment Agents\"], \"nci_thesaurus_concept_id\": \"C274\", \"name\": \"Antineoplastic Agent\", \"description\": \"\", \"category\": \"agent category\", \"type\": \"Biological/Vaccine\", \"parents\": [\"C1909\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C63333\", \"name\": \"Biomarker Analysis\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C74957\", \"name\": \"Mixed Category Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25294\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lab Test\", \"Lab Tests\", \"Laboratory Test\", \"Test\", \"Tests\", \"Laboratory Procedure\"], \"nci_thesaurus_concept_id\": \"C25294\", \"name\": \"Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}], \"name\": \"Treatment (pembrolizumab)\", \"description\": \"Beginning 14 days before standard of care radiation therapy, patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive standard of care radiation therapy daily for 25 fractions. Patients also receive standard of care carboplatin IV and paclitaxel IV weekly during radiation therapy. Treatment repeats every 3 weeks for a minimum of 4 cycles in the absence of disease progression or unacceptable toxicity. Within 6-16 weeks after completing chemoradiotherapy, patients undergo surgical resection per standard of care. Patients then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 3 cycles in the absence of disease progression or unacceptable toxicity.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2017-01290\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II clinical trial studies the side effects of pembrolizumab in treating patients with esophageal and gastric cancer that has spread from where it started to nearby tissue or lymph node. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body\\u2019s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.\", \"brief_title\": \"Pembrolizumab in Treating Patients with Locally Advanced Esophageal and Gastric Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 38, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2017-07-07\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": null, \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Multiple\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Manisha Palta\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}, {\"other_ids\": null, \"amendment_date\": \"2019-02-24T00:00:00\", \"keywords\": null, \"dcp_id\": null, \"interventional_model\": \"Single Group\", \"lead_org\": \"Duke University Medical Center\", \"eligibility\": {\"unstructured\": [{\"inclusion_indicator\": true, \"display_order\": 1, \"description\": \"Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast\\r\\n* Biopsy tissue (either slides or block) from outside institutions will be reviewed to confirm diagnosis\"}, {\"inclusion_indicator\": true, \"display_order\": 2, \"description\": \"Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric or multifocal disease, no pregnant women, and no comorbid conditions precluding surgery)\"}, {\"inclusion_indicator\": true, \"display_order\": 3, \"description\": \"Clinical T1N0M0 invasive carcinoma or ductal carcinoma in situ (DCIS) < or equal to 2 cm\"}, {\"inclusion_indicator\": true, \"display_order\": 4, \"description\": \"60 years of age or older or 50-59 with a low (0-17) oncotype score; oncotype is not required for women diagnosed with DCIS\"}, {\"inclusion_indicator\": true, \"display_order\": 5, \"description\": \"Estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) (HER2 status is not required for women diagnosed with DCIS)\"}, {\"inclusion_indicator\": true, \"display_order\": 6, \"description\": \"Women of child-bearing potential must consent to use adequate contraception during the course of the study; female subjects must agree to use a medically acceptable contraceptives including: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use\"}, {\"inclusion_indicator\": true, \"display_order\": 7, \"description\": \"White blood cell (WBC) > 3000 (within 45 days of consent)\"}, {\"inclusion_indicator\": true, \"display_order\": 8, \"description\": \"Hemoglobin (Hgb) > 9 (within 45 days of consent)\"}, {\"inclusion_indicator\": true, \"display_order\": 9, \"description\": \"Platelets > 100000 (within 45 days of consent)\"}, {\"inclusion_indicator\": true, \"display_order\": 10, \"description\": \"Magnetic resonance imaging (MRI) is required for radiation treatment planning on this study; a diagnostic MRI performed within 60 days of obtaining consent is acceptable and will not be repeated; subjects who have not had a diagnostic MRI will be required to have a research treatment planning MRI with contrast ordered by a radiation oncologist; these subjects must have a glomerular filtration rate (GFR) >= 60 ml/min\"}, {\"inclusion_indicator\": true, \"display_order\": 11, \"description\": \"Outside breast imaging will be reviewed at Duke to confirm findings are consistent with trial eligibility\"}, {\"inclusion_indicator\": false, \"display_order\": 12, \"description\": \"Neoadjuvant chemotherapy\"}, {\"inclusion_indicator\": false, \"display_order\": 13, \"description\": \"Breast implant in the breast to be treated with stereotactic body radiation therapy (SBRT)\"}, {\"inclusion_indicator\": false, \"display_order\": 14, \"description\": \"Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)\"}, {\"inclusion_indicator\": false, \"display_order\": 15, \"description\": \"Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at length\"}, {\"inclusion_indicator\": false, \"display_order\": 16, \"description\": \"HER-2+ (HER2 status is not required for women diagnosed with DCIS)\"}, {\"inclusion_indicator\": false, \"display_order\": 17, \"description\": \"Positive serum pregnancy test\"}, {\"inclusion_indicator\": false, \"display_order\": 18, \"description\": \"Insufficient breast imaging to judge clinical stage\"}, {\"inclusion_indicator\": false, \"display_order\": 19, \"description\": \"Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement\"}, {\"inclusion_indicator\": false, \"display_order\": 20, \"description\": \"Subjects in whom treatment planning constraints cannot be met\"}], \"structured\": {\"max_age\": \"999 Years\", \"max_age_number\": 999, \"min_age_unit\": \"Years\", \"max_age_unit\": \"Years\", \"max_age_in_years\": 999, \"gender\": \"FEMALE\", \"min_age\": \"50 Years\", \"accepts_healthy_volunteers\": false, \"min_age_number\": 50, \"min_age_in_years\": 50}}, \"sites\": [{\"org_state_or_province\": \"NC\", \"contact_name\": \"Rachel C. Blitzblau\", \"contact_phone\": \"919-668-5213\", \"recruitment_status_date\": \"2015-10-21\", \"org_address_line_2\": null, \"org_va\": false, \"org_address_line_1\": \"2301 Erwin Road\", \"org_tty\": null, \"org_family\": \"Duke Cancer Institute\", \"org_postal_code\": \"27710\", \"contact_email\": \"rachel.blitzblau@duke.edu\", \"recruitment_status\": \"ACTIVE\", \"org_city\": \"Durham\", \"org_email\": null, \"org_country\": \"United States\", \"org_fax\": \"919-684-5653\", \"org_phone\": \"888-275-3853\", \"org_name\": \"Duke University Medical Center\", \"org_coordinates\": {\"lon\": -78.94, \"lat\": 35.9995}}], \"completion_date_type_code\": null, \"detail_description\": \"PRIMARY OBJECTIVES:\\r\\nI. Determine physician reported rates of good/excellent cosmesis at baseline and 6 months, 1, 2, and 3 years post-treatment as measured by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) (NRG) cosmesis scale.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\nI. Ki-67 will be assessed as a measure of tumor response.\\r\\nII. Determine patient-reported rates of good/excellent cosmesis at baseline and 6 months, 1, 2, and 3 years post-treatment as measured by the NRG cosmesis scale. Assess patient-reported quality of life (Functional Assessment of Cancer Therapy-Breast [FACT-B]) and patient satisfaction at the same time points.\\r\\nIII. Assess locoregional control in the treated breast relative to historical controls.\\r\\nIV. Assess the impact of radiation on gene expression.\\r\\nV. Assess the impact of radiation on circulating cell-free deoxyribonucleic acid (DNA) via serum markers and oxidative stress as measured by urinary biomarkers.\\r\\nVI. To review treatment plans, evaluate delivery techniques and assess positioning verification images.\\r\\n\\r\\nOUTLINE:\\r\\nPatients undergo single-fraction partial breast irradiation at baseline. Approximately 10 days later, patients undergo lumpectomy.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 1-2 months, every 4-6 months for 2 years, every 6-12 months for 3 years, and then yearly for 5 years.\", \"official_title\": \"A Phase II Evaluation of Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer\", \"_phase_sort_order\": 2, \"collaborators\": [{\"name\": \"National Cancer Institute\", \"functional_role\": \"FUNDING_SOURCE\"}], \"associated_studies\": null, \"outcome_measures\": [{\"time_frame\": \"Baseline up to 10 years\", \"name\": \"Change in gene expression\", \"description\": \"The impact of radiation on gene expression will be analyzed.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 36 months\", \"name\": \"Change in mean of patient-reported rate of good/excellent cosmesis\", \"description\": \"Will be estimated with 95% CI.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 36 months\", \"name\": \"Change in quality of life and patient satisfaction assessed by Functional Assessment of Cancer Therapy-Breast\", \"description\": \"For each scale, the mean and its 95% CI\\u2019s will be estimated at each time point; boxplots will be used to estimate the distribution of these scales at each time point.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"At core biopsy and 5-7 weeks post radiation therapy\", \"name\": \"Change in rate of ki-67\", \"description\": \"Will be estimated with 95% CI\\u2019s.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Baseline up to 36 months\", \"name\": \"Change in rate of physician-reported rate of good/excellent cosmesis\", \"description\": \"Will be estimated with 95% confidence interval (CI).\", \"type_code\": \"PRIMARY\"}, {\"time_frame\": \"Up to 10 years\", \"name\": \"Circulating cell-free deoxyribonucleic acid (DNA) assessed in serum\", \"description\": \"Will assess the impact of radiation on circulating cell-free DNA via serum markers and oxidative stress as measured by urinary biomarkers.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 10 years\", \"name\": \"Delivery techniques evaluation\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 10 years\", \"name\": \"Positioning verification images\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Up to 10 years\", \"name\": \"Review treatment plans\", \"description\": null, \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time from start of treatment to date of local or regional failure, whichever comes first; distant failures will be ignored; deaths will be censored, assessed up to 10 years\", \"name\": \"Time local or regional failure\", \"description\": \"The Kaplan Meier method will be used to estimate distributions.\", \"type_code\": \"SECONDARY\"}, {\"time_frame\": \"Time from start of treatment to date of distant failure, assessed up to 10 years\", \"name\": \"Time to distant failure\", \"description\": \"The Kaplan Meier method will be used to estimate distributions.\", \"type_code\": \"SECONDARY\"}], \"phase\": \"II\", \"central_contact\": {\"phone\": null, \"name\": null, \"type\": null, \"email\": null}, \"primary_purpose\": \"TREATMENT\", \"number_of_arms\": 1, \"_study_protocol_type_sort_order\": 0, \"nct_id\": \"NCT02482376\", \"biomarkers\": [{\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ER Alpha Positive\", \"ER Positive\", \"ER+\", \"ER-Alpha Positive\", \"ERA Positive\", \"ESR Positive\", \"ESR1 Positive\", \"ESRA Positive\", \"ESTRR Positive\", \"Estrogen Receptor 1 Positive\", \"Estrogen Receptor Alpha Positive\", \"NR3A1 Positive\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Positive\", \"Positive\", \"Positive Estrogen Receptor\", \"estrogen receptor positive\"], \"nci_thesaurus_concept_id\": \"C15492\", \"name\": \"Estrogen Receptor Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C101267\", \"C16150\", \"C16612\", \"C177692\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35682\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C16150\", \"C101267\", \"C38349\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"ERBB2 Negative\", \"HER-2 Negative\", \"HER2 Negative\"], \"nci_thesaurus_concept_id\": \"C68749\", \"name\": \"HER2/Neu Negative\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16152\", \"C165233\", \"C16612\", \"C17756\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C35681\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\", \"parents\": [\"C165233\", \"C16152\", \"C17756\"]}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25872\", \"name\": \"Kinase Family Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\", \"C25871\"], \"parents\": [\"C25871\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C54362\", \"name\": \"Transcription Regulation Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Positive\", \"positive test result\"], \"nci_thesaurus_concept_id\": \"C35682\", \"name\": \"Positive Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER Alpha Status\", \"ER Status\", \"ER-Alpha Status\", \"ERA Status\", \"ESR Status\", \"ESR1 Status\", \"ESRA Status\", \"ESTRR Status\", \"Estrogen Receptor\", \"Estrogen Receptor 1 Status\", \"Estrogen Receptor Alpha Status\", \"NR3A1 Status\", \"Nuclear Receptor Subfamily 3 Group A Member 1 Status\"], \"nci_thesaurus_concept_id\": \"C16150\", \"name\": \"Estrogen Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C3367\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C38349\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"LAB_RESULT\", \"Lab Findings\", \"Laboratory Finding\", \"Laboratory Report\", \"Labs\", \"TEST RESULT\", \"Test Result\", \"test result\", \"test_result\"], \"nci_thesaurus_concept_id\": \"C36292\", \"name\": \"Laboratory Test Result\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25871\", \"name\": \"Phosphotransferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\", \"C25870\"], \"parents\": [\"C25870\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2 Status\", \"Her2/Neu Value\"], \"nci_thesaurus_concept_id\": \"C16152\", \"name\": \"HER2/Neu Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C17756\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\", \"C3367\", \"C36292\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C94299\", \"C17756\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25870\", \"name\": \"Transferase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21281\"], \"parents\": [\"C21281\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20103\", \"name\": \"Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C21295\"], \"parents\": [\"C21295\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ERBB2\", \"Erb-b2 Receptor Tyrosine Kinase 2 Gene\", \"HER2\", \"HER2/Neu\", \"NEU\"], \"nci_thesaurus_concept_id\": \"C17756\", \"name\": \"ERBB2 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20719\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C20719\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Proto-Oncogene, Transcription Factor\"], \"nci_thesaurus_concept_id\": \"C20420\", \"name\": \"Transcription Factor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C54362\"], \"parents\": [\"C54362\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Negative\", \"negative test result\"], \"nci_thesaurus_concept_id\": \"C35681\", \"name\": \"Negative Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\", \"C77140\"], \"parents\": [\"C77140\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C94299\", \"name\": \"Receptor Status\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C36292\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Expressed\", \"Expression Detected\"], \"nci_thesaurus_concept_id\": \"C177692\", \"name\": \"Expression Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35682\", \"C36292\", \"C7057\", \"C77140\"], \"parents\": [\"C35682\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20709\", \"name\": \"Nuclear Receptor Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C21295\", \"C54362\"], \"parents\": [\"C20103\", \"C20420\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21295\", \"name\": \"Ligand Binding Protein Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER\", \"ESR1\", \"Estrogen Receptor 1 Gene\"], \"nci_thesaurus_concept_id\": \"C38349\", \"name\": \"ESR1 Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Absent\", \"LOST\", \"Loss of Expression\", \"Negative\", \"Not Expressed\"], \"nci_thesaurus_concept_id\": \"C165233\", \"name\": \"Expression Negative\", \"semantic_types\": [\"Cell or Molecular Dysfunction\"], \"type\": [], \"ancestors\": [\"C3367\", \"C35681\", \"C7057\", \"C77140\"], \"parents\": [\"C35681\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Genes\", \"gene\"], \"nci_thesaurus_concept_id\": \"C16612\", \"name\": \"Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Diagnostic Test Result\", \"Test Result\"], \"nci_thesaurus_concept_id\": \"C77140\", \"name\": \"Clinical Test Result\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C3367\", \"C7057\"], \"parents\": [\"C3367\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C21281\", \"name\": \"Enzyme Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\"], \"parents\": [\"C16612\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C20719\", \"name\": \"Receptor Tyrosine Kinase Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [], \"ancestors\": [\"C16612\", \"C20103\", \"C21281\", \"C21295\", \"C25870\", \"C25871\", \"C25872\"], \"parents\": [\"C25872\", \"C20103\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"PGR\", \"PR\", \"Progesterone Receptor Gene\"], \"nci_thesaurus_concept_id\": \"C28656\", \"name\": \"PGR Gene\", \"semantic_types\": [\"Gene or Genome\"], \"type\": [\"reference_gene\"], \"ancestors\": [\"C16612\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C54362\"], \"parents\": [\"C20709\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"ER and/or PR +\", \"ER and/or PR Positive\", \"Estrogen Receptor and/or Progesterone Receptor Positive\"], \"nci_thesaurus_concept_id\": \"C101267\", \"name\": \"Hormone Receptor Positive\", \"semantic_types\": [\"Laboratory or Test Result\"], \"type\": [], \"ancestors\": [\"C16612\", \"C177692\", \"C20103\", \"C20420\", \"C20709\", \"C21295\", \"C28656\", \"C3367\", \"C35682\", \"C36292\", \"C38349\", \"C54362\", \"C7057\", \"C77140\", \"C94299\"], \"parents\": [\"C177692\", \"C94299\", \"C38349\", \"C28656\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"semantic_types\": [\"Conceptual Entity\"], \"type\": [\"branch\"], \"ancestors\": [], \"parents\": [], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}, {\"eligibility_criterion\": \"inclusion\", \"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Observable Entity\", \"finding\"], \"nci_thesaurus_concept_id\": \"C3367\", \"name\": \"Finding\", \"semantic_types\": [\"Finding\"], \"type\": [], \"ancestors\": [\"C7057\"], \"parents\": [\"C7057\"], \"assay_purpose\": \"Eligibility Criterion - Inclusion\"}], \"classification_code\": \"Efficacy\", \"current_trial_status_date\": \"2015-10-21\", \"diseases\": [{\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Ductal Carcinoma In Situ\", \"Breast Ductal Carcinoma In Situ, NOS\", \"Breast Ductal Carcinoma In Situ, Not Otherwise Specified\", \"DCIS\", \"Ductal Breast Carcinoma In Situ\", \"Ductal Carcinoma In Situ\", \"Ductal Carcinoma In Situ of Breast\", \"Ductal Carcinoma In Situ of the Breast\", \"Ductal carcinoma in situ\", \"Intraductal Breast Carcinoma\", \"Intraductal Carcinoma\", \"Intraductal Carcinoma of Breast\", \"Intraductal Carcinoma of the Breast\", \"Non-Infiltrating Ductal Adenocarcinoma of Breast\", \"Non-Infiltrating Ductal Adenocarcinoma of the Breast\", \"Non-Infiltrating Ductal Breast Adenocarcinoma\", \"Non-Infiltrating Ductal Breast Carcinoma\", \"Non-Infiltrating Ductal Carcinoma of Breast\", \"Non-Infiltrating Ductal Carcinoma of the Breast\", \"Non-Infiltrating Intraductal Adenocarcinoma\", \"Non-Infiltrating Intraductal Adenocarcinoma of Breast\", \"Non-Infiltrating Intraductal Adenocarcinoma of the Breast\", \"Non-Infiltrating Intraductal Breast Adenocarcinoma\", \"Non-Infiltrating Intraductal Carcinoma\", \"Non-Invasive Ductal Adenocarcinoma of Breast\", \"Non-Invasive Ductal Adenocarcinoma of the Breast\", \"Non-Invasive Ductal Breast Adenocarcinoma\", \"Non-Invasive Ductal Breast Carcinoma\", \"Non-Invasive Ductal Carcinoma of Breast\", \"Non-Invasive Ductal Carcinoma of the Breast\", \"Non-Invasive Intraductal Adenocarcinoma of Breast\", \"Non-Invasive Intraductal Adenocarcinoma of the Breast\", \"Non-Invasive Intraductal Breast Adenocarcinoma\", \"ductal carcinoma in situ\", \"intraductal carcinoma\"], \"nci_thesaurus_concept_id\": \"C2924\", \"name\": \"Ductal Carcinoma In Situ (DCIS)\", \"type\": [\"stage\", \"grade\", \"subtype\"], \"parents\": [\"C139534\", \"C4017\", \"C27942\", \"C6877\", \"C3641\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Stage IA Breast Cancer AJCC v7\", \"stage IA breast cancer\"], \"nci_thesaurus_concept_id\": \"C85835\", \"name\": \"Stage IA Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C88375\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": true, \"synonyms\": [\"Infiltrating Breast Carcinoma\", \"Infiltrating Carcinoma of Breast\", \"Infiltrating Carcinoma of the Breast\", \"Invasive Breast Carcinoma\", \"Invasive Carcinoma of Breast\", \"Invasive Carcinoma of the Breast\", \"Invasive Mammary Carcinoma\", \"Invasive breast carcinoma\", \"Invasive mammary carcinoma\", \"infiltrating breast cancer\", \"invasive breast cancer\"], \"nci_thesaurus_concept_id\": \"C9245\", \"name\": \"Invasive Breast Cancer\", \"type\": [\"subtype\"], \"parents\": [\"C4872\", \"C9480\"]}, {\"inclusion_indicator\": \"TRIAL\", \"is_lead_disease\": false, \"synonyms\": [\"Early Stage Breast Carcinoma\", \"Early-Stage Breast Carcinoma\", \"early-stage breast cancer\"], \"nci_thesaurus_concept_id\": \"C94774\", \"name\": \"Early-Stage Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v8 Anatomic Stage\"], \"nci_thesaurus_concept_id\": \"C139533\", \"name\": \"Breast Cancer by AJCC v8 Anatomic Stage\", \"type\": [\"stage\"], \"parents\": [\"C139532\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Intraductal Breast Neoplasm\"], \"nci_thesaurus_concept_id\": \"C36083\", \"name\": \"Breast Intraductal  Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Malignant Breast Tumor\", \"Malignant Neoplasm of Breast\", \"Malignant Neoplasm of the Breast\", \"Malignant Tumor of Breast\", \"Malignant Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C9335\", \"name\": \"Malignant Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C2910\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C9480\", \"name\": \"Invasive Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C8505\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Diagnosis\", \"Disease\", \"Disease or Disorder\", \"Disease or Disorder, Non-Neoplastic\", \"Diseases\", \"Diseases and Disorders\", \"Disorder\", \"Disorders\", \"condition\", \"disease\", \"disease term\", \"disease type\", \"disease_term\", \"disease_type\", \"disorder\"], \"nci_thesaurus_concept_id\": \"C2991\", \"name\": \"Other Disease\", \"type\": [\"maintype\"], \"parents\": [\"C7057\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Glandular Cell Epithelial Neoplasm\", \"Glandular Cell Epithelium Neoplasm\"], \"nci_thesaurus_concept_id\": \"C7132\", \"name\": \"Glandular Cell Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C3709\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Ductal Carcinoma\", \"Duct Adenocarcinoma\", \"Duct Carcinoma\", \"Ductal Adenocarcinoma\", \"Ductal Carcinoma\", \"Ductal Carcinoma of Breast\", \"Ductal Carcinoma of the Breast\", \"Ductal adenocarcinoma\", \"ductal carcinoma\"], \"nci_thesaurus_concept_id\": \"C4017\", \"name\": \"Ductal Breast Carcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C5214\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma\", \"Breast cancer, NOS\", \"Cancer of Breast\", \"Cancer of the Breast\", \"Carcinoma of Breast\", \"Carcinoma of the Breast\", \"Mammary Carcinoma\", \"breast cancer\"], \"nci_thesaurus_concept_id\": \"C4872\", \"name\": \"Breast Cancer\", \"type\": [\"maintype\"], \"parents\": [\"C2916\", \"C9335\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Glandular intraepithelial neoplasia, grade III\"], \"nci_thesaurus_concept_id\": \"C6877\", \"name\": \"Grade III Glandular Intraepithelial Neoplasia\", \"type\": [\"stage\", \"grade\", \"subtype\"], \"parents\": [\"C4123\", \"C7662\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Anatomic Stage 0 Breast Cancer AJCC v8\", \"Anatomic Stage 0 Breast Carcinoma AJCC v8\"], \"nci_thesaurus_concept_id\": \"C139534\", \"name\": \"Stage 0 Breast Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C139533\", \"C2917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Stage I Breast Cancer AJCC v7\"], \"nci_thesaurus_concept_id\": \"C88375\", \"name\": \"Stage I Breast Cancer\", \"type\": [\"stage\"], \"parents\": [\"C91230\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"AIS\", \"Adenocarcinoma in situ\", \"Adenocarcinoma in situ, NOS\"], \"nci_thesaurus_concept_id\": \"C4123\", \"name\": \"Adenocarcinoma In Situ\", \"type\": [\"stage\", \"grade\", \"subtype\"], \"parents\": [\"C2852\", \"C2917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7662\", \"name\": \"High Grade Glandular Intraepithelial Neoplasia\", \"type\": [\"grade\"], \"parents\": [\"C27269\", \"C7348\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7057\", \"name\": \"Disease, Disorder or Finding\", \"type\": [], \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Neoplasia\", \"Neoplasm\", \"Neoplasm, NOS\", \"Neoplasms, NOS\", \"Neoplastic Disease\", \"Neoplastic Growth\", \"Tumor, NOS\", \"neoplasia\", \"neoplasm\", \"tumor\"], \"nci_thesaurus_concept_id\": \"C3262\", \"name\": \"Other Neoplasm\", \"type\": [\"maintype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Precancerous State\", \"Premalignant Condition\", \"Premalignant State\"], \"nci_thesaurus_concept_id\": \"C3341\", \"name\": \"Precancerous Condition\", \"type\": [\"subtype\"], \"parents\": [\"C8278\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Cancer Stage 0\", \"Breast Cancer in situ\", \"Breast Carcinoma in situ\", \"Carcinoma in situ of Breast\", \"Carcinoma in situ of the Breast\", \"In situ Breast Cancer\", \"Non-Infiltrating Breast Carcinoma\", \"Non-Infiltrating Carcinoma of Breast\", \"Non-Infiltrating Carcinoma of the Breast\", \"Non-Invasive Breast Carcinoma\", \"Non-Invasive Carcinoma of Breast\", \"Non-Invasive Carcinoma of the Breast\", \"Stage 0 Breast Cancer AJCC v6\", \"Stage 0 Breast Cancer AJCC v6 and v7\", \"Stage 0 Breast Cancer AJCC v7\", \"Stage 0 Breast Carcinoma\", \"Stage 0 Carcinoma of Breast\", \"Stage 0 Carcinoma of the Breast\", \"breast cancer in situ\", \"stage 0 breast carcinoma in situ\"], \"nci_thesaurus_concept_id\": \"C3641\", \"name\": \"Stage 0 Breast Cancer\", \"type\": [\"stage\", \"grade\"], \"parents\": [\"C90513\", \"C91230\", \"C2917\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v6 Stage\"], \"nci_thesaurus_concept_id\": \"C90513\", \"name\": \"Breast Cancer by AJCC v6 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Adenocarcinoma of Breast\", \"Adenocarcinoma of the Breast\", \"Mammary adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C5214\", \"name\": \"Breast Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2852\", \"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, MALIGNANT\", \"Carcinoma\", \"Carcinoma, NOS\", \"Epithelial Carcinoma\", \"Epithelial tumor, malignant\", \"Epithelioma Malignant\", \"Malignant Epithelial Neoplasm\", \"Malignant Epithelial Tumor\", \"Malignant Epithelioma\", \"carcinoma\", \"epithelial carcinoma\"], \"nci_thesaurus_concept_id\": \"C2916\", \"name\": \"Other Carcinoma\", \"type\": [\"maintype\"], \"parents\": [\"C3709\", \"C9305\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"ADENOCARCINOMA, MALIGNANT\", \"Adenocarcinoma, NOS\", \"adenocarcinoma\"], \"nci_thesaurus_concept_id\": \"C2852\", \"name\": \"Adenocarcinoma\", \"type\": [\"subtype\"], \"parents\": [\"C2916\", \"C7132\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Tumor Morphology\", \"Tumor_Morphology\"], \"nci_thesaurus_concept_id\": \"C4741\", \"name\": \"Neoplasm by Morphology\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C27269\", \"name\": \"Glandular Cell Intraepithelial Neoplasia\", \"type\": [\"subtype\"], \"parents\": [\"C7132\", \"C8366\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7348\", \"name\": \"High Grade Intraepithelial Neoplasia\", \"type\": [\"grade\"], \"parents\": [\"C8366\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C3263\", \"name\": \"Neoplasm by Site\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"DIN\", \"Ductal Intraepithelial Neoplasia\", \"Intraductal Proliferative Lesion\", \"Intraductal Proliferative Lesion of the Breast\", \"Mammary Intraepithelial Neoplasia, Ductal Type\"], \"nci_thesaurus_concept_id\": \"C27942\", \"name\": \"Breast Intraductal Proliferative Lesion\", \"type\": [\"subtype\"], \"parents\": [\"C36083\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CA\", \"Cancer\", \"Malignancy\", \"Malignant Growth\", \"Malignant Neoplastic Disease\", \"Malignant Tumor\", \"NEOPLASM, MALIGNANT\", \"Neoplasm, malignant\", \"Tumor, malignant, NOS\", \"Unclassified tumor, malignant\", \"cancer\", \"malignancy\"], \"nci_thesaurus_concept_id\": \"C9305\", \"name\": \"Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C7062\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"CARCINOMA, IN SITU, MALIGNANT\", \"CIS\", \"Epithelial Tumor, In situ, Malignant\", \"Intraepithelial Carcinoma\", \"Non-invasive Carcinoma\", \"carcinoma in situ\", \"stage 0 disease\"], \"nci_thesaurus_concept_id\": \"C2917\", \"name\": \"Carcinoma In Situ\", \"type\": [\"stage\", \"grade\", \"subtype\"], \"parents\": [\"C2916\", \"C3341\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Disease\", \"Breast Diseases\"], \"nci_thesaurus_concept_id\": \"C26709\", \"name\": \"Breast Disorder\", \"type\": [\"subtype\"], \"parents\": [\"C27551\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v7 Stage\"], \"nci_thesaurus_concept_id\": \"C91230\", \"name\": \"Breast Cancer by AJCC v7 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Carcinoma by AJCC v8 Stage\"], \"nci_thesaurus_concept_id\": \"C139532\", \"name\": \"Breast Cancer by AJCC v8 Stage\", \"type\": [\"stage\"], \"parents\": [\"C4872\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Epithelial Neoplasms, NOS\", \"Epithelioma\", \"Epithelioma, malignant\"], \"nci_thesaurus_concept_id\": \"C3709\", \"name\": \"Epithelial Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C4741\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Disease by Site\"], \"nci_thesaurus_concept_id\": \"C27551\", \"name\": \"Disorder by Site\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Breast Tumor\", \"Neoplasm of Breast\", \"Neoplasm of the Breast\", \"Tumor of Breast\", \"Tumor of the Breast\"], \"nci_thesaurus_concept_id\": \"C2910\", \"name\": \"Breast Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C26709\", \"C3263\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Epithelial Dysplasia\", \"Intraepithelial Neoplasm\"], \"nci_thesaurus_concept_id\": \"C8366\", \"name\": \"Intraepithelial Neoplasia\", \"type\": [\"subtype\"], \"parents\": [\"C3709\", \"C3341\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C7062\", \"name\": \"Neoplasm by Special Category\", \"type\": [\"subtype\"], \"parents\": [\"C3262\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": false, \"synonyms\": [\"Cancer Related Condition\", \"Cancer-Related Problem or Condition\", \"Oncologic Complications\", \"cancer related problem/condition\", \"problem/condition, cancer related\", \"problem/condition, cancer-related\"], \"nci_thesaurus_concept_id\": \"C8278\", \"name\": \"Cancer-Related Condition\", \"type\": [\"subtype\"], \"parents\": [\"C2991\"]}, {\"inclusion_indicator\": \"TREE\", \"is_lead_disease\": true, \"synonyms\": [\"Infiltrating Malignant Neoplasm\", \"infiltrating cancer\", \"invasive cancer\"], \"nci_thesaurus_concept_id\": \"C8505\", \"name\": \"Invasive Malignant Neoplasm\", \"type\": [\"subtype\"], \"parents\": [\"C9305\"]}], \"_primary_purpose_sort_order\": 0, \"protocol_id\": \"Pro00063848\", \"active_sites_count\": 1, \"arms\": [{\"interventions\": [{\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Laboratory Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C64263\", \"name\": \"Laboratory Biomarker Analysis\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C63333\", \"C74957\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Quality of Life Assessment\", \"Quality-of-Life Assessment\"], \"nci_thesaurus_concept_id\": \"C15584\", \"name\": \"Quality-of-Life Assessment\", \"description\": null, \"category\": \"other\", \"type\": \"Other\", \"parents\": [\"C15747\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Lumpectomy of Breast\", \"Partial Mastectomy\", \"Lumpectomy\"], \"nci_thesaurus_concept_id\": \"C15755\", \"name\": \"Lumpectomy\", \"description\": null, \"category\": \"other\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15280\"]}, {\"inclusion_indicator\": \"TRIAL\", \"synonyms\": [\"Partial Breast Irradiation\"], \"nci_thesaurus_concept_id\": \"C116439\", \"name\": \"Partial Breast Irradiation\", \"description\": null, \"category\": \"other\", \"type\": \"Radiation\", \"parents\": [\"C116438\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Biomarker Analysis\"], \"nci_thesaurus_concept_id\": \"C63333\", \"name\": \"Biomarker Analysis\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C25218\", \"name\": \"Intervention or Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C16203\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C16203\", \"name\": \"Clinical or Research Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C43431\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C43431\", \"name\": \"Activity\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": []}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C74957\", \"name\": \"Mixed Category Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25294\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Lab Test\", \"Lab Tests\", \"Laboratory Test\", \"Test\", \"Tests\", \"Laboratory Procedure\"], \"nci_thesaurus_concept_id\": \"C25294\", \"name\": \"Laboratory Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Supportive Therapy\", \"Symptom Management\", \"Therapy, Supportive\", \"Supportive Care\"], \"nci_thesaurus_concept_id\": \"C15747\", \"name\": \"Supportive Care\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49236\", \"name\": \"Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Other\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"BCS\", \"BCT\", \"Breast-Conserving Surgery\", \"Breast Conservation Treatment\"], \"nci_thesaurus_concept_id\": \"C15280\", \"name\": \"Breast Conservation Treatment\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15774\", \"C157802\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Breast Cancer Treatment\", \"Breast Cancer, Treatment\"], \"nci_thesaurus_concept_id\": \"C15774\", \"name\": \"Breast Cancer Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C79427\", \"C16212\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C79427\", \"name\": \"Breast Cancer Diagnostic or Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C79426\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C79426\", \"name\": \"Cancer Diagnostic or Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Therapy\", \"Cancer Treatment\", \"Malignant Neoplasm Therapy\", \"Malignant Neoplasm Treatment\"], \"nci_thesaurus_concept_id\": \"C16212\", \"name\": \"Cancer Therapeutic Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C79426\", \"C49236\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C157802\", \"name\": \"Breast Surgery\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C49163\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C49163\", \"name\": \"Surgical Procedure by Site or System\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C15329\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [], \"nci_thesaurus_concept_id\": \"C15329\", \"name\": \"Surgical Procedure\", \"description\": \"\", \"category\": \"none\", \"type\": \"Procedure/Surgery\", \"parents\": [\"C25218\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Breast Irradiation\"], \"nci_thesaurus_concept_id\": \"C116438\", \"name\": \"Breast Irradiation\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C15313\"]}, {\"inclusion_indicator\": \"TREE\", \"synonyms\": [\"Cancer Radiotherapy\", \"Irradiate\", \"Irradiated\", \"Irradiation\", \"RT\", \"Radiation\", \"Radiotherapeutics\", \"Radiotherapy\", \"Therapy, Radiation\", \"Radiation Therapy\"], \"nci_thesaurus_concept_id\": \"C15313\", \"name\": \"Radiation Therapy\", \"description\": \"\", \"category\": \"none\", \"type\": \"Radiation\", \"parents\": [\"C49236\"]}], \"name\": \"Treatment (partial breast irradiation, lumpectomy)\", \"description\": \"Patients undergo single-fraction partial breast irradiation at baseline. Approximately 10 days later, patients undergo lumpectomy.\", \"type\": \"EXPERIMENTAL\"}], \"study_model_code\": null, \"nci_id\": \"NCI-2015-01856\", \"why_study_stopped\": null, \"brief_summary\": \"This phase II trial studies how well single-fraction partial breast irradiation before surgery works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph nodes. Single-fraction partial breast irradiation is a specialized external beam radiation therapy that focuses on a specific part of the breast. Giving single-fraction partial breast radiation before surgery may kill more tumor cells and reduce the amount of normal tissue that needs to be removed.\", \"brief_title\": \"Single-Fraction Partial Breast Radiation Therapy before Surgery in Treating Patients with Early Stage Breast Cancer\", \"study_population_description\": null, \"sampling_method_code\": null, \"minimum_target_accrual_number\": 100, \"_current_trial_status_sort_order\": 0, \"start_date\": \"2015-10-21\", \"record_verification_date\": \"2021-10-19\", \"ctep_id\": null, \"current_trial_status\": \"Active\", \"study_model_other_text\": null, \"masking\": {\"role_caregiver\": null, \"masking\": \"OPEN\", \"role_investigator\": null, \"role_outcome_assessor\": null, \"role_subject\": null, \"allocation_code\": \"NA\"}, \"acronym\": null, \"anatomic_sites\": [\"Breast\"], \"ccr_id\": null, \"start_date_type_code\": \"ACTUAL\", \"principal_investigator\": \"Rachel C. Blitzblau\", \"study_source\": \"Institutional\", \"completion_date\": null, \"study_subtype_code\": null, \"study_protocol_type\": \"Interventional\"}]}\n"
     ]
    }
   ],
   "source": [
    "def url_maker(date, start_index):\n",
    "    \n",
    "    s_date = date.strftime(\"%Y-%m-%d\")\n",
    "    \n",
    "    url = \"https://clinicaltrialsapi.cancer.gov/api/v2/trials?size=20&record_verification_date_gte=\" + s_date\n",
    "    url += '&from=' + str(start_index) \n",
    "\n",
    "    payload = {}\n",
    "    headers = {\n",
    "        'x-api-key': 'mbxhNtV14K6tiaQ5IUHt2m0wpaKrz9H2cMAz1nHg',\n",
    "    }\n",
    "    full_data = requests.request(\"GET\", url, headers=headers, data=payload)\n",
    "    \n",
    "    print(full_data.text)\n",
    "\n",
    "url_maker(date.today() - datetime.timedelta(days=1), 0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
